

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2017267804 B2**

(54) Title
Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers

(51) International Patent Classification(s)
A61K 31/4439 (2006.01) **A61P 31/12** (2006.01)
A61K 31/675 (2006.01) **A61P 37/04** (2006.01)
A61P 9/10 (2006.01) **A61P 37/06** (2006.01)

(21) Application No: **2017267804** (22) Date of Filing: **2017.05.22**

(87) WIPO No: **WO17/201532**

(30) Priority Data

(31)	Number	(32)	Date	(33)	Country
	15/161,137		2016.05.20		US

(43) Publication Date: **2017.11.23**

(44) Accepted Journal Date: **2023.04.27**

(71) Applicant(s)
BioMed Valley Discoveries, Inc.

(72) Inventor(s)
Saha, Saurabh;Welsch, Dean;Decrescenzo, Gary;Roix, Jeffrey James

(74) Agent / Attorney
FB Rice Pty Ltd, L 33 477 Collins Street, Melbourne, VIC, 3000, AU

(56) Related Art
WO 2015/095842 A2
WO 2015/095834 A2
MATTEO S C, et al., "Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients", Clinical Cancer Research, (Jan 2015), vol. 21, pages 98-105
WO 2015/095833 A1
WO 2016/025649 A1
Fofaria N M, et al., "Overexpression of Mcl-1 confers resistance to BRAFv600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma", Oncotarget, (Oct 2015), vol 6, pages 40535-40556
WO 2015/095819 A2



(51) International Patent Classification:

A61K 31/4439 (2006.01) *A61P 31/12* (2006.01)
A61K 31/675 (2006.01) *A61P 37/04* (2006.01)
A61P 9/10 (2006.01) *A61P 37/06* (2006.01)

(21) International Application Number:

PCT/US2017/033843

(22) International Filing Date:

22 May 2017 (22.05.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

15/161,137 20 May 2016 (20.05.2016) US

(71) **Applicant:** BIOMED VALLEY DISCOVERIES, INC.
 [US/US]; 4520 Main Street, 16th Fl., Kansas City, Missouri
 64111 (US).

(72) **Inventors:** SAHA, Saurabh; 44 Carisbrooke Road,
 Wellesley Hills, Massachusetts 02481 (US). WELSCH,
 Dean; 10427 NW River Hills Place, Parkville, Missouri
 64152 (US). DECRESCENZO, Gary; 6135 Westwood
 Court, Parkville, Missouri 64152 (US). ROIX, Jeffrey
 James; 658 E. Broadway St., Apt. 2, Boston, Massachusetts
 02127 (US).

(74) **Agent:** HOOPER, Kevin C.; Bryan Cave LLP, 1290 Av-
 enue of the Americas, New York, New York 10104 (US).

(81) **Designated States** (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
 HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR,
 KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
 TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) **Designated States** (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
 KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CAN-
 CERS

FIG. 1A



(57) **Abstract:** The present invention provides, *inter alia*, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway inhibitor therapy. Also provided are methods for identifying a subject having cancer who would benefit from therapy with an ERK inhibitor and methods for inhibiting phosphorylation of RSK in a cancer cell that is refractory or resistant to a non-ERK MAPK pathway inhibitor.



METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims benefit to U.S. Patent Application Serial No. 15/161,137, filed on May 20, 2016, which is a continuation in part of PCT international application no. PCT/US2014/071749, filed December 19, 2014, which claims benefit of U.S. Patent Application Serial No. 61/919,551, filed on December 20, 2013, all of which are incorporated by reference in their entireties as if recited in full herein.

FIELD OF INVENTION

[0002] The present invention provides, *inter alia*, methods, pharmaceutical compositions, and kits for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway inhibitor therapy.

INCORPORATION BY REFERENCE OF SEQUENCE LISTING

[0003] This application contains references to amino acids and/or nucleic acid sequences that have been filed concurrently herewith as sequence listing text file "0398850pct.txt", file size of 351 KB, created on May 20, 2016. The aforementioned sequence listing is hereby incorporated by reference in its entirety pursuant to 37 C.F.R. § 1.52(e)(5).

BACKGROUND OF THE INVENTION

[0004] Drug inhibitors that target components of the mitogen-activated protein kinases (MAPK) signaling pathway show clinical efficacy in a variety of cancers, particularly those bearing mutations in the BRAF protein kinase. Both RAF and MEK

inhibitors are approved for single-agent use in advanced metastatic BRAF mutant melanoma. Either alone or in combination, BRAF and MEK inhibitor activity is unpredictable in other cancers, with promising efficacy in BRAF mutant thyroid and lung cancer, but only marginal activity in BRAF mutant colorectal cancer.

[0005] As with other targeted therapies, patterns of disease response to RAF and MEK inhibitors appear to be influenced by the intrinsic genetic heterogeneity present in the cancers where the drugs are used. For instance, it has been shown that certain genetic alterations, including PTEN and other changes that activate the PI3K cell growth signaling pathway, may predict a poor initial response, and/or relatively rapid progression, in BRAF mutant melanoma treated with the RAF inhibitor vemurafenib. Likewise, direct mutations in MEK gene loci appear to emerge in tumors that have progressed following either BRAF, MEK, or combined drug treatment. Several additional examples, from RAS and RAF gene amplification and splicing mutations, suggest that acquired drug resistance is produced when oncogenic pleiotropy encounters the selective pressure of targeted drug treatment.

[0006] In view of the foregoing, there is a need for novel targeted agents that would ideally inhibit diverse nodes of oncogenic pathways, and also be effective in combinations by inducing a burden of selective pressures that exceeds the adaptive capacity of diverse cancer genomes. The present application is directed to meeting these and other needs.

[0006a] Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general

knowledge in the field relevant to the present disclosure as it existed before the priority date of each of the appended claims.

[0006b] Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

SUMMARY OF THE INVENTION

[0006c] In one aspect, there is provided a method of treating a BRAF600 mutation-positive melanoma in a human, comprising administering between about 450 mg to about 600 mg BID of BVD-523 or a pharmaceutically acceptable salt thereof to the human.

[0006d] In another aspect, there is provided use of BVD-523 or a pharmaceutically acceptable salt thereof for treating a human having a BRAF600 mutation-positive melanoma, wherein the BVD-523 or pharmaceutically acceptable salt thereof is administered to the human at a dose of between about 450 mg to about 600 mg BID.

[0006e] In another aspect, there is provided use of BVD-523 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a BRAF600 mutation-positive melanoma in a human, wherein the medicament is formulated to administer between about 450 mg to about 600 mg BID of the BVD-523 or pharmaceutically acceptable salt thereof to the human.

[0007] One embodiment of the present invention is a method for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway inhibitor therapy. The method comprises

administering to the subject an effective amount of BVD-523 or a pharmaceutically acceptable salt thereof.

[0008] Another embodiment of the present invention is a method for treating or ameliorating the effects of a cancer in a subject. The method comprises:

- (a) identifying a subject with cancer that has become refractory or resistant to BRAF inhibitor therapy, MEK inhibitor therapy, or BRAF and MEK inhibitor therapy; and
- (b) administering to the subject with said refractory or resistant cancer an effective amount of an ERK inhibitor, which is BVD-523 or a pharmaceutically acceptable salt thereof.

[0009] A further embodiment of the present invention is a method for treating or ameliorating the effects of cancer in a subject, which cancer is refractory or resistant to BRAF inhibitor therapy, MEK inhibitor therapy, or both. The method comprises administering to the subject an effective amount of BVD-523 or a pharmaceutically acceptable salt thereof.

[0010] Another embodiment of the present invention is a method for identifying a subject having cancer who would benefit from therapy with an ERK inhibitor. The method comprises:

- (a) obtaining a biological sample from the subject; and
- (b) screening the sample to determine whether the subject has one or more of the following markers:
 - (i) a switch between RAF isoforms,
 - (ii) upregulation of receptor tyrosine kinase (RTK) or NRAS signaling,

- (iii) reactivation of mitogen activated protein kinase (MAPK) signaling,
- (iv) the presence of a MEK activating mutation,
- (v) amplification of mutant BRAF,
- (vi) STAT3 upregulation,
- (vii) mutations in the allosteric pocket of MEK that directly block binding of inhibitors to MEK or lead to constitutive MEK activity,

wherein the presence of one or more of the markers confirms that the subject's cancer is refractory or resistant to BRAF and/or MEK inhibitor therapy and that the subject would benefit from therapy with an ERK inhibitor, which is BVD-523 or a pharmaceutically acceptable salt thereof.

[0011] A further embodiment of the present invention is a pharmaceutical composition for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway therapy. The composition comprises a pharmaceutically acceptable carrier or diluent and an effective amount of BVD-523 or a pharmaceutically acceptable salt thereof.

[0012] Another embodiment of the present invention is a kit for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway therapy. The kit comprises any of the pharmaceutical compositions according to the present invention packaged together with instructions for its use.

[0013] Another embodiment of the present invention is a method for inhibiting phosphorylation of RSK in a cancer cell that is refractory or resistant to a non-ERK MAPK pathway inhibitor. The method comprises contacting the cancer cell with an

effective amount of BVD-523 or a pharmaceutically acceptable salt thereof for a period of time sufficient for phosphorylation of RSK in the cancer cell to be inhibited.

[0014] Another embodiment of the present invention is a method of treating a subject having an unresectable or metastatic BRAF600 mutation-positive melanoma comprising administering to the subject 600 mg BID of BVD-523 or a pharmaceutically acceptable salt thereof.

[0015] Another embodiment of the present invention is a composition for treating a subject having an unresectable or metastatic BRAF600 mutation-positive melanoma, the composition comprising 600 mg of BVD-523 or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier, adjuvant, or vehicle.

BRIEF DESCRIPTION OF THE DRAWINGS

[0016] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0017] FIG. 1A – FIG. 1C show the progress of a dose escalation study in a human malignant melanoma cell line (A375 cells) for month 1. Various treatments (trametinib (a type 2 MEK inhibitor), dabrafenib (a BRAF inhibitor), and BVD-523 (an ERK1/2 inhibitor)) are as labeled.

[0018] FIG. 2A – FIG. 2H show the results of a proliferation assay that tracks changes in sensitivity to the escalated agent(s) at month 1. Various treatments (trametinib, dabrafenib, BVD-523, and paclitaxel) are as labeled on the top of the graph. The caption to the right of the graph shows the various types of cells generated from the dose escalation study. For example, “dabrafenib” refers to the

cells that have been treated with the highest dose of dabrafenib from month 1 of the dose escalation study. Parental refers to the control cells that have not been treated with drugs. FIG. 2A, FIG. 2C and FIG. 2G are normalized to control, whereas FIG. 2D, FIG. 2F and FIG. 2H show the raw data.

[0019] FIG. 3A – FIG. 3D show the progress of a dose escalation study in A375 cells for month 2. Various treatments (trametinib, dabrafenib, and BVD-523) are as labeled.

[0020] FIG. 4A – FIG. 4H show the results of a proliferation assay that tracks changes in sensitivity to the escalated agent(s) at month 2. Various treatments (trametinib, dabrafenib, BVD-523, and paclitaxel) are as labeled on the top of the graph. The caption to the right of the graph shows the various types of cells generated from the dose escalation study. For example, “dabrafenib” refers to the cells that have been treated with the highest dose of dabrafenib from month 2 of the dose escalation study. Parental refers to the control cells that have not been treated with drugs. FIG. 4A, FIG. 4C and FIG. 4G are normalized to control, whereas FIG. 4D, FIG. 4F and FIG. 4H show the raw data.

[0021] FIG. 5A – FIG. 5H show only the parental and BVD-523 cell line data from FIG. 4A – FIG. 4H. Various treatments (trametinib, dabrafenib, BVD-523, and paclitaxel) are as labeled. FIG. 5A, FIG. 5C and FIG. 5G are normalized to control, whereas FIG. 5D, FIG. 5F and FIG. 5H show the raw data.

[0022] FIG. 6A – FIG. 6D show the progress of the dose escalation study in a human malignant cell line (A375 cells) for month 3. Various treatments (trametinib, dabrafenib, and BVD-523) are as labeled.

[0023] FIG. 7 is a histogram showing the results of a proliferation assay as applied to cells grown in the DMSO control wells from the dose escalation assay.

[0024] FIG. 8A – FIG. 8D are a set of line graphs showing proliferation assays for month 3 of the study. Various treatments (trametinib, dabrafenib, BVD-523, and paclitaxel) are as labeled on the top of the graph. The caption to the right of the graph shows the various types of cells generated from the dose escalation study. For example, “dabrafenib” refers to the cells that have been treated with the highest dose of dabrafenib from month 3 of the dose escalation study. Parental refers to the control cells that have not been treated with drugs.

[0025] FIG. 9A – FIG. 9D show only the parental, dabrafenib, and BVD-523 cell line data from FIG. 8A – FIG. 8D.

[0026] FIG. 10A is a dose matrix showing % inhibition of the trametinib/dabrafenib combination in A375 cells using the Alamar Blue cell viability assay. FIG. 10B is a dose matrix showing excess over Bliss for the trametinib/dabrafenib combination. FIG. 10C and FIG. 10D show % viability relative to DMSO only treated controls for dabrafenib and trametinib single agent treatments in A375 cells using the Alamar Blue cell viability assay. FIG. 10E shows % viability relative to DMSO only treated controls for dabrafenib and trametinib combination treatments in A375 cells using the Alamar Blue cell viability assay.

[0027] FIG. 11A is a dose matrix showing % inhibition of the trametinib/dabrafenib combination in A375 cells using the CellTiter-Glo cell viability assay. FIG. 11B is a dose matrix showing excess over Bliss for the trametinib/dabrafenib combination. FIG. 11C and FIG. 11D show % viability relative to DMSO only treated controls for dabrafenib and trametinib single agent treatments in A375 cells using the CellTiter-Glo cell viability assay. FIG. 11E shows % viability relative to DMSO only treated controls for dabrafenib and trametinib combination treatments in A375 cells using the CellTiter-Glo cell viability assay.

[0028] FIG. 12A is a dose matrix showing % inhibition of the BVD-523/dabrafenib combination in A375 cells using the Alamar Blue cell viability assay. FIG. 12B is a dose matrix showing excess over Bliss for the BVD-523/dabrafenib combination. FIG. 12C and FIG. 12D show % viability relative to DMSO only treated controls for dabrafenib and BVD-523 single agent treatments in A375 cells using the Alamar Blue cell viability assay. FIG. 12E shows % viability relative to DMSO only treated controls for dabrafenib and BVD-523 combination treatments in A375 cells using the Alamar Blue cell viability assay.

[0029] FIG. 13A is a dose matrix showing % inhibition of the BVD-523/dabrafenib combination in A375 cells using the CellTiter-Glo cell viability assay. FIG. 13B is a dose matrix showing excess over Bliss for the BVD-523/dabrafenib combination. FIG. 13C and FIG. 13D show % viability relative to DMSO only treated controls for dabrafenib and BVD-523 single agent treatments in A375 cells using the CellTiter-Glo cell viability assay. FIG. 13E shows % viability relative to DMSO only treated controls for dabrafenib and BVD-523 combination treatments in A375 cells using the CellTiter-Glo cell viability assay.

[0030] FIG. 14A is a dose matrix showing % inhibition of the trametinib/BVD-523 combination in A375 cells using the Alamar Blue cell viability assay. FIG. 14B is a dose matrix showing excess over Bliss for the trametinib/BVD-523 combination. FIG. 14C and FIG. 14D show % viability relative to DMSO only treated controls for BVD-523 and trametinib single agent treatments in A375 cells using the Alamar Blue cell viability assay. FIG. 14E shows % viability relative to DMSO only treated controls for BVD-523 and trametinib combination treatments in A375 cells using the Alamar Blue cell viability assay.

[0031] FIG. 15A is a dose matrix showing % inhibition of the trametinib/BVD-523 combination in A375 cells using the CellTiter-Glo cell viability assay. FIG. 15B is a dose matrix showing excess over Bliss for the trametinib/BVD-523 combination. FIG. 15C and FIG. 15D show % viability relative to DMSO only treated controls for BVD-523 and trametinib single agent treatments in A375 cells using the CellTiter-Glo cell viability assay. FIG. 15E shows % viability relative to DMSO only treated controls for BVD-523 and trametinib combination treatments in A375 cells using the CellTiter-Glo cell viability assay.

[0032] FIG. 16A – FIG. 16D are a set of images showing Western blot analysis of MAPK signaling in A375 cells after a 4 hour treatment with various concentrations (in nM) of BVD-523, dabrafenib (Dab), and Trametinib (Tram). 40 µg of total protein was loaded in each lane except where indicated otherwise. In this experiment, duplicate samples were collected. FIG. 16A and FIG. 16B show results from duplicate samples. Similarly, FIG. 16C and FIG. 16D also show results from duplicate samples. In FIG. 16A and FIG. 16B, pRSK1 had a relatively weak signal in A375 cells compared to other markers. A different pRSK1-S380 antibody from Cell Signaling (cat. #11989) was tested but did not give a detectable signal (data not shown). In FIG. 16C and FIG. 16D, pCRAF-338 gave a minimal signal.

[0033] FIG. 17A – FIG. 17D are a set of images showing Western blot analysis of MAPK signaling in a human colorectal carcinoma cell line (HCT116 cells) after a 4 hour treatment with various concentrations (in nM) of BVD-523, dabrafenib (Dab), and Trametinib (Tram). 40 µg of total protein was loaded in each lane except where indicated otherwise. In this experiment, duplicate samples were collected. FIG. 17A and FIG. 17B show results from duplicate samples. Similarly, FIG. 17C and FIG. 17D also show results from duplicate samples. In FIG. 17A and FIG. 17B,

pRSK1 levels appear to be very low in HCT116 cells, and in FIG. 17C and FIG. 17D, pCRAF-338 signal was also very weak.

[0034] FIG. 18A – FIG. 18D are a set of images showing Western blot analysis of cell cycle and apoptosis signaling in A375 melanoma cells after a 24 hour treatment with various concentrations (in nM) of BVD-523 (“BVD523”), trametinib (“tram”) and/or dabrafenib (“Dab”) as labelled. 50 µg of total protein was loaded in each lane except where indicated otherwise. In this experiment, duplicate samples were collected. FIG. 18A and FIG. 18B show results from duplicate samples. Similarly, FIG. 18C and FIG. 18D also show results from duplicate samples. In FIG. 18A and FIG. 18B, no band of a size corresponding to cleaved PARP (89 kDa) was apparent.

[0035] FIG. 19 shows that BVD-523 can treat acquired resistance to targeted drugs *in-vivo*. A patient-derived line, ST052C, was isolated from a BRAFV600E melanoma patient that progressed following 10 months of therapy with MAPK-pathway directed therapies. Treated *ex vivo*, ST052C exhibited acquired cross-resistance to dabrafenib at 50 mg/kg BID. Meanwhile, BVD-523 was effective in ST052C as a single-agent at 100 mg/kg BID.

[0036] FIG. 20 is a flowchart showing the dose escalation protocol used herein.

[0037] FIG. 21 shows a schematic of the mitogen-activated protein kinases (MAPK) pathway.

[0038] FIG. 22A – FIG. 22E show the results of single agent proliferation assays. Proliferation results are shown for treatment with BVD-523 (FIG. 22A), SCH772984 (FIG. 22B), Dabrafenib (FIG. 22C), Trametinib (FIG. 22D), and Paclitaxel (FIG. 22E).

[0039] FIG. 23A – FIG. 23O show the results of the combination of BVD-523 and Dabrafenib. FIG. 23A shows a dose matrix showing inhibition (%) for the combination in RKO parental cells. FIG. 23B – FIG. 23C show the results of single agent proliferation assays for the combination in FIG. 23A. FIG. 23D shows Loewe excess for the combination in FIG. 23A and FIG. 23E shows Bliss excess for the combination in FIG. 23A. FIG. 23F shows a dose matrix showing inhibition (%) for the combination in RKO MEK1 (Q56P/+) – clone 1 cells. FIG. 23G – FIG. 23H show the results of single agent proliferation assays for the combination in FIG. 23F. FIG. 23I shows Loewe excess for the combination in FIG. 23F and FIG. 23J shows Bliss excess for the combination in FIG. 23F. FIG. 23K shows a dose matrix showing inhibition (%) for the combination in RKO MEK1 (Q56P/+) – clone 2 cells. FIG. 23L – FIG. 23M show the results of single agent proliferation assays for the combination in FIG. 23K. FIG. 23N shows Loewe excess for the combination in FIG. 23K and FIG. 23O shows Bliss excess for the combination in FIG. 23K.

[0040] FIG. 24A – FIG. 24O show the results of the combination of SCH772984 and Dabrafenib. FIG. 24A shows a dose matrix showing inhibition (%) for the combination in RKO parental cells. FIG. 24B – FIG. 24C show the results of single agent proliferation assays for the combination in FIG. 24A. FIG. 24D shows Loewe excess for the combination in FIG. 24A and FIG. 24E shows Bliss excess for the combination in FIG. 24A. FIG. 24F shows a dose matrix showing inhibition (%) for the combination in RKO MEK1 (Q56P/+) – clone 1 cells. FIG. 24G – FIG. 24H show the results of single agent proliferation assays for the combination in FIG. 24F. FIG. 24I shows Loewe excess for the combination in FIG. 24F and FIG. 24J shows Bliss excess for the combination in FIG. 24F. FIG. 24K shows a dose matrix showing inhibition (%) for the combination in RKO MEK1 (Q56P/+) – clone 2 cells.

FIG. 24L – FIG. 24M show the results of single agent proliferation assays for the combination in FIG. 24K. FIG. 24N shows Loewe excess for the combination in FIG. 24K and FIG. 24O shows Bliss excess for the combination in FIG. 24K.

[0041] FIG. 25A – FIG. 25O show the results of the combination of Trametinib and Dabrafenib. FIG. 25A shows a dose matrix showing inhibition (%) for the combination in RKO parental cells. FIG. 25B – FIG. 25C show the results of single agent proliferation assays for the combination in FIG. 25A. FIG. 25D shows Loewe excess for the combination in FIG. 25A and FIG. 25E shows Bliss excess for the combination in FIG. 25A. FIG. 25F shows a dose matrix showing inhibition (%) for the combination in RKO MEK1 (Q56P/+) – clone 1 cells. FIG. 25G – FIG. 25H show the results of single agent proliferation assays for the combination in FIG. 25F. FIG. 25I shows Loewe excess for the combination in FIG. 25F and FIG. 25J shows Bliss excess for the combination in FIG. 25F. FIG. 25K shows a dose matrix showing inhibition (%) for the combination in RKO MEK1 (Q56P/+) – clone 2 cells. FIG. 25L – FIG. 25M show the results of single agent proliferation assays for the combination in FIG. 25K. FIG. 25N shows Loewe excess for the combination in FIG. 25K and FIG. 25O shows Bliss excess for the combination in FIG. 25K.

[0042] FIG. 26A shows Low Volumes for the combinations tested. FIG. 26B shows Bliss Volumes for the combinations tested. FIG. 26C shows Synergy Scores for the combinations tested.

[0043] FIG. 27A – FIG. 27I show the changes in MAPK and Effector Pathway Signaling in MEK acquired resistance. Isogenic RKO parental and MEK1 (Q56P/+) cells were treated with compound for 4 or 24h and then immuno-blotted with the indicated antibodies. Dabrafenib was the BRAF inhibitor and trametinib was the MEK inhibitor. FIG. 27A shows increased signaling in RKO MEK1 (Q56P/+) cells. FIG.

27B – FIG. 27C show the results of a 4 hour treatment in Experiment 1 (See, Example 7) in RKO Parental (27B) and RKO MEK1 (Q56P/+) (27C) cells. FIG. 27D – FIG. 27E show the results of a 4 hour treatment in Experiment 2 (See, Example 7) in RKO Parental (27D) and RKO MEK1 (Q56P/+) (27E) cells. FIG. 27F – FIG. 27G show the results of a 4 hour treatment in Experiment 2 (See, Example 7) in RKO Parental (27F) and RKO MEK1 (Q56P/+) (27G) cells. FIG. 27H – FIG. 27I show a summary of results in RKO Parental (27H) and RKO MEK1 (Q56P/+) (27I) cells.

[0044] FIG. 28A – FIG. 28E show the results of the combination of BVD-523 and SCH772984. FIG. 28A shows a dose matrix showing inhibition (%) for the combination in A375 cells. FIG. 28B – FIG. 28C show the results of single agent proliferation assays for the combination in FIG. 28A. FIG. 28D shows Loewe excess for the combination in FIG. 28A and FIG. 28E shows Bliss excess for the combination in FIG. 28A.

[0045] FIG. 29A – FIG. 29F show discovery and characterization of the novel ERK1/2 inhibitor BVD-523 (ulixertinib). FIG. 29A shows that BVD-523 demonstrates inhibition in a reversible ATP-competitive manner. This is demonstrated by a linear increase in IC_{50} values for inhibition of ERK2 with increasing ATP concentration as shown in FIG. 29B. FIG. 29C shows a representative plot of the dose-response curve and FIG. 29D shows a plot of IC_{50} over time. FIG. 29E shows BVD-523 binding to ERK2 and phospho-ERK2 (pERK2), compared with negative control protein p38. FIG. 29F shows BVD-523 binding to ERK2 compared with the ERK inhibitors SCH772984 and pyrazolylpyrrole.

[0046] FIG. 30A – FIG. 30D show that BVD 523 inhibits cellular proliferation and enhances caspase 3 and caspase 7 activity *in vitro*. FIG. 30A shows that BVD-523 demonstrates preferential activity in cells with MAPK pathway mutations, as

defined by the presence of mutations in *RAS* family members and *RAF*. In addition, as shown in FIG. 30B, BVD-523 blocks sensitive cell lines in the G1 phase of the cell cycle. FIG. 30C shows that BVD-523 induced a concentration- and time-dependent increase in caspase activity in the A375, WM266, and LS411N cancer cell lines after 72 hours of exposure. FIG. 30D shows that the MAPK pathway and effector proteins are modulated by acute (4-hour) and prolonged (24-hour) BVD-523 treatment in *BRAF*^{V600E}-mutant A375 cells.

[0047] FIG. 31A – FIG. 31C show *in vivo* BVD-523 anti-tumor activity. BVD-523 monotherapy inhibits tumor growth in (FIG. 31A) A375 and (FIG. 31B) Colo205 cell line xenograft models (^a*P*<0.0001, compared with vehicle control; CPT-11 dosed on Day 14 and Day 18 only). Abbreviations: BID, twice daily; CMC, carboxymethylcellulose; QD, every day; Q4D, every 4 days. FIG. 31C shows that in Colo205 xenografts, increased ERK1/2 phosphorylation correlates with BVD-523 concentration.

[0048] FIG. 32A shows signaling effects of ERK1/2 inhibitors. Using RPPA, effects on proteins are measured in cell lines (A375, AN3Ca, Colo205, HCT116, HT29 and MIAPaca2) following treatment with ERK1/2 inhibitors BVD-523 (BVD), Vx11e (Vx), GDC-0994 (GDC), or SCH722984 (SCH). FIG. 32B shows that the ERK inhibitors BVD-523, GDC-0994, and Vx11e have differential effects on phospho-ERK (ERK 1/2 T202 Y204) compared with SCH722984; phospho-RSK (p90 RSK 380) and Cyclin D1 are inhibited by the ERK inhibitors tested. Abbreviations: BRAFi, BRAF inhibitors; MEKi, MEK inhibitors. FIG. 32C shows a western blot assay of cellular and nuclear fractions from a RKO cell line following treatment with BVD-523, trametinib, SCH722984, or dabrafenib. Histone H3 (nuclear localized protein) and HSP90 (cytoplasmically localized protein) were included as positive controls to

confirm that the nuclear and cytoplasmic fractions were properly enriched; nuclear fractions have high H3 and cytoplasmic fractions have higher HSP90.

[0049] FIG. 33 shows that the ERK inhibitors BVD-523, Vx11, GDC-0994, and SCH772984 (SCH) demonstrate cell line-dependent changes in phospho-ATK levels. Abbreviation: DMSO, dimethyl sulfoxide.

[0050] FIG. 34A – FIG. 34D show that BVD-523 demonstrates activity in models of resistance to BRAF/MEK inhibition. The appearance of resistance to BVD-523, dabrafenib, or trametinib in *BRAF*^{V600E} A375 cells following exposure to increasing concentrations of drug is indicated. A strict set of “criteria” was applied to determine when the dose could be increased in order to ensure that the kinetics of the acquisition of resistance between treatments was comparable. See, Example 1. Time is shown against multipliers of IC₅₀; each point on the plotted line represents a change of medium or cell split. FIG. 34A shows that adapting cells to growth in the presence of BVD-523 was more challenging than with either dabrafenib or trametinib. FIG. 34B shows that BVD-523 sensitivity is retained in A375 cells cultured to acquire resistance to combined BRAF (dabrafenib) + MEK (trametinib) inhibition. In FIG. 34C, cells were treated with compound for 96 h and viability was assessed using CellTiter-Glo[®]. BVD-523 activity is retained in *BRAF*^{V600E} RKO cells cross-resistant to BRAF (dabrafenib) and MEK (trametinib) inhibitors due to endogenous heterozygous knock-in of *MEK1*^{Q56P}. FIG. 34D shows that BVD-523 inhibition of pRSK in *BRAF*^{V600E}-mutant cell line RKO is maintained in the presence of *MEK1*^{Q56P}, which confers resistance to MEK and BRAF inhibition. Knock-in of *KRAS* mutant alleles into SW48 cell lines significantly diminishes sensitivity to the MEK inhibitors trametinib and selumetinib, while comparatively sensitivity to BVD-523 is retained.

[0051] FIG. 35A shows BVD-523 *in vivo* activity in xenografts derived from a vemurafenib-relapsed patient. Mean tumor volume ($\pm$ SEM) is shown for BVD-523 100 mg/kg BID alone, dabrafenib 50 mg/kg BID alone, and BVD-523 100 mg/kg BID plus dabrafenib 50 mg/kg BID. Abbreviations: BID, twice daily; SEM, standard error of mean.

[0052] FIG. 36A – FIG. 36D show the benefit of combined BVD-523 and BRAF inhibition. FIG. 36A – FIG. 36B show that the combination of BVD-523 plus dabrafenib exhibited superior antitumor activity compared with treatment with either agent alone in a A375 *BRAF*^{V600E}-mutant melanoma cell line xenograft model with a tumor start volume of 75-144 mm³. FIG. 36C – FIG. 36D show similar data from the same model with an enlarged tumor volume (700 -800 mm³) at the start of dosing. Plots of mean tumor growth (left panels) and Kaplan-Meier survival (right panels) are presented for each study. Abbreviations: BID, twice daily; QD, once daily.

[0053] FIG. 37A shows that, in SW48 colorectal cells engineered with *KRAS* alleles, response to paclitaxel was unaltered compared to control. FIG. 37B shows combination interactions between BVD-523 and vemurafenib, which were assessed using an 8 × 10 matrix of concentrations using the Loewe Additivity and Bliss Independence Models, and analyzed with Horizon's Chalice, Bioinformatics Software. Chalice enables potential synergistic interactions to be identified by displaying the calculated excess inhibition over that predicted as being additive across the dose matrix as a heat map, and by reporting a quantitative "Synergy Score" based on the Loewe model. The results suggest that interactions between BVD-523 and vemurafenib are at least additive, and in some cases synergistic in melanoma cell lines carrying a *BRAF*^{V600E} mutation. FIG. 37C shows that BVD-523 in combination with dabrafenib markedly delays the onset of acquired resistance in

A375 *BRAF*^{V600E} melanoma cells. The temporal acquisition of resistance in response to escalating concentrations of dabrafenib alone or in combination with BVD-523 or trametinib was assessed. Strict criteria were applied as to when the dose could be increased to ensure that the kinetics of adaptation was comparable between treatments. See, Example 1.

[0054] FIG. 38 shows that BVD-523 inhibits *ex vivo* PMA-stimulated RSK1/2 phosphorylation in human whole blood. Averages of BVD-523 concentration data set are indicated by (—). *n* = 20 for each concentration of BVD-523. Abbreviations: PBMC, peripheral blood mononuclear cells; RSK, ribosomal S6 kinase.

[0055] FIG. 39A shows steady-state BVD-523 pharmacokinetics (Cycle 1, Day 15). The dashed red line indicates an EC₅₀ 200 ng/mL HWB. Abbreviations: AUC, area under the curve; BID, twice daily; C_{max}, maximum concentration; EC₅₀, 50% maximum effective concentration; HWB, human whole blood; SD, standard deviation. FIG. 39B shows pharmacodynamic inhibition of ERK phosphorylation by BVD-523 in human whole blood. Abbreviations: BID, twice daily; pRSK, phospho-RSK; RSK, ribosomal S6 kinase.

[0056] FIG. 40A shows the best radiographic response in patients treated with BVD-523. Included are all patients with disease measured by RECIST v1.1 who received ≥1 dose of study treatment and had >1 on-treatment tumor assessment (25/27; 2 did not receive both scans of target lesions). Response was measured as the change from baseline in the sum of the longest diameter of each target lesion. Dose shown is that which the patient was receiving at the time of response. The dashed line indicates the threshold for a partial response according to RECIST v1.1. Abbreviations: CRC, colorectal cancer; NET, neuroendocrine tumors; NSCLC, non-small cell lung cancer; NSGCT, nonseminomatous germ cell tumors; PNET,

pancreatic NET; PTC, papillary thyroid cancer; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1; SLD, sum of the largest diameter. FIG. 40B shows a computerized tomography scan of a confirmed partial response in a 61-year-old patient with a *BRAF*-mutant melanoma treated with BVD-523.

[0057] FIG. 41 shows tumor response and tumor progression. Shown is a swimmer plot of tumor response, tumor progression, and duration of treatment in response-evaluable patients treated with BVD-523. Origin of the vertical axis corresponds to randomization date or reference start date. Analysis cut-off date: December 1, 2015. Abbreviation: BID, twice daily.

DETAILED DESCRIPTION OF THE INVENTION

[0058] One embodiment of the present invention is a method for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway inhibitor therapy. The method comprises administering to the subject an effective amount of BVD-523 or a pharmaceutically acceptable salt thereof.


[0059] As used herein, the terms "treat," "treating," "treatment" and grammatical variations thereof mean subjecting an individual subject to a protocol, regimen, process or remedy, in which it is desired to obtain a physiologic response or outcome in that subject, e.g., a patient. In particular, the methods and compositions of the present invention may be used to slow the development of disease symptoms or delay the onset of the disease or condition, or halt the progression of disease development. However, because every treated subject may not respond to a particular treatment protocol, regimen, process or remedy, treating

does not require that the desired physiologic response or outcome be achieved in each and every subject or subject population, e.g., patient population. Accordingly, a given subject or subject population, e.g., patient population may fail to respond or respond inadequately to treatment.

[0060] As used herein, the terms “ameliorate”, “ameliorating” and grammatical variations thereof mean to decrease the severity of the symptoms of a disease in a subject.

[0061] As used herein, a “subject” is a mammal, preferably, a human. In addition to humans, categories of mammals within the scope of the present invention include, for example, farm animals, domestic animals, laboratory animals, etc. Some examples of farm animals include cows, pigs, horses, goats, etc. Some examples of domestic animals include dogs, cats, etc. Some examples of laboratory animals include primates, rats, mice, rabbits, guinea pigs, etc.

[0062] In the present invention, BVD-523 corresponds to a compound according to formula (I):



and pharmaceutically acceptable salts thereof. BVD-523 may be synthesized according to the methods disclosed, *e.g.*, in U.S. Patent No. 7,354,939. Enantiomers

and racemic mixtures of both enantiomers of BVD-523 are also contemplated within the scope of the present invention. BVD-523 is an ERK1/2 inhibitor with a mechanism of action that is believed to be, e.g., unique and distinct from certain other ERK1/2 inhibitors, such as SCH772984 and the pyrimidinal structure used by Hatzivassiliou et al. (2012). For example, other ERK1/2 inhibitors, such as SCH772984, inhibit autophosphorylation of ERK (Morris et al., 2013), whereas BVD-523 allows for the autophosphorylation of ERK while still inhibiting ERK. (See, e.g., FIG. 18).

[0063] As used herein, the words “resistant” and “refractory” are used interchangeably. Being “resistant” to non-ERK MAPK pathway inhibitor therapy treatments means that non-ERK MAPK inhibitors have reduced efficacy in treating cancer.



[0064] As used herein, a “non-ERK MAPK inhibitor” means any substance that reduces the activity, expression or phosphorylation of proteins or other members of the MAPK pathway that results in a reduction of cell growth or an increase in cell death, with the exception of ERK1/2 inhibitors. As used herein, an “ERK1/2 inhibitor” means those substances that (i) directly interact with ERK1 and/or ERK2, e.g., by binding to ERK1/2 and (ii) decrease the expression or the activity of ERK1 and/or ERK2 protein kinases. Therefore, inhibitors that act upstream of ERK1/2, such as MEK inhibitors and RAF inhibitors, are not ERK1/2 inhibitors according to the present invention (but they are non-ERK MAPK inhibitors). Non-limiting examples of ERK1/2 inhibitors according to the present invention include AEZS-131 (Aeterna Zentaris), AEZS-136 (Aeterna Zentaris), BVD-523 (BioMed Valley Discoveries, Inc.), SCH-722984 (Merck & Co.), SCH-772984 (Merck & Co.), SCH-900353 (MK-8353) (Merck & Co.), pharmaceutically acceptable salts thereof, and combinations thereof.





[0065] An overview of the mammalian MAPK cascades is shown in FIG. 21. The MAPK pathway is reviewed in *e.g.*, Akinleye et al., 2013. Briefly, with respect to the ERK1/2 module in FIG. 21 (light purple box), the MAPK 1/2 signaling cascade is activated by ligand binding to receptor tyrosine kinases (RTK). The activated receptors recruit and phosphorylate adaptor proteins Grb2 and SOS, which then interact with membrane-bound GTPase Ras and cause its activation. In its activated GTP-bound form, Ras recruits and activates RAF kinases (A-RAF, B-RAF, and C-RAF/RAF-1). The activated RAF kinases activate MAPK 1/2 (MKK1/2), which in turn catalyzes the phosphorylation of threonine and tyrosine residues in the activation sequence Thr-Glu-Tyr of ERK1/2. With respect to the JNK/p38 module (yellow box in FIG. 21), upstream kinases, MAP3Ks, such as MEKK1/4, ASK1/2, and MLK1/2/3, activate MAP2K3/6 (MKK3/6), MAP2K4 (MKK4), and MAP2K7 (MKK7). These MAP2K's then activate JNK protein kinases, including JNK1, JNK2, and JNK3, as well as p38 $\alpha/\beta/\gamma/\delta$. To execute their functions, JNKs activate several transcription factors, including c-Jun, ATF-2, NF-ATc1, HSF-1 and STAT3. With respect to the ERK5 module (blue box in FIG. 21), the kinases upstream of MAP2K5 (MKK5) are MEKK2 and MEKK3. The best characterized downstream target of MEK5 is ERK5, also known as big MAP kinase 1 (BMK1) because it is twice the size of other MAPKs.


[0066] Non-limiting examples of non-ERK MAPK pathway inhibitors according to the present invention include RAS inhibitors, RAF inhibitors (such as, *e.g.*, inhibitors of A-RAF, B-RAF, C-RAF (RAF-1)), MEK inhibitors, and combinations thereof. Preferably, the non-ERK MAPK pathway inhibitors are BRAF inhibitors, MEK inhibitors, and combinations thereof.

[0067] As used herein, a “RAS inhibitor” means those substances that (i) directly interact with RAS, *e.g.*, by binding to RAS and (ii) decrease the expression or the activity of RAS. Non-limiting exemplary RAS inhibitors include, but are not limited to, farnesyl transferase inhibitors (such as, *e.g.*, tipifarnib and lonafarnib), farnesyl group-containing small molecules (such as, *e.g.*, salirasib and TLN-4601), DCAI, as disclosed by Maurer (Maurer *et al.*, 2012), Kobe0065 and and Kobe2602, as disclosed by Shima (Shima *et al.*, 2013), HBS 3 (Patgiri *et al.*, 2011), and AIK-4 (Allinky).

[0068] As used herein, a “RAF inhibitor” means those substances that (i) directly interact with RAF, *e.g.*, by binding to RAF and (ii) decrease the expression or the activity of RAF, such as, *e.g.*, A-RAF, B-RAF, and C-RAF (RAF-1). Non-limiting exemplary RAF inhibitors, including BRAF inhibitors, include:









Compound 16

(Id.),




Compound 18

(Id.),




Compound 19

(Id.),




Compound 20

(Id.),




Compound 21

(Id.),




Compound 22

(Id.),




Compound 23

(Id.),




Compound 24

(Id.), Compound




25

(Id.), Compound 26




(Id.), Compound 27




(Id.),

Compound 28




(Id.),

Compound 30




(Id.),

Compound 31




(Id.),

Compound 32




(Id.),




Compound 33

(Id.),




Compound 34

(Id.),




Compound 35

(Id.),




Compound 36

(Id.),




Compound 37

(Id.),




Compound 38

(Id.),



Compound 39

(Id.),



Compound 40

(Id.),

AAL881 (Novartis); AB-024 (Ambit Biosciences), ARQ-736 (ArQule), ARQ-761 (ArQule), AZ628 (Axon Medchem BV), BeiGene-283 (BeiGene), BIIB-024 (MLN 2480) (Sunesis & Takeda), b-raf inhibitor (Sareum), BRAF kinase inhibitor (Selexagen Therapeutics), BRAF siRNA 313 (tacaccagcaagctagatgca) and 523 (cctatcgtagagtcttctctg) (Liu *et al.*, 2007), CTT239065 (Institute of Cancer Research), dabrafenib (GSK2118436), DP-4978 (Deciphera Pharmaceuticals), HM-95573 (Hanmi), GDC-0879 (Genentech), GW-5074 (Sigma Aldrich), ISIS 5132 (Novartis), L779450 (Merck), LBT613 (Novartis), LErafAON (NeoPharm, Inc.), LGX-818 (Novartis), pazopanib (GlaxoSmithKline), PLX3202 (Plexxikon), PLX4720 (Plexxikon), PLX5568 (Plexxikon), RAF-265 (Novartis), RAF-365 (Novartis), regorafenib (Bayer Healthcare Pharmaceuticals, Inc.), RO 5126766 (Hoffmann-La

Roche), SB-590885 (GlaxoSmithKline), SB699393 (GlaxoSmithKline), sorafenib (Onyx Pharmaceuticals), TAK 632 (Takeda), TL-241 (Teligene), vemurafenib (RG7204 or PLX4032) (Daiichi Sankyo), XL-281 (Exelixis), ZM-336372 (AstraZeneca), pharmaceutically acceptable salts thereof, and combinations thereof.

[0069] As used herein, a “MEK inhibitor” means those substances that (i) directly interact with MEK, e.g., by binding to MEK and (ii) decrease the expression or the activity of MEK. Thus, inhibitors that act upstream of MEK, such as RAS inhibitors and RAF inhibitors, are not MEK inhibitors according to the present invention. Non-limiting examples of MEK inhibitors include anthrax toxin, antroquinonol (Golden Biotechnology), ARRY-142886 (6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide) (Array BioPharma), ARRY-438162 (Array BioPharma), AS-1940477 (Astellas), AS-703988 (Merck KGaA), bentamapimod (Merck KGaA), BI-847325 (Boehringer Ingelheim), E-6201 (Eisai), GDC-0623 (Hoffmann-La Roche), GDC-0973 (cobimetinib) (Hoffmann-La Roche), L783277 (Merck), lethal factor portion of anthrax toxin, MEK162 (Array BioPharma), PD 098059 (2-(2'-amino-3'-methoxyphenyl)-oxanaphthalen-4-one) (Pfizer), PD 184352 (CI-1040) (Pfizer), PD-0325901 (Pfizer), pimasertib (Santhera Pharmaceuticals), RDEA119 (Ardea Biosciences/Bayer), refametinib (AstraZeneca), RG422 (Chugai Pharmaceutical Co.), RO092210 (Roche), RO4987655 (Hoffmann-La Roche), RO5126766 (Hoffmann-La Roche), selumetinib (AZD6244) (AstraZeneca), SL327 (Sigma), TAK-733 (Takeda), trametinib (Japan Tobacco), U0126 (1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene) (Sigma), WX-554 (Wilex), YopJ polypeptide (Mittal *et al.*, 2010), pharmaceutically acceptable salts thereof, and combinations thereof.

[0070] In one aspect of this embodiment, substantially all phosphorylation of ribosomal s6 kinase (RSK) is inhibited after administration of BVD-523 or a pharmaceutically acceptable salt thereof. As used herein in the context of RSK phosphorylation, “substantially all” means a reduction of greater than 50% reduction, preferably greater than 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% reduction.

[0071] In another aspect of this embodiment, the cancer has MAPK activity. As used herein, having “MAPK activity” means that proteins downstream of ERK are still active, even if proteins upstream of ERK may not be active. Such a cancer may be a solid tumor cancer or a hematologic cancer.

[0072] In the present invention, cancers include both solid and hemotologic cancers. Non-limiting examples of solid cancers include adrenocortical carcinoma, anal cancer, bladder cancer, bone cancer (such as osteosarcoma), brain cancer, breast cancer, carcinoid cancer, carcinoma, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, extrahepatic bile duct cancer, Ewing family of cancers, extracranial germ cell cancer, eye cancer, gallbladder cancer, gastric cancer, germ cell tumor, gestational trophoblastic tumor, head and neck cancer, hypopharyngeal cancer, islet cell carcinoma, kidney cancer, large intestine cancer, laryngeal cancer, leukemia, lip and oral cavity cancer, liver tumor/cancer, lung tumor/cancer, lymphoma, malignant mesothelioma, Merkel cell carcinoma, mycosis fungoides, myelodysplastic syndrome, myeloproliferative disorders, nasopharyngeal cancer, neuroblastoma, oral cancer, oropharyngeal cancer, osteosarcoma, ovarian epithelial cancer, ovarian germ cell cancer, pancreatic cancer, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pituitary cancer, plasma cell neoplasm, prostate cancer, rhabdomyosarcoma, rectal cancer, renal cell cancer,

transitional cell cancer of the renal pelvis and ureter, salivary gland cancer, Sezary syndrome, skin cancers (such as cutaneous t-cell lymphoma, Kaposi's sarcoma, mast cell tumor, and melanoma), small intestine cancer, soft tissue sarcoma, stomach cancer, testicular cancer, thymoma, thyroid cancer, urethral cancer, uterine cancer, vaginal cancer, vulvar cancer, and Wilms' tumor.

[0073] Examples of hematologic cancers include, but are not limited to, leukemias, such as adult/childhood acute lymphoblastic leukemia, adult/childhood acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and hairy cell leukemia, lymphomas, such as AIDS-related lymphoma, cutaneous T-cell lymphoma, adult/childhood Hodgkin lymphoma, mycosis fungoides, adult/childhood non-Hodgkin lymphoma, primary central nervous system lymphoma, Sézary syndrome, cutaneous T-cell lymphoma, and Waldenstrom macroglobulinemia, as well as other proliferative disorders such as chronic myeloproliferative disorders, Langerhans cell histiocytosis, multiple myeloma/plasma cell neoplasm, myelodysplastic syndromes, and myelodysplastic/myeloproliferative neoplasms.

[0074] Preferably, the cancer is selected from the group consisting of a cancer of the large intestine, breast cancer, pancreatic cancer, skin cancer, and endometrial cancers. More preferably, the cancer is melanoma.

[0075] In another aspect of this embodiment, the method further comprises administering to the subject at least one additional therapeutic agent effective for treating or ameliorating the effects of the cancer. The additional therapeutic agent may be selected from the group consisting of an antibody or fragment thereof, a cytotoxic agent, a toxin, a radionuclide, an immunomodulator, a photoactive

therapeutic agent, a radiosensitizing agent, a hormone, an anti-angiogenesis agent, and combinations thereof.

[0076] As used herein, an "antibody" encompasses naturally occurring immunoglobulins as well as non-naturally occurring immunoglobulins, including, for example, single chain antibodies, chimeric antibodies (e.g., humanized murine antibodies), and heteroconjugate antibodies (e.g., bispecific antibodies). Fragments of antibodies include those that bind antigen, (e.g., Fab', F(ab')₂, Fab, Fv, and rIgG). See also, e.g., Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, Ill.); Kuby, J., Immunology, 3rd Ed., W.H. Freeman & Co., New York (1998). The term antibody also includes bivalent or bispecific molecules, diabodies, triabodies, and tetrabodies. The term "antibody" further includes both polyclonal and monoclonal antibodies.

[0077] Examples of therapeutic antibodies that may be used in the present invention include rituximab (Rituxan), Cetuximab (Erbix), bevacizumab (Avastin), and Ibritumomab (Zevalin).

[0078] Cytotoxic agents according to the present invention include DNA damaging agents, antimetabolites, anti-microtubule agents, antibiotic agents, etc. DNA damaging agents include alkylating agents, platinum-based agents, intercalating agents, and inhibitors of DNA replication. Non-limiting examples of DNA alkylating agents include cyclophosphamide, mechlorethamine, uramustine, melphalan, chlorambucil, ifosfamide, carmustine, lomustine, streptozocin, busulfan, temozolomide, pharmaceutically acceptable salts thereof, prodrugs, and combinations thereof. Non-limiting examples of platinum-based agents include cisplatin, carboplatin, oxaliplatin, nedaplatin, satraplatin, triplatin tetranitrate, pharmaceutically acceptable salts thereof, prodrugs, and combinations thereof.

Non-limiting examples of intercalating agents include doxorubicin, daunorubicin, idarubicin, mitoxantrone, pharmaceutically acceptable salts thereof, prodrugs, and combinations thereof. Non-limiting examples of inhibitors of DNA replication include irinotecan, topotecan, amsacrine, etoposide, etoposide phosphate, teniposide, pharmaceutically acceptable salts thereof, prodrugs, and combinations thereof. Antimetabolites include folate antagonists such as methotrexate and premetrexed, purine antagonists such as 6-mercaptopurine, dacarbazine, and fludarabine, and pyrimidine antagonists such as 5-fluorouracil, arabinosylcytosine, capecitabine, gemcitabine, decitabine, pharmaceutically acceptable salts thereof, prodrugs, and combinations thereof. Anti-microtubule agents include without limitation vinca alkaloids, paclitaxel (Taxol®), docetaxel (Taxotere®), and ixabepilone (Ixempra®). Antibiotic agents include without limitation actinomycin, anthracyclines, valrubicin, epirubicin, bleomycin, plicamycin, mitomycin, pharmaceutically acceptable salts thereof, prodrugs, and combinations thereof.

[0079] Cytotoxic agents according to the present invention also include an inhibitor of the PI3K/Akt pathway. Non-limiting examples of an inhibitor of the PI3K/Akt pathway include A-674563 (CAS # 552325-73-2), AGL 2263, AMG-319 (Amgen, Thousand Oaks, CA), AS-041164 (5-benzo[1,3]dioxol-5-ylmethylene-thiazolidine-2,4-dione), AS-604850 (5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-thiazolidine-2,4-dione), AS-605240 (5-quinoxilin-6-methylene-1,3-thiazolidine-2,4-dione), AT7867 (CAS # 857531-00-1), benzimidazole series, Genentech (Roche Holdings Inc., South San Francisco, CA), BML-257 (CAS # 32387-96-5), CAL-120 (Gilead Sciences, Foster City, CA), CAL-129 (Gilead Sciences), CAL-130 (Gilead Sciences), CAL-253 (Gilead Sciences), CAL-263 (Gilead Sciences), CAS # 612847-09-3, CAS # 681281-88-9, CAS # 75747-14-7, CAS # 925681-41-0, CAS # 98510-

80-6, CCT128930 (CAS # 885499-61-6), CH5132799 (CAS # 1007207-67-1), CHR-4432 (Chroma Therapeutics, Ltd., Abingdon, UK), FPA 124 (CAS # 902779-59-3), GS-1101 (CAL-101) (Gilead Sciences), GSK 690693 (CAS # 937174-76-0), H-89 (CAS # 127243-85-0), Honokiol, IC87114 (Gilead Science), IPI-145 (Intellikine Inc.), KAR-4139 (Karus Therapeutics, Chilworth, UK), KAR-4141 (Karus Therapeutics), KIN-1 (Karus Therapeutics), KT 5720 (CAS # 108068-98-0), Miltefosine, MK-2206 dihydrochloride (CAS # 1032350-13-2), ML-9 (CAS # 105637-50-1), Naltrindole Hydrochloride, OXY-111A (NormOxys Inc., Brighton, MA), perifosine, PHT-427 (CAS # 1191951-57-1), PI3 kinase delta inhibitor, Merck KGaA (Merck & Co., Whitehouse Station, NJ), PI3 kinase delta inhibitors, Genentech (Roche Holdings Inc.), PI3 kinase delta inhibitors, Incozen (Incozen Therapeutics, Pvt. Ltd., Hyderabad, India), PI3 kinase delta inhibitors-2, Incozen (Incozen Therapeutics), PI3 kinase inhibitor, Roche-4 (Roche Holdings Inc.), PI3 kinase inhibitors, Roche (Roche Holdings Inc.), PI3 kinase inhibitors, Roche-5 (Roche Holdings Inc.), PI3-alpha/delta inhibitors, Pathway Therapeutics (Pathway Therapeutics Ltd., South San Francisco, CA), PI3-delta inhibitors, Cellzome (Cellzome AG, Heidelberg, Germany), PI3-delta inhibitors, Intellikine (Intellikine Inc., La Jolla, CA), PI3-delta inhibitors, Pathway Therapeutics-1 (Pathway Therapeutics Ltd.), PI3-delta inhibitors, Pathway Therapeutics-2 (Pathway Therapeutics Ltd.), PI3-delta/gamma inhibitors, Cellzome (Cellzome AG), PI3-delta/gamma inhibitors, Cellzome (Cellzome AG), PI3-delta/gamma inhibitors, Intellikine (Intellikine Inc.), PI3-delta/gamma inhibitors, Intellikine (Intellikine Inc.), PI3-delta/gamma inhibitors, Pathway Therapeutics (Pathway Therapeutics Ltd.), PI3-delta/gamma inhibitors, Pathway Therapeutics (Pathway Therapeutics Ltd.), PI3-gamma inhibitor Evotec (Evotec), PI3-gamma inhibitor, Cellzome (Cellzome AG), PI3-gamma inhibitors, Pathway Therapeutics (Pathway Therapeutics Ltd.), PI3K

delta/gamma inhibitors, Intellikine-1 (Intellikine Inc.), PI3K delta/gamma inhibitors, Intellikine-1 (Intellikine Inc.), pictilisib (Roche Holdings Inc.), PIK-90 (CAS # 677338-12-4), SC-103980 (Pfizer, New York, NY), SF-1126 (Semafore Pharmaceuticals, Indianapolis, IN), SH-5, SH-6, Tetrahydro Curcumin, TG100-115 (Targegen Inc., San Diego, CA), Triciribine, X-339 (Xcovery, West Palm Beach, FL), XL-499 (Evotech, Hamburg, Germany), pharmaceutically acceptable salts thereof, and combinations thereof.

[0080] In the present invention, the term “toxin” means an antigenic poison or venom of plant or animal origin. An example is diphtheria toxin or portions thereof.

[0081] In the present invention, the term “radionuclide” means a radioactive substance administered to the patient, *e.g.*, intravenously or orally, after which it penetrates via the patient’s normal metabolism into the target organ or tissue, where it delivers local radiation for a short time. Examples of radionuclides include, but are not limited to, I-125, At-211, Lu-177, Cu-67, I-131, Sm-153, Re-186, P-32, Re-188, In-114m, and Y-90.

[0082] In the present invention, the term “immunomodulator” means a substance that alters the immune response by augmenting or reducing the ability of the immune system to produce antibodies or sensitized cells that recognize and react with the antigen that initiated their production. Immunomodulators may be recombinant, synthetic, or natural preparations and include cytokines, corticosteroids, cytotoxic agents, thymosin, and immunoglobulins. Some immunomodulators are naturally present in the body, and certain of these are available in pharmacologic preparations. Examples of immunomodulators include, but are not limited to, granulocyte colony-stimulating factor (G-CSF), interferons,

imiquimod and cellular membrane fractions from bacteria, IL-2, IL-7, IL-12, CCL3, CCL26, CXCL7, and synthetic cytosine phosphate-guanosine (CpG).

[0083] In the present invention, the term “photoactive therapeutic agent” means compounds and compositions that become active upon exposure to light. Certain examples of photoactive therapeutic agents are disclosed, e.g., in U.S. Patent Application Serial No. 2011/0152230 A1, “Photoactive Metal Nitrosyls For Blood Pressure Regulation And Cancer Therapy.”

[0084] In the present invention, the term “radiosensitizing agent” means a compound that makes tumor cells more sensitive to radiation therapy. Examples of radiosensitizing agents include misonidazole, metronidazole, tirapazamine, and trans sodium crocetin.

[0085] In the present invention, the term “hormone” means a substance released by cells in one part of a body that affects cells in another part of the body. Examples of hormones include, but are not limited to, prostaglandins, leukotrienes, prostacyclin, thromboxane, amylin, antimüllerian hormone, adiponectin, adrenocorticotrophic hormone, angiotensinogen, angiotensin, vasopressin, atriopeptin, brain natriuretic peptide, calcitonin, cholecystokinin, corticotropin-releasing hormone, enkephalin, endothelin, erythropoietin, follicle-stimulating hormone, galanin, gastrin, ghrelin, glucagon, gonadotropin-releasing hormone, growth hormone-releasing hormone, human chorionic gonadotropin, human placental lactogen, growth hormone, inhibin, insulin, somatomedin, leptin, lipoic acid, luteinizing hormone, melanocyte stimulating hormone, motilin, orexin, oxytocin, pancreatic polypeptide, parathyroid hormone, prolactin, prolactin releasing hormone, relaxin, renin, secretin, somatostatin, thrombopoietin, thyroid-stimulating hormone,

testosterone, dehydroepiandrosterone, androstenedione, dihydrotestosterone, aldosterone, estradiol, estrone, estriol, cortisol, progesterone, calcitriol, and calcidiol.

[0086] Some compounds interfere with the activity of certain hormones or stop the production of certain hormones. These hormone-interfering compounds include, but are not limited to, tamoxifen (Nolvadex®), anastrozole (Arimidex®), letrozole (Femara®), and fulvestrant (Faslodex®). Such compounds are also within the meaning of hormone in the present invention.

[0087] As used herein, an “anti-angiogenesis” agent means a substance that reduces or inhibits the growth of new blood vessels, such as, e.g., an inhibitor of vascular endothelial growth factor (VEGF) and an inhibitor of endothelial cell migration. Anti-angiogenesis agents include without limitation 2-methoxyestradiol, angiostatin, bevacizumab, cartilage-derived angiogenesis inhibitory factor, endostatin, IFN- α , IL-12, itraconazole, linomide, platelet factor-4, prolactin, SU5416, suramin, tasquinimod, tecogalan, tetrathiomolybdate, thalidomide, thrombospondin, thrombospondin, TNP-470, ziv-aflibercept, pharmaceutically acceptable salts thereof, prodrugs, and combinations thereof.

[0088] Another embodiment of the present invention is a method for treating or ameliorating the effects of a cancer in a subject. The method comprises:

(a) identifying a subject with cancer that has become refractory or resistant to BRAF inhibitor therapy, MEK inhibitor therapy, or BRAF and MEK inhibitor therapy; and

(b) administering to the subject with said refractory or resistant cancer an effective amount of an ERK inhibitor, which is BVD-523 or a pharmaceutically acceptable salt thereof.

[0089] Suitable and preferred subjects are as disclosed herein. In this embodiment, the methods may be used to treat the cancers disclosed above. In accordance with the present invention, the cancer may have MAPK activity.

[0090] In one aspect of this embodiment, identifying a subject with cancer that is refractory or resistant to BRAF and/or MEK inhibitor therapy comprises:

- (a) obtaining a biological sample from the subject; and
- (b) screening the sample to determine whether the subject has become resistant to an inhibitor therapy selected from the group consisting of BRAF inhibitor therapy, MEK inhibitor therapy, and combinations thereof.

[0091] In the present invention, biological samples include, but are not limited to, blood, plasma, urine, skin, saliva, and biopsies. Biological samples are obtained from a subject by routine procedures and methods which are known in the art.

[0092] Preferably, screening for a cancer that is refractory or resistant to BRAF inhibitor therapy may comprise, *e.g.*, identifying (i) a switch between RAF isoforms, (ii) upregulation of RTK or NRAS signaling, (iii) reactivation of mitogen activated protein kinase (MAPK) signaling, (iv) the presence of a MEK activating mutation, and combinations thereof.

[0093] A switch between RAF isoforms may occur in subjects having acquired resistance to BRAF inhibitor therapy. To detect such a switch, BRAF inhibitor-resistant tumor cells may be retrieved from a patient and analyzed via Western blotting for ERK and phospho-ERK levels in the presence of a BRAF inhibitor. Comparison with BRAF inhibitor-sensitive cells treated with a BRAF inhibitor may reveal higher levels of phospho-ERK in BRAF inhibitor-resistant tumor cells, implying that a switch has taken place in which another RAF isoform phosphorylates ERK in

place of BRAF. Confirmation of which RAF isoform has taken over may involve sh/siRNA-mediated knockdown of ARAF and CRAF individually in BRAF inhibitor-resistant cells exposed to a BRAF inhibitor, followed by subsequent Western blotting for ERK and phospho-ERK levels. If, for example, ARAF knockdown in BRAF inhibitor-resistant cells exposed to a BRAF inhibitor still results in high levels of phospho-ERK, it would indicate that CRAF has taken over phosphorylating ERK. Likewise, if CRAF was knocked down in BRAF inhibitor-resistant cells exposed to BRAF inhibitor and ERK was still highly phosphorylated, it would mean that ARAF has taken over ERK phosphorylation. RAF isoform switching may also involve simultaneous knockdown of ARAF and CRAF in BRAF inhibitor-resistant cells in the presence of BRAF inhibitor, effectively blocking all RAF-mediated phosphorylation. A resulting decrease in ERK phosphorylation would indicate that the BRAF inhibitor-resistant cells have the capacity to switch between RAF isoforms in order to phosphorylate ERK (Villanueva, et al., 2010).

[0094] Upregulation of RTK or NRAS signaling may also be a cause of BRAF inhibitor resistance. Detection may, e.g., first involve using Western blotting protocols with phospho-specific antibodies to analyze the activation of the downstream RAF effectors MEK1/2 and ERK1/2. If BRAF inhibitor-resistant cells show high activation levels of these proteins in the presence of a BRAF inhibitor, RTK or NRAS upregulation may be the cause. Gene expression profiling (or other related methods) of BRAF inhibitor-resistant cells in the presence of a BRAF inhibitor may reveal higher expression levels of KIT, MET, EGFR, and PDGFR β RTKs as compared to BRAF inhibitor-sensitive cells. Real-time quantitative polymerase chain reaction experiments, or other similar procedures, focusing on any of these genes may confirm higher expression levels while phospho-RTK arrays (R&D Systems,

Minneapolis, MN) may show elevated activation-associated tyrosine phosphorylation. Alternatively, NRAS activation may be detected by various gene sequencing protocols. Activating mutations in NRAS, particularly Q61K, may indicate that B-RAF signaling has been bypassed. In melanoma cells, activated NRAS uses C-RAF to signal to MEK-ERK. Thus, activated NRAS may enable a similar bypass pathway in BRAF inhibitor-resistant cells exposed to BRAF inhibitor. Further confirmation of these mechanisms in a given BRAF inhibitor-resistant sample may be accomplished, for example, using sh/siRNA-mediated knockdown of upregulated RTKs or activated NRAS in the presence of BRAF inhibitor. Any significant levels of growth inhibition may indicate that upregulation of RTK or NRAS signaling is the cause of BRAF inhibition in that particular sample (Nazarian, et al., 2010).

[0095] Detecting reactivation of MAPK signaling in BRAF inhibitor-resistant cells may indicate another bypass mechanism for BRAF inhibitor resistance. COT and C-RAF have been shown to be upregulated in a BRAF V600E background exposed to BRAF inhibitor. Quantitative real-time RT-PCR, *e.g.*, may reveal increased COT expression in BRAF inhibitor-resistant cells in the presence of BRAF inhibitor. Furthermore, sh/siRNA-mediated knockdown of COT in BRAF inhibitor-resistant cells in the presence of BRAF inhibitor may reduce the viability of BRAF inhibitor-resistant cells, indicating that these particular cells may be sensitive to COT inhibition and/or combination BRAF inhibitor/MEK inhibitor treatments (Johannessen, et al., 2010).

[0096] Reactivation of MAPK signaling may also be accomplished in a BRAF inhibitor-resistant background by activating mutations in MEK1. Targeted, massively parallel sequencing of genomic DNA from a BRAF inhibitor-resistant tumor may

reveal activating mutations in MEK1, such as C121S, G128D, N122D, and Y130, among others. Other, undocumented mutations in MEK1 may be analyzed by, for example, expressing the particular mutation in a BRAF inhibitor-sensitive cell line such as A375. Determining levels of growth inhibition in these cells upon exposure to BRAF inhibitor may indicate if the MEK1 mutation is causing resistance to BRAF inhibitory therapy. To confirm such a finding, Western blotting for elevated levels of phospho-ERK1/2 in cells ectopically expressing the MEK1 mutation may indicate that the MEK1 mutation is allowing the BRAF inhibitor-resistant tumor to bypass BRAF and promote phosphorylation of ERK through MEK1 (Wagle, et al., 2011).

[0097] In accordance with the present invention, screening for a cancer that is refractory or resistant to MEK inhibitor therapy may comprise, *e.g.*, identifying (i) amplification of mutant BRAF, (ii) STAT3 upregulation, (iii) mutations in the allosteric pocket of MEK that directly block binding of inhibitors to MEK or lead to constitutive MEK activity, and combinations thereof.

[0098] Amplification of mutant BRAF may cause MEK inhibitor resistance. MEK inhibitor resistance is typically associated with high levels of phosphorylated ERK and MEK in the presence of a MEK inhibitor, which may be assessed via, for example, Western blotting. Amplification of mutant BRAF in MEK inhibitor-resistant cell lines may be detected by, for example, fluorescence in situ hybridization (FISH) or quantitative PCR from genomic DNA of the resistant cell lines. Confirmation that BRAF amplification is a primary cause of MEK inhibitor resistance may entail using BRAF-targeted sh/siRNAs in resistant cells. If a significant decrease in MEK or ERK phosphorylation is observed, BRAF amplification may be a suitable target for further therapeutic approaches. (Corcoran, et al., 2010).

[0099] Identifying STAT3 upregulation may indicate that a particular tumor sample is resistant to MEK inhibitor therapy. Genome-wide expression profiling may reveal the STAT3 pathway to be upregulated in a tumor. Other techniques, such as Western blotting for phospho-STAT3 and real-time qPCR for the STAT pathway-associated genes JAK1 and IL6ST may reveal upregulated STAT3. Further confirmation that STAT3 upregulation causes MEK inhibitor resistance in a particular sample may comprise the use of sh/siRNAs against STAT3 in the sample followed by appropriate Western blotting for MEK and ERK activation as well as phospho-STAT3 and total STAT3. Growth inhibition studies may show that STAT3 knockdown sensitizes previously MEK inhibitor-resistant cells to MEK inhibition. A similar effect may be seen if the sample were exposed to a STAT3 inhibitor such as JSI-124. Additional confirmation that STAT3 upregulation is the cause of MEK inhibitor resistance in a particular tumor could arise from Western blotting for BIM expression, including BIM-EL, BIM-L, and BIM-SL. BIM expression leads to MEK inhibitor-induced apoptosis, thus STAT3 upregulation may lower BIM levels. STAT3 is known to regulate the expression of miR 17-92, which suppresses BIM expression. Upregulated STAT3 may lead to higher levels of miR 17-92, which will lower BIM levels and promote resistance to MEK inhibition. Thus, real-time qPCR of miR 17-92 levels may also assist in assessing whether STAT3 upregulation is causing MEK inhibition resistance in a particular sample. (Dai, et al., 2011).

[0100] Mutations in the allosteric pocket of MEK that can directly block binding of inhibitors to MEK or lead to constitutive MEK activity may be detected by methods disclosed below. Such mutations have been identified previously by Emery and colleagues (Emery, et al., 2009) as well as Wang and colleagues (Wang et al.,

2011). Other mutations may affect MEK1 codons located within or abutting the N-terminal negative regulatory helix, such as P124L and Q56P. (*Id.*).

[0101] Methods for identifying mutations in nucleic acids, such as the above identified MEK genes, are known in the art. Nucleic acids may be obtained from biological samples. In the present invention, biological samples include, but are not limited to, blood, plasma, urine, skin, saliva, and biopsies. Biological samples are obtained from a subject by routine procedures and methods which are known in the art.

[0102] Non-limiting examples of methods for identifying mutations include PCR, sequencing, hybrid capture, in-solution capture, molecular inversion probes, fluorescent in situ hybridization (FISH) assays, and combinations thereof.

[0103] Various sequencing methods are known in the art. These include, but are not limited to, Sanger sequencing (also referred to as dideoxy sequencing) and various sequencing-by-synthesis (SBS) methods as disclosed in, e.g., Metzker 2005, sequencing by hybridization, by ligation (for example, WO 2005021786), by degradation (for example, U.S. Patent Nos. 5,622,824 and 6,140,053) and nanopore sequencing (which is commercially available from Oxford Nanopore Technologies, UK). In deep sequencing techniques, a given nucleotide in the sequence is read more than once during the sequencing process. Deep sequencing techniques are disclosed in e.g., U.S. Patent Publication No. 20120264632 and International Patent Publication No. WO2012125848.

[0104] PCR-based methods for detecting mutations are known in the art and employ PCR amplification, where each target sequence in the sample has a corresponding pair of unique, sequence-specific primers. For example, the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP)

method allows for rapid detection of mutations after the genomic sequences are amplified by PCR. The mutation is discriminated by digestion with specific restriction endonucleases and is identified by electrophoresis. See, e.g., Ota et al., 2007. Mutations may also be detected using real time PCR. See, e.g., International Application publication No. WO2012046981.

[0105] Hybrid capture methods are known in the art and are disclosed in e.g., U.S. Patent Publication No. 20130203632 and U.S. Patent Nos. 8,389,219 and 8,288,520. These methods are based on the selective hybridization of the target genomic regions to user-designed oligonucleotides. The hybridization can be to oligonucleotides immobilized on high or low density microarrays (on-array capture), or solution-phase hybridization to oligonucleotides modified with a ligand (e.g. biotin) which can subsequently be immobilized to a solid surface, such as a bead (in-solution capture).

[0106] Molecular Inversion Probe (MIP) techniques are known in the art and are disclosed in e.g., Absalan et al., 2008. This method uses MIP molecules, which are special "padlock" probes (Nilsson et al, 1994) for genotyping. A MIP molecule is a linear oligonucleotide that contains specific regions, universal sequences, restriction sites and a Tag (index) sequence (16-22 bp). A MIP hybridizes directly around the genetic marker/SNP of interest. The MIP method may also use a number of "padlock" probe sets that hybridize to genomic DNA in parallel (Hardenbol et al., 2003). In case of a perfect match, genomic homology regions are ligated by undergoing an inversion in configuration (as suggested by the name of the technique) and creating a circular molecule. After the first restriction, all molecules are amplified with universal primers. Amplicons are restricted again to ensure short fragments for hybridization on a microarray. Generated short fragments are labeled

and, through a Tag sequence, hybridized to a cTag (complementary strand for index) on an array. After the formation of Tag-cTag duplex, a signal is detected.

[0107] The following Tables 1, 2, and 3 show the SEQ ID Nos. of representative nucleic acid and amino acid sequences of wild type BRAF, N-RAS, and MEK1 from various animals in the sequence listing. These sequences may be used in methods for identifying subjects with mutant BRAF, N-RAS, and MEK1 genotypes.

Table 1 – BRAF sequences

SEQ ID NO.	polypeptide or nucleic acid sequence	Organism	Other information
1	nucleic acid	human	
2	polypeptide	human	
3	nucleic acid	rat (<i>Rattus norvegicus</i>)	
4	polypeptide	rat (<i>Rattus norvegicus</i>)	
5	nucleic acid	mouse, <i>Mus musculus</i>	
6	polypeptide	mouse, <i>Mus musculus</i>	
7	nucleic acid	rabbit, <i>Oryctolagus cuniculus</i>	
8	polypeptide	rabbit, <i>Oryctolagus cuniculus</i>	
9	nucleic acid	guinea pig, <i>Cavia porcellus</i>	
10	polypeptide	guinea pig, <i>Cavia porcellus</i>	
11	nucleic acid	dog, <i>Canis lupus familiaris</i>	variant x1
12	polypeptide	dog, <i>Canis lupus familiaris</i>	variant x1
13	nucleic acid	dog, <i>Canis lupus familiaris</i>	variant x2
14	polypeptide	dog, <i>Canis lupus familiaris</i>	variant x2
15	nucleic acid	cat, <i>Felis catus</i>	
16	polypeptide	cat, <i>Felis catus</i>	

SEQ ID NO.	polypeptide or nucleic acid sequence	Organism	Other information
17	nucleic acid	cow, Bos taurus	variant X1
18	polypeptide	cow, Bos taurus	variant X1
19	nucleic acid	cow, Bos taurus	variant X2
20	polypeptide	cow, Bos taurus	variant X2
21	nucleic acid	cow, Bos taurus	variant X3
22	polypeptide	cow, Bos taurus	variant X3
23	nucleic acid	cow, Bos taurus	variant X4
24	polypeptide	cow, Bos taurus	variant X4
25	nucleic acid	cow, Bos taurus	variant X5
26	polypeptide	cow, Bos taurus	variant X5
27	nucleic acid	cow, Bos taurus	variant X6
28	polypeptide	cow, Bos taurus	variant X6
29	nucleic acid	cow, Bos taurus	variant X7
30	polypeptide	cow, Bos taurus	variant X7
31	nucleic acid	cow, Bos taurus	variant X8
32	polypeptide	cow, Bos taurus	variant X8
33	nucleic acid	cow, Bos taurus	variant X9
34	polypeptide	cow, Bos taurus	variant X9
35	nucleic acid	cow, Bos taurus	variant X10
36	polypeptide	cow, Bos taurus	variant X10
37	nucleic acid	cow, Bos taurus	variant X11
38	polypeptide	cow, Bos taurus	variant X11
39	nucleic acid	cow, Bos taurus	variant 2
40	polypeptide	cow, Bos taurus	variant 2
41	nucleic acid	horse, Equus caballus	
42	polypeptide	horse, Equus caballus	
43	nucleic acid	chicken, Gallus gallus	
44	polypeptide	chicken, Gallus gallus	

Table 2 – N-RAS sequences

SEQ ID NO.	polypeptide or nucleic acid sequence	Organism	Other information
45	nucleic acid	human	
46	polypeptide	human	
47	nucleic acid	rat (Rattus norvegicus)	
48	polypeptide	rat (Rattus norvegicus)	
49	nucleic acid	mouse, Mus musculus	
50	polypeptide	mouse, Mus musculus	

SEQ ID NO.	polypeptide or nucleic acid sequence	Organism	Other information
51	nucleic acid	guinea pig, <i>Cavia porcellus</i>	
52	polypeptide	guinea pig, <i>Cavia porcellus</i>	
53	nucleic acid	guinea pig, <i>Cavia porcellus</i>	variant X1
54	polypeptide	guinea pig, <i>Cavia porcellus</i>	variant X1
55	nucleic acid	dog, <i>Canis lupus familiaris</i>	
56	polypeptide	dog, <i>Canis lupus familiaris</i>	
57	nucleic acid	cat, <i>Felis catus</i>	
58	polypeptide	cat, <i>Felis catus</i>	
59	nucleic acid	cow, <i>Bos taurus</i>	
60	polypeptide	cow, <i>Bos taurus</i>	
61	nucleic acid	chicken, <i>Gallus gallus</i>	
62	polypeptide	chicken, <i>Gallus gallus</i>	

Table 3 – MEK1 sequences

SEQ ID NO.	polypeptide or nucleic acid sequence	Organism
63	nucleic acid	human
64	polypeptide	human
65	nucleic acid	rat (<i>Rattus norvegicus</i>)
66	polypeptide	rat (<i>Rattus norvegicus</i>)
67	nucleic acid	mouse, <i>Mus musculus</i>
68	polypeptide	mouse, <i>Mus musculus</i>
69	nucleic acid	rabbit, <i>Oryctolagus cuniculus</i>
70	polypeptide	rabbit, <i>Oryctolagus cuniculus</i>
71	nucleic acid	guinea pig, <i>Cavia porcellus</i>
72	polypeptide	guinea pig, <i>Cavia porcellus</i>
73	nucleic acid	dog, <i>Canis lupus familiaris</i>
74	polypeptide	dog, <i>Canis lupus familiaris</i>
75	nucleic acid	cat, <i>Felis catus</i>
76	polypeptide	cat, <i>Felis catus</i>
77	nucleic acid	cow, <i>Bos taurus</i>
78	polypeptide	cow, <i>Bos taurus</i>
79	nucleic acid	horse, <i>Equus caballus</i>
80	polypeptide	horse, <i>Equus caballus</i>
81	nucleic acid	chicken, <i>Gallus gallus</i>
82	polypeptide	chicken, <i>Gallus gallus</i>

[0108] In another aspect of this embodiment, the method further comprises administering at least one additional therapeutic agent, preferably an inhibitor of the PI3K/Akt pathway, as disclosed herein.

[0109] A further embodiment of the present invention is a method for treating or ameliorating the effects of cancer in a subject, which cancer is refractory or resistant to BRAF inhibitor therapy, MEK inhibitor therapy, or both. The method comprises administering to the subject an effective amount of BVD-523 or a pharmaceutically acceptable salt thereof.

[0110] Suitable and preferred subjects are as disclosed herein. In this embodiment, the methods may be used to treat the cancers disclosed above, including those cancers with the mutational backgrounds, resistance profiles, and MAPK activity identified above. Methods of identifying such mutations are also as set forth above.

[0111] In a further aspect of this embodiment, the method further comprises administering to the subject at least one additional therapeutic agent, preferably an inhibitor of the PI3K/Akt pathway, as disclosed herein.

[0112] Another embodiment of the present invention is a method for identifying a subject having cancer who would benefit from therapy with an ERK inhibitor. The method comprises:

- (a) obtaining a biological sample from the subject; and
- (b) screening the sample to determine whether the subject has one or more of the following markers:
 - (i) a switch between RAF isoforms,
 - (ii) upregulation of RTK or NRAS signaling,

- (iii) reactivation of mitogen activated protein kinase (MAPK) signaling,
- (iv) the presence of a MEK activating mutation,
- (v) amplification of mutant BRAF,
- (vi) STAT3 upregulation,
- (vii) mutations in the allosteric pocket of MEK that directly block binding of inhibitors to MEK or lead to constitutive MEK activity,

wherein the presence of one or more of the markers confirms that the subject's cancer is refractory or resistant to BRAF and/or MEK inhibitor therapy and that the subject would benefit from therapy with an ERK inhibitor, which is BVD-523 or a pharmaceutically acceptable salt thereof.

[0113] Suitable and preferred subjects are as disclosed herein. In this embodiment, the methods may be used to identify a subject having cancers disclosed above, including those cancers with the mutational backgrounds, resistance profiles, and MAPK activity identified above. Methods of identifying such mutations are also as set forth above.

[0114] In one aspect of this embodiment, the method further comprises administering BVD-523 or a pharmaceutically acceptable salt thereof to a subject having one or more of the markers. Preferably, the method additionally comprises administering to the subject having one or more of the markers at least one additional therapeutic agent, preferably an inhibitor of the PI3K/Akt pathway, as disclosed herein.

[0115] An additional embodiment of the present invention is a pharmaceutical composition for treating or ameliorating the effects of a cancer in a subject, which

cancer is refractory or resistant to non-ERK MAPK pathway therapy. The composition comprises a pharmaceutically acceptable carrier or diluent and an effective amount of BVD-523 or a pharmaceutically acceptable salt thereof.

[0116] Suitable and preferred subjects and types of non-ERK MAPK pathway inhibitor therapy are as disclosed herein. In this embodiment, the pharmaceutical composition may be used to treat the cancers disclosed above, including those cancers with the mutational backgrounds, resistance profiles, and MAPK activity identified above. Methods of identifying such mutations are also as set forth above.

[0117] In one aspect of this embodiment, the pharmaceutical composition further comprises at least one additional therapeutic agent, preferably an inhibitor of the PI3K/Akt pathway, as disclosed herein.

[0118] Another embodiment of the present invention is a kit for treating or ameliorating the effects of a cancer in a subject, which cancer is refractory or resistant to non-ERK MAPK pathway therapy. This kit comprises any pharmaceutical composition according to the present invention packaged together with instructions for its use.

[0119] The kits may also include suitable storage containers, *e.g.*, ampules, vials, tubes, etc., for each pharmaceutical composition and other reagents, *e.g.*, buffers, balanced salt solutions, etc., for use in administering the pharmaceutical compositions to subjects. The pharmaceutical compositions and other reagents may be present in the kits in any convenient form, such as, *e.g.*, in a solution or in a powder form. The kits may further include a packaging container, optionally having one or more partitions for housing the pharmaceutical composition and other optional reagents.

[0120] Suitable and preferred subjects and types of non-ERK MAPK pathway inhibitor therapy are as disclosed herein. In this embodiment, the kit may be used to treat the cancers disclosed above, including those cancers with the mutational backgrounds, resistance profiles, and MAPK activity identified herein. Methods of identifying such mutations are as set forth above.

[0121] In one aspect of this embodiment, the kit further comprises at least one additional therapeutic agent, preferably an inhibitor of the PI3K/Akt pathway, as disclosed herein.

[0122] Another embodiment of the present invention is a method for inhibiting phosphorylation of RSK in a cancer cell that is refractory or resistant to a non-ERK MAPK pathway inhibitor. The method comprises contacting the cancer cell with an effective amount of BVD-523 or a pharmaceutically acceptable salt thereof for a period of time sufficient for phosphorylation of RSK in the cancer cell to be inhibited. In this embodiment, "contacting" means bringing BVD-523 or a pharmaceutically acceptable salt thereof and optionally one or more additional therapeutic agents into close proximity to the cancer cells. This may be accomplished using conventional techniques of drug delivery to mammals, or in the *in vitro* situation by, e.g., providing BVD-523 or a pharmaceutically acceptable salt thereof and optionally other therapeutic agents to a culture media in which the cancer cells are located. In the *ex vivo* situation, contacting may be carried out by, e.g., providing BVD-523 or a pharmaceutically acceptable salt thereof and optionally other therapeutic agents to a cancerous tissue.

[0123] Suitable and preferred types of non-ERK MAPK pathway inhibitors are as disclosed herein. In this embodiment, effecting cancer cell death may be accomplished in cancer cells having various mutational backgrounds, resistance

profiles, and MAPK activity as disclosed above. Methods of identifying such mutations are also as set forth above.

[0124] The methods of this embodiment, which may be carried out *in vitro*, *ex vivo*, or *in vivo*, may be used to effect cancer cell death, by e.g., killing cancer cells, in cells of the types of cancer disclosed herein.

[0125] In one aspect of this embodiment, greater than 50% of RSK phosphorylation is inhibited. In another aspect of this embodiment, greater than 75% of RSK phosphorylation is inhibited. In an additional aspect of this embodiment, greater than 90% of RSK phosphorylation is inhibited. In a further aspect of this embodiment, greater than 95% of RSK phosphorylation is inhibited. In another aspect of this embodiment, greater than 99% of RSK phosphorylation is inhibited. In an additional aspect of this embodiment, 100% of RSK phosphorylation is inhibited.

[0126] In a further aspect of this embodiment, the cancer cell is a mammalian cancer cell. Preferably, the mammalian cancer cell is obtained from a mammal selected from the group consisting of humans, primates, farm animals, and domestic animals. More preferably, the mammalian cancer cell is a human cancer cell.

[0127] In a further aspect of this embodiment, the contacting step comprises administering BVD-523 or a pharmaceutically acceptable salt to a subject from whom the cancer cell was obtained.

[0128] In the present invention, an "effective amount" or a "therapeutically effective amount" of a compound or composition disclosed herein is an amount of such compound or composition that is sufficient to effect beneficial or desired results as described herein when administered to a subject. Effective dosage forms, modes of administration, and dosage amounts may be determined empirically, and making such determinations is within the skill of the art. It is understood by those skilled in

the art that the dosage amount will vary with the route of administration, the rate of excretion, the duration of the treatment, the identity of any other drugs being administered, the age, size, and species of mammal, e.g., human patient, and like factors well known in the arts of medicine and veterinary medicine. In general, a suitable dose of a compound or composition according to the invention will be that amount of the composition, which is the lowest dose effective to produce the desired effect. The effective dose of a compound or composition of the present invention may be administered as two, three, four, five, six or more sub-doses, administered separately at appropriate intervals throughout the day.

[0129] A suitable, non-limiting example of a dosage of a BVD-523 and other anti-cancer agents disclosed herein is from about 1 mg/kg to about 2400 mg/kg per day, such as from about 1 mg/kg to about 1200 mg/kg per day, 75 mg/kg per day to about 300 mg/kg per day, including from about 1 mg/kg to about 100 mg/kg per day. Other representative dosages of such agents include about 1 mg/kg, 5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 60 mg/kg, 70 mg/kg, 75 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 125 mg/kg, 150 mg/kg, 175 mg/kg, 200 mg/kg, 250 mg/kg, 300 mg/kg, 400 mg/kg, 500 mg/kg, 600 mg/kg, 700 mg/kg, 800 mg/kg, 900 mg/kg, 1000 mg/kg, 1100 mg/kg, 1200 mg/kg, 1300 mg/kg, 1400 mg/kg, 1500 mg/kg, 1600 mg/kg, 1700 mg/kg, 1800 mg/kg, 1900 mg/kg, 2000 mg/kg, 2100 mg/kg, 2200 mg/kg, and 2300 mg/kg per day. The effective dose of BVD-523 and other anti-cancer agents disclosed herein, may be administered as two, three, four, five, six or more sub-doses, administered separately at appropriate intervals throughout the day.

[0130] The BVD-523, other inhibitors, and various other anti-cancer agents disclosed herein, or a pharmaceutical composition of the present invention may be

administered in any desired and effective manner: for oral ingestion, or as an ointment or drop for local administration to the eyes, or for parenteral or other administration in any appropriate manner such as intraperitoneal, subcutaneous, topical, intradermal, inhalation, intrapulmonary, rectal, vaginal, sublingual, intramuscular, intravenous, intraarterial, intrathecal, or intralymphatic. Further, BVD-523, other inhibitors, and various other anti-cancer agents disclosed herein, or a pharmaceutical composition of the present invention may be administered in conjunction with other treatments. BVD-523, other inhibitors, and various other anti-cancer agents disclosed herein, or a pharmaceutical composition of the present invention may be encapsulated or otherwise protected against gastric or other secretions, if desired.

[0131] The pharmaceutical compositions of the invention comprise one or more active ingredients in admixture with one or more pharmaceutically-acceptable diluents or carriers and, optionally, one or more other compounds, drugs, ingredients and/or materials. Regardless of the route of administration selected, the agents/compounds of the present invention are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art. See, *e.g.*, Remington, The Science and Practice of Pharmacy (21st Edition, Lippincott Williams and Wilkins, Philadelphia, PA.).

[0132] Pharmaceutically acceptable diluents or carriers are well known in the art (see, *e.g.*, Remington, The Science and Practice of Pharmacy (21st Edition, Lippincott Williams and Wilkins, Philadelphia, PA.) and The National Formulary (American Pharmaceutical Association, Washington, D.C.)) and include sugars (*e.g.*, lactose, sucrose, mannitol, and sorbitol), starches, cellulose preparations, calcium phosphates (*e.g.*, dicalcium phosphate, tricalcium phosphate and calcium hydrogen

phosphate), sodium citrate, water, aqueous solutions (e.g., saline, sodium chloride injection, Ringer's injection, dextrose injection, dextrose and sodium chloride injection, lactated Ringer's injection), alcohols (e.g., ethyl alcohol, propyl alcohol, and benzyl alcohol), polyols (e.g., glycerol, propylene glycol, and polyethylene glycol), organic esters (e.g., ethyl oleate and triglycerides), biodegradable polymers (e.g., polylactide-polyglycolide, poly(orthoesters), and poly(anhydrides)), elastomeric matrices, liposomes, microspheres, oils (e.g., corn, germ, olive, castor, sesame, cottonseed, and groundnut), cocoa butter, waxes (e.g., suppository waxes), paraffins, silicones, talc, silicylate, etc. Each pharmaceutically acceptable diluent or carrier used in a pharmaceutical composition of the invention must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject. Diluents or carriers suitable for a selected dosage form and intended route of administration are well known in the art, and acceptable diluents or carriers for a chosen dosage form and method of administration can be determined using ordinary skill in the art.

[0133] The pharmaceutical compositions of the invention may, optionally, contain additional ingredients and/or materials commonly used in pharmaceutical compositions. These ingredients and materials are well known in the art and include (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (2) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, hydroxypropylmethyl cellulose, sucrose and acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, sodium starch glycolate, cross-linked sodium carboxymethyl cellulose and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary

ammonium compounds; (7) wetting agents, such as cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, and sodium lauryl sulfate; (10) suspending agents, such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth; (11) buffering agents; (12) excipients, such as lactose, milk sugars, polyethylene glycols, animal and vegetable fats, oils, waxes, paraffins, cocoa butter, starches, tragacanth, cellulose derivatives, polyethylene glycol, silicones, bentonites, silicic acid, talc, salicylate, zinc oxide, aluminum hydroxide, calcium silicates, and polyamide powder; (13) inert diluents, such as water or other solvents; (14) preservatives; (15) surface-active agents; (16) dispersing agents; (17) control-release or absorption-delaying agents, such as hydroxypropylmethyl cellulose, other polymer matrices, biodegradable polymers, liposomes, microspheres, aluminum monostearate, gelatin, and waxes; (18) opacifying agents; (19) adjuvants; (20) wetting agents; (21) emulsifying and suspending agents; (22), solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan; (23) propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane; (24) antioxidants; (25) agents which render the formulation isotonic with the blood of the intended recipient, such as sugars and sodium chloride; (26) thickening agents; (27) coating materials, such as lecithin; and (28) sweetening, flavoring, coloring, perfuming and preservative agents. Each such ingredient or

material must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject. Ingredients and materials suitable for a selected dosage form and intended route of administration are well known in the art, and acceptable ingredients and materials for a chosen dosage form and method of administration may be determined using ordinary skill in the art.

[0134] The pharmaceutical compositions of the present invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, powders, granules, a solution or a suspension in an aqueous or non-aqueous liquid, an oil-in-water or water-in-oil liquid emulsion, an elixir or syrup, a pastille, a bolus, an electuary or a paste. These formulations may be prepared by methods known in the art, e.g., by means of conventional pan-coating, mixing, granulation or lyophilization processes.

[0135] Solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules and the like) may be prepared, e.g., by mixing the active ingredient(s) with one or more pharmaceutically-acceptable diluents or carriers and, optionally, one or more fillers, extenders, binders, humectants, disintegrating agents, solution retarding agents, absorption accelerators, wetting agents, absorbents, lubricants, and/or coloring agents. Solid compositions of a similar type may be employed as fillers in soft and hard-filled gelatin capsules using a suitable excipient. A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using a suitable binder, lubricant, inert diluent, preservative, disintegrant, surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine. The tablets, and other solid dosage forms, such as dragees, capsules, pills and granules, may

optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein. They may be sterilized by, for example, filtration through a bacteria-retaining filter. These compositions may also optionally contain opacifying agents and may be of a composition such that they release the active ingredient only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. The active ingredient can also be in microencapsulated form.

[0136] Liquid dosage forms for oral administration include pharmaceutically-acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. The liquid dosage forms may contain suitable inert diluents commonly used in the art. Besides inert diluents, the oral compositions may also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents. Suspensions may contain suspending agents.

[0137] The pharmaceutical compositions of the present invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more active ingredient(s) with one or more suitable nonirritating diluents or carriers which are solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound. The pharmaceutical compositions of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such pharmaceutically-acceptable diluents or carriers as are known in the art to be appropriate.

[0138] Dosage forms for the topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, drops

and inhalants. The active agent(s)/compound(s) may be mixed under sterile conditions with a suitable pharmaceutically-acceptable diluent or carrier. The ointments, pastes, creams and gels may contain excipients. Powders and sprays may contain excipients and propellants.

[0139] The pharmaceutical compositions of the present invention suitable for parenteral administrations may comprise one or more agent(s)/compound(s) in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain suitable antioxidants, buffers, solutes which render the formulation isotonic with the blood of the intended recipient, or suspending or thickening agents. Proper fluidity can be maintained, for example, by the use of coating materials, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. These pharmaceutical compositions may also contain suitable adjuvants, such as wetting agents, emulsifying agents and dispersing agents. It may also be desirable to include isotonic agents. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption.

[0140] In some cases, in order to prolong the effect of a drug (*e.g.*, pharmaceutical formulation), it is desirable to slow its absorption from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility.

[0141] The rate of absorption of the active agent/drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered agent/drug may be

accomplished by dissolving or suspending the active agent/drug in an oil vehicle. Injectable depot forms may be made by forming microencapsule matrices of the active ingredient in biodegradable polymers. Depending on the ratio of the active ingredient to polymer, and the nature of the particular polymer employed, the rate of active ingredient release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue. The injectable materials can be sterilized for example, by filtration through a bacterial-retaining filter.

[0142] The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampules and vials, and may be stored in a lyophilized condition requiring only the addition of the sterile liquid diluent or carrier, for example water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the type described above.

[0143] The present invention provides treatment of cancer which is refractory or resistant to non-ERK MAPK pathway inhibitor therapy and discloses combinations shown to enhance the effects of ERK inhibitors. Herein, applicants have also shown that the combination of different ERK inhibitors is likewise synergistic. Therefore, it is contemplated that the effects of the combinations described herein can be further improved by the use of one or more additional ERK inhibitors. Accordingly, some embodiments of the present invention include one or more additional ERK inhibitors.

[0144] The present invention also provides a method of treating a subject having an unresectable or metastatic BRAF600 mutation-positive melanoma comprising administering to the subject 600 mg BID of BVD-523 or a pharmaceutically acceptable salt thereof.

[0145] In some embodiments of the invention, the mutation is a BRAF^{V600E} mutation.

[0146] The present invention also provides a composition for treating a subject having an unresectable or metastatic BRAF600 mutation-positive melanoma, the composition comprising 600 mg of BVD-523 or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0147] The following examples are provided to further illustrate the methods of the present invention. These examples are illustrative only and are not intended to limit the scope of the invention in any way.

EXAMPLES

Example 1

MATERIALS AND METHODS

[0148] Cancer cell lines were maintained in cell culture under standard media and serum conditions. For dose escalation studies, A375 cells were split, grown to about 40-60% confluence, and then treated with the initial dose of the specified drug. Table 4 shows a summary of drug treatments that were escalated.

Table 4 - Summary of Treatments Being Escalated

Treatment	Inhibitor
1	Trametinib (MEKi)
2	Dabrafenib (BRAFi)
3	BVD-523 (ERKi)
4	Dabrafenib (BRAFi) + Trametinib (MEKi)
5	Dabrafenib (BRAFi) + BVD-523 (ERKi)
6	Trametinib (MEKi) + BVD-523 (ERKi)

[0149] Single agent dose escalations were performed based on Little *et al.*, 2011 and are outlined in FIG. 20. Cells were then allowed to grow until 70-90% confluence and split. Split ratios were kept as “normal” as possible and reasonably consistent between treatments (e.g. a minimum of 50% of the normal split ratio of the parentals). Medium was refreshed every 3-4 days. When cells again reached about 40-60% confluence, the dose was escalated. In the event that the 40-60% window was missed, the cells were split again and dosed once they reached 40-60% confluence. Again, medium was refreshed every 3-4 days. The process was repeated as required (FIG. 20).

[0150] For single agent treatments, starting concentrations and dose increases were conducted by starting with the approximate IC_{50} , escalating in small increments or, gently, for the initial 4-5 doses, doubling the dose, increasing by the same increment for the next 4 doses, then moving to 1.5-fold increases in concentration for subsequent doses.

[0151] For combination treatments, starting concentrations and dose increases were conducted by starting with half of the approximate IC_{50} of each compound (combination assay suggests this will result in about 40-70% inhibition range), escalating as per single agents (i.e. doing an initial doubling and then increasing by the same increment for the next 4 doses, then moving to 1.5-fold increases in concentration). Table 5 shows the projected dose increases using these schemes.

Table 5 - Projected Dose Increases – Month 1

Dose				Dab/Tram		Dab/523		Tram/523	
	Tram (nM)	Dab (nM)	BVD-523 (μM)	Dab (nM)	Tram (nM)	Dab (nM)	523 (μM)	Tram (nM)	523 (μM)
1	1	5	0.16	2.5	0.5	2.5	0.08	0.5	0.08
2	2	10	0.32	5	1	5	0.16	1	0.16
3	3	15	0.48	7.5	1.5	7.5	0.24	1.5	0.24
4	4	20	0.64	10	2	10	0.32	2	0.32
5	5	25	0.80	12.5	2.5	12.5	0.40	2.5	0.40
6	8	38	1.2	19	4	19	0.6	4	0.6
7	11	56	1.8	28	6	28	0.9	6	0.9
8	17	84	2.7	42	8	42	1.4	8	1.4
9	25	127	4.1	63	13	63	2.0	13	2.0
10	38	190	6.1	95	19	95	3.0	19	3.0
11	57	285	9.1	142	28	142	4.6	28	4.6
12	85	427	13.7	214	43	214	6.8	43	6.8
13	128	641	20.5	320	64	320	10.3	64	10.3
14	192	961	30.8	481	96	481	15.4	96	15.4
15	288	1442	46.1	721	144	721	23.1	144	23.1
16	432	2162	69.2	1081	216	1081	34.6	216	34.6
17	649	3244	103.8	1622	324	1622	51.9	324	51.9
18	973	4865	155.7	2433	487	2433	77.8	487	77.8
19	1460	7298	233.5	3649	730	3649	116.8	730	116.8
20	2189	10947	350.3	5474	1095	5474	175.2	1095	175.2

[0152] Clonal resistant cell populations were derived from resistant cell pools by limiting dilution.

[0153] Proliferation assays were used to track changes in sensitivity to the escalated agent(s) at appropriate time intervals (e.g. each month, although the timing is dependent on adequate cell numbers being available). For proliferation assays, cells were seeded in 96-well plates at 3000 cells per well in drug-free DMEM medium containing 10% FBS and allowed to adhere overnight prior to addition of compound or vehicle control. Compounds were prepared from DMSO stocks to give a final concentration range as shown in FIG. 2A – FIG. 2H. The final DMSO

concentration was constant at 0.1%. Test compounds were incubated with the cells for 96 hours at 37°C and 5% CO₂ in a humidified atmosphere. Alamar Blue 10% (v/v) was then added and incubated for 4 hours and fluorescent product was detected using a BMG FLUOstar plate reader. The average media only background value was deducted and the data analyzed using a 4-parameter logistic equation in GraphPad Prism. Paclitaxel was used as a positive control.

[0154] Proliferation assays for month 1 were initiated at day 28 using cells growing in the concentrations of each agent indicated in Table 6.

Table 6 - Initial Concentrations of Drugs Used in Proliferation Assays – Month 1

Line	Dab	Tram	BVD-523
Parental	-	-	-
Tram	-	2 nM	-
Dab	15 nM	-	-
BVD-523	-	-	0.48 µM
Tram + Dab	5 nM	1 nM	-
Dab + BVD-523	7.5 nM	-	0.24 µM
Tram + BVD-523	-	1 nM	0.16 µM

[0155] Proliferation assays for month 2 were initiated at day 56 using cells growing in the concentrations of each agent indicated in Table 7.

Table 7 - Initial Concentrations of Drugs Used in Proliferation Assays - Month 2

Line	Dab	Tram	BVD-523
Parental	-	-	-
Tram	-	8 nM	-
Dab	127 nM	-	-
BVD-523	-	-	0.8 µM
Tram + Dab	10 nM	2 nM	-

Dab + BVD-523	12.5 nM	-	0.4 μ M
Tram + BVD-523	-	2 nM	0.32 μ M

[0156] At the end of the 3 month escalation period, cultures were maintained at the top concentration for 2 weeks prior to the final round of proliferation assays and potential single cell cloning. As the proliferation assays/single cell cloning required actively proliferating cells, for treatments where cells were proliferating very slowly at the top concentration or that were only recently escalated, a backup culture was also maintained at a lower concentration (Table 8). For the BVD-523 treatment, where cells appeared to have almost completely stopped growing and looked particularly fragile at the top concentration (1.8 μ M), cultures were maintained at a lower concentration for the 2 week period.

Table 8 - Details of Treatments Being Cultured at a Fixed Concentration for 2 Weeks

Treatment	Inhibitor	Culture 1	Backup Culture
1	Tram	160 nM	80 nM
2	Dab	3.2 μ M	-
3	BVD-523	1.2 μ M	0.8 μ M
4	Dab + Tram	D: 160 nM T: 30 nM	D: 80 nM T: 16 nM
5	Dab + BVD-523	D: 42 nM 523: 1.4 μ M	D: 28 nM 523: 0.9 μ M
6	Tram + BVD-523	T: 4 nM 523: 0.6 μ M	T: 2.5 nM 523: 0.4 μ M

[0157] Proliferation assays for month 3 used cells growing in the concentrations of each agent indicated in Table 9.

Table 9 - Initial Concentrations of Drugs Used in Proliferation Assays - Month 3

Line	Dab	Tram	BVD-523
Parental	-	-	-
Tram	-	160 nM	-
Dab	3.2 μ M	-	-
BVD-523	-	-	1.2 μ M
Tram + Dab	80 nM	16 nM	-
Dab + BVD-523	28 nM	-	0.9 μ M
Tram + BVD-523	-	2.5 nM	0.4 μ M

[0158] For combination studies, A375 cells (ATCC) were seeded into triplicate 96-well plates at a cell density of 3000 cells/well in DMEM plus 10% FBS and allowed to adhere overnight prior to addition of test compound or vehicle control. Combinations were tested using a 10x8 dose matrix with a final DMSO concentration of 0.2%. A 96 hour assay incubation period followed, with subsequent addition of Alamar Blue 10% (v/v) and 4 hours incubation prior to reading on a fluorescent plate reader. After reading Alamar Blue, the medium/Alamar Blue mix was flicked off and 100 μ l of CellTiter-Glo/PBS (1:1) added and the plates processed as per the manufacturers instructions (Promega). Media only background values were subtracted before the data was analysed. The Bliss additivity model was then applied.

[0159] In brief, predicted fractional inhibition values for combined inhibition were calculated using the equation $C_{\text{bliss}} = A + B - (A \times B)$ where A and B are the fractional inhibitions obtained by drug A alone or drug B alone at specific concentrations. C_{bliss} is the fractional inhibition that would be expected if the combination of the two drugs were exactly additive. C_{bliss} values are subtracted from the experimentally observed fractional inhibition values to give an 'excess over Bliss' value. Excess over Bliss values greater than 0 indicate synergy, whereas values

less than 0 indicate antagonism. Excess over Bliss values are plotted as heat maps $\pm$ SD.

[0160] The single and combination data are also presented as dose-response curves generated in GraphPad Prism (plotted using % viability relative to DMSO only treated controls).

[0161] For focused combination studies, the Alamar Blue viability assays were performed as described above for combination studies. Additionally, Caspase-Glo 3/7 assays were performed. In brief, HCT116 cells were seeded in triplicate in white 96-well plates at a cell density of 5000 cells/well in McCoy's 5A plus 10% FBS. A375 cells were seeded at a density of 5000 cells/well in DMEM plus 10% FBS. Cells were allowed to adhere overnight prior to addition of test compound or vehicle control. The final concentration of DMSO was 0.2%, and 800nM staurosporine was included as a positive control. 24 and 48 hour assay incubation periods were used. Then, Caspase-Glo® 3/7 50% (v/v) was added, plates were mixed for 5 minutes on an orbital shaker and incubated for 1 hour at room temperature prior to reading on a luminescent plate reader. Media only background values were subtracted before the data was analysed.

[0162] For Differential Scanning Fluorimetry, SYPRO orange (5,000 $\times$ solution, Invitrogen) was diluted (1:1,000) in buffer solution (10 mM HEPES, 150 mM NaCl, pH 7.5). HisX6 tagged proteins included inactive ERK2, active ERK2 (ppERK2), or p38 α at a final concentration of 1 μ M. The protein/dye solution and compounds in 100% DMSO were added to wells (2% v/v final DMSO concentration) to achieve the desired final concentrations, mixed, and placed into an RT-PCR instrument. Next, a melting curve was run from 25–95°C at a rate of 1°C per minute and the melting temperature (T_m) was determined for each protein in the absence or

presence of compounds. The change in T_m (ΔT_m) in the presence of various drug concentrations is presented.

[0163] For K_i determination of ERK1, activated ERK1 (10 nM) was incubated with various concentrations of the compounds in 2.5% (v/v) DMSO for 10 minutes at 30°C in 0.1 M HEPES buffer (pH 7.5), 10 mM $MgCl_2$, 2.5 mM phosphoenolpyruvate, 200 μ M nicotinamide adenine dinucleotide (NADH), 150 μ g/mL pyruvate kinase, 50 μ g/mL lactate dehydrogenase, and 200 μ M Erktide peptide. The reaction was initiated by the addition of 65 μ M of ATP. Decreased absorbance rate (340 nm) was monitored and the IC_{50} was determined as a function of inhibitor concentration.

[0164] For K_i determination of ERK2, the inhibitory activity of BVD-523 against ERK2 was determined using a radiometric assay, with final concentration of the components being 100 mM HEPES (pH 7.5), 10 mM $MgCl_2$, 1 mM dithiothreitol (DTT), 0.12 nM ERK2, 10 μ M myelin basic protein (MBP), and 50 μ M ^{33}P - γ -ATP. All reaction components, with the exception of ATP and MBP, were premixed and aliquoted (33 μ L) into a 96-well plate. A stock solution of compound in DMSO was used to make up to 500-fold dilutions; a 1.5- μ L aliquot of DMSO or inhibitor in DMSO was added to each well. The reaction was initiated by adding the substrates ^{33}P - γ -ATP and MBP (33 μ L). After 20 minutes the reaction was quenched with 20% (w/v) trichloroacetic acid (TCA) (55 μ L) containing 4 mM ATP, transferred to the GF/B filter plates, and washed 3 times with 5% (w/v) TCA). Following the addition of Ultimate Gold™ scintillant (50 μ L), the samples were counted in a Packard TopCount. From the activity versus concentration titration curve, the K_i value was determined by fitting the data to an equation for competitive tight binding inhibition kinetics using Prism software, version 3.0.

[0165] For IC₅₀ determination of ERK2, activity was assayed by a standard coupled-enzyme assay. The final concentrations were as follows: 0.1 M HEPES (pH 7.5), 10 mM MgCl₂, 1 mM DTT, 2.5 mM phosphoenolpyruvate, 200 μM NADH, 50 μg/mL pyruvate kinase, 10 μg/mL lactate dehydrogenase, 65 μM ATP, and 800 μM peptide (ATGPLSPGPFGR). All of the reaction components except ATP were premixed with ERK and aliquoted into assay-plate wells. BVD-523 in DMSO was introduced into each well, keeping the concentration of DMSO per well constant. BVD-523 concentrations spanned a 500-fold range for each titration. The assay-plate was incubated at 30°C for 10 minutes in the plate reader compartment of the spectrophotometer (molecular devices) before initiating the reaction by adding ATP. The absorbance change at 340 nm was monitored as a function of time; the initial slope corresponds to the rate of the reaction. The rate versus concentration of the BVD-523 titration curve was fitted either to an equation for competitive tight-binding inhibition kinetics to determine a value for K_i or to a 3-parameter fit to determine the IC₅₀ using Prism software, version 3.0.

[0166] For apoptosis assays, cells were plated at 2×10^4 cells per well in a 96-well plate and allowed to attach overnight or grow to 50% confluency. Cells were treated with a serial dilution of BVD-523 in media (final volume 200 μL, concentration ranges 4–0.25 μM) and incubated for 48 hours in a 37°C CO₂ incubator. Cells were washed with 100 μL of PBS, and 60 μL of radioimmunoprecipitation assay buffer was added (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1.0% [w/v] NP-40, 0.5% [w/v] sodium deoxycholate, 1% [w/v] SDS), then incubated for 10 minutes at 4°C to lyse the cells. A 30-μL lysate aliquot was added to 100 μL of caspase assay buffer (120 mM HEPES, 12 mM EDTA, 20 mM dithiothreitol, 12.5 μg/mL AC-DEVD-AMC caspase substrate) and incubated at RT from 4 hours to overnight. The plate was read in a

fluorimeter (excitation wavelength 360 nm, emission wavelength 460 nm). The remaining 30 μ L of lysate was analyzed for total protein content using the BioRad Protein Assay Kit (sample-to-working reagent ratio of 1:8). Final normalized caspase activity was derived as fluorescence units per μ g protein and converted to a fold increase in caspase activity when compared with DMSO controls.

[0167] For measurement of antitumor activity in A375 xenografts, xenografts were initiated with A375 cells maintained by serial subcutaneous transplantation in female athymic nude mice. Each test mouse received an A375 tumor fragment (1 mm^3) implanted subcutaneously in the right flank. Once tumors reached target size ($80\text{--}120\text{ mm}^3$), animals were randomized into treatment and control groups, and drug treatment was initiated.

[0168] To evaluate BVD-523 monotherapy, BVD-523 in 1% (w/v) carboxymethylcellulose (CMC) was administered orally, per os (p.o.), BID at doses of 5, 25, 50, 100, or 150 mg/kg. Oral temozolomide was administered as a positive reference compound at 75 or 175 mg/kg once daily (QD) for a total of five treatments (QD $\times$ 5).

[0169] The efficacy of BVD-523 in combination with dabrafenib was evaluated in mice randomized into 9 groups of 15 and 1 group of 10 (Group 10). Dabrafenib was administered p.o. at 50 or 100 mg/kg QD and BVD-523 was administered p.o. at 50 or 100 mg/kg BID, alone and in combination, until study end; vehicle-treated and temozolomide-treated (150 mg/kg QD $\times$ 5) control groups were also included. Combination dosing was stopped on Day 20 to monitor for tumor regrowth. Animals were monitored individually and euthanized when each tumor reached an endpoint volume of 2000 mm^3 , or the final day (Day 45), whichever came first, and median time to endpoint (TTE) calculated. The combination was also evaluated in an

upstaged A375 model where larger tumors in the range 228–1008 mm³ were evaluated. Here, mice were randomized into 1 group (Group 1) of 14 and 4 groups (Groups 2–5) of 20. Dosing was initiated on Day 1 with dabrafenib plus BVD-523 (25 mg/kg dabrafenib + 50 mg/kg BVD-523 or 50 mg/kg dabrafenib + 100 mg/kg BVD-523), with each agent given p.o. BID until study end. The study included 50-mg/kg dabrafenib and 100-mg/kg BVD-523 monotherapy groups as well as a vehicle-treated control group. Tumors were measured twice weekly. Combination dosing was stopped on Day 42 to monitor for tumor regrowth through study end (Day 60). Treatment outcome was determined from % TGD, defined as the percent increase in median TTE for treated versus control mice, with differences between groups analyzed via log rank survival analysis. For TGI analysis, %TGI values were calculated and reported for each treatment (T) group versus the control (C) using the initial (i) and final (f) tumor measurements based on the following formula: %TGI=1-Tf-Ti/Cf-C. Mice were also monitored for CR and PR responses. Animals with a CR at the end of the study were additionally classified as TFS.

[0170] For measurement of BVD-523 activity in Colo205 xenografts, human Colo205 cells were cultured in RPMI 1640 supplemented with 10% (v/v) fetal bovine serum (FBS), 100 units/mL penicillin, 100 µg/mL streptomycin (Invitrogen), and 2 mM L-glutamine. Cells were cultured for fewer than four passages prior to implantation. Female athymic nude mice (19–23 g) were injected subcutaneously with 2×10^6 Colo205 cells into the right dorsal axillary region on Day 0.

[0171] Mice with an approximate tumor volume of 200 mm³ were randomized into 6 experimental groups. Vehicle control, 1% CMC (w/v), was prepared weekly. BVD-523 was suspended in 1% (w/v) CMC at the desired concentration and homogenized on ice at 6,500 rpm for 50 minutes. BVD-523 suspensions were

prepared weekly and administered p.o. BID at total daily doses of 50, 100, 150, and 200 mg/kg (n = 12/group) on an 8- or 16-hour dosing schedule for 13 days. The vehicle control (n = 12) was administered using the same dosing regimen. CPT-11 was administered as a positive reference compound (n = 12). Each 1 mL of CPT-11 injection contained 20 mg irinotecan, 45 mg sorbitol, and 0.9 mg lactic acid. CPT-11 was administered at 100 mg/kg/day intraperitoneally every 4 days for 2 consecutive doses.

[0172] For measurement of ERK1/2 Isotope-Tagged Internal Standard (ITIS) Mass Spectrometry in Colo205 Xenografts, frozen tumors were lysed in 10 volumes of ice cold lysis buffer (10 mM TRIS-HCl, pH 8.0, 10 mM MgCl₂, 1% (v/v) Triton X-100, Complete™ Protease Inhibitor Cocktail [Roche, cat. No. 1836170], Phosphatase Inhibitor Cocktail I [Sigma, cat. No. P-2850], Phosphatase Inhibitor Cocktail II [Sigma cat. No. 5726], and benzonase [Novagen cat. No. 70664]). Lysates were clarified by centrifugation (100,000 × g for 60 minutes at 4°C) and the supernatants adjusted to 2 mg/mL with lysis buffer. ERK1 was immunoprecipitated using agarose-coupled and pan-anti-ERK1 (Santa Cruz Biotechnology cat. No. sc-93ac) antibodies. Immunoprecipitated proteins were resolved by SDS-PAGE and stained with SYPRO Ruby (Invitrogen), and the ERK bands excised via razor. Gel slices were washed in 300 µL of 20 mM NH₄HCO₃, diced into small pieces, and placed in Page Eraser Tip (The Nest Group cat no. SEM0007). Gel fragments were reduced and alkylated prior to trypsin digestion. Tryptic fragments were isolated in 75 µL of 50% (v/v) Acetonitrile, 0.2% (v/v) trifluoroacetic acid and the resulting sample concentrated to 0–10 µL in a SpeedVac.

[0173] For ITIS analysis, digested samples were spiked with heavy-atom labeled peptide standards and fractional phosphorylation was quantified by coupled

liquid chromatography-tandem mass spectrometry (MS). Nanocapillary chromatography was performed using a Rheos 2000 binary pump from Flux Instruments delivering nanoscale flow after 1:750 splitting, an LC Packings Inertsil nano-precolumn (C18, 5 mm, 100Å, 30 mm ID × 1 mm), and a New Objective PicoFrit AQUASIL resolving column (C18, 5 mm, 75/15 mm ID × 10 cm), which also served as an electrospray ionization (ESI) emitter. An Applied Biosystem API 3000 mass spectrometer coupled with a nano-ESI source was used for MS analysis. An in-house-made gas nozzle connected to a nebulizing gas source was used to help steady nano-flow spray. Data were acquired in a multiple reaction monitoring (MRM) mode: nebulizing gas at 3; curtain gas at 7; collision gas at 5; ion spray voltage at 2150 volts, exit potential at 10 volts; Q1/Q3 resolution Low/Unit; and dwell time of 65 msec for all MRM channels. All raw MS data were processed using a combination of the Analyst software suite from Applied Biosystem and custom tools.

[0174] For assessment of drug sensitivity in cell-line models of acquired resistance, drug sensitivity of dose-escalated A375 cells and isogenic RKO cells was assessed in 96-hour proliferation assays. RKO isogenic cells (McCoy's 5A containing 10% [v/v] FBS) or dose-escalated A375 cells (DMEM containing 10% FBS) were seeded into 96-well plates and allowed to adhere overnight prior to addition of compound or vehicle control. Note that the dose-escalated A375 cells were seeded in the absence of inhibitor. Compounds were prepared from 0.1% (v/v) DMSO stocks to give a final concentration as indicated. Test compounds were incubated with the cells for 96 hours at 37°C in a 5% CO₂ humidified atmosphere. For the RKO cells, CellTiter-Glo® reagent (Promega) was added according to manufacturer's instructions and luminescence detected using a BMG FLUOstar plate reader. For the A375 assays Alamar blue (ThermoFisher) 10% (v/v) was added and

incubated for 4h, and fluorescent product was then detected using a BMG FLUOstar. The average media only background value was deducted and the data analyzed using a 4-parameter logistic equation in GraphPad Prism.

[0175] IC₅₀ Determination of ERK1 was measured in a final reaction volume of 25 μ L. ERK1 (human) (5–10 mU) was incubated with 25 mM Tris (pH 7.5), 0.02 mM ethyleneglycoltetracetic acid, 250 μ M peptide, 10 mM Mg acetate, and γ -³³P-ATP (specific activity approximately 500 cpm/pmol, concentration as required). Adding Mg ATP initiated the reaction. After incubation for 40 minutes at room temperature (RT), the reaction was stopped by adding 5 μ L of a 3% (w/v) phosphoric acid solution. Then, 10 μ L of the reaction was spotted onto a P30 filtermat, and washed 3 times for 5 minutes in 75 mM of phosphoric acid then once in methanol before drying and scintillation counting.

[0176] RKO MEK1 Q56P Isogenic cells were produced by Horizon Discovery (Cambridge, UK; #HD 106-019) using a recombinant AAV-mediated gene targeting strategy. Briefly, rAAV virus was generated following transfection of the appropriate targeting vector and helper vectors in HEK293T cells, purified using an AAV purification kit (Virapur, San Diego, USA) and titrated using qPCR. Parental homozygous RKO cells (homozygous wild type for MEK1) were then infected with rAAV virus and clones that had integrated the selection cassette were identified by G418 selection and expanded. Correctly targeted clones that were heterozygous for knock-in of the MEK1 Q56P point mutation into a single allele were identified by PCR and sequencing.

[0177] Isogenic SW48 cell lines heterozygous for knock-in of mutant KRAS (De Roock et al 2010, JAMA, 304, 1812-1820) were obtained from Horizon Discovery (Catalogue numbers; HD 103-002, HD 103-006 HD 103-007, HD 103-009,

HD 103-010, HD 103-011, HD 103-013). For proliferation assay, cells were seeded into 96-well plates in McCoy's 5A medium supplemented with 10% FBS and allowed to adhere overnight prior to addition of compound or vehicle control. Test compounds were incubated with the cells for 96 hours at 37°C in a 5% CO₂ atmosphere. Viability was then assessed using Alamar blue.

[0178] The proprietary KinaseProfiler assay was conducted at Upstate Discovery and employed radiometric detection similar to that employed by Davies et al, was used to profile the selectivity of BVD-523 against a panel of 70 kinases.

[0179] A drug sensitivity analysis was carried out as part of The Genomics of Drug Sensitivity in Cancer Project using high-throughput screening, as previously described (Yang et al. 2013).

[0180] For Western blot analysis, A375 cells were seeded onto 10cm dishes in Dulbecco's Modified Eagle's Medium plus 10% (v/v) FBS. Cells were allowed to adhere overnight prior to the addition of test compound or vehicle. For experiments with RKO cells, these cells were seeded in 6-well plates or 10cm dishes with McCoy's 5A + 10% (v/v) FBS. Cells were then treated at the desired concentration and duration. Cells were harvested by trypsinization, pelleted, and snap frozen. Lysates were prepared with RIPA buffer supplemented with protease and phosphatase inhibitor cocktails (Roche), clarified by centrifugation at 11,000 rpm for 10 minutes, and quantitated by bicinchoninic acid assay. Samples were resolved by SDS-PAGE, blotted onto polyvinylidene difluoride membranes, and probed using antibodies (i.e., pRB [Ser780], cat. no. 9307; CCND1, cat. no. ab6152; BCL-xL, cat. no. 2762; PARP, cat. no. 9542; DUSP6, cat. no. 3058S) directed to the indicated targets.

[0181] For Reverse Phase Protein Analysis (RPPA), A375, MIAPaCa-2, HCT116, Colo205, HT-29, and AN3Ca cells (ATCC) were plated at 80% confluence, allowed to recover overnight (MIAPaCa-2 cells were plated at 30% confluence and allowed to recover for 3 days), then treated with 10 μ M of each compound (i.e., BVD-523, SCH722984, GDC-0994, or Vx-11e) for 6 hours at 37°C. Control wells were treated with DMSO at 0.1% (v/v) for 6 hours prior to cell lysate generation. Samples were then analyzed using reverse-phase protein microarray technology (Theranostics Health).

[0182] For analysis of pERK IHC in Colo205 xenografts, xenograft tumors were processed overnight in 70% through 100% graded ethanols, cleared in two changes of xylene, infiltrated with paraffin, and embedded into paraffin blocks. Then, 5- μ m sections were cut and placed onto positively charged glass slides and baked for at least 30 minutes, but not longer than 1 hour, at 60°C. A single section from each animal and dose group was probed with anti-phospho p42/p44 MAPK antibody (pERK [1:100], CST; Cat no. 9101; Lot no. 16), counterstained with hematoxylin, and then analyzed microscopically using a Zeiss Axioplan 2 microscope. An isotype control (rabbit, Zymed laboratories, catalog no. 08-6199, lot no. 40186458) was run as a negative control.

[0183] For FACS analysis, cells were scraped and pelleted at 1,500 rpm for 5 minutes, then re-suspended in 1 mL of buffer and frozen at -70°C. The frozen cells were thawed and centrifuged again, followed by 10 minutes of re-suspension in 0.25 mL of Buffer A (trypsin in spermine tetrahydrochloride detergent buffer) to disaggregate cell clumps and digest cell membranes and cytoskeletons. Buffer B (trypsin inhibitor and Ribonuclease I in buffer, 0.2 mL) was added for 10 minutes in the dark. The resulting DNA-stained nuclei were filtered and analyzed by FACS. The

histograms were analyzed to establish the proportion of cells in the G1, S, and G2/M phases of the cell cycle based on the presence of n and $2n$ DNA (or higher) content.

[0184] For measurement of *in vitro* combination activity, five thousand G-361 cells were seeded into triplicate 96-well plates containing McCoy's 5A with 10% (v/v) FBS and allowed to adhere overnight. The vemurafenib/BVD-523 combination was tested using a 10×8 dose matrix. Compounds were incubated with the cells for 72 hours at 37°C in a 5% CO₂ humidified atmosphere. CellTiter-Glo reagent was added according to manufacturer's instructions and luminescence detected using a MBG FLUOstar plate reader. The interactions across the dose matrix were determined by the Loewe Additivity and Bliss independence models using Horizon's Chalice Combination Analysis Software.

[0185] For generating compound resistance *in vitro* by dose escalation, A375 parental cells (ATCC CRL-1619) were grown to ~40–60% confluence in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% heat-inactivated FBS and penicillin/streptomycin, then treated with initial doses of BVD-523, trametinib, or dabrafenib either alone or in combination at or slightly below each compound's IC₅₀; for combination studies, initial dosing was half of each compound's IC₅₀. Cells were allowed to grow until ~70–90% confluence and split; medium was refreshed every 3–4 days. When cells again reached ~40–60% confluence, the dose was escalated by the same increment (equivalent to the starting concentration) then moved to 1.5-fold increases in concentration followed by a further move to 2-fold increases if the cells continued to adapt rapidly (e.g., the first six doses of the dabrafenib escalation were: 5, 10, 15, 20, 25, and 37.5 nM). This process was repeated as required.

[0186] Cell viability assays for FIG. 30A were performed by a Resazurin (Alamar Blue) metabolic assay after 5 days in drug in full serum under high glucose

conditions. Cells were seeded in 384-well microplates at ~15%-50% confluence in medium with 10% FBS and penicillin/streptavidin plus high glucose (18-25 mM). The optimal cell number for each cell line was determined to optimize growth during drugging. For adherent cell lines, after overnight incubation cells were treated with 9 concentrations of each compound (2-fold dilutions series) using liquid handling robotics, and returned to the incubator for assay at a 96-h time point. For suspension cell lines, cells were treated with compound immediately after plating and returned to the incubator for a 96-h time point. Cells were then stained with 55 µg/ml Resazurin (Sigma) prepared in glutathione-free media for 4 hours. Quantitation of fluorescent signal intensity was performed using a fluorescent plate reader at excitation and emission wavelengths of 535/595 nm for Resazurin. All screening plates were subjected to stringent quality control measures. Effects on cell viability were measured and a curve-fitting algorithm was applied to the raw dataset to derive a multi-parameter description of drug response, including the half maximal inhibitory concentration (IC₅₀). IC₅₀ is expressed in natural log of the IC₅₀ in µM (LN_IC₅₀; EXP returns IC₅₀ in µM). Extrapolation of the IC₅₀ was allowed for where it yielded very high values. If desired the data was restricted to the tested concentration range by capping IC₅₀ values at the maximum tested concentration (and the minimum tested concentration for low values).

[0187] For efficacy testing of BVD-523 in a patient-derived xenograft (AT052C) representing melanoma from a BRAF^{V600E} patient that had become clinically refractory to vemurafenib. Tumor fragments were harvested from host animals and implanted into immune-deficient mice. The study was initiated at a mean tumor volume of approximately 170 mm³, at which point the animals were randomized into four groups including a control (1% [v/v] CMC p.o., BID×31) and

three treatment groups (BVD-523 [100 mg/kg], dabrafenib [50 mg/kg], or BVD-523/dabrafenib [100/50 mg/kg], n = 10/group); All treatment drugs were administered p.o. on a BID×31 schedule.

[0188] For IC₅₀ determination for the inhibition of PMA-stimulated RSK1 phosphorylation by BVD-523 in human whole blood samples, IC₅₀ values for the inhibition of PMA stimulated RSK1 phosphorylation by BVD-523 were determined for 10 healthy donors (aged 22–61 years) using an 8-point concentration curve ranging from 10 μM to 5 nM of BVD-523. Controls consisted of 3 unstimulated samples and 3 PMA-stimulated samples for each donor. Both phosphor-RSK (pRSK) and total RSK levels were determined and data were calculated using pRSK/RSK levels for each sample.

[0189] Thirty milliliters of blood was drawn from each donor into sodium heparin vacutainers. One mL of whole blood was added to each of twenty-two 2-mL microtubes per donor. The microtubes tubes were labeled with the donor number (1 through 10) and the subsequent treatment designation: “A” for PMA stimulation only (maximum), “B” for BVD-523-containing samples that received PMA stimulation; and “C” for the unstimulated samples (minimum). Dimethyl sulfoxide (DMSO) was added to all tubes in groups A and C to a final concentration of 0.1%. Samples were then rocked gently at room temperature.

[0190] BVD-523 (10 mM in 100% DMSO) was serially diluted with 3-fold dilutions into 100% DMSO. These serially diluted BVD-523 samples in 100% DMSO were then diluted 10-fold in Dulbecco's Modified Eagle Medium containing 10% fetal bovine serum and penicillin/streptomycin/glutamine, and 10 μL of each of these working solutions was added per mL of blood for each designated BVD-523 concentration. Each concentration of BVD-523 was run in duplicate, two 1-mL blood

samples each, yielding 16 total samples for the full 8-point concentration curve. Samples were then rocked gently at room temperature for a minimum of 2 hours but not longer than 3 hours.

[0191] Human whole blood samples in groups A and B for all donors were stimulated with PMA at a final concentration of 100 nM for 20 minutes at room temperature. Samples in group C were not treated with PMA but were rocked and handled as all other samples.

[0192] Upon completion of PMA treatment for each sample, peripheral blood mononuclear cells were isolated from the human whole blood. One mL of blood from each sample was gently layered onto 0.75 mL of room-temperature Histopaque 1077 in a 2-mL microcentrifuge tube. The samples were centrifuged for 2 minutes at 16,000 x g in an Eppendorf microcentrifuge. The interface and upper layers were removed and added to tubes containing 1 mL of cold Dulbecco's phosphate-buffered saline (DPBS). These samples were then centrifuged for 30 seconds at 16,000 x g to pellet the cells. The buffer supernatant was removed by aspiration and the pellets were re-suspended in 1 mL of cold DPBS. The pellets from each sample were then re-pelleted as above. The buffer was removed by aspiration and the pellets were lysed as indicated below.

[0193] Complete lysis buffer consisted of Meso Scale Discovery Tris lysis buffer, 1X Halt Protease inhibitor cocktail, 1X Phosphatase inhibitor cocktail 2, 1X Phosphatase inhibitor cocktail 3, 2 mM phenylmethanesulfonyl fluoride, and 0.1% sodium dodecyl sulfate. Lysis buffer was kept on ice and made fresh for each sample group. Final cell pellets were lysed by the addition of 120 μ L of complete lysis buffer. Samples were vortexed until the cell pellet disappeared and then flash

frozen on dry ice. Samples were stored at -20°C prior to measurement of pRSK and total RSK by ELISA.

[0194] For the pRSK ELISA (PathScan), thawed lysates were combined 1:1 with sample diluent (provided in ELISA kit): 120 μL of lysate added to 120 μL of sample diluent in a round bottom 96-well plate. This combination was then transferred to the pRSK microwells at 100 μL per well. For the total RSK ELISA (PathScan), 20 μL of the lysate already diluted 1:1 in sample diluent was further diluted in 200 μL of sample diluent in a round bottom 96-well plate. This combination was then transferred to the total RSK microwells at 100 μL per well. The plates were sealed with a plate seal and incubated 16 to 18 hours at 4°C , a time that was shown to yield the best detection of the target protein. Both ELISAs were developed according to the kit instructions.

[0195] Patients aged ≥ 18 years were eligible for participation if they had noncurable, histologically confirmed metastatic or advanced stage malignant tumors; an ECOG performance status of 0 or 1; adequate renal, hepatic, bone marrow, and cardiac function; and a life expectancy ≥ 3 months. Patients may have received up to 2 prior lines of chemotherapy for their metastatic disease. Exclusion criteria were known uncontrolled brain metastases; gastrointestinal conditions which could impair absorption of study medication; history or current evidence/risk of retinal vein occlusion or central serous retinopathy; and concurrent therapy with drugs known to be strong inhibitors of CYP1A2, CYP2D6, and CYP3A4 or strong inducers of CYP3A4. All participants provided informed consent prior to initiation of any study procedures.

[0196] Patients that received at least one dose of BVD-523 were included in the analysis using SAS (version 9.3) software. The data cutoff was December 1, 2016. This study is registered with ClinicalTrials.gov, number NCT01781429.

[0197] The present invention presents data from an open-label, multicenter phase I study to assess the safety, pharmacokinetics, and pharmacodynamics of escalating doses of BVD-523 in patients with advanced malignancies. The dosing regimen combined both accelerated titration and standard cohort 3+3 dose escalation schema, which were used jointly to identify the MTD and RP2D of BVD-523 in patients with advanced solid tumors. One to 6 patients per treatment cohort were assigned to receive sequentially higher oral doses of BVD-523 on a BID schedule (12-hour intervals) in 21-day cycles, starting at a dose of 10 mg BID. BVD-523 was administered BID continuously in 21-day cycles at the following doses: 10 mg (n = 1); 20 mg (n = 1); 40 mg (n = 1); 75 mg (n = 1); 150 mg (n = 1); 300 mg (n = 4); 600 mg (n = 7); 750 mg (n = 4); and 900 mg (n = 7).

[0198] Patients received BID oral doses until disease progression, unacceptable toxicity, or a clinical observation satisfying another withdrawal criterion. Dose escalations occurred in up to 100% increments in single-patient cohorts until 1 patient experienced a $\geq$ Grade 2 toxicity (excluding alopecia or diarrhea). Cohorts were then expanded to at least 3 patients each and subsequent dose-escalation increments were reduced from up to 100% to a maximum of 50%. When at least 1 patient in a 3-patient cohort experienced a DLT, up to 3 additional patients were treated at this dose level. When more than 1 DLT occurred in ≤ 6 patients, this dose level was defined as the nontolerated dose and dose escalation was stopped. Inpatient dose escalation was allowed, provided the patients receiving the highest current dose had been observed for at least 3 weeks and dose-limiting side effects

were reported in fewer than 2 of 6 patients assigned to a given dose. Patients experiencing DLTs or unacceptable toxicity had their treatment interrupted until the toxicity returned to $\leq$ Grade 1. Resumption of BVD-523 treatment was then initiated at the next lower dose level tested or at a 20% to 30% dose decrease, aligning with capsule dosage.

[0199] The primary objective of the phase I study was to define the safety and tolerability of BVD-523 by determining the dose-limiting toxicities, the MTD, and the RP2D. The secondary objectives included the determination of the pharmacokinetic profile of BVD-523 in patients with advanced malignancies and the investigation of any preliminary clinical effects on tumor response, as assessed by physical or radiologic exam using RECIST v1.1. The exploratory objectives included evaluation of pharmacodynamic marker (biomarker) measures and investigation of preliminary clinical effects on tumor response assessed by ^{18}F -FDG-PET as indicated.

[0200] For determination of MTD, DLT, and RP2D, MTD was defined as the highest dose cohort at which $\leq 33\%$ of patients experienced BVD-523-related DLTs in the first 21 days of treatment. DLT was defined as a BVD-related toxicity in the first 21 days of treatment that resulted in $\geq$ Grade 4 hematologic toxicity for >1 day; Grade 3 hematologic toxicity with complications (e.g., thrombocytopenia with bleeding); $\geq$ Grade 3 nonhematologic toxicity, except untreated nausea, vomiting, constipation, pain, and rash (these become DLTs if the AE persisted despite adequate treatment); or a treatment interruption exceeding 3 days in Cycle 1 (or the inability to begin in Cycle 2 for >7 days) due to BVD-523-related toxicity.

[0201] The RP2D could be as high as the MTD and was determined in discussion with the clinical investigators, the medical monitor, and the sponsor. Observations related to pharmacokinetics, pharmacodynamics, and any cumulative

toxicity observed after multiple cycles were included in the rationale supporting the RP2D.

[0202] With regard to safety assessments, AEs were defined as any untoward medical occurrence in a patient who was administered a medicinal product that does not necessarily have a causal relationship with BVD-523, and was coded using the MedDRA coding dictionary. An SAE was any untoward medical occurrence that occurred at any dose that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, or resulted in persistent or significant disability/incapacity or a congenital anomaly/birth defect. The severity of AEs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Grading Scale, version 4.

[0203] Safety evaluations were conducted at baseline, on Days 8, 15, 22, 29, 36, and 43, and, in patients who continued treatment, every 3 weeks or if clinically indicated thereafter. Each evaluation included a physical examination and clinical laboratory studies. Electrocardiograms were repeated if clinically significant and at the discretion of the investigator. The investigators made judgments regarding whether or not AEs were related to study drug and followed up until resolution or stabilization, or the AE was judged to be no longer clinically significant.

[0204] For pharmacokinetic analysis, the pharmacokinetic population consisted of patients who received at least one dose of BVD-523 and had evaluable pharmacokinetic data for plasma and/or urine. Blood samples were collected prior to dosing, and then at 0.5 ($\pm$ 5 min), 1 ($\pm$ 5 min), 2 ($\pm$ 10 min), 4 ($\pm$ 10 min), 6 ($\pm$ 10 min), 8 ($\pm$ 10 min), and 12 ($\pm$ 2 hr) hours on Day 1 (Visit 2; baseline/initiation of treatment) and Day 15 (Visit 4; at steady state) after the morning dose. On Day 22, prior to dose administration, a final blood sample was collected for pharmacokinetic

analyses. Urine samples were collected predose and at the 1- to 6-hour and 6- to 12- $\pm$ 2-hour intervals postdose on Days 1 and 15. Plasma and urine samples were analyzed for BVD-523 and metabolites using validated LC/MS/MS methods. Standard pharmacokinetic parameters were obtained using Phoenix WinNonlin (Pharsight) with a noncompartmental method. Relationship between dose and exposure was calculated using standard least-squares regression analysis.

[0205] For pharmacodynamic confirmation of target inhibition by BVD-523, targeted ERK inhibition by BVD-523 was determined by examining pRSK as a target biomarker in human whole blood samples obtained from patients with advanced solid tumors (N = 27) who had received different doses of BVD-523 (10–900 mg BID) during the phase I study. The activity of BVD-523 from 4 timepoints (baseline predose, baseline 4 hours postdose, Day 15 predose, and Day 15 4 hours postdose) was expressed as a percent activity (pRSK) of PMA-stimulated blood incubated with BVD-523.

[0206] For measurement of antitumor response, tumor measurements based on physical examination occurred at baseline and on the first day of each treatment cycle. CT and other assessments were made every 2 to 3 cycles. Findings were assessed in accordance with RECIST v1.1: CR was defined as disappearance of all target lesions; PR was defined as a $\geq 30\%$ decrease in the sum of the longest diameters of target lesions, taking baseline measurements as reference; stable disease was defined as being of neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the baseline measurement. Metabolic response was assessed by visualizing tumor uptake of ^{18}F -glucose via ^{18}F -FDG-PET scanning prior to receiving the first dose of BVD-523 and at Day 15 (Visit 4).

Example 2**Dose Escalation and Proliferation Assays – Month 1****Dose Escalation Progress – Month 1**

[0207] A375 cells were dose escalated using BVD-523, dabrafenib, and trametinib either as single agents or in combination. Doses were increased in small increments during the first month. Other than a marked reduction in growth rate, cells generally tolerated the escalations well and the doses were planned to be more aggressively escalated using larger increments in month 2. FIG. 1A – FIG. 1C show month 1 progress for the dose escalation studies.

Proliferation Assay Results – Month 1

[0208] Proliferation assays were performed to assess the response of the escalated cells lines vs. parental cell line, to BVD-523, dabrafenib, and trametinib treatments.

[0209] FIG. 2A – FIG. 2H show normalized and raw proliferation assay results from month 1 of the studies. Note that differences in max signals in DMSO controls between different treatments (FIG. 2D, FIG. 2F, and FIG. 2H) suggest differential growth rates between treatments. These differences may influence the responses of lines to inhibitors in the proliferation assays.

Table 10 shows IC₅₀ data for month 1 of the studies.

Table 10 - IC₅₀ Data - Month 1

Compound	Cell Line, Relative IC ₅₀ (nM)						
	Par*	Tram	Dab	BVD-523	Dab/Tram	Dab/523	Tram/523
Dabrafenib	6	29	about 161	8	58	68	11
Trametinib	0.5	2.2	2.5	0.7	3.9	3.1	2.5
BVD-523	189	335	350	268	300	412	263
Paclitaxel	2.2	3.0	3.3	3.4	3.5	3.4	3.4

*Par = Parental cell line

[0210] There were early hints that cells grown in the presence of escalating doses of dabrafenib or trametinib, either as single agents or in combinations, were exhibiting decreased responses to these two agents in proliferation assays.

[0211] In the early stages of month 2, the growth rate of cells in the dabrafenib only treatment notably increased relative to the early stages of month 1. This enabled an increased rate of progression and suggested that resistance was becoming apparent.

Example 3

Dose Escalation and Proliferation Assays – Month 2

Dose Escalation Progress – Month 2

[0212] The second month of studies saw most treatments move into a phase where doses were increased in greater increments (1.5-fold) compared to the initial gentle escalation phase. The single agent escalation of dabrafenib and trametinib was quickest, with cells growing in concentrations equivalent to 100x parental cell IC₅₀ (FIG. 3A and FIG. 3B). The single agent escalation of BVD-523 progressed more slowly compared to dabrafenib and trametinib (FIG. 3C). See FIG. 3D for a comparison of the single agent escalations. BVD-523 escalated cells had a more “fragile” appearance and there was a greater number of floating cells compared to the dabrafenib and trametinib escalated populations.

[0213] The combined agent escalations progressed more slowly than the single agent treatments. The BVD-523/trametinib combination was particularly effective in preventing cells from progressing.

Proliferation Assay Results – Month 2

[0214] Proliferation assays on single agent escalated dabrafenib and trametinib cell populations revealed modest shifts in the dose response curves, suggesting that an additional period of escalation would be beneficial to further enrich for resistant cells. Interestingly, in the proliferations assay, there was evidence to suggest that cells exposed to BVD-523 grew less well upon inhibitor withdrawal, perhaps indicating a level of addiction.

[0215] FIG. 4A – FIG. 4H show normalized and raw proliferation assay results from month 2 of the studies. Note that differences in max signals in DMSO controls between different treatments (FIG. 4D, FIG. 4F, and FIG. 4H) suggest differential growth rates between treatments. These differences may influence the responses of lines to inhibitors in the proliferation assays.

[0216] FIG. 5A – FIG. 5H show normalized and raw proliferation assay results from month 2 of the studies with a focus on parental and BVD-523 line data only.

[0217] Table 11 shows IC₅₀ data for month 2 of the studies. Relative IC₅₀s were determined from 4-parameter curve fits in Prism.

Table 11 - IC₅₀ Data - Month 2

Compound	Cell Line, Relative IC ₅₀ (nM)						
	Par*	Tra	Dab	BVD-523	Dab/Tram	Dab/523	Tram/523
Dabrafenib	4.1	6.2	11.5	697	256	218	68
Trametinib	0.4	0.7	1.1	24.3	12.6	6.2	4.6
BVD-523	187	252	284	1706	561	678	435
Paclitaxel	3.7	8.9	1.9	6.5	4.7	4.2	8.9

*Par = Parental cell line

Example 4**Dose Escalation and Proliferation Assays – Month 3**

Dose Escalation Progress – Month 3

[0218] FIG. 6A – FIG. 6C show single and combination agent escalation for month 3 of the studies. FIG. 6D shows a comparison of single agent escalations.

Proliferation Assay Results – Month 3

[0219] FIG. 7 shows an assessment of growth during the proliferation assay in DMSO control wells. FIG. 8A – FIG. 8D show results from month 3 of the studies. FIG. 9A – FIG. 9D show results from month 3 of the studies with a focus on single treatment cell lines.

[0220] Table 12 shows IC₅₀ data for month 3 of the studies. Relative IC₅₀s were determined from 4-parameter curve fits in Prism. IC₅₀ values were not determined for the cell line escalated with trametinib due to a lack of growth during the assay (ND: not done).

Table 12 - IC₅₀ Data - Month 3

Compound	Cell Line, Relative IC ₅₀ (nM)						
	Par*	Tram	Dab	BVD-523	Dab/Tram	Dab/523	Tram/523
Dabrafenib	2.1	ND	2.5	18.4	17.9	337	73
Trametinib	0.2	ND	0.4	1.7	2.7	90	11.2
BVD-523	129	ND	198	433	323	1151	296
Paclitaxel	1.9	ND	1.9	6.5	4.7	4.2	8.9

*Par = Parental cell line

[0221] FIG. 19 shows single and combination agent escalation for month 3 of the studies. Cell line variants were obtained that could grow in the presence of dabrafenib or trametinib at concentrations greater than 100 times the IC₅₀ of these agents in parental A375 cell. In comparison, cell lines resistant to BVD-523 could only be maintained in less than 10X of parental IC₅₀ concentration. Sensitivity testing suggested dabrafenib and trametinib-resistant cell lines remained relatively

sensitive to BVD-523; the increased IC₅₀ “shift” for BVD-523 in resistant cell lines was more modest than those corresponding IC₅₀ increases following dabrafenib or trametinib treatment. Likewise, compared to dabrafenib or trametinib treatment, more complete inhibition of cell growth was observed when resistant cell lines were treated with BVD-523 at concentrations 10-fold above its IC₅₀ in the parental A375 line. In total, patterns of resistance and cross-sensitivity suggest BVD-523 may remain effective in settings of acquired resistance.

Example 5

Combination Study Results

[0222] As expected, A375 cells, which carry a BRAF (V600E) mutation, were sensitive to dabrafenib. Single agent IC₅₀ values calculated using Alamar Blue (FIG. 10A – FIG. 10E, FIG. 12A – FIG. 12E, and FIG. 14A – FIG. 14E) were generally slightly lower for Dabrafenib and BVD-523 compared to those derived using CellTiter-Glo (FIG. 11A – FIG. 11E, FIG. 13A – FIG. 13E, and FIG. 15A – FIG. 15E). Published IC₅₀ values for Dabrafenib and Trametinib in a 72 hour CellTiter-Glo assay were 28 ± 16nM and 5 ± 3nM respectively (Greger *et al.*, 2012; King *et al.*, 2013) – the single agent results reported here are consistent with these values. There was some evidence for a window of synergy in all treatments. Variation between triplicates was low, however, there was some evidence of edge effects that likely explains the apparent enhanced growth observed in some treatments versus the no drug control (e.g. particularly apparent in the Trametinib/BVD-523 combination). This makes the interpretation of the Bliss analysis more challenging as in some treatments it may have resulted in the artefactual enhancement in the level of synergy.

[0223] The combination assays were repeated for A375 cells. Single agent BVD-523, Trametinib and Dabrafenib potencies were consistent with those reported in the previous studies disclosed herein.

[0224] In sum, taken together the data show that MEK and BRAF resistant cells could be overcome by treatment with the ERK inhibitor, BVD-523.

Example 6

BVD-523 altered markers of MAPK kinase activity and effector function

[0225] For Western blot studies, HCT116 cells (5×10^6) were seeded into 10 cm dishes in McCoy's 5A plus 10% FBS. A375 cells (2.5×10^6) were seeded into 10 cm dishes in DMEM plus 10% FBS. Cells were allowed to adhere overnight prior to addition of the indicated amount of test compound (BVD-523) or vehicle control. Cells were treated for either 4 or 24 hours before isolation of whole-cell protein lysates, as specified below. Cells were harvested by trypsinisation, pelleted and snap frozen. Lysates were prepared with RIPA (Radio-Immunoprecipitation Assay) buffer, clarified by centrifugation and quantitated by bicinchoninic acid assay (BCA) assay. 20-50 μ g of protein was resolved by SDS-PAGE electrophoresis, blotted onto PVDF membrane and probed using the antibodies detailed in Table 13 (for the 4-hour treatment) and Table 14 (for the 24-hour treatment) below.

Table 13 – Antibody Details

Antigen	Size (kDa)	Supplier	Cat No	Dilution	Incubation/Block Conditions	Secondary
pRSK1/2 pS380	90	Cell Signaling	9335	1:1000	o/n 4°C 5% BSA	anti-rabbit
pRSK1/2 pS380	90	Cell Signaling	11989	1:2000	o/n 4°C 5% BSA	anti-rabbit
pRSK-T359/S363	90	Millipore	04-419	1:40000	o/n 4°C 5% BSA	anti-rabbit
Total RSK	90	Cell Signaling	9333	1:1000	o/n 4°C 5% BSA	anti-rabbit

Antigen	Size (kDa)	Supplier	Cat No	Dilution	Incubation/Block Conditions	Secondary
pErk 1/2	42/44	Cell Signaling	9106S	1:500	o/n 4°C 5% milk	anti-mouse
Total ERK	42/44	Cell Signaling	9102	1:2000	o/n 4°C 5% milk	anti-rabbit
pMEK1/2	45	Cell Signaling	9154	1:1000	o/n 4°C 5% BSA	anti-rabbit
Total MEK	45	Cell Signaling	9126	1:1000	o/n 4°C 5% BSA	anti-rabbit
pS6-pS235	32	Cell Signaling	2211S	1:3000	o/n 4°C 5% milk	anti-rabbit
Total S6	32	Cell Signaling	2217	1:2000	o/n 4°C 5% milk	anti-rabbit
DUSP6	48	Cell Signaling	3058S	1:1000	o/n 4°C 5% BSA	anti-rabbit
Total CRAF	73	BD Bio-sciences	610152	1:2000	o/n 4°C 5% milk	anti-mouse
pCRAF-Ser338	73	Cell Signaling	9427	1:1000	o/n 4°C 5% BSA	anti-rabbit
pRB (Ser780)	105	Cell Signaling	9307	1:2000	o/n 4°C 5% BSA	anti-rabbit
β-Actin	42	Sigma	A5441	1:500,000	o/n 4°C 5% milk	anti-mouse

Table 14 – Antibody details

Antigen	Size (kDa)	Supplier	Cat No	Dilution	Incubation/Block Conditions	Secondary
pRB (Ser780)	105	Cell Signaling	9307	1:2000	o/n 4°C 5% BSA	anti-rabbit
CCND1	34	Abcam	ab6152	1:500	o/n 4°C 5% milk	anti-mouse
Bim-EL	23	Millipore	AB17003	1:1000	o/n 4°C 5% BSA	anti-rabbit
Bim-EL	23	Cell Signaling	2933	1:1000	o/n 4°C 5% BSA	anti-rabbit
BCL-xL	30	Cell Signaling	2762	1:2000	o/n 4°C 5% BSA	anti-rabbit
PARP	116/89	Cell Signaling	9542	1:1000	o/n 4°C 5% milk	anti-rabbit
Cleaved Caspase 3	17,19	Cell Signaling	9664X	1:1000	o/n 4°C 5% milk	anti-rabbit
DUSP6	48	Cell Signaling	3058S	1:1000	o/n 4°C 5% BSA	anti-rabbit
pRSK1/2	90	Cell	9335	1:1000	o/n 4°C 5%	anti-rabbit

Antigen	Size (kDa)	Supplier	Cat No	Dilution	Incubation/Block Conditions	Secondary
pS380		Signaling			BSA	
pRSK1/2 pS380	90	Cell Signaling	11989	1:2000	o/n 4°C 5% BSA	anti-rabbit
pRSK-T359/S363	90	Millipore	04-419	1:40000	o/n 4°C 5% BSA	anti-rabbit
Total RSK	90	Cell Signaling	9333	1:1000	o/n 4°C 5% BSA	anti-rabbit
pErk 1/2	42/44	Cell Signaling	9106S	1:500	o/n 4°C 5% milk	anti-mouse
Total ERK	42/44	Cell Signaling	9102	1:2000	o/n 4°C 5% milk	anti-rabbit
B-Actin	42	Sigma	A5441	1:500,000	o/n 4°C 5% milk	anti-mouse

[0226] FIG. 16A – FIG. 16D, FIG. 17A – FIG. 17D, and FIG. 18A – FIG. 18D show Western blot analyses of cells treated with BVD-523 at various concentrations for the following: 1) MAPK signaling components in A375 cells after 4 hours; 2) cell cycle and apoptosis signaling in A375 24 hours treatment with various amounts of BVD-523; and 3) MAPK signaling in HCT-116 cells treated for 4 hours. The results show that acute and prolonged treatment with BVD-523 in RAF and RAS mutant cancer cells in-vitro affects both substrate phosphorylation and effector targets of ERK kinases. The concentrations of BVD-523 required to induce these changes is typically in the low micromolar range.

[0227] Changes in several specific activity markers are noteworthy. First, the abundance of slowly migrating isoforms of ERK kinase increase following BVD-523 treatment; modest changes can be observed acutely, and increase following prolonged treatment. While this could indicate an increase in enzymatically active, phosphorylated forms of ERK, it remains noteworthy that multiple proteins subject to both direct and indirect regulation by ERK remain “off” following BVD-523 treatment. First, RSK1/2 proteins exhibit reduced phosphorylation at residues that are strictly

dependent on ERK for protein modification (T359/S363). Second, BVD-523 treatment induces complex changes in the MAPK feedback phosphatase, DUSP6: slowly migrating protein isoforms are reduced following acute treatment, while total protein levels are greatly reduced following prolonged BVD-523 treatment. Both of these findings are consistent with reduced activity of ERK kinases, which control DUSP6 function through both post-translational and transcriptional mechanisms. Overall, despite increases in cellular forms of ERK that are typically thought to be active, it appears likely that cellular ERK enzyme activity is fully inhibited following either acute or prolonged treatment with BVD-523.

[0228] Consistent with these observations, effector genes that require MAPK pathway signaling are altered following treatment with BVD-523. The G1/S cell-cycle apparatus is regulated at both post-translational and transcriptional levels by MAPK signaling, and cyclin-D1 protein levels are greatly reduced following prolonged BVD-523 treatment. Similarly, gene expression and protein abundance of apoptosis effectors often require intact MAPK signaling, and total levels of Bim-EL increase following prolonged BVD-523 treatment. As noted above, however, PARP protein cleavage and increased apoptosis were not noted in the A375 cell background; this suggests that additional factors may influence whether changes in BVD-523/ERK-dependent effector signaling are translated into definitive events such as cell death and cell cycle arrest.

[0229] Consistent with the cellular activity of BVD-523, marker analysis suggests that ERK inhibition alters a variety of molecular signaling events in cancer cells, making them susceptible to both decreased cell proliferation and survival.

[0230] In sum, FIG. 16A – FIG. 16D, FIG. 17A – FIG. 17D, and FIG. 18A – FIG. 18D show that BVD-523 inhibits the MAPK signaling pathway and may be more favorable compared to RAF or MEK inhibition in this setting.

[0231] Finally, properties of BVD-523 may make this a preferred agent for use as an ERK inhibitor, compared to other agents with a similar activity. It is known that kinase inhibitor drugs display unique and specific interactions with their enzyme targets, and that drug efficacy is strongly influenced by both the mode of direct inhibition, as well as susceptibility to adaptive changes that occur following treatment. For example, inhibitors of ABL, KIT, EGFR and ALK kinases are effective only when their cognate target is found in active or inactive configurations. Likewise, certain of these inhibitors are uniquely sensitive to either secondary genetic mutation, or post-translational adaptive changes, of the protein target. Finally, RAF inhibitors show differential potency to RAF kinases present in certain protein complexes and/or subcellular localizations. In summary, as ERK kinases are similarly known to exist in diverse, variable, and complex biochemical states, it appears likely that BVD-523 may interact with and inhibit these targets in a fashion that is distinct and highly preferable to other agents.

Example 7

Effects of BVD-523 and Benchmark ERK BRAF and MEK Inhibitors on Viability and MAPK Signalling

Single Agent Proliferation Assay

[0232] Cells were seeded in 96-well plates at the densities indicated in Table 15 in McCoy's 5A containing 10% FBS and allowed to adhere overnight prior to addition of compound or vehicle control. Compounds were prepared from DMSO stocks to give the desired final concentrations. The final DMSO concentration was

constant at 0.1%. Test compounds were incubated with the cells for 96h at 37°C, 5% CO₂ in a humidified atmosphere. CellTiter-Glo® reagent (Promega, Madison, WI) was added according to manufacturer's instructions and luminescence detected using the BMG FLUOstar plate reader (BMG Labtech, Ortenberg, Germany). The average media only background value was deducted and the data analysed using a 4-parameter logistic equation in GraphPad Prism (GraphPad Software, La Jolla, CA).

Combination Proliferation Assay

[0233] Cells were seeded into triplicate 96-well plates at the densities indicated in Table 15 in McCoy's 5A containing 10% FBS and allowed to adhere overnight prior to addition of test compound or vehicle control. Combinations were tested using a 10x8 dose matrix. The final DMSO concentration was constant at 0.2%.

[0234] Test compounds were incubated with the cells for 96h at 37°C, 5% CO₂ in a humidified atmosphere. Cells were stained with Hoechst stain and fluorescence detected as described above. The average media only background value was deducted and the data analysed.

[0235] Combination interactions across the dose matrix were determined by the Loewe Additivity and Bliss independence models using Chalice™ Combination Analysis Software (Horizon Discovery Group, Cambridge, MA) as outlined in the user manual (available at chalice.horizondiscovery.com/chalice-portal/documentation/analyzer/home.jsp). Synergy is determined by comparing the experimentally observed level of inhibition at each combination point with the value expected for additivity, which is derived from the single-agent responses along the edges of the matrix. Potential synergistic interactions were identified by displaying the calculated excess inhibition over that predicted as being additive across the dose

matrix as a heat map, and by reporting a quantitative 'Synergy Score' based on the Loewe model. The single agent data derived from the combination assay plates were presented as dose-response curves generated in Chalice™.

Table 15 - Cell Line Seeding Density

Cell Line	Seeding density (cells/well)		
	96-well Proliferation	6-Well Western	10cm dish Westerns
RKO Parental	1000	1×10^5	2.5×10^6
RKO MEK1 (Q56P/+) Clone 1	1250	Not tested	Not tested
RKO MEK1 (Q56P/+) Clone 2	1000	7.5×10^3	2×10^6

Western Blotting

[0236] Cells were seeded into 6-well plates (Experiment 1) or 10cm dishes (Experiment 2) at the densities indicated in Table 15 in McCoy's 5A containing 10% FBS and allowed to adhere overnight prior to addition of compound or vehicle control. Test compounds were added and incubated with the cells for 4 or 24h at 37°C, 5% CO₂ in a humidified atmosphere. Cells were harvested by trypsinisation, pelleted by centrifugation and snap frozen on dry ice.

[0237] Lysates were prepared using RIPA buffer (50mM Tris-hydrochloride, pH 8.0; 150mM sodium chloride; 1.0% Igepal CA-630 (NP-40); 0.5% sodium deoxycholate; 0.1% sodium dodecyl sulphate; 1xcomplete EDTA-free protease inhibitor cocktail (Roche, Nutley, NJ; cat 05 892 791 001); 1xphosSTOP phosphatase inhibitor cocktail (Roche Nutley, NJ; cat. 04 906 837 001)) and clarified by centrifugation at 11,000 rpm for 10min in a bench-top centrifuge.

[0238] Total protein in the lysates was quantitated by BCA assay according to the manufacturer's instructions (Pierce™ BCA Protein Assay Kit; Thermo Scientific,

Waltham, MA; cat. 23225), boiled in sample buffer (NuPAGE LDS Sample Buffer; (Invitrogen, Carlsbad, CA; cat. NP0007)) and stored at -80°C.

[0239] Equal amounts of protein (40µg) were resolved on NuPAGE 4-12% Bis-Tris gels (Invitrogen, Carlsbad, CA; cat. WG1402BOX) and blotted onto PVDF membranes using iBlot gel transfer stacks (Invitrogen, Carlsbad, CA; cat. IB4010-01) on an iBlot gel transfer device (Invitrogen Carlsbad, CA) according to the manufacturer's instructions.

[0240] Blots were probed using the antibodies and block conditions detailed in Table 16. Western blots were developed using Pierce™ ECL2 Western blotting substrate (Thermo Scientific, Waltham, MA; cat. 80196) and imaged using a FluorChem M Western blot imager (ProteinSimple, San Jose, CA).

Table 16 – Antibodies and Western Blotting Conditions

Antigen	Size (kDa)	Supplier	Cat No	Dilution	Incubation/block Conditions	Secondary
pRSK-T358/S363	90	Millipore	04-419	1:20000	o/n 4°C 5% BSA	anti-rabbit
Total RSK	90	Cell Signaling	9333	1:1000	o/n 4°C 5% BSA	anti-rabbit
pErk 1/2	42/44	Cell Signaling	9106S	1:500	o/n 4°C 5% milk	anti-mouse
Total ERK	42/44	Cell Signaling	9102	1:2000	o/n 4°C 5% milk	anti-rabbit
pMEK1/2	45	Cell Signaling	9154	1:1000	o/n 4°C 5% BSA	anti-rabbit
Total MEK	45	Cell Signaling	9126	1:1000	o/n 4°C 5% BSA	anti-rabbit
DUSP6	48	Cell Signaling	3058S	1:1000	o/n 4°C 5% BSA	anti-rabbit
pRB (Ser780)	105	Cell Signaling	9307	1:2000	o/n 4°C 5% BSA	anti-rabbit
CCND1	34	Abcam	ab6152	1:500	o/n 4°C 5% milk	anti-mouse
B-Actin	42	Sigma	A5441	1:100,000	o/n 4°C 5% milk	anti-mouse
Anti-rabbit HRP-conjugated secondary	-	Cell Signaling	7074S	1:2000	1h room temp; Block matched to primary Antibody	-
Anti-mouse HRP-conjugated secondary	-	Cell Signaling	7076	1:5000	1h room temp; Block matched to primary Antibody	-

[0241] The MEK1 (Q56P) mutation exemplifies a class of clinically relevant MEK1/2 activating mutations known to up-regulate the MAPK pathway and drive acquired resistance to BRAF or MEK inhibitors.

[0242] This study used a pair of RKO BRAF(V600E) cell lines that are isogenic for the presence or absence of a MEK1 (Q56P) activating mutation, to assess the effect that activating MEK mutations have in response to the novel ERK inhibitor BVD-523 versus other benchmark MAPK inhibitors.

[0243] Effects of on cell viability were assessed by quantitating cellular ATP levels using CellTiter-Glo® after 96h. Single agent assays demonstrated that the double mutant BRAF(V600E)::MEK1(Q56P) cells displayed a markedly reduced

sensitivity to inhibition with benchmark clinical BRAF (exemplified by Dabrafenib) or MEK (exemplified by Trametinib) inhibitors relative to the parental BRAF(V600E) cells, which demonstrates the suitability of this isogenic model for recapitulating the acquired resistance known to be associated with this class of mutation in the clinic (Table 17).

Table 17 – Single Agent IC₅₀ Values

Compound	RKO Parental	RKO MEK1 Q56P/+ Cl.1	RKO MEK1 Q56P/+ Cl.2
BVD-523	0.20	0.17	0.18
SCH772984	0.04	0.14	0.12
Dabrafenib	n.d.	n.d.	n.d.
Trametinib	0.006	0.093	0.080
Paclitaxel	0.002	0.002	0.002

n.d. – not determined, only a partial dose response achieved

[0244] In contrast, response to BVD-523 was identical in both the parental and double mutant cells, indicating that BVD-523 is not susceptible to this mechanism of acquired resistance.

[0245] These results were identical in two independently derived double mutant BRAF(V600E)::MEK1(Q56P) cell line clones confirming that these differences in response versus the parental cells were specifically related to the presence of the MEK1 mutation rather than an unrelated clonal artifact (FIG. 22A – FIG. 22E). Similar results were also observed with a second mechanistically distinct benchmark ERK inhibitor (SCH772984), which supports the notion that these observations are specifically related to inhibition of ERK and not due to an off-target effect.

[0246] The effect of combining BVD-523 with a BRAF inhibitor (exemplified by Dabrafenib) was also assessed in these cell lines across a matrix of concentrations using the Loewe Additivity or Bliss Independence models with Horizon's Chalice™

combination analysis software (FIG. 23 – FIG. 23O and FIG. 24A - FIG. 24O). The presence of potentially synergistic interactions was then assessed by displaying the calculated excess inhibition over that predicted as being additive across the dose matrix as a heat map, and by calculating a 'Volume Score' that shows whether the overall response to a combination is synergistic (positive values), antagonistic (negative values) or additive (~ 0).

[0247] The results suggest that the BVD-523::Dabrafenib combination was mainly additive in the parental and mutant cell line. In contrast, the combination of a MEK inhibitor (trametinib) plus Dabrafenib, while being mostly additive in the parental cell line, showed strong synergy in the double mutant BRAF(V600E)::MEK1(Q56P) cell line (FIG. 25A – FIG. 25O). Loewe Volumes, Bliss Volumes and Synergy scores for the combinations tested are shown in Tables 18 - 20, respectively and are shown graphed in FIG. 26A – FIG. 26C.

Table 18 – Loewe Volumes

	RKO Parental	RKO MEK1 (Q56P) - Clone 1	RKO MEK1 (Q56P) - Clone 2
BVD-523 x Dabrafenib	3.54	2.88	2.35
Dabrafenib x SCH772984	5.2	6.79	6.14
Dabrafenib x Trametinib	5.68	12.6	11.6

Table 19 – Bliss Volumes

	RKO Parental	RKO MEK1 (Q56P) - Clone 1	RKO MEK1 (Q56P) - Clone 2
BVD-523 x Dabrafenib	-0.894	0.527	1.42
Dabrafenib x SCH772984	0.209	4.3	5.07
Dabrafenib x Trametinib	0.353	10.8	9.87

Table 20 – Synergy Scores

	RKO Parental	RKO MEK1 (Q56P) - Clone 1	RKO MEK1 (Q56P) - Clone 2
BVD-523 x Dabrafenib	3.18	2.31	1.77
Dabrafenib x SCH772984	4.56	5.57	4.36
Dabrafenib x Trametinib	5.58	11	9.83

[0248] Effects on MAPK pathway signaling was assessed by Western blotting. The levels of basal ERK phosphorylation (DMSO samples) was markedly up-regulated in the MEK1(Q56P)-expressing line relative to parental further confirming that this isogenic model faithfully recapitulates the expected phenotype for the expression of MEK activating acquired resistance mutations.

[0249] In the parental BRAF(V600E) RKO cells, a reduced level of RSK1/2 phosphorylation is observed following acute treatment with RAF, MEK and ERK kinase inhibitors at pharmacologically active concentrations. In contrast, isogenic, double mutant BRAFV600E::MEK1Q56P cells do not exhibit reduced RSK phosphorylation following BRAF or MEK inhibitor treatment, while BVD-523 remains effective at similar concentrations (FIG. 27A – FIG. 27I). The dotted lines indicate that the trametinib-treated samples (plus matched DMSO control) and blots are derived from a separate experiment to the BRAFi and BVD-523 treated samples.

[0250] Changes in effector gene signaling consistent with cell growth inhibition patterns are observed following prolonged inhibitor treatment. In parental RKO lines, a reduced level of phosphorylated pRB is observed following prolonged MEK and ERK inhibitor treatment. At the level of pRB modulation, MEK1 mutant lines appear insensitive to low concentration MEK inhibitor treatment, while higher concentrations remain effective. Critically, BVD-523 potency against pRB activity does not appear to

be strongly affected by MEK mutation. Surprisingly, RAF inhibitor treatment does not affect pRB status, despite potent inhibition of upstream signaling, in both parental and MEK mutant backgrounds.

[0251] In summary, these results show that BVD-523 is not susceptible to acquired resistance driven by MEK activating mutations such as MEK1 (Q56P). In addition they suggest that in combination the interactions between BVD-523 and BRAFi (exemplified by Dabrafenib) are additive irrespective of the presence of a MEK activating mutation.

Example 8

Combination Interactions Between ERK inhibitors

[0252] RAF mutant melanoma cell line A375 cells were cultured in DMEM with 10% FBS and seeded into triplicate 96-well plates at an initial density of 2000 cells per well. Combination interactions between ERK inhibitors BVD-523 and SCH772984 were analyzed after 72 hours as described above in Example 4. Viability was determined using CellTiter-Glo® reagent (Promega, Madison, WI) according to manufacturer's instructions and luminescence was detected using the BMG FLUOstar plate reader (BMG Labtech, Ortenberg, Germany).

[0253] Visualization of the Loewe and Bliss 'excess inhibition' heat maps suggested that the combination of BVD-523 and SCH772984 was mainly additive with windows of potential synergy in mid-range doses (FIG. 28A – FIG. 28E).

[0254] In summary, these results suggest that interactions between BVD-523 and SCH772984 are at least additive, and in some cases synergistic.

Example 9

Targeting the MAPK Signaling Pathway in Cancer: Promising Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

[0255] Treatment strategies for cancer have evolved from classic cytotoxic-based approaches to agents that counteract the effects of genetic lesions that drive aberrant signaling essential to tumor proliferation and survival. For example, the ERK module of the mitogen-activated protein kinase (MAPK) signaling cascade (RAS-RAF-MEK-ERK) (Cargnello and Rouxx 2011) can be engaged by several receptor tyrosine kinases (e.g., EGFR and ErbB-2) in addition to constitutively activated mutations of pathway components such as *RAS* and *BRAF* (Gollob et al. 2006). Through aberrant activation of ERK signaling, genetic alterations in *RAS* or *BRAF* result in rapid tumor growth, increased cell survival, and resistance to apoptosis (Poulikakos et al. 2011, Corcoran et al. 2010, Nazarian et al. 2010, Shi et al. 2014, Wagle et al. 2011). Activating mutations of *RAS* family members *KRAS* and *NRAS* are found in ~30% of all human cancers, with particularly high incidence in pancreatic (Kanda et al. 2012) and colorectal cancer (Arrington et al. 2014). Constitutively activating mutations in the *BRAF* gene that normally encodes for valine at amino acid 600 have been observed in melanoma, thyroid carcinoma, colorectal cancer, and non-small cell lung cancer (Hall et al. 2014). Cancers bearing genetic mutations that result in changes of the downstream components ERK and MEK have also been reported (Ojesina et al. 2014, Arcila et al. 2015). Alterations that activate the MAPK pathway are also common in the setting of resistance to targeted therapies (Groenendijk et al. 2014). Thus, targeting the MAPK pathway terminal master kinases (ERK1/2) is a promising strategy for tumors harboring such pathway activating alterations (e.g., *BRAF*, *NRAS*, and *KRAS*).

Three MAPK pathway-targeting drugs have been approved by the US Food and Drug Administration (FDA) for single-agent treatment of nonresectable or metastatic cutaneous melanoma with *BRAF*^{V600} mutations: the BRAF inhibitors vemurafenib

and dabrafenib and the MEK inhibitor trametinib. Furthermore, the combination of dabrafenib and trametinib is also approved in this indication (Queirolo et al. 2015 and Massey et al. 2015). An additional MEK inhibitor, cobimetinib, is approved in this indication as part of a combination regimen with BRAF inhibitors. Clinical experience with these drugs validates the MAPK pathway as a therapeutic target. In phase III trials of patients with *BRAF*^{V600}-mutant melanoma, the single agents vemurafenib and dabrafenib demonstrated superior response rates (approximately 50% vs. 5–19%) and median progression-free survival (PFS, 5.1–5.3 months vs. 1.6–2.7 months) over cytotoxic chemotherapy (dacarbazine) (Chapman et al. 2011 and Hauschild et al. 2012). Furthermore, clinical use of concomitant BRAF- plus MEK-targeted therapies has demonstrated that simultaneous targeting of different nodes in the MAPK pathway can enhance the magnitude and duration of response. First-line use of BRAF plus MEK-targeted agents (dabrafenib/trametinib or cobimetinib/vemurafenib) further improved median overall survival compared with single-agent BRAF inhibition (Robert et al. 2015, Long et al. 2015, Larkin et al. 2014). Thus, combined BRAF-/MEK-targeted therapy is a valuable treatment option for patients with metastatic melanoma with *BRAF*^{V600} mutations.

[0257] Despite improvements in clinical outcomes seen with BRAF-/MEK-inhibitor combination therapies, durable benefit is limited by the eventual development of acquired resistance and subsequent disease progression, with median PFS ranging from approximately 9 to 11 months. (Robert et al. 2015, Long et al. 2015, Larkin et al. 2014, and Flaherty et al. 2012). Genetic mechanisms of acquired resistance to single-agent BRAF inhibition have been intensely studied, and identification of resistance mechanisms include splice variants of *BRAF* (Poulikakos et al. 2011), *BRAF*^{V600E} amplification (Corcoran et al. 2010), *MEK* mutations (Wagle

et al. 2014), *NRAS* mutations, and RTK activation (Nazarian et al. 2010 and Shi et al. 2014). Resistance mechanisms in the setting of BRAF-/MEK-inhibitor combination therapy are beginning to emerge and mirror that of BRAF single-agent resistance (Wagle et al. 2014 and Long et al. 2014). These genetic events all share in common the ability to reactivate ERK signaling. Indeed, reactivated MAPK pathway signaling as measured by ERK transcriptional targets is common in tumor biopsies from BRAF inhibitor-resistant patients (Rizos et al. 2014). Furthermore, ERK1/2 reactivation has been observed in the absence of a genetic mechanism of resistance (Carlino et al. 2015). Therefore, the quest to achieve durable clinical benefit has led researchers to focus on evaluating additional agents that target the downstream MAPK components ERK1/2. Inhibiting ERK may provide important clinical benefit to patients with acquired resistance to BRAF/MEK inhibition. ERK family kinases have shown promise as therapeutic targets in preclinical cancer models, including those cancers resistant to BRAF or MEK inhibitors (Morris et al. 2013 and Hatzivassiliou et al. 2012). However, the potential use of such ERK1/2 inhibitors expands beyond acquired-resistance in melanoma.

[0258] Targeting ERK1/2 is a rational strategy in any tumor type harboring known drivers of MAPK, not only BRAF/MEK therapy-relapsed patients. As ERK1 and ERK2 reside downstream in the pathway, they represent a particularly attractive treatment strategy within the MAPK cascade that may avoid upstream resistance mechanisms. Here, preclinical characterization of BVD-523 (ulixertinib) in models of MAPK pathway-dependent cancers is reported, including drug-naïve and BRAF/MEK therapy acquired-resistant models. Results of a phase I dose-finding study of BVD-523 are included as a companion publication in this journal. See, Examples 17-24.

[0259] In the present invention, BVD-523 was shown to be a potent, highly selective, reversible, small molecule ATP-competitive inhibitor of ERK1/2 with *in vitro* and *in vivo* anticancer activity.

[0260] BVD-523 (ulixertinib) was identified and characterized as a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity. BVD-523 caused reduced proliferation and enhanced caspase activity, most notably in cells harboring MAPK (RAS-RAF-MEK) pathway mutations. In *in vivo* *BRAF*^{V600E} xenograft studies, BVD-523 showed dose-dependent growth inhibition and tumor regressions. Interestingly, BVD-523 inhibited phosphorylation of target substrates despite increased phosphorylation of ERK1/2. BVD-523 also demonstrated antitumor activity in models of acquired resistance to single-agent and combination BRAF/MEK targeted therapy. Synergistic antiproliferative effects in a *BRAF*^{V600E}-mutant melanoma cell line xenograft model were also demonstrated when BVD-523 was used in combination with BRAF inhibition. These studies suggest that BVD-523 holds promise as a treatment for ERK-dependent cancers, including those whose tumors have acquired resistance to other treatments targeting upstream nodes of the MAPK pathway.

Example 10

Discovery and Initial Characterization of a Novel ERK1/2 inhibitor, BVD-523

(Ulixertinib)

[0261] Following extensive optimization of leads originally identified using a high-throughput, small-molecule screen (Aronov et al. 2009), a novel adenosine triphosphate (ATP)-competitive ERK1/2 inhibitor, BVD-523 (ulixertinib) was identified (FIG. 29 A). BVD-523 is a potent ERK inhibitor with a K_i of 0.04 ± 0.02 nM against ERK2. It was shown to be a reversible, competitive inhibitor of ATP, as the IC_{50}

values for ERK2 inhibition increased linearly with increasing ATP concentration (FIG. 29B and FIG. 29C). The IC_{50} remained nearly constant for incubation times ≥ 10 minutes, suggesting rapid equilibrium and binding of BVD-523 with ERK2 (FIG. 29D). BVD-523 is also a tight-binding inhibitor of recombinant ERK1 (Rudolph et al. 2015), exhibiting a K_i of <0.3 nM.

[0262] Binding of BVD-523 to ERK2 was demonstrated using calorimetric studies and compared to data generated using the ERK inhibitors SCH772984 and pyrazolylpyrrole (Arovov et al. 2007). All compounds bound and stabilized inactive ERK2 with increasing concentration, as indicated by positive ΔT_m values (FIG. 29E). The 10- to 15-degree change in ΔT_m observed with BVD-523 and SCH-772984 is consistent with compounds that have low-nanomolar binding affinities (Fedorov et al. 2012). BVD-523 demonstrated a strong binding affinity to both phosphorylated active ERK2 (pERK2) and inactive ERK2 (FIG. 29F). A stronger affinity to pERK2 compared with inactive ERK2 was observed. BVD-523 did not interact with the negative control protein p38 α MAP kinase (FIG. 29F).

[0263] BVD-523 demonstrated excellent ERK1/2 kinase selectivity based on biochemical counter-screens against 75 kinases in addition to ERK1 and ERK2. The ATP concentrations were approximately equal to the K_m in all assays. Kinases inhibited to greater than 50% by 2 μ M BVD-523 were retested to generate K_i values (or apparent K_i ; Table 21). Twelve of the 14 kinases had a K_i of <1 μ M. The selectivity of BVD-523 for ERK2 was >7000 -fold for all kinases tested except ERK1, which was inhibited with a K_i of <0.3 nM (10-fold). Therefore, BVD-523 is a highly potent and selective inhibitor of ERK1/2.

Table 21 - BVD-523 displays selectivity for ERK1 and ERK2 kinases.

Kinase	Ki (μM)
CDK1/cyclinB	0.07 ^a
CDK2/cyclinA	0.36
CDK5/p35	0.09 ^a
CDK6/cyclinD3	0.09 ^a
ERK1	0.0003
ERK2	0.00004
GSK3b	0.32
JNK2α	0.65 ^a
JNK3	1.3
P38γ	0.45 ^a
P38δ	0.24 ^a
ROCKI	11.1
ROCKII	0.27 ^a
RSK3	0.45
^a Apparent. <50% inhibition at 2μM: ABL, AKT3, AMPK, AUR1, AUR2, AXL, BLK, CAMKII, CAMKIV, CHK1, CHK2, CK1, CK2, CSK, EGFR, EPHB4, FES, FGFR3, FLT3, FYN, IGF1R, IKKα, IKKβ, IKKγ, IRAK4, IRTK, ITK, JAK3, JNK1α 1, KDR, LCK, LYN, cMET, MKK4, MKK6, MKK7β, MLK2, MSK1, MST2, NAK, NEK2, p38α, p38β, p70S6K, PAK2, PDGFRα, PDK1, PKA, PKCα, PKCβ II, PKCγ, PKCδ, PRAK, PRK2, cRAF, SGK, SRC, SYK, TAK1, TIE2, ZAP70	

Example 11

BVD-523 Preferentially Inhibits Cellular Proliferation and Enhances Caspase-3/7 Activity *in vitro* in Cancer Cell Lines with MAPK Pathway-Activating

Mutations

[0264] BVD-523 cellular activity was assessed in a panel of approximately 1,000 cancer cell lines of various lineages and genetic backgrounds (FIG. 30A and Table 22). Cell lines were classified as MAPK wild type (wt) or mutant depending on

the absence or presence of mutations in *RAS* family members and *BRAF*. Although some MAPK-wt cell lines were sensitive to BVD-523, generally BVD-523 inhibited proliferation preferentially in cells with MAPK pathway alterations.

[0265] Next, the growth and survival impact of BVD-523 treatment on sensitive cells was characterized. Fluorescence activated cell sorting (FACS) analysis was performed on *BRAF*^{V600E}-mutant melanoma cell line UACC-62 following treatment with BVD-523 at 500 nM or 2000 nM for 24 hours. Treated cells were arrested in the G1 phase of the cell cycle in a concentration-dependent manner (FIG. 30B).

[0266] In addition, caspase-3/7 activity was analyzed as a measure of apoptosis in multiple human cancer cell lines. A concentration- and cell-line-dependent increase in caspase 3/7 was observed following treatment with BVD-523 for 72 hours (FIG. 30C). BVD-523 treatment resulted in pronounced caspase-3/7 induction in a subset of MAPK-activated cell lines harboring a *BRAF*^{V600} mutation (A375, WM266, and LS411N). This is consistent with earlier observations for preferential inhibition of proliferation by BVD-523 in MAPK pathway-mutant cancer cell lines (FIG. 30A).

[0267] To further characterize the mechanism of action and effects on signaling elicited by BVD-523, the levels of various effector and MAPK-related proteins were assessed in BVD-523-treated *BRAF*^{V600E}-mutant A375 melanoma cells (FIG. 30D). Phospho-ERK1/2 levels increased in a concentration-dependent manner after 4 and 24 hours of BVD-523 treatment. Despite prominent concentration-dependent increases in pERK1/2 observed with 2 μ M BVD-523 treatment, phosphorylation of the ERK1/2 target RSK1/2 was reduced at both 4 and 24 hours, which is consistent with sustained inhibition. Total protein levels of DUSP6,

a distal marker of ERK1/2 activity, were also attenuated at 4 and 24 hours. Following 24 hours of treatment with BVD-523, the apoptotic marker BIM-EL increased in a dose-dependent manner, while cyclin D-1 and pRB was attenuated at 2 μ M. All effects are consistent with on-target ERK1/2 inhibition.

Example 12

BVD-523 Demonstrates *In Vivo* Antitumor Activity in *BRAF*^{V600E}-Mutant Cancer

Cell Line Xenograft Models

[0268] Based on our *in vitro* findings that BVD-523 reduced proliferation and induced apoptosis in a concentration-dependent manner, BVD-523 was administered by oral gavage to demonstrate its *in vivo* anti-tumor activity in models with MAPK/ERK-pathway dependency. Xenograft models of melanoma (cell line A375), and colorectal cancer (cell line Colo205), were utilized, both of which harbor a *BRAF*^{V600E} mutation.

[0269] In A375 cell line xenografts, BVD-523 efficacy was compared with the control cytotoxic alkylating agent temozolomide following 14 days of treatment. BVD-523 demonstrated significant dose-dependent antitumor activity starting at 50 mg/kg twice daily (BID) (FIG. 31A). Doses of 50 and 100 mg/kg BID significantly attenuated tumor growth, with tumor growth inhibition (TGI) of 71% ($P=0.004$) and 99% ($P<0.001$), respectively. Seven partial regressions (PRs) were noted in the 100 mg/kg BID group; no regression responses were noted in any other group. The efficacy observed compared favorably with that of temozolomide, which when administered at 75 and 175 mg/kg resulted in modest dose-dependent TGI of 34% ($P>0.05$) and 78% ($P=0.005$), respectively.

[0270] Additionally, BVD-523 demonstrated antitumor efficacy in a Colo205 human colorectal cancer cell line xenograft model (FIG. 31B). BVD-523 again

showed significant dose-dependent tumor regressions at doses of 50, 75, and 100 mg/kg BID, yielding mean tumor regressions T/T_i (T = End of treatment, T_i = Treatment initiation) of -48.2%, -77.2%, and -92.3%, respectively (all $P < 0.0001$). Regression was not observed at the lowest dose of BVD-523 (25 mg/kg BID); however, significant tumor growth inhibition, with a T/C (T = Treatment, C = Control) of 25.2% ($P < 0.0001$), was observed. Although not well tolerated, the positive control chemotherapeutic agent irinotecan (CPT-11) showed significant antitumor activity, inhibiting Colo205 tumor growth with a T/C of 6.4% ($P < 0.0001$). However, even at its maximum tolerated dose in mice, CPT-11 was not as effective as BVD-523 at doses of 50, 75, or 100 mg/kg BID.

[0271] To establish the relationship between pharmacokinetics and pharmacodynamics, BVD-523 plasma concentrations were compared with pERK1/2 levels measured in the tumor by immunohistochemistry and isotope-tagged internal standard mass spectrometry over a 24-hour period following a single 100 mg/kg oral dose of BVD-523 (FIG. 31C). Phosphorylation of ERK1/2 was low in untreated tumors (0 hours). Following treatment with BVD-523, ERK1/2 phosphorylation steadily increased from 1 hour post-dose to maximal levels at 8 hours post-dose, then returned to pre-dose levels by 24 hours. This increase in pERK1/2 correlated with BVD-523 drug plasma concentrations. The *in vivo* observation of increased pERK1/2 with BVD-523 treatment is consistent with earlier *in vitro* findings (FIG. 30D).

Example 13

BVD-523 Results in ERK1/2 Substrate Inhibition Despite Increased ERK1/2

Phosphorylation

[0272] To examine the effects of BVD-523 on signaling relative to other known ERK1/2 inhibitors (SCH772984, GDC-0994, and Vx-11e) (Morris et al. 2013 and Liu et al. 2015), a large-scale reverse phase protein array (RPPA) of approximately 40 proteins was employed in a variety of cell lines with sensitivity to ERK inhibition. Cell lines with common alterations in *BRAF* and *RAS* were assayed: *BRAF*^{V600E} mutant lines A375, Colo205, and HT29; *KRAS*^{G12C}-mutant cell line MIAPACa-2; *KRAS*^{G13D}-mutant cell line HCT116; and AN3Ca with atypical *HRAS*^{F82L} mutation. Changes in protein levels are shown as a percentage change from dimethyl sulfoxide (DMSO)-treated parental control (FIG. 32A and Table 23). All ERK inhibitors elicited qualitatively similar protein effects, with the exception of phosphorylation of ERK1/2 (pERK1/2 [ERK1/2 -T202, -Y204]); SCH772984 inhibited pERK1/2 in all cell lines, while BVD-523, GDC-0994, and Vx-11e markedly increased pERK1/2. Phospho-p90 RSK (pRSK1) and cyclin D1, which are proximal and distal targets of pERK1/2, respectively, were similarly inhibited by all inhibitors tested regardless of the degree of ERK1/2 phosphorylation (FIG. 32B). These independent findings for BVD-523 are consistent with studies showing that phosphorylation of ERK1/2 substrates RSK1/2 remained inhibited despite dramatically elevated pERK1/2 by Western blots in A375 cells (FIG. 32D), in addition to protein-binding studies demonstrating BVD-523 binding and stabilization of pERK1/2 and inactive ERK1/2 (FIG. 29E and FIG 29F). Therefore, measuring increased pERK1/2 levels could be considered as a clinical pharmacodynamic biomarker for BVD-523, while quantifying inhibition of ERK1/2 targets such as pRSK1 and DUSP6 as well could serve a similar purpose.

[0273] Additional protein changes are of note in this RPPA dataset (FIG. 32A). Decreased pS6-ribosomal protein appears to be another pharmacodynamic marker of ERK1/2 inhibition, as evidenced in all cell lines with all compounds (FIG. 32B).

Furthermore, prominent induction of pAKT appears to be a cell line-dependent observation, where each ERK1/2 inhibitor induced pAKT in cell lines A375 and AN3CA cells (FIG. 33). Interestingly, the degree of inhibition of survival marker pBAD appears to differ between compounds, with only modest inhibition of pBAD by GDC-0994 compared with the other ERK1/2 inhibitors tested (FIG. 32A).

[0274] Next, how BVD-523 affects cellular localization of ERK1/2 and downstream target pRSK in a *BRAF*^{V600E}-mutant RKO colorectal cell line (FIG. 32C) was investigated. In resting cells, ERK1/2 localizes to the cytoplasm, and once stimulated pERK1/2 migrates to target organelles, particularly the nucleus where transcriptional targets are activated (Wainstein et al. 2016). In DMSO-treated control cells, pERK1/2 is evident in both nuclear and cytoplasmic fractions, which is likely reflective of MAPK pathway activity due to the presence of *BRAF*^{V600E} in this cell line. Treatment with BVD-523 resulted in elevated pERK1/2 in the nucleus and cytoplasm as well as a modest increase in nuclear total ERK1/2 compared with DMSO-treated cells, suggesting that compound-induced stabilization of pERK1/2 stimulates some nuclear translocation. Despite increased pERK1/2 in both compartments, pRSK levels are lower in the cytoplasmic and nuclear compartments compared with DMSO control. Comparator MAPK signaling inhibitors (i.e., trametinib, SCH7722984, dabrafenib) inhibited phosphorylation of ERK1/2 and RSK, as reflected by lower levels in the nuclear and cytoplasmic compartments. These data again suggest that BVD-523-associated increases in pERK1/2 are evident in both the cytoplasm and nucleus; however, this does not translate to activation of target substrates. This is consistent with data presented in FIG. 30D and FIG. 32A.

Example 14

BVD-523 Exhibited Activity in *In Vitro* Models of BRAF and MEK Inhibitor

Resistance

[0275] Emergence of resistance to BRAF and MEK inhibitors limits their clinical efficacy. Here, the experiments sought to model and compare the development of resistance to BRAF (dabrafenib), MEK (trametinib), and ERK1/2 (BVD-523) inhibition *in vitro*. Over several months, *BRAF*^{V600E}-mutant A375 cells were cultured in progressively increasing concentrations of each inhibitor. Drug-resistant A375 cell lines were readily obtained following growth in high concentrations of trametinib or dabrafenib, while developing cell lines with resistance to BVD-523 proved challenging (FIG. 34A). Overall, these *in vitro* data suggest that at concentrations yielding similar target inhibition, resistance to BVD-523 is delayed compared with dabrafenib or trametinib, and may translate to durable responses in the clinic.

[0276] Reactivation and dependence on ERK1/2 signaling is a common feature of acquired resistance to BRAF/MEK inhibition (Morris et al. 2013 and Hatzivassiliou et al. 2012); therefore, the activity of BVD-523 in *in vitro* models of acquired resistance was evaluated. First, a dabrafenib and trametinib combination-resistant A375 population was obtained using the increased concentration method described. The IC₅₀ and IC₅₀-fold change from parental A375 for dabrafenib, trametinib, and BVD-523 in the BRAF/MEK combination-resistant population is shown in Table 24. BVD-523 IC₅₀ was modestly shifted (2.5-fold), while dabrafenib and trametinib were more significantly shifted (8.5-fold and 13.5-fold, respectively) (Table 24). The cytotoxic agent paclitaxel was tested as a control with only a modest shift in potency observed. These data support the investigation of BVD-523 in the

setting of BRAF/MEK therapy resistance, although the mechanism of resistance in this cell population remains to be characterized.

Table 24 – BVD-523 activity in models of BRAF/MEK inhibition

Cell Line	Dabrafenib	Trametinib	BVD-523	Paclitaxel
Parental (IC ₅₀ nM)	2.1	0.2	129	1.9
BRAFi- + MEKi- resistant (IC ₅₀ nM)	17.9	2.7	323	3.5
Fold Change	+8.5	+13.5	+2.5	+1.8

[0277] To further investigate the tractability of ERK1/2 inhibition in a model with a known mechanism of BRAF inhibitor resistance, AAV-mediated gene targeting was used to generate a pair of RKO *BRAF*^{V600E}-mutant cell lines isogenic for the presence or absence of an engineered heterozygous knock-in of *MEK1*^{Q56P}-activating mutation (Trunzer et al. 2013 and Emery et al. 2009). *MEK1/2* mutations, including *MEK1*^{Q56P}, have been implicated in both single-agent BRAF and combination BRAF/MEK therapy-acquired resistance in patients (Wagle et al. 2011, Wagle et al. 2014, Emery et al. 2009 and Johnson et al. 2015). Single-agent assays demonstrated that relative to the parental *BRAF*^{V600E}::*MEK1*^{wt} cells, the double-mutant *BRAF*^{V600E}::*MEK1*^{Q56P} cells displayed a markedly reduced sensitivity to the BRAF inhibitors vemurafenib and dabrafenib and the MEK inhibitor trametinib (FIG. 34B). In contrast, response to BVD-523 was essentially identical in both the parental and *MEK*^{Q56P}-mutant cells, indicating that BVD-523 is not susceptible to this mechanism of acquired resistance. These results were confirmed in 2 independently derived double-mutant *BRAF*^{V600E}::*MEK1*^{Q56P} cell line clones, thus validating that results were specifically related to the presence of the *MEK1*^{Q56P} mutation rather

than an unrelated clonal artifact (data not shown). Similar results were also observed with a second mechanistically distinct ERK1/2 inhibitor (SCH772984), supporting the expectation that these observations are specifically related to mechanistic inhibition of ERK1/2 and not due to an off-target compound effect.

[0278] To further characterize the mechanistic effects of BVD-523 on MAPK pathway signaling in *BRAF*^{V600E}::*MEK1*^{Q56P} cell lines, protein levels were assessed by Western blot (FIG. 34C). In the parental *BRAF*^{V600E} RKO cells, a reduced level of pRSK1/2 was observed following 4-hour treatment with BRAF (vemurafenib), MEK (trametinib), or ERK1/2 (BVD-523) inhibitors at pharmacologically active concentrations. In contrast, isogenic double-mutant *BRAF*^{V600E}::*MEK1*^{Q56P} cells did not exhibit reduced RSK phosphorylation following BRAF or MEK inhibitor treatment, while BVD-523 remained effective in inhibiting pRSK1/2 to a level comparable to parental RKO. Similarly, pRB is reduced, indicating G0/G1 arrest, by 24 hours of BVD-523 treatment in both parental RKO and *BRAF*^{V600E}::*MEK1*^{Q56P}.

[0279] Acquired *KRAS* mutations are also known drivers of resistance to MAPK pathway inhibitors. To understand the susceptibility of BVD-523 to this mechanism of resistance, an isogenic panel of clinically relevant *KRAS* mutations in colorectal cell line SW48 was used. Sensitivity to BVD-523 was compared with MEK inhibitors selumetinib and trametinib (FIG. 34D). Sensitivity to paclitaxel was unaltered (FIG. 37A). While several mutant *KRAS* alleles conferred robust to intermediate levels of resistance to MEK inhibition, sensitivity to BVD-523 was unaltered by the majority of alleles, and where a shift in sensitivity was observed, it was not to the extent observed with trametinib or selumetinib. Overall, these data suggest that BVD-523 is more efficacious in this context than MEK inhibitors.

Example 15

BVD-523 Demonstrates *In Vivo* Activity in a BRAF Inhibitor-Resistant Patient-Derived Melanoma Xenograft Model

[0280] To confirm and extend the antitumor effects of BVD-523 observed in *in vitro* models of *BRAF*-/MEK-acquired resistance, a *BRAF*-resistant xenograft model derived from a patient with resistance to vemurafenib was utilized. BVD-523 was dosed by oral gavage at 100 mg/kg BID for 28 days, both alone and in combination with dabrafenib at 50 mg/kg BID (FIG. 35). As expected, minimal antitumor activity was demonstrated for single-agent dabrafenib (22% TGI). BVD-523 activity was significant compared with vehicle control ($P \leq 0.05$), with a TGI of 78%. In this model, combining BVD-523 with dabrafenib resulted in a TGI of 76% ($P \leq 0.05$); therefore, further benefit was not gained for the combination compared with single-agent BVD-523 in this model of *BRAF*-acquired resistance.

Example 16

Combination Therapy with BVD-523 and a BRAF Inhibitor Provides Promising Antitumor Activity

[0281] Patients with *BRAF*-mutant cancer may acquire resistance to combined *BRAF*/MEK therapy (Wagle et al. 2014), warranting consideration of other combination approaches within the MAPK pathway. The anti-proliferative effects of combining BVD-523 with the *BRAF* inhibitor vemurafenib was assessed in the *BRAF*^{V600E}-mutant melanoma cell line G-361. As anticipated, single agents BVD-523 and vemurafenib were both active, and modest synergy was observed when combined (FIG. 37B). This indicates that BVD-523 combined with *BRAF* inhibitors are at least additive and potentially synergistic in melanoma cell lines carrying a *BRAF*^{V600E} mutation. Furthermore, generating acquired resistance *in vitro* following

continuous culturing of *BRAF*^{V600E} mutant cell line (A375) in BRAF inhibitor plus BVD-523 was challenging. In contrast generating resistance to dabrafenib alone occurred relatively rapidly (FIG. 37C). Even resistance to combined dabrafenib and trametinib emerged before dabrafenib plus trametinib.

[0282] The benefit of combined BRAF and ERK inhibition may not be fully realized in *in vitro* combination studies where concentrations are not limited by tolerability. To understand the benefit of the combination, efficacy was assessed *in vivo* utilizing xenografts of the *BRAF*^{V600E}-mutant human melanoma cell line A375. Due to the noteworthy response to combination treatment, dosing in the combination groups was stopped on Day 20 to monitor for tumor regrowth, and was reinitiated on Day 42 (FIG. 36A). Tumors were measured twice weekly until the study was terminated on Day 45. The median time to endpoint (TTE) for controls was 9.2 days, and the maximum possible tumor growth delay (TGD) of 35.8 days was defined as 100%. Temozolomide treatment resulted in a TGD of 1.3 days (4%) and no regressions. The 50- and 100-mg/kg dabrafenib monotherapies produced TGDs of 6.9 days (19%) and 19.3 days (54%), respectively, a significant survival benefit ($P<0.001$), and 1 PR in the 100-mg/kg group. The 100-mg/kg BVD-523 monotherapy resulted in a TGD of 9.3 days (26%), a significant survival benefit ($P<0.001$), and 2 durable complete responses. The combinations of dabrafenib with BVD-523 each produced the maximum possible 100% TGD with noteworthy regression responses, and statistically superior overall survival compared with their corresponding monotherapies ($P<0.001$). The lowest dose combination produced a noteworthy 7/15 tumor-free survivors (TFS), and the 3 higher-dosage combinations produced a total of 43/44 TFS, consistent with curative or near-curative activity (FIG. 36B). In

summary, the combination of dabrafenib with BVD-523 produced a greater number of TFS and superior efficacy to either single agent.

[0283] Based on the activity of BVD-523 plus dabrafenib in A375 xenograft models with a starting tumor volume of approximately 75–144 mm³, a follow-up experiment was conducted to determine the efficacy of combination therapy in “upstaged” A375 xenografts (average tumor start volume, 700–800 mm³) (FIG. 36C). The median TTE for controls was 6.2 days, establishing a maximum possible TGD of 53.8 days, which was defined as 100% TGD for the 60-day study. BVD-523 100-mg/kg monotherapy produced a negligible TGD (0.7 day, 1%) and no significant survival difference from controls ($P>0.05$). The distribution of TTEs and 2 PRs suggested there may have been a subset of responders to treatment with BVD-523 alone. Dabrafenib 50-mg/kg monotherapy was efficacious, yielding a TGD of 46.2 days (86%) and a significant survival benefit compared with controls ($P<0.001$). This group had 5 PRs and 5 CRs, including 3 TFS, among the 11 evaluable mice (FIG. 36D). Both combinations of dabrafenib with BVD-523 produced the maximum 100% TGD and a significant survival benefit compared with controls ($P<0.001$). Each combination produced 100% regression responses among evaluable mice, though there were distinctions in regression activity. The 25-mg/kg dabrafenib and 50-mg/kg BVD-523 combination had 2 PRs and 8 CRs, with 6/10 TFS, whereas the 50-mg/kg dabrafenib and 100-mg/kg BVD-523 combination had 11/11 TFS on Day 60 (FIG. 36D). Overall, these data support the rationale for frontline combination of BVD-523 with BRAF-targeted therapy in *BRAF*^{V600}-mutant melanoma, and this is likely to extend to other tumor types harboring this alteration.

DISCUSSION

[0284] BVD-523 is a potent, highly selective, reversible, small molecule ATP-competitive inhibitor of ERK1/2 with activity in *in vivo* and *in vitro* cancer models. *In vitro*, BVD-523 demonstrated potent inhibition against several human tumor cell lines, particularly those harboring activating mutations in the MAPK signaling pathway, consistent with its mechanism of action. BVD-523 elicited changes in downstream target and effector proteins, including inhibition of direct substrate of ERK1/2, pRSK, and total DUSP6 protein levels. These findings are in line with those of previous studies of other ERK1/2 inhibitors, which demonstrated effective suppression of pRSK with ERK1/2 inhibition (Morris et al. 2013 and Hatzivassiliou et al. 2012). Interestingly, BVD-523 treatment resulted in a marked increase in ERK1/2 phosphorylation *in vitro* and *in vivo*. Similar to our findings, an increase in pERK1/2 has been reported with the ERK1/2 inhibitor Vx11e; conversely, pERK1/2 inhibition occurs with SCH772984 (Morris et al. 2013). Although differences in pERK1/2 levels were observed among the various ERK1/2 inhibitors tested, downstream effectors (i.e., pRSK1 and total DUSP6) were similarly inhibited. These findings suggest quantifying ERK1/2 target substrates, such as pRSK1, may serve as reliable pharmacodynamic biomarkers for BVD-523-mediated inhibition of ERK1/2 activity.

[0285] While BRAF (dabrafenib, vemurafenib) and MEK (trametinib, cobimetinib) inhibitors validate the MAPK pathway as a therapeutic target, particularly in patients with *BRAF*^{V600} mutations, the antitumor response is limited by the emergence of acquired resistance and subsequent disease progression. Resistance has been attributed to the upregulation and activation of compensatory signaling molecules (Nazarian et al. 2010, Villanueva et al. 2010, Johannessen et al. 2010 and Wang et al. 2011), amplification of the target genes (Corcoran et al. 2010), and activating mutations of pathway components (e.g., *RAS*, *MEK*) (Wagle et al.

2011, Emery et al. 2009 and Wang et al. 2011). Reactivation of the ERK1/2 pathway is one common consequence of acquired resistance mechanism. When introduced into the *BRAF*^{V600E}-mutant melanoma cell line A375, *MEK*^{Q56P} conferred resistance to MEK and BRAF inhibition (Wagle et al. 2011). By contrast, BVD-523 retained its potent inhibitory activity in the engineered *MEK*^{Q56P} cell line, indicating that ERK1/2 inhibition is effective in the setting of upstream activating alterations which can arise in response to BRAF/MEK treatment. As further evidence of a role for BVD-523 in the context of acquired resistance, efficacy of BVD-523 was evident in a xenograft model derived from a tumor sample from a patient whose disease progressed on vemurafenib; the BRAF inhibitor dabrafenib was not effective in this model. These data support a role for targeting ERK1/2 in the setting of BRAF/MEK resistance, and complement previously published findings (Morris et al. 2013 and Hatzivassiliou et al. 2012). To further characterize resistance to inhibitors of the MAPK pathway, the emergence of resistance to BVD-523 itself was investigated. It was found that single-agent treatment of cancer cells with BVD-523 was durable and more challenging to develop resistance compared with other agents targeting upstream MAPK signaling components (i.e., dabrafenib, trametinib). This may suggest that acquiring resistance to ERK1/2-targeting agents is harder to achieve than acquiring resistance to BRAF or MEK therapy, potentially due to the fact that BVD-523 preferentially targets the more conserved active conformation of the ATP binding site. However, *in vitro* studies with other ERK1/2 inhibitors have identified specific mutants in ERK1/2 that drive resistance (Jha et al. 2016 and Goetz et al. 2014); these specific mutations have yet to be identified in clinical samples from ERK1/2 inhibitor-relapsed patients.

[0286] The potential clinical benefit of ERK1/2 inhibition with BVD-523 extends beyond the setting of BRAF/MEK therapy-resistant patients. As ERK1/2 is a

downstream master node within this MAPK pathway, its inhibition is attractive in numerous cancer settings where tumor growth depends on MAPK signaling. Approximately 30% of all cancers harbor *RAS* mutations; therefore, targeting downstream ERK1/2 with BVD-523 is a rational treatment approach for these cancers. Furthermore, results from a study by Hayes et al. indicate that prolonged ERK1/2 inhibition in *KRAS*-mutant pancreatic cancer is associated with senescent-like growth suppression (Hayes et al. 2016). However, a combination approach may be required for maximal and durable attenuation of MAPK signaling in the setting of *RAS* mutations. For example, MEK inhibition in *KRAS*-mutant colorectal cancer cell results in an adaptive response of ErbB family activation, which dampens the response to MEK inhibition (Sun et al. 2014). Similar context-specific adaptive responses may occur following ERK1/2 inhibition with BVD-523. The optimal treatment combinations for various genetic profiles and cancer histologies are the subject of ongoing research. In addition to *BRAF*^{V600} and *RAS* mutations, other alterations which drive MAPK are emerging. For example, novel *RAF* fusions and atypical non-V600 *BRAF* mutations which promote RAF dimerization activate the MAPK pathway (Yao et al. 2015). *BRAF* inhibitors such as vemurafenib and dabrafenib which inhibit *BRAF*^{V600}-mutant monomer proteins have been shown to be inactive in atypical *RAF* alterations which drive MAPK signaling in a dimerization-dependent manner (Yao et al. 2015). However, treatment with BVD-523 to target downstream ERK1/2 in these tumors may be a novel approach to addressing this unmet medical need.

[0287] In the setting of *BRAF*^{V600}-mutant melanoma tumors, combined *BRAF* and MEK inhibition exemplifies how agents targeting different nodes of the same pathway can improve treatment response and duration. Our combination studies in

BRAF^{V600E}-mutant xenografts of human melanoma cell line A375 provides support for combination therapy with BVD-523 and BRAF inhibitors. The combination demonstrated superior benefit relative to single-agent treatments, including results consistent with curative responses. The clinical efficacy and tolerability of combined BRAF/BVD-523 therapy remains to be determined. It would not be unreasonable to expect that a BRAF/ERK1/2 combination will at least be comparable in efficacy to a targeted BRAF/MEK combination. Furthermore, the *in vitro* observation that acquired resistance to BVD-523 is more challenging to achieve compared with other MAPK pathway inhibitors suggests that the BRAF/BVD-523 inhibitor combination has the potential to provide a more durable response.

[0288] Significant progress has also been made using immunotherapy for melanoma. The US FDA has approved various immune checkpoint inhibitors for the treatment of advanced melanoma, including the cytotoxic T-lymphocyte antigen-4 targeted agent ipilimumab and the programmed death -1 inhibitors pembrolizumab and nivolumab. Combining BVD-523 with such immunotherapies is an attractive therapeutic option; further investigation is warranted to explore dosing schedules and to assess whether synergistic response can be achieved.

[0289] Based on the preclinical data, BVD-523 may hold promise for treatment of patients with malignancies dependent on MAPK signaling, including those whose tumors have acquired resistance to other treatments. The clinical development of BVD-523 is described below. See, Examples 17-24

Example 17

Phase I Dose-Escalation Study of the First-in-Class Novel Oral ERK1/2 Kinase Inhibitor BVD-523 (ulixertinib) in Patients With Advanced Solid Tumors

[0290] The present invention describes the first-in-human dose escalation study of an ERK1/2 inhibitor for the treatment of patients with advanced solid tumors. BVD-523 has an acceptable safety profile with favorable pharmacokinetics and early evidence of clinical activity.

[0291] Mitogen-activated protein kinase (MAPK) signaling via the RAS-RAF-MEK-ERK cascade plays a critical role in oncogenesis; thus attracting significant interest as a therapeutic target. This ubiquitous pathway is composed of RAS upstream of a cascade of the protein kinases RAF, MEK1/2, and ERK1/2. RAS is activated by GTP binding, which in turn results in activation of each protein kinase sequentially. Although they appear to be the only physiologic substrates for MEK1/2, ERK1/2 have many targets in the cytoplasm and nucleus, including the transcription factors Elk1, c-Fos, p53, Ets1/2, and c-Jun (Shaul et al. 2007). ERK1/2 activation and kinase activity influences cellular proliferation, differentiation, and survival through a variety of mechanisms (Rasola et al. 2010), including activation of the ribosomal S6 kinase (RSK) family members (Romeo et al. 2012).

[0292] Constitutive, aberrant activation of the RAS-RAF-MEK1/2-ERK1/2 signaling pathway has been identified and implicated in the development or maintenance of many cancers (Schubbert et al. 2007 and Gollob et al. 2006). Mutations in *RAS* family genes, such as *KRAS*, *NRAS*, and *HRAS* are the most common, with activating *RAS* mutations occurring in ≈30% of human cancers (Schubbert et al. 2007). *KRAS* mutations are prevalent in pancreatic (>90%) (Kanda et al. 2012), biliary tract (3%–50%) (Hezel et al. 2014), colorectal (30%–50%) (Arrington et al. 2012), lung (27%) (Pennycuik et al. 2012), ovarian (15%–39%) (Dobrzycka et al. 2009), and endometrioid endometrial (18%) (O'Hara and Bell 2012) cancers; *NRAS* mutations are prevalent in melanoma (20%) (Khattak et al. 2013).

and myeloid leukemia (8%–13%) (Yohe 2015); and *HRAS* mutations are prevalent in bladder (12%) cancer (Fernández-Medarde and Santos 2011). Mutations in *RAF* family genes, most notably *BRAF*, are frequent, particularly in melanoma. *BRAF* mutations have been identified in 66% of malignant melanomas and in ~7% of a wide range of other cancers (Davies et al. 2002), while *MEK* mutations are rarer, occurring at an overall frequency of 8% in melanomas (Nikolaev et al. 2012). In contrast, *ERK* mutations resulting in tumorigenesis have been reported only rarely to date (Deschenes-Simard et al. 2014).

[0293] The US Food and Drug Administration (FDA) has approved two selective *BRAF* inhibitors, vemurafenib and dabrafenib, as monotherapies for patients with *BRAF*^{V600}-mutant metastatic melanoma (Tafinlar [package insert] and Zelboraf [package insert]). Though response rates for these targeted therapies can be as high as 50% in patients with *BRAF*^{V600} mutations, duration of response is often measured in months, not years (Hauschild et al. 2012 and McArthur et al. 2014). The *MEK*1/2 inhibitor trametinib is also approved as a monotherapy in this setting (Mekinist [package insert]), but is more commonly used in combination with the *BRAF* inhibitor dabrafenib. First-line use of trametinib administered in combination with dabrafenib offers an even greater improvement in overall survival compared with vemurafenib monotherapy without increased overall toxicity (Robert et al. 2015), highlighting the potential utility of simultaneously targeting multiple proteins of this MAPK signaling pathway. This therapeutic combination was also associated with a lower incidence of *MEK* inhibitor-associated rash and *BRAF* inhibitor-induced hyperproliferative skin lesions compared with each single agent alone (Flaherty et al. 2012). Recently, a phase III trial also demonstrated significant improvements in overall survival (25.1 vs. 18.7 months, hazard ratio [HR] 0.71,

$P=0.0107$), progression-free survival (PFS) (11.0 vs. 8.8 months, HR 0.67, $P=0.0004$), and overall response (69% vs. 53%; $P=0.0014$) with dabrafenib plus trametinib versus dabrafenib alone in patients with $BRAF^{V600E/K}$ mutation-positive melanoma (Long et al. 2015). Similarly, significant improvements in PFS (9.9 vs. 6.2 months, HR 0.51, $P<0.001$) and the rate of complete response (CR) or partial response (PR) (68% vs. 45%; $P<0.001$) have been demonstrated with the combination of cobimetinib plus vemurafenib compared with vemurafenib alone (Larkin et al. 2014). To this end, FDA approval was recently granted for the combination of vemurafenib and cobimetinib for $BRAF^{V600E/K}$ -mutated melanoma. Based on these and related findings, the combination of a BRAF inhibitor plus a MEK inhibitor has become a standard targeted treatment option for patients with metastatic melanoma containing $BRAF^{V600E/K}$ mutations.

[0294] Though BRAF/MEK-targeted combination therapy has been demonstrated to provide significant additional benefit beyond single-agent options, most patients eventually develop resistance and disease progression after ~12 months (Robert et al. 2015, Flaherty et al. 2012 and Long et al. 2015). Several mechanisms of acquired resistance following either single-agent or combination therapies have been identified, including the generation of *BRAF* splicing variants, *BRAF* amplification, development of *NRAS* or *MEK* mutations, and upregulation of bypass pathways (Poulikakos et al. 2011, Corcoran et al. 2010, Nazarian et al. 2010, Shi et al. 2014, Johannessen et al. 2010, Wagle et al. 2011, Wagle et al. 2014 and Ahronian et al. 2015). Central to many of these mechanisms of resistance is the reactivation of ERK signaling, which enables the rapid recovery of MAPK pathway signaling and escape of tumor cells from single-agent BRAF or combination BRAF/MEK inhibitor therapies (Paraiso et al. 2010). ERK inhibition may provide the

opportunity to avoid or overcome resistance from upstream mechanisms, as it is the most distal master kinase of this MAPK signaling pathway. This is supported by preclinical evidence that inhibition of ERK by small molecule inhibitors acted to both inhibit the emergence of resistance and overcome acquired resistance to BRAF and MEK inhibitors (Morris et al. 2013 and Hatzivassiliou et al. 2012).

[0295] BVD-523 is a highly potent, selective, reversible, ATP-competitive ERK1/2 inhibitor which has been shown to reduce tumor growth and induce tumor regression in *BRAF* and *RAS* mutant xenograft models. Furthermore, single-agent BVD-523 inhibited human xenograft models that were cross-resistant to both BRAF and MEK inhibitors. See, Examples 9-16. Therefore, an open-label, first-in-human study (Clinicaltrials.gov identifier, NCT01781429) of oral BVD-523 to identify both the maximum tolerated dose and the recommended dose for further study was undertaken. The present study also aimed to assess pharmacokinetic and pharmacodynamic properties as well as preliminary efficacy in patients with advanced cancers.

Example 18

Patient Characteristics

[0296] A total of 27 patients were enrolled and received at least one dose of study drug from April 4, 2013 to December 1, 2015. Baseline demographics and disease characteristics are shown in Table 25. The median patient age was 61 years (range, 33–86 years). Fifty-two percent (14/27) of patients were male and 63% (17/27) had an Eastern Cooperative Oncology Group (ECOG) performance status of 1. Melanoma was the most common cancer (30%; *BRAF* mutation present in 7/8 of these patients). The remaining patients had colorectal (19%; 5/27), papillary thyroid (15%; 4/27), or non-small cell lung cancer (NSCLC) (7%; 2/27), and 8 (30%) were

classified as having other cancers (2 pancreatic, 1 appendiceal, 1 nonseminomatous germ cell, 1 ovarian and 3 with unknown primary). The majority of patients had received 2 or more prior lines of systemic therapy, with 41% (11/27) receiving 2 to 3 and 48% (13/27) receiving >3 prior lines of systemic therapy.

Table 25 – Baseline demographics and clinical characteristics of patients

Parameter	N = 27
Median age, years (range)	61 (33–86)
Sex, n (%)	
Female	13 (48)
Male	14 (52)
Ethnicity, n (%)	
Not Hispanic/Latino	27 (100)
ECOG performance status	
0	10 (37)
1	17 (63)
Cancer type, n (%)	
Melanoma ^a	8 (30)
Colorectal	5 (19)
Papillary thyroid	4 (15)
Non-small cell lung	2 (7)
Other ^b	8 (30)
Molecular abnormalities, n (%) ^c	
<i>BRAF</i> mutant	13 (48)
<i>KRAS</i> mutant	6 (22)
<i>NRAS</i> mutant	2 (7)

Other ^d	7 (26)
Unknown	4 (15)
Number of prior systemic anticancer regimens, n (%)	
0	1 (4)
1	2 (7)
2–3	11 (41)
>3	13 (48)
Prior BRAF/MEK-targeted therapy ^e , n (%)	11 (41)
BRAF	5 (19)
MEK	6 (22)
BRAF/MEK	2 (7)

^aSeven were *BRAF* mutant and 1 was unknown.

^bTwo pancreatic, 1 appendiceal, 1 non-seminomatous germ cell, 1 ovarian, 3 unknown primary.

^cPatients may have more than 1 molecular abnormality.

^dOther molecular abnormalities included *ERCC1*, *RRM1*, thymidylate synthetase, *GNAS*, *MEK1*, *TP53*, *CREBBP*, *ROS1*, *PTEN*, *AKT3*, and *PIK3CA*.

^eSome patients were treated with more than one BRAF inhibitor.

Abbreviation: ECOG, Eastern Cooperative Oncology Group.

Example 19

Ex Vivo Effects of BVD-523 on RSK1/2 Phosphorylation

[0297] An *ex vivo* biomarker assay that could be used to support clinical studies was developed to demonstrate the inhibitory effects of BVD-523 on ERK activity. The assay extends preclinical cellular data where inhibitors of MAPK

signaling, such as BVD-523, dabrafenib, trametinib, and vemurafenib, have been shown to inhibit RSK phosphorylation as a function of inhibitor concentration in *BRAF* mutant cancer cell lines. See, Examples 9-16. Specifically, ERK inhibitor-dependent inhibition of phorbol 12-myristate 13-acetate (PMA)-stimulated phosphorylation of the ERK substrate RSK1 in whole blood was used as a target marker. When BVD-523 was added directly to whole blood from healthy volunteers, PMA-stimulated RSK phosphorylation decreased with increasing concentrations of BVD-523 (FIG. 38). The mean IC_{50} for the cumulative data was 461 ± 20 nM for BVD-523, with a maximum inhibition of $75.8 \pm 2.7\%$ at 10 μ M BVD-523. Maximum inhibition was defined as the RSK phosphorylation measured in the presence of 10 μ M BVD-523. Patient-derived whole blood samples, collected just prior to dosing or at defined timepoints following dosing with BVD-523, were similarly treated and RSK phosphorylation levels quantitated.

Example 20

Dose Escalation, Dose-Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD), and Recommended Phase II Dose (RP2D)

[0298] As per protocol, 5 single-patient cohorts (from 10 to 150 mg twice-daily [BID]) proceeded without evidence of a DLT. The 300-mg BID cohort was expanded to more fully characterize BVD-523 exposures. One of 6 patients given 600 mg BID experienced a DLT of Grade 3 rash. The 900-mg BID dose exceeded the MTD, with one patient experiencing Grade 3 pruritus and elevated aspartate aminotransferase (AST) and another patient experiencing Grade 3 diarrhea, vomiting, dehydration, and elevated creatinine (Table 26). The subsequent intermediate dose of 750 mg BID also exceeded the MTD, with DLTs of Grade 3 rash and Grade 2 diarrhea in 1

patient and Grade 2 hypotension, elevated creatinine, and anemia in another patient.

Therefore, the MTD and RP2D were determined to be 600 mg BID.

Table 26 - Dose-limiting toxicities in Cycle 1 (21 days)

Dose, mg (BID)	DLT Frequency	DLT Description
10	0/1	N/A
20	0/1	N/A
40	0/1	N/A
75	0/1	N/A
150	0/1	N/A
300	0/4	N/A
600	1/8	Rash (Grade 3)
750 ^a	2/4	Rash (Grade 3), diarrhea (Grade 2) Hypotension (Grade 2), elevated creatinine (Grade 2), anemia (Grade 2), delay to cycle 2 dosing
900	2/7	Pruritus (Grade 3), elevated AST (Grade 3) Diarrhea (Grade 3), vomiting (Grade 3), dehydration (Grade 3), elevated creatinine (Grade 3)

^aIntermediate dose.

Abbreviations: AST, aspartate transaminase, BID, twice daily; DLT, dose-limiting toxicity; N/A, not applicable.

Example 21

Adverse Events (AEs)

[0299] Investigator-assessed treatment-related AEs of any grade were noted in 26 of 27 patients (96%). The most common treatment-related AEs (>30%) were rash (predominately acneiform) (70%), fatigue (59%), diarrhea (52%), and nausea (52%) (Table 27). No patients experienced a Grade 4 or 5 treatment-related AE or discontinued treatment due to a treatment-related AE. Most events were Grade 1 to 2, with treatment-related Grade 3 events noted in 13 of 27 patients (48%). The only Grade 3 treatment-related events present in $\geq 10\%$ of patients were diarrhea (15%) and increased liver function tests (11%), all of which occurred above the 600-mg BID dose.

Table 27 - Adverse events possibly/definitely related to BVD-523 in $\geq 10\%$ of patients

	N=27		
Event	Any grade, n (%)	Grade 1 or 2, n (%)	Grade 3^a, n (%)
Rash	20 (74)	18 (67)	2 ^b (7)
Fatigue	17 (63)	16 (59)	1 (4)
Diarrhea	16 (59)	12 (44)	4 (15)
Nausea	14 (52)	14 (52)	0
Vomiting	8 (30)	7 (26)	1 (4)
Anorexia	6 (22)	6 (22)	0
Pruritus	6 (22)	6 (22)	0
Anemia	5 (19)	3 (11)	2 (7)
Increased creatinine	5 (19)	4 (15)	1 (4)
Dehydration	5 (19)	3 (11)	2 (7)
Peripheral edema	4 (15)	4 (15)	0

Increased LFTs (ALT and AST)	4 (14)	1 (4)	3 (11)
Blurry/dimmed vision ^c	3 (11)	3 (11)	0
Constipation	3 (11)	3 (11)	0
Fever	3 (11)	3 (11)	0

^aNo patients experienced Grade 4 or 5 AEs that were possibly or definitely related to BVD-523 treatment.

^bAcneiform and maculo-papular rash.

^cOne Grade 1 event of related central serous retinopathy.

Analysis cut-off date: December 1, 2015.

Abbreviations: AEs, adverse events; ALT, alanine transaminase; AST, aspartate transaminase; LFTs, liver function tests.

[0300] Fourteen patients experienced a total of 28 serious AEs (SAEs). Nine of these were considered to be related or possibly related to BVD-523 by the investigator, which included dehydration, diarrhea, or elevated creatinine (2 patients each), vomiting, nausea, and fever (1 patient each). All other SAEs were considered to be unrelated to treatment with BVD-523. Dose reductions resulting from AEs occurred in 3 patients during the study: 1 patient reduced from 600 mg BID to 300 mg BID and 2 patients reduced from 900 mg BID to 600 mg BID.

Example 22

Pharmacokinetics

[0301] Single-dose and steady-state pharmacokinetics of BVD-523 are summarized in FIG. 39A and Table 28. Generally, orally administered BVD-523 was slowly absorbed in patients with advanced malignancies. After reaching the

maximum concentration ($C_{\max}$), plasma BVD-523 levels remained sustained for approximately 2 to 4 hours. Subsequently, plasma drug concentrations slowly declined. Since plasma drug concentrations were measured only up to 12 hours after the morning dose, it was not possible to calculate an effective or terminal phase elimination rate. BVD-523 pharmacokinetics were linear and dose proportional in terms of both $C_{\max}$ and area under the curve (AUC) when administered up to 600 mg BID. A further increase in exposure was not observed as the dose increased from 600 to 900 mg BID. The $C_{\max}$ reached the level of the EC_{50} based on the *ex vivo* whole blood assay (≈ 200 ng/mL) for all doses above 20 mg BID. Additionally, steady-state exposures remained at or above the target EC_{50} for dose levels of ≥ 150 mg BID throughout the dosing period. Minimal plasma accumulation of BVD-523 and its metabolites were observed on Day 15 at the lower (<75 mg BID) dose levels, whereas accumulation ranged from approximately 1.3- to 4.0-fold for the higher dose levels. Predose concentrations on Day 22 were generally similar to those on Day 15, indicating that steady state had already been attained by Day 15 (data not shown). The degree of interpatient variability in plasma exposure to BVD-523 and its metabolites was considered moderate and not problematic.

Table 28 - Steady-state BVD-523 pharmacokinetics (Cycle 1, Day 15)

Dose, mg ^a	n ^b	C _{max} ^c , ng/ml ± SD		AUC _{0-12h} ^c , ng·hr/ml ± SD	
		Day 1	Day 15	Day 1	Day 15
10	1	48.2	45.7	220	234
20	1	14.9	15.8	91.7	98.7
40	1	100	191	614	999
150	1	193	326	817	2770
300	4 ^b	765 ± 234	586 ± 257	4110 ± 1140	4460 ± 2460
600 ^e	7 ^d	1110 ± 589	2750 ± 1740	2750 ± 1740	24400 ± 16200
750	4 ^b	1450 ± 539	2290 ± 1790 ^f	10700 ± 1120 ^g	23300 ± 19800 ^f
900	7 ^e	1430 ± 1010	1720 ± 328	10800 ± 6320 ^h	15900 ± 1300 ^h

^aDose level administered twice daily; ^bn=3 on Day 15; ^cNumber of subjects for Day 15 at the 600 mg dose level includes two subjects who started Day 1 dosing at 900 mg and were later reduced to 600 mg; ^dn=8 on Day 15; ^en=4 on Day 15; ^fOne subject started on Day 1 dosing at 750 mg and was later reduced to 450 mg. Day 15 parameters for this subject reflect at least 10 consecutive doses at 450mg/dose. Individual Day 15 parameters were 1300 ng/ml for C_{max} and 30700 ng·hr/ml for AUC_{0-12h}; ^gn=3; ^hn=5.

[0302] The urinary excretion after first dose and at steady state of BVD-523 was negligible (<0.2% of the dose) at all dose levels within 12 hours postdose, and not dose-related within this very low percentage range. Renal clearance appeared to be dose-independent. Individual renal clearance values ranged from 0.128 to 0.0895 L/hr (where n = 1 per dose level) and mean values ranged from 0.0149 to 0.0300 L/hr (where n ≥3).

Example 23

Pharmacodynamic Confirmation of Target Inhibition by BVD-523

[0303] To confirm on-target and pathway inhibition by BVD-523, RSK-1 phosphorylation was examined as a target biomarker in human whole blood samples from patients with solid tumors who received BVD-523. Steady state whole blood samples collected just prior to Day 15 dosing from BVD-523-treated patients displayed concentration-dependent inhibition of PMA stimulated ERK activity (FIG. 39B), ranging from 0% ERK inhibition with BVD-523 dosing at 10 mg BID to 93 ± 8% ERK inhibition with dosing at 900 mg BID. The plasma concentrations of BVD-523 that yielded 50% inhibition of ERK phosphorylation were similar whether BVD-523

was spiked directly into healthy volunteer plasma or was present following oral dosing of patients.

Example 24

Antitumor Effects

[0304] Tumor response to BVD-523 was assessed in 25 evaluable patients using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1); 2 patients did not receive both scans of target lesions and were thus not evaluated using RECIST v1.1. No patients achieved a complete response, but 3 patients (all patients with melanoma with *BRAF*^{V600} mutations) achieved a partial response (129 days [BRAF/MEK-inhibitor naïve], 294 days ongoing at [refractory to prior BRAF/MEK inhibitors], 313 days ongoing by the data cutoff date [intolerant to other BRAF/MEK inhibitors]) (FIG. 40A). Interestingly, all 3 partial responders had *BRAF*-mutant melanoma. One partial responder, who was receiving BVD-523 at a dose of 450 mg BID, had an approximate 70% reduction in the sum of target lesions from baseline, while the other partial responders showed reductions of 47.0% and 33.6%. Stable disease was demonstrated in 18 patients, with 6 having stable disease for more than 6 months, and 6 additional patients having stable disease for more than 3 months. In this study, 4 patients displayed progressive disease at first evaluation.

[0305] FIG. 40B shows computed tomography (CT) scans of 1 of the 3 partial responders (RECIST v1.1) who had progressed on prior vemurafenib and subsequent dabrafenib/trametinib treatment; a durable partial response was observed following dosing of BVD-523 600 mg BID for >300 days. BVD-523 was associated with a metabolic response using fluorodeoxyglucose-positive emission tomography (¹⁸F-FDG-PET) in 5 of 16 evaluable patients.

[0306] FIG. 41 depicts the time to response and the duration of response in the study population. The two patients who demonstrated responses to BVD-523 remained on study and continued with BVD-523 treatment as of the study cutoff date (>500 days); additionally, one patient with bronchoalveolar NSCLC (not enough tissue for molecular profiling) had been on treatment for >700 days with stable disease. Twenty-four of 27 patients (90%) discontinued treatment due to progressive disease (22/27, 82%) or other reasons (2/27, 7%). The mean duration of BVD-523 treatment before discontinuation was 4.7 months.

DISCUSSION

[0307] The present invention presents results from a first-in-human study evaluating the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BVD-523 in 27 patients with advanced solid tumors. In this dose-escalation study, oral treatment with BVD-523 resulted in both radiographic responses by RECIST v1.1 (3 partial responses) and prolonged disease stabilization in some patients, the majority of whom had been treated with ≥ 2 prior systemic therapies. Evidence of BVD-523-dependent inhibition of metabolic response in tumors was established in a subset of patients by imaging tumor uptake of ^{18}F -glucose. Drug exposures increased linearly with increasing doses up to 600 mg BID, with exposures at 600 mg BID providing near complete 24/7 inhibition of ERK-dependent substrate (RSK-1) phosphorylation in an *ex vivo* whole blood assay. Furthermore, tolerability to BVD-523 was manageable when administered up to its MTD and RP2D, determined to be 600 mg BID.

[0308] BVD-523 was generally well tolerated, with manageable and reversible toxicity. The most common AEs were rash (usually acneiform), fatigue, and gastrointestinal side effects, including nausea, vomiting, and diarrhea. The safety

profile of BVD-523 is consistent with its selective inhibition of the MAPK pathway; the AE profile shows considerable overlap with MEK inhibitor experience. However, toxicities associated with any targeted therapy may include dependence on both the specific mechanism and the degree of target inhibition as well as any off-target effects (Zelboraf [package insert] and Hauschild et al. 2012). Ongoing and future investigations will extend both the efficacy and safety profile demonstrated in this dose-escalation study, and will guide how the unique profile of the ERK inhibitor BVD-523 might be used as a single agent or in combination with other agents.

[0309] Durable responses by RAF and MEK inhibitors are often limited by intrinsic and eventual acquired resistance, with a common feature often involving reactivation of the ERK pathway (Poulikakos et al. 2011, Corcoran et al. 2010, Nazarian et al. 2010, Shi et al. 2014, Johannessen et al. 2010, Wagle et al. 2011, Wagle et al. 2014, Ahronian et al. 2015 and Paraiso et al. 2010). Thus, ERK inhibition with BVD-523 alone or in combination with other MAPK signaling pathway inhibitors may have the potential to delay the development of resistance to existing therapies and to benefit a broader patient population. That ERK inhibitors, including BVD-523, retain their potency in BRAF- and MEK-resistant cell lines provide preclinical evidence for the use of ERK inhibitors in patients with acquired resistance to standard of care (BRAF/MEK combination therapy) See, e.g., Examples 9-16. Importantly, in this study, a patient whose cancer had progressed after experiencing stable disease when treated initially with a BRAF inhibitor (vemurafenib) and subsequently with a combination of *BRAF* and MEK inhibitors (dabrafenib/trametinib) had a partial response when receiving single-agent BVD-523. This patient has remained on-study for a total of 708 days, as of the cutoff date of the study reported herein. Based in part on the antitumor effects observed in this patient, the FDA has

designated as a Fast Track development program the investigation of BVD-523 for the treatment of patients with unresectable or metastatic *BRAF*^{V600} mutation-positive melanoma that is refractory to or has progressed following treatment with a BRAF and/or MEK inhibitor(s). Precise definition of exactly how BVD-523 might best support patient care (eg, as a single agent or in various combinations) requires additional clinical studies.

[0310] In summary, the present examples present data from an initial data from the dose escalation portion of a phase I study evaluating BVD-523, a novel first-in-class ERK inhibitor, as a treatment for patients with advanced cancers. Continuous, twice-daily oral treatment with BVD-523 resulted in antitumor effects in several patients, including patients either naïve to or having progressed on available MAPK pathway-targeted therapies. BVD-523 was generally well tolerated in this advanced cancer patient population and toxicities were manageable; the MTD and RP2D were 600 mg BID. BVD-523 exposures increased linearly up to the RP2D and robust pharmacodynamics effects were evident at this dose level. An expansion of this phase I clinical study is currently underway to confirm and extend the observations made in the dose-escalation phase. Specifically, patients are being enrolled into molecularly classified expansion cohorts (e.g., *NRAS*, *BRAF*, *MEK* or *ERK* alterations) across various tumor histologies. Furthermore, expansion cohorts are evaluating the use of BVD-523 in patients with cancer who are either naïve to available MAPK pathway therapies or those whose disease has progressed on such treatments.

Documents

ABSALAN, Farnaz, Mostafa Ronaghi (2008). Molecular Inversion Probe Assay.

Methods in Molecular Biology 396. Humana Press. pp. 315–330.

- AHRONIAN LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, et al. Clinical acquired resistance to RAF inhibitor combinations in *BRAF*-mutant colorectal cancer through MAPK pathway alterations. *Cancer Discov* 2015;5:358–67.
- ARCILA ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, et al. MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking. *Clin Cancer Res* 2015;21:1935-43.
- ARONOV AM, Baker C, Bemis GW, Cao J, Chen G, Ford PJ, et al. Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors. *J Med Chem* 2007;50:1280-7.
- ARONOV AM, Tang Q, Martinez-Botella G, Bemis GW, Cao J, Chen G, et al. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. *J Med Chem* 2009;52:6362-8.
- ARRINGTON AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J, et al. Prognostic and predictive roles of *KRAS* mutation in colorectal cancer. *Int J Mol Sci* 2012;13:12153-68.
- CARGNELLO M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. *Microbiol Mol Biol Rev* 2011;75:50-83.
- CARLINO MS, Fung C, Shahheydari H, Todd JR, Boyd SC, Irvine M, et al. Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. *Clin Cancer Res* 2015;21:98-105.

- CHAPMAN PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med* 2011;364:2507-16.
- CORCORAN, R.B., et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. *Sci Signal* (2010);3(149): ra84.
- DAI, B., et al. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. *Cancer Res* (2011);71:3658-3668.
- DAVIES H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the *BRAF* gene in human cancer. *Nature* 2002;417:949–54.
- DESCHENES-SIMARD X, Kottakis F, Meloche S, Ferbeyre G. ERKs in cancer: friends or foes? *Cancer Res* 2014;74:412–9.
- DOBRYZYCKA B, Terlikowski SJ, Kowalczyk O, Niklinska W, Chyczewski L, Kulikowski M. Mutations in the *KRAS* gene in ovarian tumors. *Folia Histochem Cytobiol* 2009;47:221–4.
- EMERY, C.M., et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. *PNAS* (2009); 106(48):20411-6.
- FEDOROV O, Niesen FH, Knapp S. Kinase inhibitor selectivity profiling using differential scanning fluorimetry. *Methods Mol Biol* 2012;795:109-18.
- FERNÁNDEZ-MEDARDE A, Santos E. Ras in cancer and developmental diseases. *Genes Cancer* 2011;2:344–58.
- FLAHERTY KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *N Engl J Med* 2012;367:1694-703.

- GOETZ EM, Ghandi M, Treacy DJ, Wagle N, Garraway LA. ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. *Cancer Res* 2014;74:7079-89.
- GOLLOB JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. *Semin Oncol* 2006;33:392-406.
- GREGER, James G., et al. "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations." *Molecular cancer therapeutics* 11.4 (2012): 909-920.
- GROENENDIJK FH, Bernards R. Drug resistance to targeted therapies: deja vu all over again. *Mol Oncol* 2014;8:1067-83.
- HALL RD, Kudchadkar RR. BRAF mutations: signaling, epidemiology, and clinical experience in multiple malignancies. *Cancer Control* 2014;21:221-30.
- HARDENBOL, P., et al. Multiplexed genotyping with sequence-tagged molecular inversion probes. *Nat. Biotechnol.* 2003, no.21 , p.673-678.
- HATZIVASSILIOU, Georgia, et al. "RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth." *Nature* 464.7287 (2010): 431-435.
- HATZIVASSILIOU G, Liu B, O'Brien C, Spörke JM, Hoeflich KP, Haverty PM, et al. ERK inhibition overcomes acquired resistance to MEK inhibitors. *Mol Cancer Ther* 2012;11:1143-54.
- HAUSCHILD A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet* 2012;380:358-65.

- HAYES TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, et al. Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. *Cancer Cell* 2016;29:75-89.
- HEZEL AF, Noel MS, Allen JN, Abrams TA, Yurgelun M, Faris JE, et al. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. *Br J Cancer* 2014;111:430–6.
- JHA S, Morris EJ, Hruza A, Mansueto MS, Schroeder G, Arbanas J, et al. Dissecting therapeutic resistance to ERK inhibition. *Mol Cancer Ther* 2016;15:548-59.
- JOHANNESSEN, C.M., et al. COT/MAP3K8 drives resistance to RAF inhibition through MAP kinase pathway reactivation. *Nature* (2010);468(7326):968-972.
- JOHNSON DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, et al. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. *Eur J Cancer* 2015;51:2792-9.
- KANDA M, Matthaei H, Wu J, Hong SM, Yu J, Borges M, et al. Presence of somatic Mutations in most early-stage pancreatic intraepithelial neoplasia. *Gastroenterology* 2012;142:730-733.
- KHATTAK M, Fisher R, Turajlic S, Larkin J. Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. *Ther Adv Med Oncol* 2013;5:105–18.
- KING, Alastair J., et al. "Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions." *PloS one* 8.7 (2013): e67583.

- LARKIN J, Ascierto PA, Dréno B, Atkinson V, Liskay G, Maio M, et al. Combined vemurafenib and cobimetinib in *BRAF*-mutated melanoma. *N Engl J Med* 2014;371:1867-76.
- LITTLE, A.S., et al., Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells. *Sci. Signal.* 4, ra17 (2011).
- LIU, Dingxie, et al. "BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells." *Journal of Clinical Endocrinology & Metabolism* 92.6 (2007): 2264-2271.
- LIU B, Fu L, Zhang C, Zhang L, Zhang Y, Ouyang L, et al. Computational design, chemical synthesis, and biological evaluation of a novel ERK inhibitor (BL-EI001) with apoptosis-inducing mechanisms in breast cancer. *Oncotarget* 2015;6:6762-75.
- LONG GV, Fung C, Menzies AM, Pupo GM, Carlino MS, Hyman J, et al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. *Nat Commun* 2014;5:5694.
- LONG GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet* 2015;386:444-51.
- MANANDHAR SP, Hildebrandt ER, Schmidt WK. Small-molecule inhibitors of the Rce1p CaaX protease. *J Biomol Screen.* 2007;12(7):983–993.
- MASSEY PR, Prasad V, Figg WD, Fojo T. Multiplying therapies and reducing toxicity in metastatic melanoma. *Cancer Biol Ther* 2015;16:1014-8.

- MAURER, T, Garrenton, LS, Oh, A, Pitts, K, Anderson, DJ, Skelton, NJ, Fauber, BP, Pan, B, Malek, S, Stokoe, D, Ludlam, MJC, Bowman, KK, Wu, J, Giannetti, AM, Starovasnik, MA, Mellman, I, Jackson, PK, Rudolph, J, Wang, W, Fang, G. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. PNAS. 2012;109(14):5299-304.
- MCARTHUR GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in *BRAF*^{V600E} and *BRAF*^{V600K} mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014;15:323–32.
- MEKINIST [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2014.
- METZKER, Emerging technologies in DNA sequencing Genome Res. 2005. 15: 1767-1776.
- MITTAL, Rohit *et al.* "The acetyltransferase activity of the bacterial toxin YopJ of *Yersinia* is activated by eukaryotic host cell inositol hexakisphosphate." Journal of Biological Chemistry 285.26 (2010): 19927-19934.
- MORRIS EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 2013;3:742-50.
- NAZARIAN, R., et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468(7326):973-977.
- NIKOLAEV SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, et al. Exome sequencing identifies recurrent somatic *MAP2K1* and *MAP2K2* mutations in melanoma. Nat Genet 2012;44:133–9.

- NILSSON, M., *et al.* Padlock probes: circularizing oligonucleotides for localized DNA detection. *Science*. 1994, no.265, p.2085-2088.
- O'HARA AJ, Bell DW. The genomics and genetics of endometrial cancer. *Adv Genomics Genet* 2012;2012:33–47.
- OJESINA AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, *et al.* Landscape of genomic alterations in cervical carcinomas. *Nature* 2014;506:371-5.
- OTA *et al.*, Single nucleotide polymorphism detection by polymerase chain reaction-restriction fragment length polymorphism. *Nat Protoc*. 2007;2(11):2857-64.
- PARAISO KHT, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, *et al.* Recovery of phospho-ERK activity allows melanoma cells to escape from *BRAF* inhibitor therapy. *Br J Cancer* 2010;102:1724–30.
- PATGIRI A, Yadav, KK, Arora, PS, Bar-Sagi, D. An orthosteric inhibitor of the Ras-Sos interaction. *Nat Chem Biol*. 2011;7:585-587.
- PENNYCUICK A, Simpson T, Crawley D, Lal R, Santis G, Cane P, *et al.* Routine EGFR and KRAS mutation analysis using COLD-PCR in non-small cell lung cancer. *Int J Clin Pract* 2012;66:748–52.
- PORTER SB, Hildebrandt ER, Breevoort SR, Mokry DZ, Dore TM, Schmidt WK. Inhibition of the CaaX proteases Rce1p and Ste24p by peptidyl (acyloxy)methyl ketones. *Biochim Biophys Acta*.2007;1773(6):853–862.
- POULIKAKOS PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, *et al.* RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). *Nature* 2011;480:387-90.

- QUEIROLO P, Picasso V, Spagnolo F. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. *Cancer Treat Rev* 2015;41:519-26.
- RASOLA A, Sciacovelli M, Chiara F, Pantic B, Brusilow WS, Bernardi P. Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition. *Proc Natl Acad Sci U S A* 2010;107:726–31.
- RIZOS H, Menzies AM, Pupo GM, Carlino MS, Fung C, Hyman J, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. *Clin Cancer Res* 2014;20:1965-77.
- ROBERT C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. *N Engl J Med* 2015;372:30-9.
- ROMEO Y, Zhang X, Roux PP. Regulation and function of the RSK family of protein kinases. *Biochem J* 2012;441:553–69.
- RUDOLPH J, Xiao Y, Pardi A, Ahn NG. Slow inhibition and conformation selective properties of extracellular signal-regulated kinase 1 and 2 inhibitors. *Biochemistry* 2015;54:22-31.
- SHAUL YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. *Biochim Biophys Acta* 2007;1773:1213–26.
- SHI H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. *Cancer Discov* 2014;4:80-93.
- SHIMA, F, Yoshikawa, Y, Ye, M, Araki, M, Matsumoto, S, Liao, J, Hu, L, Sugimoto, T, Ijiri, Y, Takeda, A, Nishiyama, Y, Sato, C, Muraoka, S, Tamura, A, Osoda,

T, Tsuda, K-I, Miyakawa, T, Fukunishi, H, Shimada, J, Kumasaka, Yamamoto, M, Kataoka, T. *In silico* discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. PNAS. 2013;110(20):8182-7.

SCHUBBERT S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007;7:295–308.

SUN C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep 2014;7:86-93.

TAFLINAR [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2015.

TRUNZER K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 2013;31:1767-74.

VILLANUEVA, J., et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18:683-695.

WAGLE, N., et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. Journal of Clinical Oncology 2011;29(22):3085-3096.

WAGLE N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, et al. MAP kinase pathway alterations in *BRAF*-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 2014;4:61-8.

Wainstein E, Seger R. The dynamic subcellular localization of ERK: mechanisms of translocation and role in various organelles. *Curr Opin Cell Biol* 2016;39:15-20.

WANG, H., et al. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RAF V600E mutation. *Cancer Res* (2011);71(16):5535-45.

YANG W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. *Nucleic Acids Res* 2013;41:D955-D961.

YAO Z, Torres NM, Tao A, Gao Y, Luo L, Li Q, et al. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. *Cancer Cell* 2015;28:370-83.

YOHE S. Molecular genetic markers in acute myeloid leukemia. *J Clin Med* 2015;4:460–78.

ZELBORAF [package insert]. South San Francisco, CA: Genentech USA, Inc.; 2015.

[0311] All documents cited in this application are hereby incorporated by reference as if recited in full herein.

[0312] Although illustrative embodiments of the present invention have been described herein, it should be understood that the invention is not limited to those described, and that various other changes or modifications may be made by one skilled in the art without departing from the scope or spirit of the invention.

WHAT IS CLAIMED IS:

1. A method of treating a BRAF600 mutation-positive melanoma in a human, comprising orally administering between about 450 mg to about 600 mg BID of BVD-523 or a pharmaceutically acceptable salt thereof to the human.
2. The method according to claim 1, wherein the mutation is a BRAF^{V600E} mutation.
3. The method according to claim 1 or claim 2, wherein the melanoma has MAPK activity.
4. The method according to any one of claims 1 to 3, wherein the human has an unresectable or metastatic BRAF600 mutation-positive melanoma.
5. Use of BVD-523 or a pharmaceutically acceptable salt thereof for treating a human having a BRAF600 mutation-positive melanoma, wherein the BVD-523 or pharmaceutically acceptable salt thereof is orally administered to the human at a dose of between about 450 mg to about 600 mg BID.
6. Use of BVD-523 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a BRAF600 mutation-positive melanoma in a human, wherein the medicament is formulated to orally administer between about 450 mg to about 600 mg BID of the BVD-523 or pharmaceutically acceptable salt thereof to the human.
7. The use according to claim 5 or claim 6, wherein the mutation is a BRAF^{V600E} mutation.

8. The use according to any one of claims 5 to 7, wherein the melanoma has MAPK activity.
9. The use according to any one of claims 5-8, wherein the human has an unresectable or metastatic BRAF600 mutation-positive melanoma.

FIG. 1A




FIG. 1B




FIG. 1C




FIG. 2A




FIG. 2B




FIG. 2C





FIG. 2D



7/145

FIG. 2E




FIG. 2F




FIG. 2G





FIG. 2H



11/145

FIG. 3A





FIG. 3B



12/145

FIG. 3C




FIG. 3D




FIG. 4A




FIG. 4B




FIG. 4C





FIG. 4D



17/145

FIG. 4E




FIG. 4F




FIG. 4G




FIG. 4H




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 5E




FIG. 5F




FIG. 5G




FIG. 5H




FIG. 6A





FIG. 6B



30/145

FIG. 6C






FIG. 6D




31/145

FIG. 7



32/145

FIG. 8A



33/145

FIG. 8B




FIG. 8C




FIG. 8D




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 10A




FIG. 10B

Excess over Bliss:




FIG. 10C

FIG. 10D




FIG. 10E

A375: Dabrafenib and Trametinib (Alamar Blue)




FIG. 11A




FIG. 11B




FIG. 11C

A375: Dabrafenib single agent (CellTiter-Glo)




FIG. 11D

A375: Trametinib single agent (CellTiter-Glo)




FIG. 11E

A375: Dabrafenib and Trametinib (CellTiter-Glo)




FIG. 12A




FIG. 12B




FIG. 12C

A375: Dabrafenib single agent (Alamar Blue)




FIG. 12D

A375: BVD-0523 single agent (Alamar Blue)




FIG. 12E

A375: Dabrafenib and BVD-0523 (Alamar Blue)




FIG. 13A




FIG. 13C




FIG. 13D




FIG. 13E

A375: Dabrafenib and BVD-0523 (CellTiter-Glo)




FIG. 14A




FIG. 14C

A375: Trametinib single agent (Alamar Blue)




FIG. 14D

A375: BVD-0523 single agent (Alamar Blue)




FIG. 14E

A375: Trametinib and BVD-0523 (Alamar Blue)




FIG. 15A

% Inhibition:




FIG. 15B




FIG. 15C

A375: Trametinib single agent (CellTiter-Glo)




FIG. 15D

A375: BVD-0523 single agent (CellTiter-Glo)




FIG. 15E

A375: Trametinib and BVD-0523 (CellTiter-Glo)




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG. 17D





FIG. 17C






FIG. 18C




FIG. 18D




FIG. 19

Resistance Condition	Starting Concentration (nM)	Maintenance Concentration (nM)		
		Month 1	Month 2	Month 3
Dabrafenib_R	5	25	400	3200
Trametinib_R	1	3	40	160
BVD-523_R	160	640	1800	1200
Dabrafenib/Trametinib_R	2.5/0.5	7.5/1.5	28/6	160/30
Dabrafenib/BVD-523_R	2.5/80	10/320	28/900	42/1500
Trametinib/BVD-523_R	0.5/80	2/320	2.5/400	4/600

Resistance Condition	Multiple Above Starting Concentration		
	Month 1	Month 2	Month 3
Dabrafenib_R	5X	80X	640X
Trametinib_R	3X	40X	160X
BVD-523_R	4X	11.25X	7.5X
Dabrafenib/Trametinib_R	3X	11.2X	64X
Dabrafenib/BVD-523_R	4X	11.2X	16.8X
Trametinib/BVD-523_R	4X	5X	8X

Resistance Condition	IC50 Fold Change			
	Dabrafenib	Trametinib	BVD-523	Paclitaxel
Parental	1.00	1.00	1.00	1.00
Trametinib_R	2.51	2.60	1.78	2.53
Dabrafenib_R	3.79	3.28	1.84	0.62
BVD-523_R	238.11	108.20	16.84	2.97
Trametinib + Dabrafenib_R	103.17	38.60	4.22	1.66
Dabrafenib + BVD-523_R	71.87	18.04	4.32	1.35
Trametinib + BVD-523_R	27.51	26.69	3.81	3.96

Resistance Condition	Percent Growth at ~10X Parental IC50			
	Dabrafenib	Trametinib	BVD-523	Paclitaxel
Parental	13.30%	6.80%	0.00%	1.95%
Trametinib_R	33.53%	30.15%	20.02%	13.52%
Dabrafenib_R	36.45%	25.96%	8.21%	9.36%
BVD-523_R	230.01%	172.91%	57.49%	34.02%
Trametinib + Dabrafenib_R	131.10%	125.01%	12.65%	15.44%
Dabrafenib + BVD-523_R	93.55%	71.37%	8.70%	11.41%
Trametinib + BVD-523_R	86.71%	64.03%	27.70%	30.71%

IC50, Parental (nM)	4.11	0.38	186.21	3.65
~10X Parental concentration	30.20	3.00	3019.95	36.48

71/145

FIG. 20






FIG. 21




73/145

FIG. 22A




74/145

FIG. 22B




75/145

FIG. 22C



76/145

FIG. 22D



77/145

FIG. 22E




FIG. 23B




FIG. 23C






FIG. 23D



81/145

FIG. 23F




FIG. 23G




FIG. 23H




FIG. 23




FIG. 23J




FIG. 23K




FIG. 23L




FIG. 23M




FIG. 23O





FIG. 23N



87/145

FIG. 24A




FIG. 24B




FIG. 24C




FIG. 24D




FIG. 24E




FIG. 24F




FIG. 24G




FIG. 24H




FIG. 24J




FIG. 24I




FIG. 24K




FIG. 24L




FIG. 24M




FIG. 24N






FIG. 24N



96/145

FIG. 25A



97/145

FIG. 25B




FIG. 25C




FIG. 25D




FIG. 25E




FIG. 25F




FIG. 25G




FIG. 25H




FIG. 25I





FIG. 25J



102/145

FIG. 25K




FIG. 25L




FIG. 25M




FIG. 25N





FIG. 25O



105/145

FIG. 26A





FIG. 26B



106/145

FIG. 26C




FIG. 27A




FIG. 27B




FIG. 27C




FIG. 27D




FIG. 27E




FIG. 27F




FIG. 27G




FIG. 27H




FIG. 27I

MEK1-Q56P




FIG. 28A




FIG. 28B




FIG. 28C




FIG. 28D




FIG. 28E




FIG. 29A




FIG. 29B




FIG. 29C




FIG. 29D




FIG. 29E




FIG. 29F





FIG. 30A



121/145

FIG. 30B




FIG. 30C




FIG. 30D




FIG. 31A




FIG. 31B




FIG. 31C





FIG. 32A



127/145

FIG. 32B




FIG. 32C




FIG. 33




FIG. 34A




FIG. 34B




FIG. 34C




FIG. 34D





FIG. 35A



135/145

FIG. 36A





FIG. 36B



- G1: Vehicle; QD to end
- ◆ G2: Dabrafenib, 50 mg/kg + BVD-523, 50 mg/kg
- ◇ G3: Dabrafenib, 50 mg/kg + BVD-523, 100 mg/kg
- ◆ G4: Dabrafenib, 100 mg/kg + BVD-523, 50 mg/kg
- ◇ G5: Dabrafenib, 100 mg/kg + BVD-523, 100 mg/kg
- ◆ G6: Dabrafenib, 50 mg/kg orally; QD to end
- ◇ G7: Dabrafenib, 100 mg/kg orally; QD to end
- ◆ G8: BVD-523, 50 mg/kg orally; BID to end
- ◇ G9: BVD-523, 100 mg/kg orally; BID to end
- ◆ G10: Temozolomide, 150 mg/kg orally; QD x 5

136/145

FIG. 36C





FIG. 36D



- G1: Vehicle; po; BID to end
- ◆ G2: BVD-523, 100 mg/kg orally; BID x 41
- ◆ G3: Dabrafenib, 50 mg/kg orally; BID x 41
- ◆ G4: Dabrafenib, 25 mg/kg + BVD-523, 50 mg/kg
- ◆ G5: Dabrafenib, 50 mg/kg + BVD-523, 100 mg/kg

FIG. 37A





FIG. 37B






FIG. 38




FIG. 39B




FIG. 40B





FIG. 41



0398850pct.txt
SEQUENCE LISTING

<110> SAHA, Saurabh

<120> METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY
INHIBITOR-RESISTANT CANCERS

<130> C065272/0398850pct

<150> 15/161,137
<151> 2016-05-20

<150> PCT/US14/71749
<151> 2014-12-19

<150> US 61/919,551
<151> 2013-12-20

<160> 82

<170> PatentIn version 3.3

<210> 1
<211> 2949
<212> DNA
<213> Homo sapiens

<400> 1

cgcctccctt cccctcccc gcccgacagc ggccgctcgg gccccggctc tcggttataa	60
gatggcgggc ctgagcgggtg gcggtggttg cggcgcgagg cggggccagg ctctgttcaa	120
cggggacatg gagcccgagg ccggcgccgg cgccggcgcc gcggcctctt cggctgcgga	180
ccctgccatt ccggaggagg tgtggaatat caaacaatg attaagttga cacaggaaca	240
tatagaggcc ctattggaca aatttggttg ggagcataat ccaccatcaa tatatctgga	300
ggcctatgaa gaatacacca gcaagctaga tgcactcaa caaagagaac aacagttatt	360
ggaatctctg gggaacggaa ctgatttttc tgtttctagc tctgcatcaa tggataccgt	420
tacatcttct tcctcttcta gcctttcagt gctaccttca tctctttcag tttttcaaaa	480
tcccacagat gtggcacgga gcaaccccaa gtcaccacaa aaacctatcg ttagagtctt	540
cctgccaac aaacagagga cagtggtagc tgcaaggtgt ggagttacag tccgagacag	600
tctaaagaaa gactgatga tgagaggtct aatcccagag tgctgtgctg ttacagaat	660
tcaggatgga gagaagaaac caattggttg ggacactgat atttcctggc ttactggaga	720
agaattgcat gtggaagtgt tggagaatgt tccacttaca acacacaact ttgtacgaaa	780
aacgtttttc acctagcat tttgtgactt ttgtcgaaag ctgcttttcc agggtttccg	840
ctgtcaaaca tgtggttata aatttcacca gcgttgtagt acagaagttc cactgatgtg	900
tgtaattat gaccaacttg atttgctgtt tgtctccaag ttctttgaac accaccaat	960
accacaggaa gaggcgtcct tagcagagac tgccctaaca tctggatcat ccccttccgc	1020
accgcctcg gactctattg ggcccaaat tctcaccagt ccgtctcctt caaatccat	1080
tccaattcca cagcccttcc gaccagcaga tgaagatcat cgaaatcaat ttgggcaacg	1140
agaccgatcc tcatcagctc ccaatgtgca tataaacaca atagaacctg tcaatattga	1200

0398850pct.txt

tgacttgatt	agagaccaag	gatttcgtgg	tgatggagga	tcaaccacag	gtttgtctgc	1260
tacccccct	gcctcattac	ctggctcact	aactaacgtg	aaagccttac	agaaatctcc	1320
aggacctcag	cgagaaagga	agtcactctt	atcctcagaa	gacaggaatc	gaatgaaaac	1380
acttggtaga	cgggactcga	gtgatgattg	ggagattcct	gatgggcaga	ttacagtggg	1440
acaaagaatt	ggatctggat	catttggaac	agtctacaag	ggaaagtggc	atggtgatgt	1500
ggcagtga	atgttgaaat	tgacagcacc	tacacctcag	cagttacaag	ccttcaaaaa	1560
tgaagtagga	gtactcagga	aaacacgaca	tgtgaatata	ctactcttca	tgggctattc	1620
cacaaagcca	caactggcta	ttgttaccca	gtggtgtgag	ggctccagct	tgtatcacca	1680
tctccatata	attgagacca	aatttgagat	gatcaaactt	atagatattg	cacgacagac	1740
tgcacagggc	atggattact	tacacgcca	gtcaatcatc	cacagagacc	tcaagagtaa	1800
taatataatt	cttcatgaag	acctcacagt	aaaaataggt	gattttgggtc	tagctacagt	1860
gaaatctcga	tggagtgggt	cccatcagtt	tgaacagttg	tctggatcca	ttttgtggat	1920
ggcaccagaa	gtcatcagaa	tgcaagataa	aaatccatac	agctttcagt	cagatgtata	1980
tgcatttgga	attgttctgt	atgaattgat	gactggacag	ttaccttatt	caaacatcaa	2040
caacagggac	cagataattt	ttatggtggg	acgaggatac	ctgtctccag	atctcagtaa	2100
ggtacggagt	aactgtccaa	aagccatgaa	gagattaatg	gcagagtgcc	tcaaaaagaa	2160
aagagatgag	agaccactct	ttccccaat	tctgcctct	attgagctgc	tggcccgctc	2220
attgccaaaa	attcacgcga	gtgcatcaga	accctccttg	aatcgggctg	gtttccaaac	2280
agaggatttt	agtctatatg	cttgtgcttc	tccaaaaaca	cccatccagg	cagggggata	2340
tggtgcgttt	cctgtccact	gaaacaaatg	agtgagagag	ttcaggagag	tagcaacaaa	2400
aggaaaataa	atgaacatat	gtttgcttat	atgttaaatt	gaataaaata	ctctcttttt	2460
ttttaagggtg	aaccaaagaa	cacttggtgtg	gttaaagact	agatataatt	tttcccaaaa	2520
ctaaaattta	tacttaacat	tggattttta	acatccaagg	gttaaaatac	atagacattg	2580
ctaaaaattg	gcagagcctc	ttctagaggc	tttactttct	gttccggggt	tgtatcattc	2640
acttggttat	tttaagtagt	aaacttcagt	ttctcatgca	acttttggtg	ccagctatca	2700
catgtccact	agggactcca	gaagaagacc	ctacctatgc	ctgtgtttgc	aggtgagaag	2760
ttggcagtcg	gttagcctgg	gttagataag	gcaaactgaa	cagatctaata	ttaggaagtc	2820
agtagaattt	aataattcta	ttattattct	taataatttt	tctataacta	tttcttttta	2880
taacaatttg	gaaaatgtgg	atgtctttta	tttccttgaa	gcaataaact	aagtttcttt	2940
ttataaaaa						2949

<210> 2
 <211> 765
 <212> PRT
 <213> Homo sapiens
 <400> 2

Ala Ala Leu Ser Gly Gly Gly Gly Gly Gly Ala Glu Pro Gly Gln Ala
 1 5 10 15
 Leu Phe Asn Gly Asp Met Glu Pro Glu Ala Gly Ala Gly Ala Gly Ala
 20 25 30
 Ala Ala Ser Ser Ala Ala Asp Pro Ala Ile Pro Glu Glu Val Trp Asn
 35 40 45
 Ile Lys Gln Met Ile Lys Leu Thr Gln Glu His Ile Glu Ala Leu Leu
 50 55 60
 Asp Lys Phe Gly Gly Glu His Asn Pro Pro Ser Ile Tyr Leu Glu Ala
 65 70 75 80
 Tyr Glu Glu Tyr Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg Glu Gln
 85 90 95
 Gln Leu Leu Glu Ser Leu Gly Asn Gly Thr Asp Phe Ser Val Ser Ser
 100 105 110
 Ser Ala Ser Met Asp Thr Val Thr Ser Ser Ser Ser Ser Ser Leu Ser
 115 120 125
 Val Leu Pro Ser Ser Leu Ser Val Phe Gln Asn Pro Thr Asp Val Ala
 130 135 140
 Arg Ser Asn Pro Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe Leu
 145 150 155 160
 Pro Asn Lys Gln Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr Val
 165 170 175
 Arg Asp Ser Leu Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro Glu
 180 185 190
 Cys Cys Ala Val Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile Gly
 195 200 205
 Trp Asp Thr Asp Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val Glu
 210 215 220
 Val Leu Glu Asn Val Pro Leu Thr Thr His Asn Phe Val Arg Lys Thr
 225 230 235 240
 Phe Phe Thr Leu Ala Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe Gln
 245 250 255
 Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Gln Arg Cys Ser
 260 265 270

Thr Glu Val Pro Leu Met Cys Val Asn Tyr Asp Gln Leu Asp Leu Leu
 275 280 285

Phe Val Ser Lys Phe Phe Glu His His Pro Ile Pro Gln Glu Glu Ala
 290 295 300

Ser Leu Ala Glu Thr Ala Leu Thr Ser Gly Ser Ser Pro Ser Ala Pro
 305 310 315 320

Ala Ser Asp Ser Ile Gly Pro Gln Ile Leu Thr Ser Pro Ser Pro Ser
 325 330 335

Lys Ser Ile Pro Ile Pro Gln Pro Phe Arg Pro Ala Asp Glu Asp His
 340 345 350

Arg Asn Gln Phe Gly Gln Arg Asp Arg Ser Ser Ser Ala Pro Asn Val
 355 360 365

His Ile Asn Thr Ile Glu Pro Val Asn Ile Asp Asp Leu Ile Arg Asp
 370 375 380

Gln Gly Phe Arg Gly Asp Gly Gly Ser Thr Thr Gly Leu Ser Ala Thr
 385 390 395 400

Pro Pro Ala Ser Leu Pro Gly Ser Leu Thr Asn Val Lys Ala Leu Gln
 405 410 415

Lys Ser Pro Gly Pro Gln Arg Glu Arg Lys Ser Ser Ser Ser Ser Glu
 420 425 430

Asp Arg Asn Arg Met Lys Thr Leu Gly Arg Arg Asp Ser Ser Asp Asp
 435 440 445

Trp Glu Ile Pro Asp Gly Gln Ile Thr Val Gly Gln Arg Ile Gly Ser
 450 455 460

Gly Ser Phe Gly Thr Val Tyr Lys Gly Lys Trp His Gly Asp Val Ala
 465 470 475 480

Val Lys Met Leu Asn Val Thr Ala Pro Thr Pro Gln Gln Leu Gln Ala
 485 490 495

Phe Lys Asn Glu Val Gly Val Leu Arg Lys Thr Arg His Val Asn Ile
 500 505 510

Leu Leu Phe Met Gly Tyr Ser Thr Lys Pro Gln Leu Ala Ile Val Thr
 515 520 525

Gln Trp Cys Glu Gly Ser Ser Leu Tyr His His Leu His Ile Ile Glu
 530 535 540

0398850pct.txt

Thr Lys Phe Glu Met Ile Lys Leu Ile Asp Ile Ala Arg Gln Thr Ala
545 550 555 560

Gln Gly Met Asp Tyr Leu His Ala Lys Ser Ile Ile His Arg Asp Leu
565 570 575

Lys Ser Asn Asn Ile Phe Leu His Glu Asp Leu Thr Val Lys Ile Gly
580 585 590

Asp Phe Gly Leu Ala Thr Val Lys Ser Arg Trp Ser Gly Ser His Gln
595 600 605

Phe Glu Gln Leu Ser Gly Ser Ile Leu Trp Met Ala Pro Glu Val Ile
610 615 620

Arg Met Gln Asp Lys Asn Pro Tyr Ser Phe Gln Ser Asp Val Tyr Ala
625 630 635 640

Phe Gly Ile Val Leu Tyr Glu Leu Met Thr Gly Gln Leu Pro Tyr Ser
645 650 655

Asn Ile Asn Asn Arg Asp Gln Ile Ile Phe Met Val Gly Arg Gly Tyr
660 665 670

Leu Ser Pro Asp Leu Ser Lys Val Arg Ser Asn Cys Pro Lys Ala Met
675 680 685

Lys Arg Leu Met Ala Glu Cys Leu Lys Lys Lys Arg Asp Glu Arg Pro
690 695 700

Leu Phe Pro Gln Ile Leu Ala Ser Ile Glu Leu Leu Ala Arg Ser Leu
705 710 715 720

Pro Lys Ile His Arg Ser Ala Ser Glu Pro Ser Leu Asn Arg Ala Gly
725 730 735

Phe Gln Thr Glu Asp Phe Ser Leu Tyr Ala Cys Ala Ser Pro Lys Thr
740 745 750

Pro Ile Gln Ala Gly Gly Tyr Gly Ala Phe Pro Val His
755 760 765

<210> 3
<211> 3906
<212> DNA
<213> Rattus norvegicus

<400> 3
atggcggcgc tgagtggcgg cggtggcagc agcagcgggtg gcggtggcgg cggcggcggc 60
ggcggtggtg gcggcggcgg cggcggcgcc gaacagggac aggctctgtt caatggcgac 120
atggagccgg aggccggcgc tggcgccgcg gcctcttcgg ccgcggaccc ggccattcct 180

0398850pct.txt

gaagaggtgt	ggaatatcaa	gcaaattgatt	aagttgacac	aggaacatat	agaggcccta	240
ttggacaagt	ttggtgggga	gcataaccca	ccgtcaatat	acctggaggc	ctatgaagag	300
tacaccagca	agctagatgc	ccttcagcag	agagagcagc	agctgttgga	atccctggtt	360
tttcaaactc	ccacagatgt	atcacggaac	aaccccaagt	caccacagaa	acctatcggt	420
cgtgtcttcc	tgcccaacaa	acagaggaca	gtggtgcccg	caagatgtgg	tgtaacggtc	480
cgagacagtc	taaagaaagc	actaatgatg	aggggtctca	tcccagagtg	ctgtgctggt	540
tacagaattc	aggacggaga	gaagaaacca	attggctggg	acactgacat	ttcctggctt	600
actggagagg	agctacatgt	tgaagtacta	gagaatgttc	ctctgacaac	ccacaacttc	660
gtacggaaaa	cttttttcac	cttagcattt	tgtgactttt	gccgaaagct	gcttttccag	720
ggtttccgct	gtcaaacatg	tggttataag	tttcaccagc	gttgtagtac	agaggttcca	780
ctgatgtgtg	ttaattatga	ccaacttgat	ttgctgtttg	tctccaagtt	ctttgagcat	840
caccagtac	cacaggagga	ggccttctca	gcagagacta	cccttccatc	tggatgctct	900
tccgcacccc	cctcagactc	tattgggccc	caaatcctca	ccagtccatc	tccttcaaaa	960
tccattccaa	ttccacagcc	cttccggcca	gcagatgaag	atcatcgcaa	tcagtttggg	1020
caacgagacc	gctcctcctc	cgctcccaat	gttcatataa	acacaatcga	acctgtcaat	1080
attgatgaaa	aattcccaga	agtggaatta	caggatcaaa	gggatttgat	tagagaccag	1140
gggtttcgtg	gggatggagc	ccctttgaac	cagctgatgc	gctgtcttcg	gaaataccaa	1200
tcccggactc	ccagccccct	cctccattct	gtccccagtg	aaatagtgtt	tgattttgag	1260
cctggcccag	tgttcagagg	gtcaaccaca	ggcttgctcg	ccaccccacc	tgcttcatta	1320
cctggctcac	tcactaacgt	gaaagcctta	cagaaatctc	caggacctca	gcgggaaagg	1380
aagtcctcct	cctcctcctc	ctccacggaa	gacagaagtc	ggatgaaaac	acttggtaga	1440
agagattcaa	gtgatgattg	ggagattcct	gatggacaga	ttacagtggg	acagagaatt	1500
ggatctgggt	cctttggaac	tgtctacaag	ggaaagtggc	atggcgacgt	ggcagtgaaa	1560
atgctgaatg	tgacagcacc	cacacctcag	cagttacagg	ccttcaaaaa	cgaagtcgga	1620
gtactcagga	aaactcgaca	tgtgaacatc	ctccttttca	tgggctattc	tacaaagcca	1680
cagctggcta	ttgttacaca	gtggtgtgaa	ggctccagct	tatatacca	tctccacatc	1740
attgagacca	aatttgagat	gatcaaactt	atagatatgt	cacggcagac	tgcacagggc	1800
atggattact	tacacgcaa	gtcaatcatc	cacagagacc	tcaagagtaa	taatatat	1860
cttcatgaag	acctcacggt	aaaaataggt	gactttgggt	tagccacagt	gaagtcccga	1920
tggagtgggt	cccatcagtt	tgaacagttg	tctggatcta	ttttgtggat	ggcacccgaa	1980
gtaatcagaa	tgcaagataa	aaacccatat	agctttcagt	cagacgtgta	tgcat	2040
attgttctgt	atgaactgat	gactggtcag	ctaccttatt	caaacatcaa	caacagggat	2100
cagataat	ttatgggtggg	acgaggatac	ctatctccag	atctcagtaa	ggtacggagt	2160
aactgtccaa	aagccatgaa	gagattaatg	gcagagtgcc	tcaaaaagaa	aagagacgag	2220

0398850pct.txt

```

agaccactct ttccccaat tctcgctct attgagctgc tggcccgcgc attgccaaaa 2280
attcaccgca gtgcatcaga accctccttg aatcgggctg gtttccaaac agaagatttt 2340
agtctgtatg cttgtgcttc tccaaaaaca cccatccaag caggggggata tggagaattt 2400
gcagccttca agtagccact ccatcatggc agcatctact ctttatttct taagtcttgt 2460
gttcatacaa tttgttaaca tcaaaacaca gttctgttcc tcaaattttt tttaaagata 2520
caaaattttc aatgcataag ctcgtgtgga acagaatgga atttcctatt caacaaaaga 2580
gggaagaatg ttttaggaac cagaattctc tgctgcccgt gtttcttctt caacacaaat 2640
atcatgtgca tacaactctg cccattccca agaagaaaga ggagagaccc cgaattctgc 2700
ccttttggtg gtcaggcatg atggaaagaa tttgctgctg cagcttgga aaaattgcta 2760
tggaagtct gccagtcaac tttgcccttc taaccaccag atccatttgt ggctgggtcat 2820
ctgatggggc gatttcaatc accaagcatc gttcttgctt gttgtgggat tatgtcgtgg 2880
agcactttcc ctatccacca ccgttaattt ccgagggatg gagtaaagtc agcataccct 2940
ttgtgtagca cctgtccagt cctcaaccaa tgctatcaca gtgaagctct ttaaatttaa 3000
gtggtgggtg agtgttgagg agagactgcc ttgggggcag agaaaagggg atgctgcatc 3060
ttcttcctca cctccagctc tctcacctcg ggttgccctg cacactgggc tccgcctaac 3120
cactcgggct gggcagtgtt ggcacacatt gccgcctttt ctcatgggt ccagcaattg 3180
agcagagggg tgggggattt tttcctccac aatgtagcaa attctcagga aaatacagtc 3240
catactttcc tctcagctct tccagtcacc aaatacttac gtggctcctt tgtccaggac 3300
ataaaacacc gtggacaaca cctaattaaa agcctacaaa actgcttact gacagttttg 3360
aatgtgagac atttgtgtaa tttaaatgta aggtacaggt ctttaatttct tctattaagt 3420
ttcttctatt tttatttaaa cgaagaaaat aattttcagg ttttaattgga ataaacgaat 3480
acttcccaa agactatata ccctgaaaat tatatttttg ttaattgtaa acaactttta 3540
aaaaatggtt attatccttt tctctaccta aaattatggg aaatcttagc ataatgacaa 3600
ttatttatac tttttaaata aatggtactt gctggatcca cactaacatc tttgctaaca 3660
ttccattgt ttcttccaac ttcactccta cactacatcc tccatcctct ttctagtctt 3720
ttatctataa tatgcaacct aaaataaaaag tgggtggtgtc tccattcatt cttcttcttc 3780
cttttttccc caagcctggt cttcaaaagg ttgggtaatt tagtagctga gttccctagg 3840
tagaaataga actattaggg acattggggg tgtaggaaag cgtgaggcct gtcaccagtt 3900
gttctt 3906

```

<210> 4
 <211> 804
 <212> PRT
 <213> Rattus norvegicus
 <400> 4

Met Ala Ala Leu Ser Gly Gly Gly Gly Ser Ser Ser Gly Gly Gly Gly

1

5

10

15

Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ala Glu Gln
 20 25 30
 Gly Gln Ala Leu Phe Asn Gly Asp Met Glu Pro Glu Ala Gly Ala Gly
 35 40 45
 Ala Ala Ala Ser Ser Ala Ala Asp Pro Ala Ile Pro Glu Glu Val Trp
 50 55 60
 Asn Ile Lys Gln Met Ile Lys Leu Thr Gln Glu His Ile Glu Ala Leu
 65 70 75 80
 Leu Asp Lys Phe Gly Gly Glu His Asn Pro Pro Ser Ile Tyr Leu Glu
 85 90 95
 Ala Tyr Glu Glu Tyr Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg Glu
 100 105 110
 Gln Gln Leu Leu Glu Ser Leu Val Phe Gln Thr Pro Thr Asp Val Ser
 115 120 125
 Arg Asn Asn Pro Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe Leu
 130 135 140
 Pro Asn Lys Gln Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr Val
 145 150 155 160
 Arg Asp Ser Leu Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro Glu
 165 170 175
 Cys Cys Ala Val Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile Gly
 180 185 190
 Trp Asp Thr Asp Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val Glu
 195 200 205
 Val Leu Glu Asn Val Pro Leu Thr Thr His Asn Phe Val Arg Lys Thr
 210 215 220
 Phe Phe Thr Leu Ala Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe Gln
 225 230 235 240
 Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Gln Arg Cys Ser
 245 250 255
 Thr Glu Val Pro Leu Met Cys Val Asn Tyr Asp Gln Leu Asp Leu Leu
 260 265 270
 Phe Val Ser Lys Phe Phe Glu His His Pro Val Pro Gln Glu Glu Ala
 275 280 285

0398850pct.txt

Phe Ser Ala Glu Thr Thr Leu Pro Ser Gly Cys Ser Ser Ala Pro Pro
 290 295 300
 Ser Asp Ser Ile Gly Pro Gln Ile Leu Thr Ser Pro Ser Pro Ser Lys
 305 310 315 320
 Ser Ile Pro Ile Pro Gln Pro Phe Arg Pro Ala Asp Glu Asp His Arg
 325 330 335
 Asn Gln Phe Gly Gln Arg Asp Arg Ser Ser Ser Ala Pro Asn Val His
 340 345 350
 Ile Asn Thr Ile Glu Pro Val Asn Ile Asp Glu Lys Phe Pro Glu Val
 355 360 365
 Glu Leu Gln Asp Gln Arg Asp Leu Ile Arg Asp Gln Gly Phe Arg Gly
 370 375 380
 Asp Gly Ala Pro Leu Asn Gln Leu Met Arg Cys Leu Arg Lys Tyr Gln
 385 390 395 400
 Ser Arg Thr Pro Ser Pro Leu Leu His Ser Val Pro Ser Glu Ile Val
 405 410 415
 Phe Asp Phe Glu Pro Gly Pro Val Phe Arg Gly Ser Thr Thr Gly Leu
 420 425 430
 Ser Ala Thr Pro Pro Ala Ser Leu Pro Gly Ser Leu Thr Asn Val Lys
 435 440 445
 Ala Leu Gln Lys Ser Pro Gly Pro Gln Arg Glu Arg Lys Ser Ser Ser
 450 455 460
 Ser Ser Ser Ser Thr Glu Asp Arg Ser Arg Met Lys Thr Leu Gly Arg
 465 470 475 480
 Arg Asp Ser Ser Asp Asp Trp Glu Ile Pro Asp Gly Gln Ile Thr Val
 485 490 495
 Gly Gln Arg Ile Gly Ser Gly Ser Phe Gly Thr Val Tyr Lys Gly Lys
 500 505 510
 Trp His Gly Asp Val Ala Val Lys Met Leu Asn Val Thr Ala Pro Thr
 515 520 525
 Pro Gln Gln Leu Gln Ala Phe Lys Asn Glu Val Gly Val Leu Arg Lys
 530 535 540
 Thr Arg His Val Asn Ile Leu Leu Phe Met Gly Tyr Ser Thr Lys Pro
 545 550 555 560

Gln Leu Ala Ile Val Thr Gln Trp Cys Glu Gly Ser Ser Leu Tyr His
 565 570 575
 His Leu His Ile Ile Glu Thr Lys Phe Glu Met Ile Lys Leu Ile Asp
 580 585 590
 Ile Ala Arg Gln Thr Ala Gln Gly Met Asp Tyr Leu His Ala Lys Ser
 595 600 605
 Ile Ile His Arg Asp Leu Lys Ser Asn Asn Ile Phe Leu His Glu Asp
 610 615 620
 Leu Thr Val Lys Ile Gly Asp Phe Gly Leu Ala Thr Val Lys Ser Arg
 625 630 635 640
 Trp Ser Gly Ser His Gln Phe Glu Gln Leu Ser Gly Ser Ile Leu Trp
 645 650 655
 Met Ala Pro Glu Val Ile Arg Met Gln Asp Lys Asn Pro Tyr Ser Phe
 660 665 670
 Gln Ser Asp Val Tyr Ala Phe Gly Ile Val Leu Tyr Glu Leu Met Thr
 675 680 685
 Gly Gln Leu Pro Tyr Ser Asn Ile Asn Asn Arg Asp Gln Ile Ile Phe
 690 695 700
 Met Val Gly Arg Gly Tyr Leu Ser Pro Asp Leu Ser Lys Val Arg Ser
 705 710 715 720
 Asn Cys Pro Lys Ala Met Lys Arg Leu Met Ala Glu Cys Leu Lys Lys
 725 730 735
 Lys Arg Asp Glu Arg Pro Leu Phe Pro Gln Ile Leu Ala Ser Ile Glu
 740 745 750
 Leu Leu Ala Arg Ser Leu Pro Lys Ile His Arg Ser Ala Ser Glu Pro
 755 760 765
 Ser Leu Asn Arg Ala Gly Phe Gln Thr Glu Asp Phe Ser Leu Tyr Ala
 770 775 780
 Cys Ala Ser Pro Lys Thr Pro Ile Gln Ala Gly Gly Tyr Gly Glu Phe
 785 790 795 800
 Ala Ala Phe Lys

<210> 5

<211> 9728

<212> DNA
 <213> Mus musculus

<400> 5
 ccctcaggct cggctgcgcc ggggccgccg gcgggttcca gaggtggcct ccgccccggc 60
 cgctccgccc acgccccccg cgctccgcg cccgcctccg cccgccctgc gcctcccttc 120
 cccctccccg ccccgcgggc gccgctcggc ccggctcgcg cttcgaagat ggcggcgctg 180
 agtggcgggc gtggcagcag cagcgggtggc ggcggcgggc gtggcgggcg cgggtggcggc 240
 ggcgacggcg gcggcgggcg cgagcagggc caggctctgt tcaatggcga catggagccg 300
 gaggccggcg ctggcgccgc ggcctcttcg gctgcggacc cggccattcc tgaagaggta 360
 tggaatatca agcaaatgat taagttgaca caggaacata tagaggccct attggacaaa 420
 tttggtggag agcataacc accatcaata tacctggagg cctatgaaga gtacaccagc 480
 aagctagatg cccttcagca aagagaacag cagcttttgg aatccctggc ttttcaaact 540
 cccacagatg catcacgga caacccaag tcaccacaga aacctatcgt tagagtcttc 600
 ctgccaaca aacagaggac agtggtagcc gcaagatgtg gtgttacagt tcgagacagt 660
 ctaaagaaag cactgatgat gagaggtctc atcccagaat gctgtgctgt ttacagaatt 720
 caggatggag agaagaaacc aattggctgg gacacggaca tttcctggct tactggagag 780
 gagttacatg ttgaagtact ggagaatgtc ccacttaca cacacaactt tgtacggaaa 840
 acttttttca ccttagcatt ttgtgacttt tgccgaaagc tgcttttcca gggtttccgt 900
 tgtcaaacat gtggttataa atttcaccag cgttgtagta cagagggtcc actgatgtgt 960
 gtaaattatg accaacttga tttgctgttt gtctccaagt tctttgagca tcaccagta 1020
 ccacaggagg aggcctcctt cccagagact gcccttccat ctggatcctc ttccgcaccc 1080
 ccctcagact ctactgggcc ccaaactctc accagtccat ctccttcaaa atccattcca 1140
 attccacagc ccttccgacc agcagatgaa gatcatcgca atcagtttgg gcaacgagac 1200
 cggtcctcct cagctcccaa tgttcatata aacacaattg agcctgtgaa tatcgatgaa 1260
 aaattcccag aagtggaatt acaggatcaa agggatttga ttagagacca ggggtttcgt 1320
 ggtgatggag ccccttgaa ccaactgatg cgctgtcttc ggaaatacca atcccggact 1380
 cccagcccc tcctccattc tgtccccagt gaaatagtgt ttgattttga gcctggccca 1440
 gtgttcagag ggtcaaccac aggcctgtcc gccacccgc ctgcctcatt acctggctca 1500
 ctactaacg tgaaagcctt acagaaatct ccaggctcct agcgggaaag gaagtcattc 1560
 tcttcctcat cctcggagga cagaagtcgg atgaaaacac ttggtagaag agattcaagt 1620
 gatgactggg agattcctga tggacagatt acagtgggac agagaattgg atctgggtca 1680
 tttggaactg tctacaaggg aaagtggcat ggtgatgtgg cagtgaaaat gttgaatgtg 1740
 acagaccca cacctcaaca gctacaggcc ttcaaaaatg aagtaggagt gctcaggaaa 1800
 actcgacatg tgaatatcct ctttttcatg ggctattcta caaagccaca actggcaatt 1860
 gttacacagt ggtgtgaggg ctccagctta tatcaccatc tccacatcat tgagacaaaa 1920

0398850pct.txt

tttgagatga	tcaaacttat	agatattgct	cggcagactg	cacagggcat	ggattactta	1980
cacgccaagt	caatcatcca	cagagacctc	aagagtaata	atatatttct	tcatgaagac	2040
ctcacggtaa	aaataggtga	ctttggtcta	gccacagtga	aatctcggtg	gagtgggtcc	2100
catcagtttg	aacagttgtc	tggatctatt	ttgtggatgg	caccagaagt	aatcagaatg	2160
caagataaaa	acccgtatag	ctttcagtca	gacgtgtatg	cgtttgggat	tgttctgtac	2220
gaactgatga	ccggccagct	accttattca	aacatcaaca	acagggatca	gataattttt	2280
atggtgggac	gaggatacct	atctccagat	ctcagtaagg	tacggagtaa	ctgtccaaaa	2340
gccatgaaga	gattaatggc	agagtgcctc	aaaaagaaaa	gagacgagag	accactcttt	2400
cccaaattc	tcgcctccat	tgagctgctg	gcccgctcat	tgccaaaaat	tcaccgcagt	2460
gcatcagaac	cttccttgaa	tcgggctggt	ttccaaacag	aagatttttag	tctgtatgct	2520
tgtgcttctc	cgaaaacacc	catccaagca	gggggatatg	gagaatttgc	agccttcaag	2580
tagccagtcc	atcatggcag	catctactct	ttatttctta	agtcttgtgt	tcatacagtt	2640
tgtaacatc	aaaacacagt	tctgttcctc	aaaaaatttt	ttaaagatac	aaaattttca	2700
atgcataagt	tcatgtggaa	cagaatggaa	tttcctattc	aacaaaagag	ggaagaatgt	2760
tttaggaacc	agaattctct	gctgcccgtg	tttcttcttc	aacataacta	tcacgtgcat	2820
acaagtctgc	ccattcccaa	gaagaaagag	gagagaccct	gaattctgcc	cttttggtgg	2880
tcaggcatga	tggaaagaat	ttgctgctgc	agcttgggaa	aattgctatg	gaaagtctgc	2940
cagtcgactt	tgcccttcta	accaccagat	cagcctgtgg	ctgggtcatct	gatggggcga	3000
tttccatcac	caagcatcgt	tcttgccctat	tctgggatta	tgttgtggag	cactttccct	3060
gtccagcacc	gttcatttct	gagggatgga	gtaaatgcag	cattcccttg	tgtagcgcct	3120
gttcagtcct	cagcagctgc	tgtcacagcg	aagcttttta	cagttaagtg	gtgggggaga	3180
gttgaggaga	gcctgcctcg	gggcagagaa	aagggggtgc	tgcatcttct	tcctcacctc	3240
cagctctctc	acctcgggtt	gccttgctca	ctgggctccg	cctaaccact	caggctgctc	3300
agtgtggca	cacattgcct	tcttttctca	ttgggtccag	caattgagga	gagggttggg	3360
ggattgtttc	ctcctcaatg	tagcaaattc	tcaggaaaat	acagtccata	tcttcctctc	3420
agctcttcca	gtcaccaaat	acttacgtgg	ctcctttgtc	caggacataa	aacaccgtgg	3480
acaacaccta	attaaaagcc	tacaaaactg	cttactgaca	gttttgaatg	tgagacactt	3540
gtgtaattta	aatgtaaggt	acaggtttta	atttctgagt	ttcttctatt	tttattttaa	3600
agaagaaaat	aattttcagt	tttaattgga	ataaatgagt	acttcccaca	agactatata	3660
ccctgaaaat	tatatTTTTg	tttaattgta	acaactttta	aagaataatt	attatccttt	3720
tctctaccta	aaaattatgg	ggaatcttag	cataatgaca	attatttata	ctttttaaat	3780
aaatggtact	tgctggatcc	acactaacat	ctttgctaac	aatcccattg	tttcttccaa	3840
cttaactcct	acactacatc	ctacatcctc	tttctagtct	tttatctata	atatgcaacc	3900
taaaataaac	gtggtggcgt	ctccattcat	tctccctctt	cctgttttcc	ccaagcctgg	3960

0398850pct.txt

tcttcaaaag	gttgggtaat	cgggtccctga	gctccctagc	tggcaatgca	actattaggg	4020	
acattggagt	tgcaggagag	caggaagcct	gtccccagct	gttctttctag	aaccctaaat	4080	
cttatctttg	cacagatcaa	aagtatcacc	tcgtcacagt	tctccttagc	ctttacttac	4140	
aggtaatata	aataaaaatc	accatagtag	taaagaaaac	aactggatgg	attgatgacc	4200	
agtacctctc	agagccagga	atcttgaatc	tccaggattt	atacgtgcaa	atttaaggag	4260	
atgtacttag	caacttcaag	ccaagaactt	ccaaaatact	agcgaatcta	aaataaaaatg	4320	
gaattttgag	ttatttttta	agttcaaatt	ataattgata	ccactatgta	tttaagccta	4380	
ctcacagcaa	gttagatgga	ttttgctaaa	ctcattgccca	gactgtgggtg	gtgggtgggtg	4440	
tagtgtgcac	ctttaatcca	agcaactcag	caatcagaat	gaggtaaatac	tctgtgaata	4500	
caaggcctgc	ctagtctgca	gcgctagttc	caggatagcc	agggctacac	acacaaaaaac	4560	
cctctctcaa	aaaaaaca	attaattagt	tgataataaa	aaataactaa	agtatcatca	4620	
aaggaaggcc	tactggaagt	tttatatatt	cccagtaa	tgaaaaatat	tctgaagtta	4680	
ttaaccagtt	agcaacaatg	tgtttttaag	tcttacataa	acagagcaaa	gtcttcaaat	4740	
gtttcagagc	tgagaagata	attgtgcttg	atatgaaaaa	tagcctctcc	atatgatgtg	4800	
ccacattgaa	aggcgtcatt	acccttttaa	atacttctta	atgtggcttt	gttcccttta	4860	
cccaggatta	gctagaaaga	gctaggtagg	cttcggccac	agttgcacat	ttcgggcctg	4920	
ctgaagaatg	ggagctttga	aggctggcct	tgggtggagga	gcccctcagt	gctggaggggt	4980	
ggggcggtga	cgcagcatgg	aagtgggtcta	gacagagtgc	aaagggacag	acttctttct	5040	
catttttagta	taggggtgatg	tctcacttga	aatgagaaag	tagagttgat	attaaacgaa	5100	
gctgtgcca	gaaaccaggc	tcagggtatt	gtgagatttt	ctttttaaat	agagaatata	5160	
aaagatagaa	ataaatat	aaaccttcct	tcttat	tattc	aaatag	atttttttta	5220
tcatttgcaa	acaacataaa	aaaaggtttc	ttttgtgggg	ttttctttcc	ttcttttttt	5280	
tttttttttt	tttttaagac	tgcagataat	cttggtgagc	tcctcgga	atacaaggaa	5340	
gtccgtgttt	gtgcagagcg	ctttatgagt	aactgtatag	acagtgtggc	tgcttcactc	5400	
atcccagagg	gctgcagctg	tcggcccatg	aagtggctgc	agtgcctcgt	gagatctgct	5460	
ttgttttggt	tggagtgaag	tctttgaaag	gtttgagtgc	aactatatag	gactgttttt	5520	
aaataagtag	tattcctcat	gaactttctc	attgttaagc	tacaggaccc	aaactctacc	5580	
actaagatat	tattaacctc	aaaatgtagt	ttatagaagg	aatttgcaaa	tagaatatcc	5640	
agttcgtact	tatatgcac	ttcaacaaag	attctctgtg	acttggttga	tttggttcct	5700	
gaacagccca	tttctgtatt	tgagggttagg	agggcataat	gaggcatcct	aaaagacaat	5760	
ctgatataaa	ctgtatgcta	gatgtatgct	ggtaggggag	aaagcattct	gtaaagacat	5820	
gatttaagac	ttcagctctg	tcaaccagaa	accttgtaaa	tacttcctgt	cttggtgcag	5880	
ccccgcccct	ttgatcacac	gatgttgtct	tgtgcttgct	agacactgtc	agagctgctg	5940	
ttcgtccctc	tgcagatctc	acctgtcccc	actgcacacc	cacctcctgc	ctcttgacaga	6000	

0398850pct.txt

cctcagcatc	tagcttttagt	tggaacagat	tcagggttca	ggtgacttct	taaaaaaaaa	6060
aaaaaacctt	acctcctcag	aatgaggtaa	tgaatagtta	tttattttaa	gtatgaagag	6120
tcaggagcgc	tcgaacatga	aggtgattta	agatggttcc	tttcgtgtgt	attgtagctg	6180
agcacttggt	tttgtcctaa	agggcattat	acatttaagc	agtgattctg	tttaaagatg	6240
tttttcttta	aagggtgtagc	tcagagtatc	tgttgttgga	attggtgcca	gagtctgctt	6300
aatagatttc	agaatcctaa	gcttaagtca	gtcgcataaa	gttaagtagt	tatggtaaca	6360
ctttgctagc	catgatataa	ttctactttt	taggagtagg	tttggcaaaa	ctgtatgcct	6420
tcaaagttag	ttggccacag	ctttgtcaca	tgacacagata	ctcatctgaa	gagactgccc	6480
agctaagagg	gcggaaggat	accctttttt	cctacgattc	gcttctttgt	ccacgttggc	6540
attgttagta	ctagtttatc	agcaccttga	ccagcagatg	tcaaccaata	agctattttt	6600
aaaaccatag	ccagagatgg	agaggtcact	gtgagtagaa	acagcaggac	gcttacagga	6660
gtgaaatggg	gtagggaggc	tctagaaaaa	tatcttgaca	atttgccaaa	tgatcttact	6720
gtgccttcat	gatgcaataa	aaaagctaac	atcttagcag	aaatcagtga	tttacgaaga	6780
gagtggtccg	tctgggttta	ctcagctggg	ataatatctt	tagagtgcga	tttagactgc	6840
gaagataaat	gcactaaaga	gtttatagcc	aattcacatt	tgaaaaataa	gaaaatggta	6900
aattttcagt	gaaatatttt	tttaaagcac	ataatcccta	gtgtagccag	aaatattttac	6960
cacatagagc	agctaggctg	agatacagtc	cagtgcacatt	tctagagaaa	ccttttctac	7020
tcccacgggc	tcctcaaagc	atggaaattt	tatacaaaat	gtttgacatt	ttaagatact	7080
gctgtagttt	agttttgaaa	tagtatgtgc	tgagcagcaa	tcatgtacta	actcagagag	7140
agaaaacaac	aacaaattgt	gcacatctgatt	tgttttcaga	gaaatgctgc	caacttagat	7200
actgagttct	cagagcttca	agtgtaaact	tgccctccaa	gtcctgtttg	caaatagaagt	7260
tggctagtag	tactgactgc	tccagcacat	gatggaaggc	agggggctgt	ctctgaagtg	7320
tcttctataa	agggacaata	gaatagttag	agacctgggc	agtgtgtgtc	agctggacac	7380
tccatgctat	gggacttgca	tcttctgtcc	tcaccatccc	caagacattg	tgctttcctc	7440
agttgtcctc	tagctgtttc	actcagacac	caagatgaat	tactgatgcc	agaagggggc	7500
aaaatggcca	gtgtgttttg	gggggtgtat	cagttgactg	gacaataact	ttaatagttt	7560
cagatcattt	atcttttactt	ccattttgac	agacatttaa	atggaaattt	agtcctaact	7620
tttgtcattt	gaaaggaaaa	attaacagtt	cctataagat	acttttgagg	tggaatctga	7680
catcctaatt	ttttttcttt	tcagtgggtt	tgacagcagg	gtcttgtatg	cactaggcaa	7740
gggttctacc	actaagccac	atttcccagg	aaataaaatg	ttaacagtta	aaacatacac	7800
acaaatacac	aaacacctta	ttaccacttt	agtaaagtga	gagatgtgcg	tcctttgtct	7860
cagtcctcac	gatttcagct	gccccttgta	tgaataactc	agtctcgcta	aactgtttac	7920
ttttatttac	ctggtttgac	tagttgcagc	tatataacca	gttgtgcatg	aggacaacag	7980
ccagtgtgtt	tgttttgttt	ttgggttttt	gtggtacatt	ttttgtaaag	aattctgtag	8040

0398850pct.txt

```

attgaagtgc tctttgaaaa cagaactgag atatatttat tcttgtttagc atcaaaaaaac 8100
attttgtgca aatgatttgc ttttcctggc aggctgagta ccatatccag cgcccacaat 8160
tgcgggttcc catctacat gtccacagg gagacagacg ggaagcacat gaggggtgtg 8220
tttacagagt tgtaggagtt atgtagttct cttgttgcc tggaaatcac tgttgtttta 8280
agactgttga acccggtgtgt ttggctgggc tgtgagttac atgaagaaac tgcaaactag 8340
catatgcaga caaagctcac agactaggcg taaatggagg aaaatggacc aaaataaggc 8400
agggtgacac ataaaccttg ggcttcggag aaaactaagg gtggagatga actataatca 8460
cctgaataca atgtaagagt gcaataagtg tgcttattct aagctgtgaa cttcttttaa 8520
atcattcctt tctaatacat ttatgtatgt tccattgctg actaaaacca gctatgagaa 8580
catatgcctt tttattcatg ttaactacca gtttaagtgg ctaaccttaa tgtcttattt 8640
atcttcattt tgtattagtt tacataccag gtatgtgtgt gtgctgtact cttcttcctt 8700
ttatttgaac acacttttca ctgggtcatc tccttggcca ttccacaaca caactttggt 8760
ttggctttca atgtcacctt atttgatggc ctgtgtccca gtagcagaat ttatggtatt 8820
cccattgctg gctgctcttc cgaccctttg cttctacagc acttgtctct cctaagatag 8880
tcagaaacta actgatcagg ggatggactt caccattcat cgtgtctctt caattctatt 8940
aaatagacca ctcttgggct ttagaccagg aaaaaggaga cagctctagc catctaccaa 9000
gcctcaccct aaaaggctac ccgtacttct tgggtctgagg acaagtctcc actccagtaa 9060
gggagagggg aggaaatgct tcctgtttga aatgcagtga attcctatgg ctcctgtttc 9120
accacccgca cctatggcaa cccatataca ttctcttgt ctgtaactgc caaaggttg 9180
gtttatgtca cttcagttcc actcaagcat tgaaaagggt ctcattggagt ctgggggtgtg 9240
cccagtgaac agatggggac tttttcatta tccacagacc tctctatacc tgctttgcaa 9300
aaattataat ggagtaacta tttttaagc ttatttttca attcataaga aaaagacatt 9360
tattttcaat caaatggatg atgtctctta tcccttatcc ctcaatgttt gcttgaattt 9420
tgtttgttcc ctatacctac tccctaattc tttagttcct tcctgctcag gtcccttcat 9480
ttgtactttg gagtttttct catgtaaatt tgtataatgg aaaatattgt tcagtttgga 9540
tagaaagcat ggagaaataa ataaaaaaag atagctgaaa atcaaattga agaaatttat 9600
ttctgtgtaa agttatttaa aaactctgta ttatatttaa agaaaaaagc ccaaccccc 9660
aaaaagtgt atgtaattga tgtgaatatg cgaatactgc tataataaag attgactgca 9720
tgagagaaa 9728

```

<210> 6
 <211> 804
 <212> PRT
 <213> Mus musculus

<400> 6

Met Ala Ala Leu Ser Gly Gly Gly Gly Ser Ser Ser Gly Gly Gly Gly

1

5

10

15

Gly Gly Gly Gly Gly Gly Gly Gly Gly Asp Gly Gly Gly Gly Ala Glu
 20 25 30
 Gln Gly Gln Ala Leu Phe Asn Gly Asp Met Glu Pro Glu Ala Gly Ala
 35 40 45
 Gly Ala Ala Ala Ser Ser Ala Ala Asp Pro Ala Ile Pro Glu Glu Val
 50 55 60
 Trp Asn Ile Lys Gln Met Ile Lys Leu Thr Gln Glu His Ile Glu Ala
 65 70 75 80
 Leu Leu Asp Lys Phe Gly Gly Glu His Asn Pro Pro Ser Ile Tyr Leu
 85 90 95
 Glu Ala Tyr Glu Glu Tyr Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg
 100 105 110
 Glu Gln Gln Leu Leu Glu Ser Leu Val Phe Gln Thr Pro Thr Asp Ala
 115 120 125
 Ser Arg Asn Asn Pro Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe
 130 135 140
 Leu Pro Asn Lys Gln Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr
 145 150 155 160
 Val Arg Asp Ser Leu Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro
 165 170 175
 Glu Cys Cys Ala Val Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile
 180 185 190
 Gly Trp Asp Thr Asp Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val
 195 200 205
 Glu Val Leu Glu Asn Val Pro Leu Thr Thr His Asn Phe Val Arg Lys
 210 215 220
 Thr Phe Phe Thr Leu Ala Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe
 225 230 235 240
 Gln Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Gln Arg Cys
 245 250 255
 Ser Thr Glu Val Pro Leu Met Cys Val Asn Tyr Asp Gln Leu Asp Leu
 260 265 270
 Leu Phe Val Ser Lys Phe Phe Glu His His Pro Val Pro Gln Glu Glu
 275 280 285

Ala Ser Phe Pro Glu Thr Ala Leu Pro Ser Gly Ser Ser Ser Ala Pro
 290 295 300
 Pro Ser Asp Ser Thr Gly Pro Gln Ile Leu Thr Ser Pro Ser Pro Ser
 305 310 315 320
 Lys Ser Ile Pro Ile Pro Gln Pro Phe Arg Pro Ala Asp Glu Asp His
 325 330 335
 Arg Asn Gln Phe Gly Gln Arg Asp Arg Ser Ser Ser Ala Pro Asn Val
 340 345 350
 His Ile Asn Thr Ile Glu Pro Val Asn Ile Asp Glu Lys Phe Pro Glu
 355 360 365
 Val Glu Leu Gln Asp Gln Arg Asp Leu Ile Arg Asp Gln Gly Phe Arg
 370 375 380
 Gly Asp Gly Ala Pro Leu Asn Gln Leu Met Arg Cys Leu Arg Lys Tyr
 385 390 395 400
 Gln Ser Arg Thr Pro Ser Pro Leu Leu His Ser Val Pro Ser Glu Ile
 405 410 415
 Val Phe Asp Phe Glu Pro Gly Pro Val Phe Arg Gly Ser Thr Thr Gly
 420 425 430
 Leu Ser Ala Thr Pro Pro Ala Ser Leu Pro Gly Ser Leu Thr Asn Val
 435 440 445
 Lys Ala Leu Gln Lys Ser Pro Gly Pro Gln Arg Glu Arg Lys Ser Ser
 450 455 460
 Ser Ser Ser Ser Ser Glu Asp Arg Ser Arg Met Lys Thr Leu Gly Arg
 465 470 475 480
 Arg Asp Ser Ser Asp Asp Trp Glu Ile Pro Asp Gly Gln Ile Thr Val
 485 490 495
 Gly Gln Arg Ile Gly Ser Gly Ser Phe Gly Thr Val Tyr Lys Gly Lys
 500 505 510
 Trp His Gly Asp Val Ala Val Lys Met Leu Asn Val Thr Ala Pro Thr
 515 520 525
 Pro Gln Gln Leu Gln Ala Phe Lys Asn Glu Val Gly Val Leu Arg Lys
 530 535 540
 Thr Arg His Val Asn Ile Leu Leu Phe Met Gly Tyr Ser Thr Lys Pro
 545 550 555 560

Gln Leu Ala Ile Val Thr Gln Trp Cys Glu Gly Ser Ser Leu Tyr His
 565 570 575
 His Leu His Ile Ile Glu Thr Lys Phe Glu Met Ile Lys Leu Ile Asp
 580 585 590
 Ile Ala Arg Gln Thr Ala Gln Gly Met Asp Tyr Leu His Ala Lys Ser
 595 600 605
 Ile Ile His Arg Asp Leu Lys Ser Asn Asn Ile Phe Leu His Glu Asp
 610 615 620
 Leu Thr Val Lys Ile Gly Asp Phe Gly Leu Ala Thr Val Lys Ser Arg
 625 630 635 640
 Trp Ser Gly Ser His Gln Phe Glu Gln Leu Ser Gly Ser Ile Leu Trp
 645 650 655
 Met Ala Pro Glu Val Ile Arg Met Gln Asp Lys Asn Pro Tyr Ser Phe
 660 665 670
 Gln Ser Asp Val Tyr Ala Phe Gly Ile Val Leu Tyr Glu Leu Met Thr
 675 680 685
 Gly Gln Leu Pro Tyr Ser Asn Ile Asn Asn Arg Asp Gln Ile Ile Phe
 690 695 700
 Met Val Gly Arg Gly Tyr Leu Ser Pro Asp Leu Ser Lys Val Arg Ser
 705 710 715 720
 Asn Cys Pro Lys Ala Met Lys Arg Leu Met Ala Glu Cys Leu Lys Lys
 725 730 735
 Lys Arg Asp Glu Arg Pro Leu Phe Pro Gln Ile Leu Ala Ser Ile Glu
 740 745 750
 Leu Leu Ala Arg Ser Leu Pro Lys Ile His Arg Ser Ala Ser Glu Pro
 755 760 765
 Ser Leu Asn Arg Ala Gly Phe Gln Thr Glu Asp Phe Ser Leu Tyr Ala
 770 775 780
 Cys Ala Ser Pro Lys Thr Pro Ile Gln Ala Gly Gly Tyr Gly Glu Phe
 785 790 795 800
 Ala Ala Phe Lys

<210> 7
 <211> 2232

<212> DNA

<213> *Oryctolagus cuniculus*

<400> 7

```

atggggaatg tgtggaatat caaacaatg attaagttga cacaggagca tatagaggcc      60
ctattggaca aatttggtgg ggagcataat ccaccatcaa tataatctgga ggcctacgaa    120
gaatacacca gcaagctaga tgccctccaa caaagagaac agcagttatt ggaatcccta    180
gtttttcaaa atcccacaga tgtgtcacgg agcaacccca agtcaccaca aaaacctatt    240
gtagagtctt tcctgcccac caaacagagg acagtggtag ctgcaagatg tggagttacg    300
gttcgagaca gtctaaagaa agcgctgatg atgagaggct tgatcccaga atgctgtgct    360
gtttacagaa ttcaggatgg agagaagaag ccaattggct gggacactga tatttcctgg    420
ctcactggag aagagctgca tgtggaagtg ttagagaatg tcccactcac cacacataac    480
tttgtacgga aaactttttt caccttagca ttttgtgact tctgtagaaa gctgcttttc    540
cagggtttcc gctgtcaaac atgtggctac aaatttcacc agcgtttag tagggaagtt    600
ccactgatgt gtgttaatta tgaccaactt gatttgctgt ttgtctccaa gttctttgaa    660
caccacccag taccacagga ggaggcctcc ttagcagaga ctgccctcac atctgggtca    720
tcgccttccg cacctccctc agactctatt gggcaccaaa ttctcaccag tccgtcccct    780
tcaaaatcca ttccgattcc acagtccttc cgaccagcag atgaagatca tcgaaatcag    840
tttgggcaac gagaccggtc ttcattcagc cctaattgtc acattaacac aatagaacct    900
gtcaatattg atgaaaaatt ccagaaagtg gaattacagg atcaaaggga cttgattaga    960
gaccaagggg ttcgtggtga tggagcccct ttgaaccagc tgatgcgctg tcttcggaaa   1020
taccaatccc ggactcccag tcccctccta cttctgttcc ccagtacat agtgtttgat   1080
tttgagcctg gccagtggtt cagaggatcg accacggggt tgtctgccac tcccctgcc   1140
tcattacctg gctcactcac tagtgtgaaa gctgtacaga gatccccagg acctcagcga   1200
gagaggaagt cgtcttcctc ctcaagaagc aggaatcgaa tgaaaactct tggtagacgg   1260
gattcaagtg atgattggga gattcctgat gggcagatca ccgtgggaca gagaattgga   1320
tctggatcat ttggaaccgt ctacaaggga aaatggcacg gtgatgtggc agtaaaaatg   1380
ttgaatgtga cagcacctac acctcagcag ttacaggcct tcaaaaatga agtaggagta   1440
ctcaggaaaa cagcatgtgt gaatatacta cttttcatgg gctattccac aaagccacag   1500
ctggctattg ttaccagtg gtgtgagggc tccagtttat atcaccatct ccacatcatt   1560
gagaccaaat tcgagatgat caaacttata gatattgcac ggcagactgc acagggcatg   1620
gattacttac acgccaagtc aatcatccac agagacctca agagtaataa tatatttctt   1680
catgaagacc tcacagtaaa aataggatg tttggtctag ccacagtga atctcgatgg   1740
agtgggtccc atcagtttga acaattgtct ggatccattt tgtggatggc accagaagta   1800
atcagaatgc aagacaaaaa cccatatagc tttcagtcag atgtatatgc atttgggatt   1860
gttctgtatg aattgatgac tgggcagtta cttactcaa acatcaacaa cagggaccag   1920

```

atcattttta tgggtgggacg tggctacctg tctccagacc tcagtaaggt acggagtaac 1980
 tgtccgaaag ccatgaagag attaatggca gagtgcctca aaaagaaaag agatgagaga 2040
 ccactctttc cccaaattct cgcctccatt gagctgctgg cccgctcatt gccaaaaatc 2100
 caccgcagtg catcagaacc ctcttgaat cgggctgggt tccagacaga ggattttagt 2160
 ctatatgctt gtgcttctcc aaaaacaccc atccaggcag ggggatatgg agaatttgca 2220
 gccttcaagt ag 2232

<210> 8
 <211> 743
 <212> PRT
 <213> *Oryctolagus cuniculus*
 <400> 8

Met Gly Asn Val Trp Asn Ile Lys Gln Met Ile Lys Leu Thr Gln Glu
 1 5 10 15

His Ile Glu Ala Leu Leu Asp Lys Phe Gly Gly Glu His Asn Pro Pro
 20 25 30

Ser Ile Tyr Leu Glu Ala Tyr Glu Glu Tyr Thr Ser Lys Leu Asp Ala
 35 40 45

Leu Gln Gln Arg Glu Gln Gln Leu Leu Glu Ser Leu Val Phe Gln Asn
 50 55 60

Pro Thr Asp Val Ser Arg Ser Asn Pro Lys Ser Pro Gln Lys Pro Ile
 65 70 75 80

Val Arg Val Phe Leu Pro Asn Lys Gln Arg Thr Val Val Pro Ala Arg
 85 90 95

Cys Gly Val Thr Val Arg Asp Ser Leu Lys Lys Ala Leu Met Met Arg
 100 105 110

Gly Leu Ile Pro Glu Cys Cys Ala Val Tyr Arg Ile Gln Asp Gly Glu
 115 120 125

Lys Lys Pro Ile Gly Trp Asp Thr Asp Ile Ser Trp Leu Thr Gly Glu
 130 135 140

Glu Leu His Val Glu Val Leu Glu Asn Val Pro Leu Thr Thr His Asn
 145 150 155 160

Phe Val Arg Lys Thr Phe Phe Thr Leu Ala Phe Cys Asp Phe Cys Arg
 165 170 175

Lys Leu Leu Phe Gln Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe
 180 185 190

His Gln Arg Cys Ser Thr Glu Val Pro Leu Met Cys Val Asn Tyr Asp
 195 200 205

Gln Leu Asp Leu Leu Phe Val Ser Lys Phe Phe Glu His His Pro Val
 210 215 220

Pro Gln Glu Glu Ala Ser Leu Ala Glu Thr Ala Leu Thr Ser Gly Ser
 225 230 235 240

Ser Pro Ser Ala Pro Pro Ser Asp Ser Ile Gly His Gln Ile Leu Thr
 245 250 255

Ser Pro Ser Pro Ser Lys Ser Ile Pro Ile Pro Gln Ser Phe Arg Pro
 260 265 270

Ala Asp Glu Asp His Arg Asn Gln Phe Gly Gln Arg Asp Arg Ser Ser
 275 280 285

Ser Ala Pro Asn Val His Ile Asn Thr Ile Glu Pro Val Asn Ile Asp
 290 295 300

Glu Lys Phe Pro Glu Val Glu Leu Gln Asp Gln Arg Asp Leu Ile Arg
 305 310 315 320

Asp Gln Gly Phe Arg Gly Asp Gly Ala Pro Leu Asn Gln Leu Met Arg
 325 330 335

Cys Leu Arg Lys Tyr Gln Ser Arg Thr Pro Ser Pro Leu Leu Pro Ser
 340 345 350

Val Pro Ser Asp Ile Val Phe Asp Phe Glu Pro Gly Pro Val Phe Arg
 355 360 365

Gly Ser Thr Thr Gly Leu Ser Ala Thr Pro Pro Ala Ser Leu Pro Gly
 370 375 380

Ser Leu Thr Ser Val Lys Ala Val Gln Arg Ser Pro Gly Pro Gln Arg
 385 390 395 400

Glu Arg Lys Ser Ser Ser Ser Glu Asp Arg Asn Arg Met Lys Thr
 405 410 415

Leu Gly Arg Arg Asp Ser Ser Asp Asp Trp Glu Ile Pro Asp Gly Gln
 420 425 430

Ile Thr Val Gly Gln Arg Ile Gly Ser Gly Ser Phe Gly Thr Val Tyr
 435 440 445

Lys Gly Lys Trp His Gly Asp Val Ala Val Lys Met Leu Asn Val Thr
 450 455 460

Ala Pro Thr Pro Gln Gln Leu Gln Ala Phe Lys Asn Glu Val Gly Val
 465 470 475 480
 Leu Arg Lys Thr Arg His Val Asn Ile Leu Leu Phe Met Gly Tyr Ser
 485 490 495
 Thr Lys Pro Gln Leu Ala Ile Val Thr Gln Trp Cys Glu Gly Ser Ser
 500 505 510
 Leu Tyr His His Leu His Ile Ile Glu Thr Lys Phe Glu Met Ile Lys
 515 520 525
 Leu Ile Asp Ile Ala Arg Gln Thr Ala Gln Gly Met Asp Tyr Leu His
 530 535 540
 Ala Lys Ser Ile Ile His Arg Asp Leu Lys Ser Asn Asn Ile Phe Leu
 545 550 555 560
 His Glu Asp Leu Thr Val Lys Ile Gly Asp Phe Gly Leu Ala Thr Val
 565 570 575
 Lys Ser Arg Trp Ser Gly Ser His Gln Phe Glu Gln Leu Ser Gly Ser
 580 585 590
 Ile Leu Trp Met Ala Pro Glu Val Ile Arg Met Gln Asp Lys Asn Pro
 595 600 605
 Tyr Ser Phe Gln Ser Asp Val Tyr Ala Phe Gly Ile Val Leu Tyr Glu
 610 615 620
 Leu Met Thr Gly Gln Leu Pro Tyr Ser Asn Ile Asn Asn Arg Asp Gln
 625 630 635 640
 Ile Ile Phe Met Val Gly Arg Gly Tyr Leu Ser Pro Asp Leu Ser Lys
 645 650 655
 Val Arg Ser Asn Cys Pro Lys Ala Met Lys Arg Leu Met Ala Glu Cys
 660 665 670
 Leu Lys Lys Lys Arg Asp Glu Arg Pro Leu Phe Pro Gln Ile Leu Ala
 675 680 685
 Ser Ile Glu Leu Leu Ala Arg Ser Leu Pro Lys Ile His Arg Ser Ala
 690 695 700
 Ser Glu Pro Ser Leu Asn Arg Ala Gly Phe Gln Thr Glu Asp Phe Ser
 705 710 715 720
 Leu Tyr Ala Cys Ala Ser Pro Lys Thr Pro Ile Gln Ala Gly Gly Tyr
 725 730 735

Gly Glu Phe Ala Ala Phe Lys
740

<210> 9
<211> 2186
<212> DNA
<213> *Cavia porcellus*

```

<400> 9
atggcggcgc tcagcggcgg cgggtggcgcg gagcagggcc aggctctgtt caacggggac      60
atggagctcg aggccggcgc cggcgccgca gcctcttcgg ctgcagaccc tgccattccc      120
gaggaggtat ggaatatcaa acaaatgatt aagttgacgc aggaacacat agaggcccta      180
ttggacaaat ttggtggaga gcataatcca ccatcaatat acctggaggc ctatgaagaa      240
tacaccagca aactagatgc cctccaacaa agagaacagc agttactgga atccctcggg      300
aatggaactg atttttctgt ttctagctct gcatcactgg acaccgttac atcttcttct      360
tcttctagcc tttcagtact accttcatct ctttcagttt ttcaaaatcc tacagatgtg      420
tcacggagca accccaaatc accacaaaaa cctattgtta gagtcttcct gcccaacaaa      480
cagaggacag tggtagctgc aagggtgtgga gttacagtcc gagacagtct gaagaaagca      540
ctcatgatga gaggtcttat cccagagtgc tgtgctgtgt acagaattca ggatggagaa      600
aagaaaccaa ttggctggga cactgacatt tcctggctta ctggggaaga attacatgta      660
gaagtattgg agaattgtcc acttacaaca cacaattttg tatgtatctt tatatTTTTT      720
ttgctgtttg tctccaagtt ctttgaacac cacccaatac cacaggagga ggcttcctta      780
gcagagacca cccttacatc tggatcatcc ctttctgcac cccctcaga gtccattggg      840
cccccaattc tcaccagccc atctccttca aaatccattc caattccaca gcctttccgg      900
ccaggagagg aagatcatcg aaatcaattt gggcagcgag accggtcctc atctgctccc      960
aatgtgcata taaacacaat agaacctgtc aatattgatg atttgattag agaccaaggg     1020
tttcgtagtg atggaggatc aactacaggt ttgtctgcc cccacctgc ctcatctac      1080
ggctcactca ctaatgtgaa agccttacag aaatctccag gacctcagcg agaaaggaag     1140
tcattctcat cctcagaaga cagaaatcga atgaaaacgc ttggtagacg ggactcaagt     1200
gatgattggg agattcctga tgggcagatt acagtgggac aaagaattgg atctgggtca     1260
tttgaacag tctacaaggg gaagtggcat ggtgacgtgg cagtgaaaat gttgaatgtg     1320
acagcaccca cacctcaaca gttacaggcc ttcaaaaatg aagtaggagt actcaggaaa     1380
acacgacatg tgaatatcct actcttcatg ggctattcca caaagccaca gctagctatt     1440
gttaccaggt ggtgtgaggg ctccagctta taccaccatc tccacatcat cgagaccaaa     1500
tttgagatga tcaaacttat agatattgca cgacagactg cccagggcat ggattactta     1560
cacgccaagt caatcatcca cagagacctc aagagtaata atatatttct tcacgaagac     1620
ctcacggtta aaataggtga ttttggctta gccacagtga aatctcgatg gagtgggtcc     1680
catcagtttg aacagttgtc tggatccatt ttgtggatgg caccagaagt aatcagaatg     1740

```

0398850pct.txt

cgagataaaa acccatacag ttttcagtcc gatgtatatg catttgggat tgttctatat 1800
gaattgatga ctgggcagtt accctattca aatatcaaca acagggacca gataattttt 1860
atggtgggac gaggatatct atctccagat ctcagcaagg tacggagtaa ctgtccaaaa 1920
gccatgaaga ggtaaatggc ggagtgcctc aaaaagaaaa gagatgagag accactcttt 1980
cccaaattc tcgcctctat tgagctgctg gcccgctcat tgccaaaaat tcaccgcagt 2040
gcatcagaac cctccttgaa tcgggctggt ttccaaacag aggatttttag tctctatgct 2100
tgtgcttctc caaaaacacc catccaggca gggggatatg gtgcgtttcc tgtccactga 2160
tgcaaattaa atgagtgaga aataaa 2186

<210> 10
<211> 719
<212> PRT
<213> *Cavia porcellus*
<400> 10

Met Ala Ala Leu Ser Gly Gly Gly Gly Ala Glu Gln Gly Gln Ala Leu
1 5 10 15

Phe Asn Gly Asp Met Glu Leu Glu Ala Gly Ala Gly Ala Ala Ala Ser
20 25 30

Ser Ala Ala Asp Pro Ala Ile Pro Glu Glu Val Trp Asn Ile Lys Gln
35 40 45

Met Ile Lys Leu Thr Gln Glu His Ile Glu Ala Leu Leu Asp Lys Phe
50 55 60

Gly Gly Glu His Asn Pro Pro Ser Ile Tyr Leu Glu Ala Tyr Glu Glu
65 70 75 80

Tyr Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg Glu Gln Gln Leu Leu
85 90 95

Glu Ser Leu Gly Asn Gly Thr Asp Phe Ser Val Ser Ser Ser Ala Ser
100 105 110

Leu Asp Thr Val Thr Ser Ser Ser Ser Ser Ser Leu Ser Val Leu Pro
115 120 125

Ser Ser Leu Ser Val Phe Gln Asn Pro Thr Asp Val Ser Arg Ser Asn
130 135 140

Pro Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe Leu Pro Asn Lys
145 150 155 160

Gln Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr Val Arg Asp Ser
165 170 175

Leu Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro Glu Cys Cys Ala
 180 185 190
 Val Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile Gly Trp Asp Thr
 195 200 205
 Asp Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val Glu Val Leu Glu
 210 215 220
 Asn Val Pro Leu Thr Thr His Asn Phe Val Cys Ile Phe Ile Phe Phe
 225 230 235 240
 Leu Leu Phe Val Ser Lys Phe Phe Glu His His Pro Ile Pro Gln Glu
 245 250 255
 Glu Ala Ser Leu Ala Glu Thr Thr Leu Thr Ser Gly Ser Ser Pro Ser
 260 265 270
 Ala Pro Pro Ser Glu Ser Ile Gly Pro Pro Ile Leu Thr Ser Pro Ser
 275 280 285
 Pro Ser Lys Ser Ile Pro Ile Pro Gln Pro Phe Arg Pro Gly Glu Glu
 290 295 300
 Asp His Arg Asn Gln Phe Gly Gln Arg Asp Arg Ser Ser Ser Ala Pro
 305 310 315 320
 Asn Val His Ile Asn Thr Ile Glu Pro Val Asn Ile Asp Asp Leu Ile
 325 330 335
 Arg Asp Gln Gly Phe Arg Ser Asp Gly Gly Ser Thr Thr Gly Leu Ser
 340 345 350
 Ala Thr Pro Pro Ala Ser Leu Pro Gly Ser Leu Thr Asn Val Lys Ala
 355 360 365
 Leu Gln Lys Ser Pro Gly Pro Gln Arg Glu Arg Lys Ser Ser Ser Ser
 370 375 380
 Ser Glu Asp Arg Asn Arg Met Lys Thr Leu Gly Arg Arg Asp Ser Ser
 385 390 395 400
 Asp Asp Trp Glu Ile Pro Asp Gly Gln Ile Thr Val Gly Gln Arg Ile
 405 410 415
 Gly Ser Gly Ser Phe Gly Thr Val Tyr Lys Gly Lys Trp His Gly Asp
 420 425 430
 Val Ala Val Lys Met Leu Asn Val Thr Ala Pro Thr Pro Gln Gln Leu
 435 440 445

Gln Ala Phe Lys Asn Glu Val Gly Val Leu Arg Lys Thr Arg His Val
 450 455 460
 Asn Ile Leu Leu Phe Met Gly Tyr Ser Thr Lys Pro Gln Leu Ala Ile
 465 470 475 480
 Val Thr Gln Trp Cys Glu Gly Ser Ser Leu Tyr His His Leu His Ile
 485 490 495
 Ile Glu Thr Lys Phe Glu Met Ile Lys Leu Ile Asp Ile Ala Arg Gln
 500 505 510
 Thr Ala Gln Gly Met Asp Tyr Leu His Ala Lys Ser Ile Ile His Arg
 515 520 525
 Asp Leu Lys Ser Asn Asn Ile Phe Leu His Glu Asp Leu Thr Val Lys
 530 535 540
 Ile Gly Asp Phe Gly Leu Ala Thr Val Lys Ser Arg Trp Ser Gly Ser
 545 550 555 560
 His Gln Phe Glu Gln Leu Ser Gly Ser Ile Leu Trp Met Ala Pro Glu
 565 570 575
 Val Ile Arg Met Arg Asp Lys Asn Pro Tyr Ser Phe Gln Ser Asp Val
 580 585 590
 Tyr Ala Phe Gly Ile Val Leu Tyr Glu Leu Met Thr Gly Gln Leu Pro
 595 600 605
 Tyr Ser Asn Ile Asn Asn Arg Asp Gln Ile Ile Phe Met Val Gly Arg
 610 615 620
 Gly Tyr Leu Ser Pro Asp Leu Ser Lys Val Arg Ser Asn Cys Pro Lys
 625 630 635 640
 Ala Met Lys Arg Leu Met Ala Glu Cys Leu Lys Lys Lys Arg Asp Glu
 645 650 655
 Arg Pro Leu Phe Pro Gln Ile Leu Ala Ser Ile Glu Leu Leu Ala Arg
 660 665 670
 Ser Leu Pro Lys Ile His Arg Ser Ala Ser Glu Pro Ser Leu Asn Arg
 675 680 685
 Ala Gly Phe Gln Thr Glu Asp Phe Ser Leu Tyr Ala Cys Ala Ser Pro
 690 695 700
 Lys Thr Pro Ile Gln Ala Gly Gly Tyr Gly Ala Phe Pro Val His
 705 710 715

<210> 11
 <211> 3229
 <212> DNA
 <213> Canis familiaris

<400> 11
 gtaatgctgg attttcatgg aataagtttg acctgtgctg cagtggcctc cagcaaggta 60
 cccgcaagat gtggagttac agtccgggac agtctaaaga aagctctgat gatgagaggt 120
 ctaatcccag agtgctgtgc tgtttacaga attcaggatg gagagaagaa accgattggc 180
 tgggacactg atatttcctg gctcactgga gaggaattgc atgtagaagt gttggaaaat 240
 gttccgctta ccacacacaa ctttgtacgg aaaacttttt tcaccttagc attttgtgac 300
 ttttgtcgaa agctgctttt ccagggtttt cgctgtcaaa catgtggtta taaatttcac 360
 cagcgttgta gtacagaggt tccactgatg tgtgttaatt atgaccaact tgatttgctg 420
 tttgtctcca agttctttga acaccacca ataccacagg aggaggcctc catagcagag 480
 actgccctta cgtctggatc atcccccttct gctccccctt ccgattctcc tgggccccca 540
 attctgacca gtccgtctcc ttcaaaatcc attccaattc cacagccttt ccgaccagca 600
 gatgaagatc atcgaaatca gtttggacaa cgagaccggt cctcatcagc tccaaatgtg 660
 catataaaca caatagaacc cgtcaacatt gatgacttga ttagagacca agggtttctg 720
 agtgatggag gatcaaccac aggtttgtct gccaccccc ctgcctcatt gcctggctca 780
 ctactaatg taaaagcatt acagaaatct ccaggacctc agcgggaaag aaaatcatct 840
 tcactctcag aagataggaa tcgaatgaaa acacttggtg gacgggattc aagtgatgat 900
 tgggagatac ctgatgggca gatcacagtg ggacagagaa ttggatccgg gtcatttggg 960
 acagtctaca agggaaagtg gcatggtgac gtggcagtga aaatgttgaa tgtgacagca 1020
 cccacacctc agcagttaca ggccttcaaa aatgaagtag gagtactcag gaaaactcga 1080
 catgtgaata tcctactctt tatgggctat tcaacaaagc cccaactggc tattgttacc 1140
 cagtgggtgtg agggctccag cttatatcac catctccaca tcattgagac caaatttgag 1200
 atgataaagc ttatagatat tgcacggcag actgcacagg gcatggatta cttacacgcc 1260
 aagtcaatca tccacagaga cctcaagagt aataatattt ttcttcatga agacctcaca 1320
 gtaaaaatag gtgatttttg tctagccaca gtgaaatctc gatggagtgg gtcccatcag 1380
 tttgaacagt tgtctggatc ctttttgtgg atggcaccag aagtgatccg aatgcaagac 1440
 aaaaacccat atagcttcca gtcagatgta tacgcatttg ggattgttct atatgaattg 1500
 atgacagggc agttacctta ttcaaacatc aacaacaggg accagataat ttttatggtg 1560
 ggacgaggat atctttctcc agatctcagt aagggtacgga gtaactgtcc aaaagccatg 1620
 aagagattga tggcagagtg cctaaaaaag aaaagagatg agaggccact ctttcccaa 1680
 attctcgctt ctattgagct gctggcccg ctcattgcaa aaattcaccg cagtgcattc 1740
 gaaccctcct tgaatcgggc tggcttccaa acagaggatt ttagtctcta tgcttgcgct 1800
 tctccaaaaa caccatcca ggcaggggga tacggagaat ttgcagcctt caagtagcca 1860

0398850pct.txt

caccatcatg gcaacaacta ctcttatttc ttaagtcttg tgttcgtaca atttgttaac 1920
atcaaaacac agttctgttc ctcaaactct tttttaaaga tacagaattt tcaatgcata 1980
agctgggtgtg gaacagaatg gaatttccca tccaacaaaa gagggaagaa tgttttagga 2040
accagaattc tctgctgcca gtgtttcttc ttcaacacaa ataccacgtg catacaagtc 2100
tgcccactcc caggaaggaa gaggagagcc tgagtcttga ccttttgatg gtcaggcatg 2160
atggaaagaa actgctgcta cagcttggga gattggctgt ggagagcctg cccgtcagct 2220
ctgcccttct aaccgccaga tgagtgtgtg gctggtcacc tgacagggca gctgcaatcg 2280
ccaagcatcg ttctctttcc tgtcctggga ttttgtcgtg gagctctttc cccctagtca 2340
ccaccggttc atttctgagg gatggaacaa aaatgcagca tggcctttct gtgtgggtgca 2400
tgtccggtct ttgacaaatt tttatcaagt gaagctcttg tatttaaagt gagaatgaga 2460
ggcgaggggg ggggatcacg ttttgggtga ggggcaaagg gaatgctgca tctttttcct 2520
gaccactgg gtttctggcc tttgtttcct tgctcactga ggggtgtctgc ctataaccac 2580
gcaggctgga aagtgtggc acacattgcc ttctcttctc actgggtcca gcaatgaaga 2640
caagtgttgg ggattttttt ttttgccctc cacaatgtag caagtcttca ggaaaataca 2700
gttaatatct tcctcctaag ctcttcagat catcaagtac ttatgtggct actttgtcca 2760
gggcacaaaa tgccatggcg gtatccaatt aaaagcctac aaaactgctt gataacagtt 2820
ttgaatgtgt gagacattta tgtaatttaa atgtaaggta caagttttaa tttctgagtt 2880
tctctattat atttttatta aaaagaaaat aattttcaga ttttaattgaa ttggaataaa 2940
ataatacttc ccaccagaat tatatatcct ggaaaattgt atttttgtta tataaacaac 3000
ttttaaagaa agatcattat ccttttctct acctaaatat ggggagtctt agcataatga 3060
cagatattta taatttttaa attaatggta cttgctggat ccacactaac atctttgcta 3120
atatctcatg ttttcctcca acttactcct aactacatc ctccatcctc tttccagtct 3180
tttatctaga atatgcaacc taaaataaaa atggtggtgt ctccattca 3229

<210> 12
<211> 617
<212> PRT
<213> Canis familiaris

<400> 12

Met Leu Asp Phe His Gly Ile Ser Leu Thr Cys Ala Ala Val Ala Ser
1 5 10 15

Ser Lys Val Pro Ala Arg Cys Gly Val Thr Val Arg Asp Ser Leu Lys
20 25 30

Lys Ala Leu Met Met Arg Gly Leu Ile Pro Glu Cys Cys Ala Val Tyr
35 40 45

Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile Gly Trp Asp Thr Asp Ile
50 55 60

Ser Trp Leu Thr Gly Glu Glu Leu His Val Glu Val Leu Glu Asn Val
 65 70 75 80
 Pro Leu Thr Thr His Asn Phe Val Arg Lys Thr Phe Phe Thr Leu Ala
 85 90 95
 Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe Gln Gly Phe Arg Cys Gln
 100 105 110
 Thr Cys Gly Tyr Lys Phe His Gln Arg Cys Ser Thr Glu Val Pro Leu
 115 120 125
 Met Cys Val Asn Tyr Asp Gln Leu Asp Leu Leu Phe Val Ser Lys Phe
 130 135 140
 Phe Glu His His Pro Ile Pro Gln Glu Glu Ala Ser Ile Ala Glu Thr
 145 150 155 160
 Ala Leu Thr Ser Gly Ser Ser Pro Ser Ala Pro Pro Ser Asp Ser Pro
 165 170 175
 Gly Pro Pro Ile Leu Thr Ser Pro Ser Pro Ser Lys Ser Ile Pro Ile
 180 185 190
 Pro Gln Pro Phe Arg Pro Ala Asp Glu Asp His Arg Asn Gln Phe Gly
 195 200 205
 Gln Arg Asp Arg Ser Ser Ser Ala Pro Asn Val His Ile Asn Thr Ile
 210 215 220
 Glu Pro Val Asn Ile Asp Asp Leu Ile Arg Asp Gln Gly Phe Arg Ser
 225 230 235 240
 Asp Gly Gly Ser Thr Thr Gly Leu Ser Ala Thr Pro Pro Ala Ser Leu
 245 250 255
 Pro Gly Ser Leu Thr Asn Val Lys Ala Leu Gln Lys Ser Pro Gly Pro
 260 265 270
 Gln Arg Glu Arg Lys Ser Ser Ser Ser Glu Asp Arg Asn Arg Met
 275 280 285
 Lys Thr Leu Gly Arg Arg Asp Ser Ser Asp Asp Trp Glu Ile Pro Asp
 290 295 300
 Gly Gln Ile Thr Val Gly Gln Arg Ile Gly Ser Gly Ser Phe Gly Thr
 305 310 315 320
 Val Tyr Lys Gly Lys Trp His Gly Asp Val Ala Val Lys Met Leu Asn
 325 330 335

Val Thr Ala Pro Thr Pro Gln Gln Leu Gln Ala Phe Lys Asn Glu Val
 340 345 350
 Gly Val Leu Arg Lys Thr Arg His Val Asn Ile Leu Leu Phe Met Gly
 355 360 365
 Tyr Ser Thr Lys Pro Gln Leu Ala Ile Val Thr Gln Trp Cys Glu Gly
 370 375 380
 Ser Ser Leu Tyr His His Leu His Ile Ile Glu Thr Lys Phe Glu Met
 385 390 395 400
 Ile Lys Leu Ile Asp Ile Ala Arg Gln Thr Ala Gln Gly Met Asp Tyr
 405 410 415
 Leu His Ala Lys Ser Ile Ile His Arg Asp Leu Lys Ser Asn Asn Ile
 420 425 430
 Phe Leu His Glu Asp Leu Thr Val Lys Ile Gly Asp Phe Gly Leu Ala
 435 440 445
 Thr Val Lys Ser Arg Trp Ser Gly Ser His Gln Phe Glu Gln Leu Ser
 450 455 460
 Gly Ser Ile Leu Trp Met Ala Pro Glu Val Ile Arg Met Gln Asp Lys
 465 470 475 480
 Asn Pro Tyr Ser Phe Gln Ser Asp Val Tyr Ala Phe Gly Ile Val Leu
 485 490 495
 Tyr Glu Leu Met Thr Gly Gln Leu Pro Tyr Ser Asn Ile Asn Asn Arg
 500 505 510
 Asp Gln Ile Ile Phe Met Val Gly Arg Gly Tyr Leu Ser Pro Asp Leu
 515 520 525
 Ser Lys Val Arg Ser Asn Cys Pro Lys Ala Met Lys Arg Leu Met Ala
 530 535 540
 Glu Cys Leu Lys Lys Lys Arg Asp Glu Arg Pro Leu Phe Pro Gln Ile
 545 550 555 560
 Leu Ala Ser Ile Glu Leu Leu Ala Arg Ser Leu Pro Lys Ile His Arg
 565 570 575
 Ser Ala Ser Glu Pro Ser Leu Asn Arg Ala Gly Phe Gln Thr Glu Asp
 580 585 590
 Phe Ser Leu Tyr Ala Cys Ala Ser Pro Lys Thr Pro Ile Gln Ala Gly
 595 600 605

Gly Tyr Gly Glu Phe Ala Ala Phe Lys
 610 615

<210> 13
 <211> 1889
 <212> DNA
 <213> Canis familiaris

```

<400> 13
ggaatatcaa acaaatgatt aagttgacac aggaacatat agaagcccta ttggacaagt    60
ttggtgggga gcataatcca ccatcaatat atctggaggc ctatgaagaa tacaccagca    120
aactagatgc cctccaacag cgagaacaac agttattgga atccctgggg aatggaactg    180
atTTTTctgt ttctagctct gcatcaacgg acaccgttac atcttcttcc tcttctagcc    240
tttcagtgtc accttcatct ctttcagttt ttcaaaatcc cacagatata tcacggagca    300
atcccaagtc accacaaaaa cctatcggtt gagtcttccct gcccaataaa cagaggacgg    360
tggtacccgc aagatgtgga gttacagtcc gggacagtct aaagaaagct ctgatgatga    420
gaggtctaat cccagagtgc tgtgctgttt acagaattca ggatggagag aagaaaccga    480
ttggctggga cactgatatt tcctgggtca ctggagagga attgcatgta gaagtgttgg    540
aaaatgttcc gcttaccaca cacaactttg tacggaaaac ttttttcacc ttagcatttt    600
gtgacttttg tcgaaagctg cttttccagg gttttcgctg tcaaacatgt ggttataaat    660
ttcaccagcg ttgtagtaca gaggttccac tgatgtgtgt taattatgac caacttgatt    720
tgctgtttgt ctccaagttc tttgaacacc acccaatacc acaggaggag gcctccatag    780
cagagactgc ctttacgtct ggatcatccc cttctgtctc cccctccgat tctcctgggc    840
ccccaattct gaccagtccg tctccttcaa aatccattcc aattccacag cttttccgac    900
cagcagatga agatcatcga aatcagtttg gacaacgaga ccggtcctca tcagctccaa    960
atgtgcatat aaacacaata gaacccgtca acattgatga cttgattaga gaccaagggg   1020
ttcgtagtga tggaggatca accacagggt tgtctgccac cccccctgcc tcattgcctg   1080
gctcactcac taatgtaaaa gcattacaga aatctccagg acctcagcgg gaaagaaaat   1140
catcttcac ctcagaagat aggaatcgaa tgaaaacact tggtagacgg gattcaagtg   1200
atgattggga gatacctgat gggcagatca cagtgggaca gagaattgga tccgggtcat   1260
ttgggacagt ctacaaggga aagtggcatg gtgacgtggc agtgaaaatg ttgaatgtga   1320
cagcaccac acctcagcag ttacaggcct tcaaaaatga agtaggagta ctcaggaaaa   1380
ctcgacatgt gaatataccta ctctttatgg gctattcaac aaagcccaa ctggctattg   1440
ttaccagtg gtgtgagggc tccagcttat atcaccatct ccacatcatt gagaccaaata   1500
ttgagatgat aaagcttata gatattgcac ggcagactgc acagggcatg gattacttac   1560
acgccaagtc aatcatccac agagacctca agagtaataa ttttttctt catgaagacc   1620
tcacagtaaa aataggtgat tttggtctag ccacagtga atctcgatgg agtgggtccc   1680

```

atcagtttga acagttgtct ggatccattt tgtggatggc accagaagtg atccgaatgc 1740
aagacaaaaa cccatatagc ttccagtcag atgtatacgc atttgggatt gttctatatg 1800
aattgatgac agggcagtta ccttattcaa acatcaacaa cagggaccag ctcagatcat 1860
gatcacggtg tcatgagatc aagccccac 1889

<210> 14
<211> 615
<212> PRT
<213> Canis familiaris

<400> 14

Met Ile Lys Leu Thr Gln Glu His Ile Glu Ala Leu Leu Asp Lys Phe
1 5 10 15

Gly Gly Glu His Asn Pro Pro Ser Ile Tyr Leu Glu Ala Tyr Glu Glu
20 25 30

Tyr Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg Glu Gln Gln Leu Leu
35 40 45

Glu Ser Leu Gly Asn Gly Thr Asp Phe Ser Val Ser Ser Ser Ala Ser
50 55 60

Thr Asp Thr Val Thr Ser Ser Ser Ser Ser Ser Leu Ser Val Leu Pro
65 70 75 80

Ser Ser Leu Ser Val Phe Gln Asn Pro Thr Asp Ile Ser Arg Ser Asn
85 90 95

Pro Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe Leu Pro Asn Lys
100 105 110

Gln Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr Val Arg Asp Ser
115 120 125

Leu Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro Glu Cys Cys Ala
130 135 140

Val Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile Gly Trp Asp Thr
145 150 155 160

Asp Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val Glu Val Leu Glu
165 170 175

Asn Val Pro Leu Thr Thr His Asn Phe Val Arg Lys Thr Phe Phe Thr
180 185 190

Leu Ala Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe Gln Gly Phe Arg
195 200 205

Cys Gln Thr Cys Gly Tyr Lys Phe His Gln Arg Cys Ser Thr Glu Val
 210 215 220
 Pro Leu Met Cys Val Asn Tyr Asp Gln Leu Asp Leu Leu Phe Val Ser
 225 230 235 240
 Lys Phe Phe Glu His His Pro Ile Pro Gln Glu Glu Ala Ser Ile Ala
 245 250 255
 Glu Thr Ala Leu Thr Ser Gly Ser Ser Pro Ser Ala Pro Pro Ser Asp
 260 265 270
 Ser Pro Gly Pro Pro Ile Leu Thr Ser Pro Ser Pro Ser Lys Ser Ile
 275 280 285
 Pro Ile Pro Gln Pro Phe Arg Pro Ala Asp Glu Asp His Arg Asn Gln
 290 295 300
 Phe Gly Gln Arg Asp Arg Ser Ser Ser Ala Pro Asn Val His Ile Asn
 305 310 315 320
 Thr Ile Glu Pro Val Asn Ile Asp Asp Leu Ile Arg Asp Gln Gly Phe
 325 330 335
 Arg Ser Asp Gly Gly Ser Thr Thr Gly Leu Ser Ala Thr Pro Pro Ala
 340 345 350
 Ser Leu Pro Gly Ser Leu Thr Asn Val Lys Ala Leu Gln Lys Ser Pro
 355 360 365
 Gly Pro Gln Arg Glu Arg Lys Ser Ser Ser Ser Ser Glu Asp Arg Asn
 370 375 380
 Arg Met Lys Thr Leu Gly Arg Arg Asp Ser Ser Asp Asp Trp Glu Ile
 385 390 395 400
 Pro Asp Gly Gln Ile Thr Val Gly Gln Arg Ile Gly Ser Gly Ser Phe
 405 410 415
 Gly Thr Val Tyr Lys Gly Lys Trp His Gly Asp Val Ala Val Lys Met
 420 425 430
 Leu Asn Val Thr Ala Pro Thr Pro Gln Gln Leu Gln Ala Phe Lys Asn
 435 440 445
 Glu Val Gly Val Leu Arg Lys Thr Arg His Val Asn Ile Leu Leu Phe
 450 455 460
 Met Gly Tyr Ser Thr Lys Pro Gln Leu Ala Ile Val Thr Gln Trp Cys
 465 470 475 480

Glu Gly Ser Ser Leu Tyr His His Leu His Ile Ile Glu Thr Lys Phe
 485 490 495

Glu Met Ile Lys Leu Ile Asp Ile Ala Arg Gln Thr Ala Gln Gly Met
 500 505 510

Asp Tyr Leu His Ala Lys Ser Ile Ile His Arg Asp Leu Lys Ser Asn
 515 520 525

Asn Ile Phe Leu His Glu Asp Leu Thr Val Lys Ile Gly Asp Phe Gly
 530 535 540

Leu Ala Thr Val Lys Ser Arg Trp Ser Gly Ser His Gln Phe Glu Gln
 545 550 555 560

Leu Ser Gly Ser Ile Leu Trp Met Ala Pro Glu Val Ile Arg Met Gln
 565 570 575

Asp Lys Asn Pro Tyr Ser Phe Gln Ser Asp Val Tyr Ala Phe Gly Ile
 580 585 590

Val Leu Tyr Glu Leu Met Thr Gly Gln Leu Pro Tyr Ser Asn Ile Asn
 595 600 605

Asn Arg Asp Gln Leu Arg Ser
 610 615

<210> 15
 <211> 3521
 <212> DNA
 <213> Felis catus

<220>
 <221> misc_feature
 <222> (630)..(649)
 <223> n is a, c, g, or t

<400> 15
 atgcctaacc tcagtctctg ccaccacggc caatttgctc atgtgcccac tgtgtcggca 60
 ctgggatatt ttgtgatttg ccttggccat tgtccactgt ccttgacatt gcctgaagga 120
 gaaccactga tgctaattgtt gaaggtgacc tttgcaggct ctccactact cataccaaag 180
 atgcggcccc ctgataatcc cagagccact gtctgcacat gggcaaaaca ggctacattc 240
 tgtgcagact ggggagaaaag gttccaagaa cacagtgcc a tagttttggg cagagagttt 300
 caacacagca tagtgtctat ggcagtatct ggatttggcc gggggaagtg cccaagagga 360
 gacagtcagg ctgtgtccta cggccaagga cctgcactta tttttgcatg cagtggttta 420
 gcacagggaa gagaacgaag taggaaatcg gagccatgga aacggcagag cggaggaaac 480
 gtgcacgcgc gaggggtgggc acgaaaggaa agaaccctcc ccagaagact gcgcgagggc 540
 gtccttagga ttacgtcacg caccgccgca aaactgaaat gtactgtgtg tgggtcttta 600

0398850pct.txt

attgaactat	cttccttatg	tgcacttaan	nnnnnnnnnn	nnnnnnnnng	cggcggcggc	660
ggtggcgcg	agcagggcca	ggctctgttc	aacggggaca	tggagcccga	agccggcgcc	720
gcggcctctt	cggctgcgga	ccctgccatt	cccgaggagg	tgtggaatat	caaacaaatg	780
attaagttga	cacaggaaca	tatagaggcc	ctattggaca	aatttggtgg	ggagcataat	840
ccaccatcaa	tatatctaga	ggcctatgaa	gaatacacca	gcaagctaga	tgccctccaa	900
cagagagaac	aacagttatt	ggaatccctg	gggaatggaa	ctgatttttc	tgtttctagc	960
tctgcatcaa	cagacaccgt	tacatcttcc	tcctcttcta	gcctttcagt	gctaccttca	1020
tctctttcag	tttttcaaaa	ccccacagat	gtgtcacgga	gcaatcccaa	gtcaccacag	1080
aaacctatcg	ttagagtctt	cctgccta	aaacagagga	cagtggtagc	tgcaagatgt	1140
ggagttacag	tccgggacag	tctaaagaaa	gctctgatga	tgagagggtc	aatccctgag	1200
tgctgtgctg	tttacagaat	tcaggatgga	gagaagaaac	caattggctg	ggacactgat	1260
atctcctggc	tcaccggaga	ggaattgcat	gtagaagtgt	tggaatgtgt	tccacttaca	1320
actcacaact	ttgtatgtac	ggaaaacgtt	ttcaccttag	cattttgtga	cttttgtcga	1380
aagctgcttt	tccaagggtt	tcgctgtcaa	acgtgtgggt	ataaatttca	ccagcggtgt	1440
agtacagagg	ttccactgat	gtgtgtta	tatgaccaac	ttgatttgct	gtttgtctcc	1500
aagttctttg	aacaccaccc	aataccacag	gaggaggcct	ccatagcaga	gactgcccta	1560
acgtctggat	cgtcccttcc	tgcccccccc	tccgattcta	ctgggccccca	aattctcacc	1620
agtccgtctc	cttcaaaatc	cattccaatt	ccacagcctt	tccgaccagc	agatgaagat	1680
catcgaaatc	aatttggaca	gcgagaccgg	tcctcatcag	ctccaaatgt	gcatataaat	1740
acaatagaac	ctgtcaatat	tgatgacttg	attagagacc	aggggtttcg	tagtgatgga	1800
ggatcaacca	caggcttgct	tgccaccccc	cctgcctcat	tgccgggctc	tctcactaat	1860
gtaaaagcat	tacagaaatc	tccagggcct	cagcgggaaa	ggaaatcttc	ttcatcctca	1920
gaagatagga	atcgaatgaa	aacacttggt	agaagggtat	caagtgatga	ttgggagatt	1980
cctgatgggc	agatcacagt	gggacagaga	attggatccg	ggtcatttgg	gacagtctac	2040
aagggaaagt	ggcatggtga	tgtggcagtg	aaaatgttga	atgtgacagc	acccacacct	2100
cagcagttac	aggccttcaa	aatgaagta	ggagtactca	ggaaaactcg	gcatgtgaac	2160
atcctgctct	tcatgggcta	ttcaacaaag	ccccagctgg	ctattgtcac	ccagtgggtg	2220
gagggctcca	gcttatacca	ccatctccac	atcatcgaga	ccaaattcga	gatgatcaag	2280
ctgatagata	ttgctcggca	gactgcgcag	ggcatggatt	acttacacgc	caagtcaatc	2340
atccacagag	acctcaagag	taataatatt	tttcttcacg	aagacctcac	agtaaaaata	2400
ggtgattttg	gtctagccac	agtgaatct	cgatggagtg	ggtcccatca	gtttgaacag	2460
ttgtctggat	ccattttgtg	gatggcacca	gaagtaattc	gaatgcaaga	taaaaaccca	2520
tatagctttc	agtcagatgt	atatgcattt	gggattgttc	tatatgaatt	gatgactgga	2580
cagttacctt	attcaaacat	caacaacagg	gaccagataa	tttttatggg	gggacgagga	2640

0398850pct.txt

```
tatctttctc cagatctcag taaggtagca agtaactgtc caaaagccat gaagagattg 2700
atggcagagt gcctaaaaaa gaaaagagat gagaggccac tgtttcccca aattcttgcc 2760
tctattgagc tgctggcccc ctcattgcca aaaattcacc gcagtgcacg agaaccctcc 2820
ttgaatcggg ctggcttcca gacagaggat tttagtctct atgcttgtgc ttctccaaaa 2880
acacccatcc aggcaggggg atagtgtgcg tttcccgctc actgagataa gttagatgag 2940
tgcgcgagtg caggggggccg gggccaagga ggtggaaatg tgcgtgcttc tgtactaagt 3000
tggatagcat cttctttttt aaaaaaagat gaaccaaaga atgtgtatgt ttttaaagac 3060
tagatataat tatttcctga tctaaaatgt atacttagct ttggattttc aatatccaag 3120
ggttttcaaa atgcacagac attgctgaac atttgcagta cctcttctgg aggctttact 3180
tcctgttaca aattggtttt gtttactggc ttatcctaata tattaaactt caattaaact 3240
tttctcctgc accttttgtt atgagctatc acatgtccct tagggactcg caagagcagt 3300
actgcccccg tgtacgggct tgcaggtaga aaggggatga cgggttttaa cacctgtgtg 3360
aggcaaggca gtccgaacag atctcattta ggaagccacg agagttgaat aagttatatt 3420
tattcttagt attttttctg taactacttt ttattataac ttggaaaata tggatgtcct 3480
ttatacacct tagcaataga ctgaatttct tttataaat t 3521
```

<210> 16
 <211> 974
 <212> PRT
 <213> Felis catus

<220>
 <221> misc_feature
 <222> (210)..(217)
 <223> Xaa can be any naturally occurring amino acid

<400> 16

Met Pro Asn Leu Ser Leu Cys His His Gly Gln Phe Ala His Val Pro
 1 5 10 15

Thr Val Ser Ala Leu Gly Tyr Phe Val Ile Cys Leu Gly His Cys Pro
 20 25 30

Leu Ser Leu Thr Leu Pro Glu Gly Glu Pro Leu Met Leu Met Leu Lys
 35 40 45

Val Thr Phe Ala Gly Ser Pro Leu Leu Ile Pro Lys Met Arg Pro Pro
 50 55 60

Asp Asn Pro Arg Ala Thr Val Cys Thr Trp Ala Lys Gln Ala Thr Phe
 65 70 75 80

Cys Ala Asp Trp Gly Glu Arg Phe Gln Glu His Ser Ala Ile Val Leu
 85 90 95

Gly Arg Glu Phe Gln His Ser Ile Val Ser Met Ala Val Ser Gly Phe
 100 105 110
 Gly Arg Gly Lys Cys Pro Arg Gly Asp Ser Gln Ala Val Ser Tyr Gly
 115 120 125
 Gln Gly Pro Ala Leu Ile Phe Ala Cys Ser Gly Leu Ala Gln Gly Arg
 130 135 140
 Glu Arg Ser Arg Lys Ser Glu Pro Trp Lys Arg Gln Ser Gly Gly Asn
 145 150 155 160
 Val His Ala Arg Gly Trp Ala Arg Lys Glu Arg Thr Leu Pro Arg Arg
 165 170 175
 Leu Arg Glu Gly Ala Pro Arg Ile Thr Ser Arg Thr Pro Arg Lys Leu
 180 185 190
 Lys Cys Thr Val Cys Gly Leu Leu Ile Glu Leu Ser Ser Leu Cys Ala
 195 200 205
 Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Gly Gly Gly Gly Ala Glu
 210 215 220
 Gln Gly Gln Ala Leu Phe Asn Gly Asp Met Glu Pro Glu Ala Gly Ala
 225 230 235 240
 Ala Ala Ser Ser Ala Ala Asp Pro Ala Ile Pro Glu Glu Val Trp Asn
 245 250 255
 Ile Lys Gln Met Ile Lys Leu Thr Gln Glu His Ile Glu Ala Leu Leu
 260 265 270
 Asp Lys Phe Gly Gly Glu His Asn Pro Pro Ser Ile Tyr Leu Glu Ala
 275 280 285
 Tyr Glu Glu Tyr Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg Glu Gln
 290 295 300
 Gln Leu Leu Glu Ser Leu Gly Asn Gly Thr Asp Phe Ser Val Ser Ser
 305 310 315 320
 Ser Ala Ser Thr Asp Thr Val Thr Ser Ser Ser Ser Ser Ser Leu Ser
 325 330 335
 Val Leu Pro Ser Ser Leu Ser Val Phe Gln Asn Pro Thr Asp Val Ser
 340 345 350
 Arg Ser Asn Pro Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe Leu
 355 360 365

Pro Asn Lys Gln Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr Val
 370 375 380
 Arg Asp Ser Leu Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro Glu
 385 390 395 400
 Cys Cys Ala Val Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile Gly
 405 410 415
 Trp Asp Thr Asp Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val Glu
 420 425 430
 Val Leu Glu Asn Val Pro Leu Thr Thr His Asn Phe Val Cys Thr Glu
 435 440 445
 Asn Val Phe Thr Leu Ala Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe
 450 455 460
 Gln Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Gln Arg Cys
 465 470 475 480
 Ser Thr Glu Val Pro Leu Met Cys Val Asn Tyr Asp Gln Leu Asp Leu
 485 490 495
 Leu Phe Val Ser Lys Phe Phe Glu His His Pro Ile Pro Gln Glu Glu
 500 505 510
 Ala Ser Ile Ala Glu Thr Ala Leu Thr Ser Gly Ser Ser Pro Ser Ala
 515 520 525
 Pro Pro Ser Asp Ser Thr Gly Pro Gln Ile Leu Thr Ser Pro Ser Pro
 530 535 540
 Ser Lys Ser Ile Pro Ile Pro Gln Pro Phe Arg Pro Ala Asp Glu Asp
 545 550 555 560
 His Arg Asn Gln Phe Gly Gln Arg Asp Arg Ser Ser Ser Ala Pro Asn
 565 570 575
 Val His Ile Asn Thr Ile Glu Pro Val Asn Ile Asp Asp Leu Ile Arg
 580 585 590
 Asp Gln Gly Phe Arg Ser Asp Gly Gly Ser Thr Thr Gly Leu Ser Ala
 595 600 605
 Thr Pro Pro Ala Ser Leu Pro Gly Ser Leu Thr Asn Val Lys Ala Leu
 610 615 620
 Gln Lys Ser Pro Gly Pro Gln Arg Glu Arg Lys Ser Ser Ser Ser Ser
 625 630 635 640

Glu Asp Arg Asn Arg Met Lys Thr Leu Gly Arg Arg Asp Ser Ser Asp
 645 650 655
 Asp Trp Glu Ile Pro Asp Gly Gln Ile Thr Val Gly Gln Arg Ile Gly
 660 665 670
 Ser Gly Ser Phe Gly Thr Val Tyr Lys Gly Lys Trp His Gly Asp Val
 675 680 685
 Ala Val Lys Met Leu Asn Val Thr Ala Pro Thr Pro Gln Gln Leu Gln
 690 695 700
 Ala Phe Lys Asn Glu Val Gly Val Leu Arg Lys Thr Arg His Val Asn
 705 710 715 720
 Ile Leu Leu Phe Met Gly Tyr Ser Thr Lys Pro Gln Leu Ala Ile Val
 725 730 735
 Thr Gln Trp Cys Glu Gly Ser Ser Leu Tyr His His Leu His Ile Ile
 740 745 750
 Glu Thr Lys Phe Glu Met Ile Lys Leu Ile Asp Ile Ala Arg Gln Thr
 755 760 765
 Ala Gln Gly Met Asp Tyr Leu His Ala Lys Ser Ile Ile His Arg Asp
 770 775 780
 Leu Lys Ser Asn Asn Ile Phe Leu His Glu Asp Leu Thr Val Lys Ile
 785 790 795 800
 Gly Asp Phe Gly Leu Ala Thr Val Lys Ser Arg Trp Ser Gly Ser His
 805 810 815
 Gln Phe Glu Gln Leu Ser Gly Ser Ile Leu Trp Met Ala Pro Glu Val
 820 825 830
 Ile Arg Met Gln Asp Lys Asn Pro Tyr Ser Phe Gln Ser Asp Val Tyr
 835 840 845
 Ala Phe Gly Ile Val Leu Tyr Glu Leu Met Thr Gly Gln Leu Pro Tyr
 850 855 860
 Ser Asn Ile Asn Asn Arg Asp Gln Ile Ile Phe Met Val Gly Arg Gly
 865 870 875 880
 Tyr Leu Ser Pro Asp Leu Ser Lys Val Arg Ser Asn Cys Pro Lys Ala
 885 890 895
 Met Lys Arg Leu Met Ala Glu Cys Leu Lys Lys Lys Arg Asp Glu Arg
 900 905 910

0398850pct.txt

Pro Leu Phe Pro Gln Ile Leu Ala Ser Ile Glu Leu Leu Ala Arg Ser
 915 920 925

Leu Pro Lys Ile His Arg Ser Ala Ser Glu Pro Ser Leu Asn Arg Ala
 930 935 940

Gly Phe Gln Thr Glu Asp Phe Ser Leu Tyr Ala Cys Ala Ser Pro Lys
 945 950 955 960

Thr Pro Ile Gln Ala Gly Gly Tyr Gly Ala Phe Pro Val His
 965 970

<210> 17
 <211> 3853
 <212> DNA
 <213> Bos taurus

<400> 17
 ctacagctgcg ccgggtctca caagacggtt cccgaggtgg cccaggcgcc gtcccaccgc 60
 cgacgccgcc cgggccgcc gggccgtccc tccccgtgc ccccgctcct ccgcctccgc 120
 ctccccccgc cctcagcctc ccttccccct ccccgcccag cagcggtcgc tcggggcccgg 180
 ctctcggtta taagatggcg gcgctgagtg gcggcggcgg cggcggcgcc ggtggcgcg 240
 agcagggcca ggctctgttc aacggggaca tggagcccga ggccggcgcc gcggcctctt 300
 cggctgcgga ccccgccatt cccgaggagg tgtggaatat caaacaatg attaagttga 360
 cacaggagca tatagaggcc ctattggaca aatttggtgg ggagcataat ccaccatcaa 420
 tataatctgga ggcctatgaa gaatacacca gcaagctaga tgccctccaa caaagagaac 480
 aacagttatt ggaatccctg gggaatggaa ctgatttttc tgtttctagc tctgcatcaa 540
 cggacaccgt tacatcttct tcctcttcta gcctttcagt gctgccttca tctctttcag 600
 tttttcaaaa tcccacagat gtgtcacgga gcaaccccaa gtcaccacaa aaacctatcg 660
 ttagagtctt cctgcccatt aaacagagga cagtgggtacc tgcacggtgt ggagtcacag 720
 tccgggacag cctgaagaag gcactgatga tgagaggtct aatcccagag tgctgtgctg 780
 ttacagaat tcaggatggg gagaagaaac caattggctg ggacactgat atttcctggc 840
 ttactggaga ggagttgcat gtagaagtgt tggagaatgt tccacttaca acacacaact 900
 ttgtacggaa aacttttttc accttagcat tttgtgactt ctgtagaaag ctgcttttcc 960
 agggattccg ctgtcaaaca tgtgggtata aatttcacca gcgttgtagt acagaggttc 1020
 cactgatgtg tgtaattat gaccaactag atttgctgtt tgtctccaag ttctttgaac 1080
 accaccaat accacaggag gaggcctcct tagcagagac tacccttcca tgtggctcat 1140
 ccccttctgc acccccctcc gattctattg ggcccccaat tctcaccagt ccatctcctt 1200
 caaaatccat tccaattcca cagcctttcc gaccagcaga tgaagatcat cgaaatcagt 1260
 ttggacaacg agaccggtcc tcacagctc caaatgtgca tataaacaca atagaaccgc 1320
 tcaatattga tgacttgatt agagaccaag ggtttcgtag tgatggagga tcaaccacag 1380

0398850pct.txt

gtttatccgc	cacaccccct	gcctcattac	ctggctcact	ctctaattgtg	aaagcattgc	1440
agaaatctcc	aggacctcag	cgagaaagaa	agtcctcttc	atcctcagaa	gacaggaatc	1500
gaatgaaaac	gcttggtaga	cgggattcaa	gtgacgattg	ggagattcct	gatggacaga	1560
tcacagtggg	acaagaatt	ggatcaggg	catttgggac	agtctacaag	ggaaagtggc	1620
atggtgatgt	ggcagtgaaa	atgttgaatg	tgacagcacc	cacacctcag	cagttacagg	1680
ccttcaaaaa	tgaagtagga	gtactcagga	aaacgcgaca	tgtgaatatc	ctcctcttca	1740
tgggttattc	aacaaagcca	caactggcta	ttgttacc	gtggtgtgag	ggctccagtt	1800
tatatcatca	tctccacatc	attgagacca	aattcgagat	gatcaaactt	atagatat	1860
cacggcagac	tgacagggc	atggattact	tacacgcaa	gtcaatcatc	cacagagacc	1920
tcaagagtaa	taatattttt	cttcatgaag	acctcacagt	aaaaataggt	gattttggtc	1980
tagccacagt	gaaatctcga	tggagtgggt	cccatcagtt	tgaacagttg	tctggatcca	2040
ttttgtggat	ggcaccagaa	gtaatcagaa	tgcaagataa	aaacccatat	agctttcagt	2100
cagatgtata	tgcatTTggg	attgttctgt	atgaattgat	gaccggacag	ttaccttatt	2160
caaatatcaa	caacagggac	cagataat	ttatgggtggg	acgaggatat	ctgtctccag	2220
atctcagtaa	ggtacggagt	aactgtccaa	aagccatgaa	gagattaatg	gcagagtgcc	2280
taaaaaagaa	aagagatgaa	agaccactct	ttccccaaat	tctcgctctt	attgagctgc	2340
tggcccgc	attgccaaaa	attcaccgca	gtgcatcaga	accctccttg	aatcgggctg	2400
gcttccaaac	agaggatttt	agtctatatg	cttgtgcttc	tccaaaaaca	cccattcagg	2460
cagggggata	tggtacgttt	cctgttcact	gaaacaaacc	gagtgagtga	cagcatgtag	2520
gagggtaggg	acaaaagaaa	gtgaacaaat	gtttgcttat	atatttgTTa	aattgaatag	2580
gattttcttt	ttctttaaag	gtgaacaaga	gaacatgtgt	gtttttaaaag	tttgatata	2640
gttttcttcc	cagtctaaaa	cccatagtta	gcattacatt	ttcaacatcg	aatttttttt	2700
taattcatag	acattgctga	aaatttataa	taccttttcc	agaggcttta	cttcccatc	2760
caagtttg	ttgtttactt	ggtagtcta	atcattaaac	tttaaacttt	ccccacctac	2820
cttttgctgt	tagctatccc	gcatccatta	ggggctccaa	gaacagcact	gtctgcgtgt	2880
gtgtgtggc	aggtgggaag	ctgatggtaa	gttaggctgt	gttagtgaag	gtaaactgac	2940
caggtcta	taggagtcac	tagaattgaa	taagcttatt	tttattaata	ttttttctta	3000
taactatttc	tttttgta	aatttagaaa	atataattgt	tctttattcc	cttacagcag	3060
tataaattat	tggtgcaggt	aaccaaagat	attactgagg	agtggcatgt	ttgacatgag	3120
tgacatggtt	taactttgga	tttttagtta	atatttcttt	atatattaag	gatgtcttac	3180
acattataga	agtcaaattt	actgacaaa	gtattgcctc	ctcttcctcc	ccaaaaacac	3240
agcaaaattc	tctgggaact	cgtagcattg	ttggttttct	tttggaatgac	tatggttgcc	3300
aaacaaccaa	gtaattgatt	ttttttaaat	tattattgct	ttagattata	ctcacctctc	3360
atgatgcctg	ttagcaatca	cctttatcca	tgtgtcttgt	aaaatatctt	tcctccttat	3420

0398850pct.txt

attctttgcc caacaagagt ctacttgtaa tgaatgagta ctattttctt tttttgattc 3480
cccagtataa ttagtatgtt tagtgctttc taggacttcc actttcttat gttaaaaaaa 3540
aaaacaaact aatgtggcag tcagtatatt cttactgtga atcagagtct ttactgggaa 3600
tcaaagtga agaagcagct gttctgactt cagagtcagc ctagggacca aaaccagcct 3660
cttaaataca ccttcattta ttcagtttgg atttgtgatg attttcatta tagctgacag 3720
ttcaaggtaa ttcagtggca cacagatagc atctgcataa atgcctttct tcttgaaaat 3780
aaaggagaaa attgggaaga ctttacacca atagtttagt ctttaagtac cacagataac 3840
acacaccata aat 3853

<210> 18
<211> 764
<212> PRT
<213> Bos taurus

<400> 18

Ala Ala Leu Ser Gly Gly Gly Gly Gly Gly Gly Gly Ala Glu Gln
1 5 10 15

Gly Gln Ala Leu Phe Asn Gly Asp Met Glu Pro Glu Ala Gly Ala Ala
20 25 30

Ala Ser Ser Ala Ala Asp Pro Ala Ile Pro Glu Glu Val Trp Asn Ile
35 40 45

Lys Gln Met Ile Lys Leu Thr Gln Glu His Ile Glu Ala Leu Leu Asp
50 55 60

Lys Phe Gly Gly Glu His Asn Pro Pro Ser Ile Tyr Leu Glu Ala Tyr
65 70 75 80

Glu Glu Tyr Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg Glu Gln Gln
85 90 95

Leu Leu Glu Ser Leu Gly Asn Gly Thr Asp Phe Ser Val Ser Ser Ser
100 105 110

Ala Ser Thr Asp Thr Val Thr Ser Ser Ser Ser Ser Ser Leu Ser Val
115 120 125

Leu Pro Ser Ser Leu Ser Val Phe Gln Asn Pro Thr Asp Val Ser Arg
130 135 140

Ser Asn Pro Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe Leu Pro
145 150 155 160

Asn Lys Gln Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr Val Arg
165 170 175

Asp Ser Leu Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro Glu Cys
 180 185 190
 Cys Ala Val Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile Gly Trp
 195 200 205
 Asp Thr Asp Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val Glu Val
 210 215 220
 Leu Glu Asn Val Pro Leu Thr Thr His Asn Phe Val Arg Lys Thr Phe
 225 230 235 240
 Phe Thr Leu Ala Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe Gln Gly
 245 250 255
 Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Gln Arg Cys Ser Thr
 260 265 270
 Glu Val Pro Leu Met Cys Val Asn Tyr Asp Gln Leu Asp Leu Leu Phe
 275 280 285
 Val Ser Lys Phe Phe Glu His His Pro Ile Pro Gln Glu Glu Ala Ser
 290 295 300
 Leu Ala Glu Thr Thr Leu Pro Cys Gly Ser Ser Pro Ser Ala Pro Pro
 305 310 315 320
 Ser Asp Ser Ile Gly Pro Pro Ile Leu Thr Ser Pro Ser Pro Ser Lys
 325 330 335
 Ser Ile Pro Ile Pro Gln Pro Phe Arg Pro Ala Asp Glu Asp His Arg
 340 345 350
 Asn Gln Phe Gly Gln Arg Asp Arg Ser Ser Ser Ala Pro Asn Val His
 355 360 365
 Ile Asn Thr Ile Glu Pro Val Asn Ile Asp Asp Leu Ile Arg Asp Gln
 370 375 380
 Gly Phe Arg Ser Asp Gly Gly Ser Thr Thr Gly Leu Ser Ala Thr Pro
 385 390 395 400
 Pro Ala Ser Leu Pro Gly Ser Leu Ser Asn Val Lys Ala Leu Gln Lys
 405 410 415
 Ser Pro Gly Pro Gln Arg Glu Arg Lys Ser Ser Ser Ser Ser Glu Asp
 420 425 430
 Arg Asn Arg Met Lys Thr Leu Gly Arg Arg Asp Ser Ser Asp Asp Trp
 435 440 445

Glu Ile Pro Asp Gly Gln Ile Thr Val Gly Gln Arg Ile Gly Ser Gly
 450 455 460
 Ser Phe Gly Thr Val Tyr Lys Gly Lys Trp His Gly Asp Val Ala Val
 465 470 475 480
 Lys Met Leu Asn Val Thr Ala Pro Thr Pro Gln Gln Leu Gln Ala Phe
 485 490 495
 Lys Asn Glu Val Gly Val Leu Arg Lys Thr Arg His Val Asn Ile Leu
 500 505 510
 Leu Phe Met Gly Tyr Ser Thr Lys Pro Gln Leu Ala Ile Val Thr Gln
 515 520 525
 Trp Cys Glu Gly Ser Ser Leu Tyr His His Leu His Ile Ile Glu Thr
 530 535 540
 Lys Phe Glu Met Ile Lys Leu Ile Asp Ile Ala Arg Gln Thr Ala Gln
 545 550 555 560
 Gly Met Asp Tyr Leu His Ala Lys Ser Ile Ile His Arg Asp Leu Lys
 565 570 575
 Ser Asn Asn Ile Phe Leu His Glu Asp Leu Thr Val Lys Ile Gly Asp
 580 585 590
 Phe Gly Leu Ala Thr Val Lys Ser Arg Trp Ser Gly Ser His Gln Phe
 595 600 605
 Glu Gln Leu Ser Gly Ser Ile Leu Trp Met Ala Pro Glu Val Ile Arg
 610 615 620
 Met Gln Asp Lys Asn Pro Tyr Ser Phe Gln Ser Asp Val Tyr Ala Phe
 625 630 635 640
 Gly Ile Val Leu Tyr Glu Leu Met Thr Gly Gln Leu Pro Tyr Ser Asn
 645 650 655
 Ile Asn Asn Arg Asp Gln Ile Ile Phe Met Val Gly Arg Gly Tyr Leu
 660 665 670
 Ser Pro Asp Leu Ser Lys Val Arg Ser Asn Cys Pro Lys Ala Met Lys
 675 680 685
 Arg Leu Met Ala Glu Cys Leu Lys Lys Lys Arg Asp Glu Arg Pro Leu
 690 695 700
 Phe Pro Gln Ile Leu Ala Ser Ile Glu Leu Leu Ala Arg Ser Leu Pro
 705 710 715 720

Lys Ile His Arg Ser Ala Ser Glu Pro Ser Leu Asn Arg Ala Gly Phe
 725 730 735

Gln Thr Glu Asp Phe Ser Leu Tyr Ala Cys Ala Ser Pro Lys Thr Pro
 740 745 750

Ile Gln Ala Gly Gly Tyr Gly Thr Phe Pro Val His
 755 760

<210> 19
 <211> 4936
 <212> DNA
 <213> Bos taurus

<400> 19
 ctcagctgcg ccgggtctca caagacggtt cccgaggtgg cccaggcgcc gtcccaccgc 60
 cgacgccgcc cgggccgccc gggccgtccc tccccgtgc ccccgctcct ccgcctccgc 120
 ctccccccgc ctcagcctc ccttccccct ccccgcccag cagcggtcgc tcggggcccg 180
 ctctcggtta taagatggcg gcgctgagtg gcggcggcgg cggcggcgcc ggtggcgcg 240
 agcagggcca ggctctgttc aacggggaca tggagcccga ggccggcgcc gcggcctctt 300
 cggctgcgga ccccgccatt cccgaggagg tgtggaatat caaacaatg attaatgtga 360
 cacaggagca tatagaggcc ctattggaca aatttggtgg ggagcataat ccaccatcaa 420
 tatacttggg ggcctatgaa gaatacacca gcaagctaga tgccctccaa caaagagaac 480
 aacagttatt ggaatccctg gggaatggaa ctgatttttc tgtttctagc tctgcatcaa 540
 cggacaccgt tacatcttct tcctcttcta gcctttcagt gctgccttca tctctttcag 600
 tttttcaaaa tcccacagat gtgtcacgga gcaaccccaa gtcaccacaa aaacctatcg 660
 ttagagtctt cctgccaat aaacagagga cagtgggtacc tgcacggtgt ggagtcacag 720
 tccgggacag cctgaagaag gcaactgatga tgagaggtct aatcccagag tgctgtgctg 780
 ttacagaat tcaggatggg gagaagaaac caattggctg ggacactgat atttcctggc 840
 ttactggaga ggagttgcat gtagaagtgt tggagaatgt tccacttaca acacacaact 900
 ttgtacggaa aacttttttc accttagcat tttgtgactt ctgtagaaag ctgcttttcc 960
 agggattccg ctgtcaaaca tgttggtata aatttcacca gcgttgtagt acagaggttc 1020
 cactgatgtg tgttaattat gaccaactag atttgctgtt tgtctccaag ttctttgaac 1080
 accaccaat accacaggag gaggcctcct tagcagagac tacccttcca tgtggctcat 1140
 ccccttctgc acccccctcc gattctattg ggcccccaat tctcaccagt ccctctcctt 1200
 caaatccat tccaattcca cagcctttcc gaccagcaga tgaagatcat cgaaatcagt 1260
 ttggacaacg agaccggtcc tcatcagctc caaatgtgca tataaacaca atagaaccgc 1320
 tcaatattga tgacttgatt agagaccaag ggtttcgtag tgatggagga tcaaccacag 1380
 gtttatccgc cacacccct gcctcattac ctggctcact ctctaattgt aaagcattgc 1440
 agaaatctcc aggacctcag cgagaaagaa agtcctcttc atcctcagaa gacaggaatc 1500

0398850pct.txt

gaatgaaaac	gcttggtaga	cgggattcaa	gtgacgattg	ggagattcct	gatggacaga	1560
tcacagtggg	acaaagaatt	ggatcagggg	catttgggac	agtctacaag	ggaaagtggc	1620
atggtgatgt	ggcagtgaag	atgttgaatg	tgacagcacc	cacacctcag	cagttacagg	1680
ccttcaaaaa	tgaagtagga	gtactcagga	aaacgcgaca	tgtgaatatc	ctcctcttca	1740
tgggttattc	aacaaagcca	caactggcta	ttgttaccca	gtggtgtgag	ggctccagtt	1800
tatatcatca	tctccacatc	attgagacca	aattcgagat	gatcaaactt	atagatatgt	1860
cacggcagac	tgcacagggc	atggattact	tacacgccaa	gtcaatcatc	cacagagacc	1920
tcaagagtaa	taatattttt	cttcatgaag	acctcacagt	aaaaataggt	gatttttggtc	1980
tagccacagt	gaaatctcga	tggagtgggt	cccatcagtt	tgaacagttg	tctggatcca	2040
ttttgtggat	ggcaccagaa	gtaatcagaa	tgcaagataa	aaaccctat	agctttcagt	2100
cagatgtata	tgcatttggg	attgttctgt	atgaattgat	gaccggacag	ttaccttatt	2160
caaatatcaa	caacagggac	cagataat	ttatggtggg	acgaggatat	ctgtctccag	2220
atctcagtaa	ggtacggagt	aactgtccaa	aagccatgaa	gagattaatg	gcagagtgcc	2280
taaaaaagaa	aagagatgaa	agaccactct	ttccccaagt	aggaaagact	ctcctaagca	2340
agagacaaaa	ttcagaagtt	atcagggaaa	aagataagca	gattctcgcc	tctattgagc	2400
tgctggcccg	ctcattgcc	aaaattcacc	gcagtgcac	agaaccctcc	ttgaatcggg	2460
ctggcctcca	aacagaggat	tttagtctat	atgcttgtgc	ttctccaaaa	acacccttc	2520
aggcaggggg	atatgaagca	gatttggtc	ttacatcaaa	taaaaataga	gtagaagttg	2580
ggatttagag	atttcctgac	atgcaagaag	gaataagcaa	gaaaaaaagg	tttgttttcc	2640
ccaaatcata	tctattgtct	tttacttcta	ttttttctta	aattttttgt	gatttcagag	2700
acatgtagag	ttttattgat	acctaaacta	tgagttcttt	tttttttttt	tttttcatta	2760
ttttgatttt	tttggccaag	aggcatatgg	gatcttagct	tgagaaagca	acaattttct	2820
tgatgtcatt	ttgggtgagg	gcacatattg	ctgtgaacag	tgtggtgata	gccaccaggg	2880
accaaactca	caccgcgtgc	attgaaaggt	gaagtcttaa	acactggacc	agcagagaaa	2940
ttcctactct	atgagttctt	tttgtcatcc	cctccccgca	ccctccaccc	ccaacctaaa	3000
gtctgatgat	gaaatcaaca	actattccat	tagaagcagt	agattctggt	agcatgatct	3060
ttagtttggt	agtaagattt	tgtgctttgt	ggggttgtgt	cgttttaagg	ctaataattta	3120
agtttgtaa	atagaatgct	gttcagattg	taaaaatgag	taataaacat	ctgaagtttt	3180
ttttaagtta	tttttaacat	ggtatataca	gttgagctta	gagtttatca	ttttctgata	3240
ttctcttact	tagtagatga	attctagcca	ttttttataa	agatttctgt	taagcaaatac	3300
ctgttttcac	atgggcttcc	tttaagggat	tttagattct	gctggatatg	gtgactgctc	3360
ataagactgt	tgaaaattac	ttttaagatg	tattagaata	cttctgaaaa	aaaatagcaa	3420
ccttaaaacc	ataagcaaaa	gtagtaaggg	tgtttataca	tttctagagt	ccctgttttag	3480
gtaatagcct	cctatgattg	tactttaaat	gttttgctct	ccaaggtttt	agtaacttgg	3540

0398850pct.txt

```

cttttttct aatcagtgcc aaactcccc agttttttta actttaata tgaggtaata 3600
aatcttttac ccttccttga tcttttgact tataatacct tggtcagttg tttcttaaaa 3660
ggaatcctta aatggaaaga gacaatatca ctgtctgcag ttctgattag tagttttatt 3720
cagaatggaa aaacagatta ttcatttttg aaaattgttc aggggtatgt tcattgttag 3780
gaccttggac tttggagtca gtgcctagct atgcattcca ggtctgccat tttctggctg 3840
tgaaattttg gacaagttac ttaaccactt taaacccag ctttaagaag taaattaacc 3900
ccagtaaatt aagaagtaat agcagccact tcgtagagtt gttatgaggc tcagatgcag 3960
tgcaaagtgt tataaagtat tcagggagtc acctggtata ctataataga cactagaata 4020
gttgccaata ttatcagcat acaatctgag gattctgtca gccaatcatt agcaatctgt 4080
tgtttgttgg gacatgccag tgttctccag ttgaaatcag tagcaatcta aaaatggata 4140
gattattcct catttaaata gtgtgttcat ataagtgatt gcttggatcc ttatcagaag 4200
ttgctgttac tgaaaaatga taaggctgac taaattgtga tagttgtcag ttactaacca 4260
actcccagaa atgaataaga ggaacctatc tctagttcct agtagaaggt atggacaaaa 4320
tagtaggtga aaaataatgt cttgaacccc caaattaagt aagctttaaa gagtacaata 4380
cctcaaaggg tctttgcggt ttaaaatttg tatgctgaga atgatgttca ttgacatgtg 4440
cctatatgta attttttgat agtttaaaag gtgaaatgaa ctacagatgg gagaggctctg 4500
aattttcttg ccttcagtca aatgtgtaat gtggacatat tatttgacct gtgaatttta 4560
tcttttaaaa aagattaatt cctgcttctt ccttcctaag agttgcatta taataatgaa 4620
aatgagttga taatttgggg ggaaagtatt ctacaaatca accttattat tttaccattg 4680
gtttctgaga aattttgttc atttgaaccg tttatagctt gattagaatc atagcatgta 4740
aaacccaact gagggattat ctgcagactt aatgtagtat tatgtaagtt gtcttctttc 4800
atttcgacct tttttgcttt tgttggtgct agatctgtag tatgtagcta gtcacctttc 4860
agcgaggttt cagcgaggct tttctgtgtc tctaggttat ttgagataac ttttttaaaa 4920
ttagctcttg tcctcc 4936

```

<210> 20
 <211> 797
 <212> PRT
 <213> Bos taurus

<400> 20

Met Ala Ala Leu Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ala Glu
 1 5 10 15

Gln Gly Gln Ala Leu Phe Asn Gly Asp Met Glu Pro Glu Ala Gly Ala
 20 25 30

Ala Ala Ser Ser Ala Ala Asp Pro Ala Ile Pro Glu Glu Val Trp Asn
 35 40 45

Ile Lys Gln Met Ile Lys Leu Thr Gln Glu His Ile Glu Ala Leu Leu
 50 55 60
 Asp Lys Phe Gly Gly Glu His Asn Pro Pro Ser Ile Tyr Leu Glu Ala
 65 70 75 80
 Tyr Glu Glu Tyr Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg Glu Gln
 85 90 95
 Gln Leu Leu Glu Ser Leu Gly Asn Gly Thr Asp Phe Ser Val Ser Ser
 100 105 110
 Ser Ala Ser Thr Asp Thr Val Thr Ser Ser Ser Ser Ser Ser Leu Ser
 115 120 125
 Val Leu Pro Ser Ser Leu Ser Val Phe Gln Asn Pro Thr Asp Val Ser
 130 135 140
 Arg Ser Asn Pro Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe Leu
 145 150 155 160
 Pro Asn Lys Gln Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr Val
 165 170 175
 Arg Asp Ser Leu Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro Glu
 180 185 190
 Cys Cys Ala Val Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile Gly
 195 200 205
 Trp Asp Thr Asp Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val Glu
 210 215 220
 Val Leu Glu Asn Val Pro Leu Thr Thr His Asn Phe Val Arg Lys Thr
 225 230 235 240
 Phe Phe Thr Leu Ala Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe Gln
 245 250 255
 Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Gln Arg Cys Ser
 260 265 270
 Thr Glu Val Pro Leu Met Cys Val Asn Tyr Asp Gln Leu Asp Leu Leu
 275 280 285
 Phe Val Ser Lys Phe Phe Glu His His Pro Ile Pro Gln Glu Glu Ala
 290 295 300
 Ser Leu Ala Glu Thr Thr Leu Pro Cys Gly Ser Ser Pro Ser Ala Pro
 305 310 315 320

Pro Ser Asp Ser Ile Gly Pro Pro Ile Leu Thr Ser Pro Ser Pro Ser
 325 330 335
 Lys Ser Ile Pro Ile Pro Gln Pro Phe Arg Pro Ala Asp Glu Asp His
 340 345 350
 Arg Asn Gln Phe Gly Gln Arg Asp Arg Ser Ser Ser Ala Pro Asn Val
 355 360 365
 His Ile Asn Thr Ile Glu Pro Val Asn Ile Asp Asp Leu Ile Arg Asp
 370 375 380
 Gln Gly Phe Arg Ser Asp Gly Gly Ser Thr Thr Gly Leu Ser Ala Thr
 385 390 395
 Pro Pro Ala Ser Leu Pro Gly Ser Leu Ser Asn Val Lys Ala Leu Gln
 405 410 415
 Lys Ser Pro Gly Pro Gln Arg Glu Arg Lys Ser Ser Ser Ser Ser Glu
 420 425 430
 Asp Arg Asn Arg Met Lys Thr Leu Gly Arg Arg Asp Ser Ser Asp Asp
 435 440 445
 Trp Glu Ile Pro Asp Gly Gln Ile Thr Val Gly Gln Arg Ile Gly Ser
 450 455 460
 Gly Ser Phe Gly Thr Val Tyr Lys Gly Lys Trp His Gly Asp Val Ala
 465 470 475 480
 Val Lys Met Leu Asn Val Thr Ala Pro Thr Pro Gln Gln Leu Gln Ala
 485 490 495
 Phe Lys Asn Glu Val Gly Val Leu Arg Lys Thr Arg His Val Asn Ile
 500 505 510
 Leu Leu Phe Met Gly Tyr Ser Thr Lys Pro Gln Leu Ala Ile Val Thr
 515 520 525
 Gln Trp Cys Glu Gly Ser Ser Leu Tyr His His Leu His Ile Ile Glu
 530 535 540
 Thr Lys Phe Glu Met Ile Lys Leu Ile Asp Ile Ala Arg Gln Thr Ala
 545 550 555 560
 Gln Gly Met Asp Tyr Leu His Ala Lys Ser Ile Ile His Arg Asp Leu
 565 570 575
 Lys Ser Asn Asn Ile Phe Leu His Glu Asp Leu Thr Val Lys Ile Gly
 580 585 590

Asp Phe Gly Leu Ala Thr Val Lys Ser Arg Trp Ser Gly Ser His Gln
 595 600 605

Phe Glu Gln Leu Ser Gly Ser Ile Leu Trp Met Ala Pro Glu Val Ile
 610 615 620

Arg Met Gln Asp Lys Asn Pro Tyr Ser Phe Gln Ser Asp Val Tyr Ala
 625 630 635 640

Phe Gly Ile Val Leu Tyr Glu Leu Met Thr Gly Gln Leu Pro Tyr Ser
 645 650 655

Asn Ile Asn Asn Arg Asp Gln Ile Ile Phe Met Val Gly Arg Gly Tyr
 660 665 670

Leu Ser Pro Asp Leu Ser Lys Val Arg Ser Asn Cys Pro Lys Ala Met
 675 680 685

Lys Arg Leu Met Ala Glu Cys Leu Lys Lys Lys Arg Asp Glu Arg Pro
 690 695 700

Leu Phe Pro Gln Val Gly Lys Thr Leu Leu Ser Lys Arg Gln Asn Ser
 705 710 715 720

Glu Val Ile Arg Glu Lys Asp Lys Gln Ile Leu Ala Ser Ile Glu Leu
 725 730 735

Leu Ala Arg Ser Leu Pro Lys Ile His Arg Ser Ala Ser Glu Pro Ser
 740 745 750

Leu Asn Arg Ala Gly Phe Gln Thr Glu Asp Phe Ser Leu Tyr Ala Cys
 755 760 765

Ala Ser Pro Lys Thr Pro Ile Gln Ala Gly Gly Tyr Glu Ala Asp Leu
 770 775 780

Ala Leu Thr Ser Asn Lys Asn Arg Val Glu Val Gly Ile
 785 790 795

<210> 21
 <211> 4154
 <212> DNA
 <213> Bos taurus

<400> 21
 ctcagctgcg ccgggtctca caagacggtt cccgaggtgg cccaggcgcc gtcccaccgc 60
 cgacgccgcc cgggccgcc gggccgtccc tccccgtgc cccccgtcct ccgcctccgc 120
 ctccccccgc cctcagcctc ccttccccct cccgcccag cagcggtcgc tcgggcccgg 180
 ctctcggtta taagatggcg gcgctgagtg gcggcggcgg cggcggcggc ggtggcgcg 240
 agcagggcca ggctctgttc aacggggaca tggagcccga ggccggcgcc gcggcctctt 300

0398850pct.txt

cggctgcgga	ccccgccatt	cccgaggagg	tgtggaatat	caaacaaatg	attaagttga	360
cacaggagca	tatagaggcc	ctattggaca	aatttggtgg	ggagcataat	ccaccatcaa	420
tatatctgga	ggcctatgaa	gaatacacca	gcaagctaga	tgccctccaa	caaagagaac	480
aacagttatt	ggaatccctg	gggaatggaa	ctgatttttc	tgtttctagc	tctgcatcaa	540
cggacaccgt	tacatcttct	tcctcttcta	gcctttcagt	gctgccttca	tctctttcag	600
tttttcaaaa	tcccacagat	gtgtcacgga	gcaaccccaa	gtcaccacaa	aaacctatcg	660
ttagagtctt	cctgcccatt	aaacagagga	cagtgggtacc	tgcacggtgt	ggagtcacag	720
tccgggacag	cctgaagaag	gcactgatga	tgagaggtct	aatcccagag	tgctgtgctg	780
tttacagaat	tcaggatggg	gagaagaaac	caattggctg	ggacactgat	atttcctggc	840
ttactggaga	ggagttgcat	gtagaagtgt	tggagaatgt	tccacttaca	acacacaact	900
ttgtacggaa	aacttttttc	accttagcat	tttgtgactt	ctgtagaaag	ctgcttttcc	960
agggattccg	ctgtcaaaca	tgtggttata	aatttcacca	gcgttgtagt	acagagggttc	1020
cactgatgtg	tgtaattat	gaccaactag	atttgctgtt	tgtctccaag	ttctttgaac	1080
accacccaat	accacaggag	gaggcctcct	tagcagagac	tacccttcca	tgtggctcat	1140
ccccttctgc	acccccctcc	gattctattg	ggcccccaat	tctcaccagt	ccatctcctt	1200
caaaatccat	tccaattcca	cagcctttcc	gaccagcaga	tgaagatcat	cgaaatcagt	1260
ttggacaacg	agaccggtcc	tcatcagctc	caaattgtga	tataaacaca	atagaacccg	1320
tcaatattga	tgacttgatt	agagaccaag	ggtttcgtag	tgatggagga	tcaaccacag	1380
gtttatccgc	cacaccccct	gcctcattac	ctggctcact	ctctaattgt	aaagcattgc	1440
agaaatctcc	aggacctcag	cgagaaagaa	agtcctcttc	atcctcagaa	gacaggaatc	1500
gaatgaaaac	gcttggtaga	cgggattcaa	gtgacgattg	ggagattcct	gatggacaga	1560
tcacagtggg	aaaagaatt	ggatcagggt	catttgggac	agtctacaag	ggaaagtggc	1620
atggtgatgt	ggcagtgaat	atgttgaaat	tgacagcacc	cacacctcag	cagttacagg	1680
ccttcaaaaa	tgaagtagga	gtactcagga	aaacgcgaca	tgtgaatatc	ctcctcttca	1740
tgggttattc	aacaaagcca	caactggcta	ttgttaccca	gtgggtgtgag	ggctccagtt	1800
tatatcatca	tctccacatc	attgagacca	aattcgagat	gatcaaactt	atagatattg	1860
cacggcagac	tgcacagggc	atggattact	tacacgcca	gtcaatcatc	cacagagacc	1920
tcaagagtaa	taatattttt	cttcatgaag	acctcacagt	aaaaataggt	gattttggtc	1980
tagccacagt	gaaatctcga	tggagtgggt	cccatcagtt	tgaacagttg	tctggatcca	2040
ttttgtggat	ggcaccagaa	gtaatcagaa	tgcaagataa	aaaccatat	agctttcagt	2100
cagatgtata	tgcatttggg	attgttctgt	atgaattgat	gaccggacag	ttaccttatt	2160
caaatatcaa	caacagggac	cagataattt	ttatgggtggg	acgaggatat	ctgtctccag	2220
atctcagtaa	ggtacggagt	aactgtccaa	aagccatgaa	gagattaatg	gcagagtgcc	2280
taaaaaagaa	aagagatgaa	agaccactct	ttccccaagt	aggaaagact	ctcctaagca	2340

0398850pct.txt

agagacaaaa	ttcagaagtt	atcagggaaa	aagataagca	gattctcgcc	tctattgagc	2400
tgctggcccc	ctcattgcc	aaaattcacc	gcagtgcac	agaaccctcc	ttgaatcggg	2460
ctgggttcca	aacagaggat	tttagtctat	atgcttgtgc	ttctccaaaa	acacccattc	2520
aggcaggggg	atatggctga	gcacattgtc	catcacccac	aagtggctgg	ttctcatcgc	2580
agaatctacg	tagggaatcg	ggcgtgaaat	tcacttaaga	gatagagcag	aggaagtgtt	2640
ctgttttacg	gaatggagat	gagagttatg	agtaagttgc	ttagtcagtt	ggctttgttt	2700
tgaaaattat	tgtgttatat	ttgtgttaac	ctacttgtgt	tttgacagta	tatgtcacat	2760
aggaagaaac	ctcagactag	cataataaca	aagctcagac	taggcacaga	tgtacacaga	2820
atggacaaa	atgggatggg	ggaaggtatg	ggaataagtc	taggggtagg	gaaaaattga	2880
tgtgaggggtg	ggaaataaac	tgttaattacc	tgaaataaaa	tgtaagagtg	caataagtgt	2940
gctttttatt	ctaagctgtg	aatgggtttt	ttaaaaaaag	cattccttcc	caatgcattt	3000
gcctatgttc	catagctgat	taaaaccagc	tatataaaca	tatgcctttt	tattcatgtt	3060
aattaccaat	ataaatggct	aacctttacg	tcttatttat	cttcatgtta	tgttagttta	3120
catacagggga	tgtgtgtgtg	tgtgtatgct	ataaattttc	cctccttcgt	ttaaaaacgc	3180
gtttgttgga	tcctctctgt	ttccttaggc	catgccacag	ctcatagtct	cagcttggcc	3240
ttcctgtcac	ctgatctgaa	ggactatcac	agtgacgtag	ctcgttcatt	ggttgtacac	3300
actctaacc	ttttccttgc	tcagcaatta	ctgtgtcttc	taaaacagga	gtgtacaacc	3360
atgagattgc	aattaattgt	ttgacatatg	tccctttgaa	ttctatttat	tagttatgat	3420
tgattgtctt	ttggtttgga	ccaagaaaaa	cgaaatccca	cctccccacc	ttttcactta	3480
tttcttactt	tgaggacaat	tctgtaagag	agaggaaagg	gaactccttc	atgttttaac	3540
tgcagcaagt	taatggccct	ggtttacacc	aaacattatg	gtgattcaca	ttcacattcc	3600
tctcctctct	tgctgccaga	ggtttggtt	ttgttcagtt	ctgctcaagc	actgaaaaag	3660
ttttcatgga	gtctggagag	tgcccagtga	aaagatgggt	tttaattgtc	cacagacctt	3720
tctgttcctg	ctttgcaaaa	attacaaagg	agtaactatt	tttaaagctt	atttttcaat	3780
tcataaaaaa	gacatttatt	ttcagtcaga	tgatgtctcc	ttgtccctta	atcctcaatg	3840
tttgcttgaa	tctttttttt	ttttctgatt	ttctcccatc	cccacttctt	gataacttctt	3900
gagttctctt	tcctgctcag	gtcctttcat	ttgtactttg	gagttttttc	tcatgtaaat	3960
ttgtacaatg	gaaaatattg	ttcagtttgg	atagaacgca	tggaagaatta	aataaaaaag	4020
atagctgaaa	ttcagattga	aatttatattg	tgtaaagtta	tttaaaaact	ctgtactata	4080
taaaaggcaa	aaaaagttct	atgtacttga	tgtgaatatg	cgaatactgc	tataataaag	4140
attgactgca	tgga					4154

<210> 22
 <211> 781
 <212> PRT
 <213> Bos taurus

<400> 22

Met Ala Ala Leu Ser Gly Gly Gly Gly Gly Gly Gly Gly Ala Glu
 1 5 10 15
 Gln Gly Gln Ala Leu Phe Asn Gly Asp Met Glu Pro Glu Ala Gly Ala
 20 25 30
 Ala Ala Ser Ser Ala Ala Asp Pro Ala Ile Pro Glu Glu Val Trp Asn
 35 40 45
 Ile Lys Gln Met Ile Lys Leu Thr Gln Glu His Ile Glu Ala Leu Leu
 50 55 60
 Asp Lys Phe Gly Gly Glu His Asn Pro Pro Ser Ile Tyr Leu Glu Ala
 65 70 75 80
 Tyr Glu Glu Tyr Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg Glu Gln
 85 90 95
 Gln Leu Leu Glu Ser Leu Gly Asn Gly Thr Asp Phe Ser Val Ser Ser
 100 105 110
 Ser Ala Ser Thr Asp Thr Val Thr Ser Ser Ser Ser Ser Ser Leu Ser
 115 120 125
 Val Leu Pro Ser Ser Leu Ser Val Phe Gln Asn Pro Thr Asp Val Ser
 130 135 140
 Arg Ser Asn Pro Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe Leu
 145 150 155 160
 Pro Asn Lys Gln Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr Val
 165 170 175
 Arg Asp Ser Leu Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro Glu
 180 185 190
 Cys Cys Ala Val Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile Gly
 195 200 205
 Trp Asp Thr Asp Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val Glu
 210 215 220
 Val Leu Glu Asn Val Pro Leu Thr Thr His Asn Phe Val Arg Lys Thr
 225 230 235 240
 Phe Phe Thr Leu Ala Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe Gln
 245 250 255
 Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Gln Arg Cys Ser
 260 265 270

Thr Glu Val Pro Leu Met Cys Val Asn Tyr Asp Gln Leu Asp Leu Leu
 275 280 285
 Phe Val Ser Lys Phe Phe Glu His His Pro Ile Pro Gln Glu Glu Ala
 290 295 300
 Ser Leu Ala Glu Thr Thr Leu Pro Cys Gly Ser Ser Pro Ser Ala Pro
 305 310 315 320
 Pro Ser Asp Ser Ile Gly Pro Pro Ile Leu Thr Ser Pro Ser Pro Ser
 325 330 335
 Lys Ser Ile Pro Ile Pro Gln Pro Phe Arg Pro Ala Asp Glu Asp His
 340 345 350
 Arg Asn Gln Phe Gly Gln Arg Asp Arg Ser Ser Ser Ala Pro Asn Val
 355 360 365
 His Ile Asn Thr Ile Glu Pro Val Asn Ile Asp Asp Leu Ile Arg Asp
 370 375 380
 Gln Gly Phe Arg Ser Asp Gly Gly Ser Thr Thr Gly Leu Ser Ala Thr
 385 390 395 400
 Pro Pro Ala Ser Leu Pro Gly Ser Leu Ser Asn Val Lys Ala Leu Gln
 405 410 415
 Lys Ser Pro Gly Pro Gln Arg Glu Arg Lys Ser Ser Ser Ser Ser Glu
 420 425 430
 Asp Arg Asn Arg Met Lys Thr Leu Gly Arg Arg Asp Ser Ser Asp Asp
 435 440 445
 Trp Glu Ile Pro Asp Gly Gln Ile Thr Val Gly Gln Arg Ile Gly Ser
 450 455 460
 Gly Ser Phe Gly Thr Val Tyr Lys Gly Lys Trp His Gly Asp Val Ala
 465 470 475 480
 Val Lys Met Leu Asn Val Thr Ala Pro Thr Pro Gln Gln Leu Gln Ala
 485 490 495
 Phe Lys Asn Glu Val Gly Val Leu Arg Lys Thr Arg His Val Asn Ile
 500 505 510
 Leu Leu Phe Met Gly Tyr Ser Thr Lys Pro Gln Leu Ala Ile Val Thr
 515 520 525
 Gln Trp Cys Glu Gly Ser Ser Leu Tyr His His Leu His Ile Ile Glu
 530 535 540

0398850pct.txt

Thr Lys Phe Glu Met Ile Lys Leu Ile Asp Ile Ala Arg Gln Thr Ala
545 550 555 560

Gln Gly Met Asp Tyr Leu His Ala Lys Ser Ile Ile His Arg Asp Leu
565 570 575

Lys Ser Asn Asn Ile Phe Leu His Glu Asp Leu Thr Val Lys Ile Gly
580 585 590

Asp Phe Gly Leu Ala Thr Val Lys Ser Arg Trp Ser Gly Ser His Gln
595 600 605

Phe Glu Gln Leu Ser Gly Ser Ile Leu Trp Met Ala Pro Glu Val Ile
610 615 620

Arg Met Gln Asp Lys Asn Pro Tyr Ser Phe Gln Ser Asp Val Tyr Ala
625 630 635 640

Phe Gly Ile Val Leu Tyr Glu Leu Met Thr Gly Gln Leu Pro Tyr Ser
645 650 655

Asn Ile Asn Asn Arg Asp Gln Ile Ile Phe Met Val Gly Arg Gly Tyr
660 665 670

Leu Ser Pro Asp Leu Ser Lys Val Arg Ser Asn Cys Pro Lys Ala Met
675 680 685

Lys Arg Leu Met Ala Glu Cys Leu Lys Lys Lys Arg Asp Glu Arg Pro
690 695 700

Leu Phe Pro Gln Val Gly Lys Thr Leu Leu Ser Lys Arg Gln Asn Ser
705 710 715 720

Glu Val Ile Arg Glu Lys Asp Lys Gln Ile Leu Ala Ser Ile Glu Leu
725 730 735

Leu Ala Arg Ser Leu Pro Lys Ile His Arg Ser Ala Ser Glu Pro Ser
740 745 750

Leu Asn Arg Ala Gly Phe Gln Thr Glu Asp Phe Ser Leu Tyr Ala Cys
755 760 765

Ala Ser Pro Lys Thr Pro Ile Gln Ala Gly Gly Tyr Gly
770 775 780

<210> 23
<211> 7914
<212> DNA
<213> Bos taurus

<400> 23

ctcagctgcg	ccgggtctca	caagacggtt	cccaggtgg	cccaggcgcc	gtcccaccgc	60
cgacgccgcc	cgggccgcc	gggccgtccc	tccccgctgc	cccccgctct	ccgcctccgc	120
ctccccccgc	cctcagcctc	ccttccccct	ccccgccag	cagcggtcgc	tcggggcccg	180
ctctcggtta	taagatggcg	gcgctgagtg	gcggcgccgg	cggcgccggc	ggtggcgccg	240
agcagggcca	ggctctgttc	aacggggaca	tggagcccg	ggccggcgcc	gcggcctctt	300
cggctgcgga	ccccgccatt	cccaggagg	tgtggaatat	caaacaaatg	attaagttga	360
cacaggagca	tatagaggcc	ctattggaca	aatttggtgg	ggagcataat	ccaccatcaa	420
tatatctgga	ggcctatgaa	gaatacacca	gcaagctaga	tgccctccaa	caaagagaac	480
aacagttatt	ggaatccctg	gggaatggaa	ctgatttttc	tgtttctagc	tctgcatcaa	540
cggacaccgt	tacatcttct	tcctcttcta	gcctttcagt	gctgccttca	tctctttcag	600
tttttcaaaa	tcccacagat	gtgtcacgga	gcaaccccaa	gtcaccacaa	aaacctatcg	660
ttagagtctt	cctgcccatt	aaacagagga	cagtgggtacc	tgcacggtgt	ggagtcacag	720
tccgggacag	cctgaagaag	gcactgatga	tgagaggtct	aatcccagag	tgctgtgctg	780
tttacagaat	tcaggatggg	gagaagaaac	caattggctg	ggacactgat	atttcctggc	840
ttactggaga	ggagttgcat	gtagaagtgt	tggagaatgt	tccacttaca	acacacaact	900
ttgtacggaa	aacttttttc	accttagcat	tttgtgactt	ctgtagaaag	ctgcttttcc	960
agggattccg	ctgtcaaaca	tgtggttata	aatttcacca	gcgttgtagt	acagaggttc	1020
actgatgtg	tgtaattat	gaccaactag	atttgctgtt	tgtctccaag	ttctttgaac	1080
accaccaat	accacaggag	gaggcctcct	tagcagagac	tacccttcca	tgtggctcat	1140
ccccttctgc	acccccctcc	gattctattg	ggcccccaat	tctcaccagt	ccatctcctt	1200
caaaatccat	tccaattcca	cagcctttcc	gaccagcaga	tgaagatcat	cgaaatcagt	1260
ttggacaacg	agaccggtcc	tcatacagctc	caaattgtgca	tataaacaca	atagaacccg	1320
tcaatattga	tgacttgatt	agagaccaag	ggtttcgtag	tgatggagga	tcaaccacag	1380
gtttatccgc	cacacccctt	gcctcattac	ctggctcact	ctctaattgt	aaagcattgc	1440
agaaatctcc	aggacctcag	cgagaaagaa	agtcctcttc	atcctcagaa	gacaggaatc	1500
gaatgaaaac	gcttggtaga	cgggattcaa	gtgacgattg	ggagattcct	gatggacaga	1560
tcacagtggg	acaaagaatt	ggatcagggt	catttgggac	agtctacaag	ggaaagtggc	1620
atggtgatgt	ggcagtgaat	atgttgaaat	tgacagcacc	cacacctcag	cagttacagg	1680
ccttcaaaaa	tgaagtagga	gtactcagga	aaacgcgaca	tgtgaatatc	ctcctcttca	1740
tgggttattc	aacaaagcca	caactggcta	ttgttaccca	gtgggtgtgag	ggctccagtt	1800
tatatcatca	tctccacatc	attgagacca	aattcgagat	gatcaaactt	atagatatgt	1860
cacggcagac	tgacagggc	atggattact	tacacgcaa	gtcaatcatc	cacagagacc	1920
tcaagagtaa	taatattttt	cttcatgaag	acctcacagt	aaaaataggt	gattttggtc	1980
tagccacagt	gaaatctcga	tggagtgggt	cccatcagtt	tgaacagttg	tctggatcca	2040

0398850pct.txt

ttttgtggat	ggcaccagaa	gtaatcagaa	tgcaagataa	aaacccatat	agctttcagt	2100
cagatgtata	tgcatittggg	attgtttctgt	atgaattgat	gaccggacag	ttaccttatt	2160
caaatatcaa	caacaggggac	cagataat	ttatgggtggg	acgaggatat	ctgtctccag	2220
atctcagtaa	ggtacggagt	aactgtccaa	aagccatgaa	gagattaatg	gcagagtgcc	2280
taaaaaagaa	aagagatgaa	agaccactct	ttccccaat	tctcgcctct	attgagctgc	2340
tggtccgctc	attgccaaaa	attcaccgca	gtgcatcaga	accctccttg	aatcgggctg	2400
gcttccaaac	agaggatttt	agtctatatg	cttgtgtctc	tccaaaaaca	cccattcagg	2460
caggggggata	tgagagaattt	gcagccttca	agtagccaca	ccatcatgac	agcatctact	2520
cttattttctt	aagtcttgtg	ttcgtacaat	ttgttaacat	caaaacacag	ttctgttctt	2580
caactctttt	taaagttaaa	atttttcagt	gcataagctg	gtgtggaaca	gaaggaaatt	2640
tcccatccaa	caaaagaggg	aagaatgttt	taggaaccag	aattctctgc	tgccagtgtt	2700
tcttcttcaa	cacaaatc	acaagtctgc	ccactcccag	gaagaaagag	gagagaccct	2760
gagttctgac	cttttgatgg	tcaggcatga	tggaagaaa	ctgctgctac	agcttgggag	2820
atttgctctg	ggaagtctgc	cagtcaactt	tgcccttcta	accaccagat	caatatgtgg	2880
ctgatcatct	gatggggcag	ttgcaatcac	caagccttgt	tctctttcct	gttctgggat	2940
tgtgttggg	aacccttttc	cctagccacc	accagttcat	ttctgaggga	tggaacaaaa	3000
atgcagcatg	cccttctctg	gtgggtgcatg	ttcagtcctt	gacaaat	tacaaaaatg	3060
aagctacttt	atttaaaagg	aggggtgagag	gtgaggaggt	cactttgggt	gtggcggaaa	3120
gggaatgctg	catctttttc	ctgggctgct	ggggctctgg	ccttggcttg	ccagccggaa	3180
gcgctggcac	gcatcgcctt	cttttcccat	tggtgtccagc	aatgaagacg	agtgtttggg	3240
gttttttttt	tctccaccat	gtagcaagtt	ctcaggaaaa	tacaattgat	atcttctctc	3300
taagctcttc	caatcagtca	ccaagtactt	atgtggttac	tttgtccagg	gcacaaaatg	3360
cctgtatcta	attaaaagcc	tacaaaactg	cttgataaca	gttttgaaatg	tgagacattt	3420
atgtaattta	aatgtaaggt	acaagtttta	atctctgagt	ttcttctatt	atatttttat	3480
taaaaaaaga	aaataatttt	cagattgaat	tgagagtaaaa	taatattact	tcccactaga	3540
attatatatc	ctggaaaatt	gtatttttgt	tacataagca	gcttttaaaag	aaagatcatt	3600
acccttttct	ctacataaat	atatggggag	tcttagccta	atgacaaata	tttataattt	3660
ttaaattaat	ggtacttgct	ggatccatac	taacatcttt	actaatacct	cattgtttct	3720
tccaacttac	tcctacacta	catcctacat	cttcttccta	gtcttttatc	tagaatatgc	3780
aacctcaa	aaaaatgggtg	gtgtcctcat	tcattctcct	ccttcctttt	ttcccaagcc	3840
tgatcttcaa	aagggttggtt	aatttggcag	ctgagttcct	cccaggcag	agaatagacc	3900
aatttttaggt	gtattgggac	tgaggaggga	tgtgtaaaga	ttaacatcag	taaagaaccg	3960
ctgtggagta	attaagaact	ttgttcttta	taactggaga	atataacct	accctaacat	4020
ccctcagcct	ttactaaagt	gtggcgtaaa	tcacagtagt	agcaaagaaa	gtgactctgg	4080

0398850pct.txt

atgtgttcct	ggccagtacc	tcccttatca	tgaatgtaga	ctctctcatc	aagatttagg	4140
aatataaatc	aaatcaaag	tgcccagcca	agctatgtag	taagggactt	gaacaatatt	4200
aggcagaacc	tataaaataa	atcaggggaat	tagaaattat	ttaaagtttt	caaattgtaa	4260
attgccccgg	tgtctttcag	cctactgcca	ttatTTTTgc	tacaatacct	acatttcaga	4320
ggagggccta	ctgaaaattc	catgcaagt	gaaaataatc	ctcaagttat	taatgagttt	4380
gaaaagcaat	gagttcttaa	gtctttgtga	gtagagcaag	atcctacaaa	attcagaaat	4440
agtaaaaatg	gattcatgct	gatttgaaga	gcattctgtg	gcataatata	atgctgcac	4500
tcttttaaaa	gcagtctatt	tttcttttta	aatttgtccc	catagatgct	tttgaacatg	4560
aacatgctta	tgttaccttt	tccgaggttg	ggaagagcca	ggagctctca	ggcagggccc	4620
cctccctcag	ctgggcagga	gctgctcagg	aggagctagt	tatagaggaa	gcttagcggt	4680
ggcattttca	aaattcaagg	tgataacgct	ttcttcttcc	tttctgtttt	agaatagatt	4740
gctgtctgat	ttgaaaaagg	gaaatagatt	tgatctcaaa	tgaatctgtg	cccagaagcc	4800
aggctcaggg	tattcagaga	tttgtatagt	gccctcaaaa	aataacaaaa	ttttagcttt	4860
ccttttttct	tcttttctcc	atcaaattct	tttttctcta	gtttacaaat	gacatggaaa	4920
aggaatttcc	cctgagtttt	gtatgccttt	ttttttttgg	cttagactat	agataggcgt	4980
gttgagctcc	taagaaaata	caaggaggaa	ctctttgttg	tgagagcac	tttatgagta	5040
gtttgtgtgg	ataatatgtg	actgcttccc	tgacgagctt	gtgaggctgt	acttatgtct	5100
ttcctgtaag	gcagcttcag	tgcccttctgt	agtgtatata	aggaaagatt	acgccttctg	5160
aaaaatctca	gagcaacat	aagattattt	taaaatatgt	agtatgactg	atggactttt	5220
tcatcattaa	attagtctag	catctaaact	tttaccactg	aaataatatt	gacaaaaaag	5280
caatttataa	aaggatattg	tgaatagaaa	atacaatgtg	atcatttgta	cttatgtgca	5340
ccttaaaaga	ggaattctgt	ctagctgtca	aattctgggt	ccttaacatc	cagtccttga	5400
ttgtgattga	gatctggtag	gacgtgctgg	ggcacgctag	cagataaaat	cccgtatact	5460
ttaggataga	tgttacattt	atgtcagtg	tggcaaagag	cattgtgtag	taataaagaa	5520
ttcaagactt	cagcaatgtc	aacctgaaac	tttgtaaata	tttcctagat	tgttatttga	5580
tgagtcaca	gctctttatc	acacaatgtt	gtctttccct	catcaggcaa	ttttagaact	5640
gctgcacacc	cctcctcaga	tctcacctgc	ccctcctgta	cattcacctc	tccagccttg	5700
tgcacacctc	atttagcttt	agtttgaaac	acattgcagg	gttcagggtga	cctcttcaaa	5760
aactacctcc	tcagaatgag	gtaatgaata	gttatTTtatt	ttaaataatg	aaaagtcagg	5820
agctctagaa	tatgaagatg	atctaagatt	ttaactttta	tgtatacttg	ttgagcactc	5880
tccttttgtc	ctaaagggca	ttatacattt	aagcagtaat	actgaaaaat	gtagctcaga	5940
gtaactgaat	gttggtgaaa	gtggtgccag	aatctgtttt	aggggtacgt	atcagaatct	6000
taatcttaaa	tcggttacat	gaaattaaat	agttaatgg	aacacttgac	taacagatat	6060
aattttaatt	ttcggtaggc	ttttagcaag	acagtaagta	catcttcata	atgagtttagc	6120

0398850pct.txt

cacagcttca	tcacatgcac	agatttttcct	gttgagagac	tgcccagtta	agagggtaga	6180
atgatgaacc	atttttcagg	attctcttct	ttgtccaaac	tggcattgtg	agtgctagaa	6240
tatcagcact	ttcaaactag	tgattccaac	tattaggcta	ttaaaaagca	aaacaaacca	6300
aacaaaccat	agccagacat	gggaagttta	ctatgagtat	aaacagcaaa	tagcttacag	6360
gtcatacatt	gaaatgggtg	aggtaaggcg	ttagaaaaat	accttgacaa	tttgccaaat	6420
gatcttactg	tgccttcatg	atgcaataaa	aaaaaaaaaa	athtagcata	aatcagtgat	6480
ttgtgaagag	agcagccacc	ctgggtctaac	tcagctgtgt	taatatTTTT	tagcgtgcaa	6540
tttagactgc	aaagataaat	gcactaaaga	gtttatagcc	aaaatcacat	ttaaaaaatg	6600
agagaaaaca	caggtaaatt	ttcagtgaaac	aaaattatTT	ttttaaaagta	cataatccct	6660
agtatagtca	gatataTTTt	tcacatagag	caaataggTT	gaaatcacaa	ttcagtgaca	6720
tttctagaga	aactTTTTtct	actcccatag	gttcttcaaa	gcatggaact	tttatataac	6780
agaaatgtgt	gacgggtcatt	ttaaattgct	gtagtttggg	gctgaagtac	tgtgtgctgg	6840
gcagcaatca	catgtattaa	ctagtgagaa	aggagaaatt	aagatatagg	acagaatttg	6900
atTTtcttgt	tcccagatta	ctgctgccaa	cctagacact	gagtttccag	aggctgaaac	6960
gtaaacttgc	agctcagcaa	ctgttttgca	aagttagtgg	gactgtcctg	cttatgctgt	7020
tcaaaaatgc	tctgagggcc	aggtggggcc	tccaggggct	cctctctgag	gggacatcag	7080
actagctaac	gacctggcgg	gcggatgtga	accggacaca	ctccatgggtg	tgcttcttgt	7140
atcggtcctc	cgccaccctc	aagaaaggct	tcagcggggt	ctctagacgt	ctccactaag	7200
gtgtgttact	aacagccatg	ggttgttgag	cacccgagga	gtgcaatagc	atctctgcat	7260
gattgtatat	tggcccgaag	agaatgaagt	ggccagtgtg	ctcatgttcc	atgttgctag	7320
ctctggtaaa	ctgaaaatac	tggttaagatt	tttgTTTTat	cagtacacta	gagagtaagc	7380
tttgTTTTgt	tgTTTTtaga	taatgttttc	acttccattt	ggaaagacat	ttaaattgag	7440
tttcagtcct	aaattttgcc	agtcatggta	attagcagtt	tctatcaggt	atTTTTaagg	7500
tagaagagga	tagaaacata	agttctaaaa	gcttaaggta	accgtggttt	atTTTTaaat	7560
gtttaggggt	ggttagtctc	tacctcaaaa	aaagtgagtg	aatctTTTTat	ttcagcattc	7620
acaagttcgg	ctgttgTTTT	tgtaatacat	TTTTTTTTta	accttttgac	ccccctttac	7680
ctaagtgtca	atgtagTTTT	attaattact	aagtcagttt	cattaaaatg	tttatttagc	7740
agTTTTgact	aattgcaatg	attaatatag	ccagttgtgc	atgaggacac	agccagtgag	7800
tatatctggg	TTTTTTTTgt	gatgctTTTT	ttcttaagac	ttctgtagat	ttatgaagta	7860
ctcattgaaa	acaactaaaa	tacgtttatt	cgtgttaata	tggaaaaaaa	aaaa	7914

<210> 24
 <211> 766
 <212> PRT
 <213> Bos taurus
 <400> 24

Met Ala Ala Leu Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ala Glu
 1 5 10 15
 Gln Gly Gln Ala Leu Phe Asn Gly Asp Met Glu Pro Glu Ala Gly Ala
 20 25 30
 Ala Ala Ser Ser Ala Ala Asp Pro Ala Ile Pro Glu Glu Val Trp Asn
 35 40 45
 Ile Lys Gln Met Ile Lys Leu Thr Gln Glu His Ile Glu Ala Leu Leu
 50 55 60
 Asp Lys Phe Gly Gly Glu His Asn Pro Pro Ser Ile Tyr Leu Glu Ala
 65 70 75 80
 Tyr Glu Glu Tyr Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg Glu Gln
 85 90 95
 Gln Leu Leu Glu Ser Leu Gly Asn Gly Thr Asp Phe Ser Val Ser Ser
 100 105 110
 Ser Ala Ser Thr Asp Thr Val Thr Ser Ser Ser Ser Ser Ser Leu Ser
 115 120 125
 Val Leu Pro Ser Ser Leu Ser Val Phe Gln Asn Pro Thr Asp Val Ser
 130 135 140
 Arg Ser Asn Pro Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe Leu
 145 150 155 160
 Pro Asn Lys Gln Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr Val
 165 170 175
 Arg Asp Ser Leu Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro Glu
 180 185 190
 Cys Cys Ala Val Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile Gly
 195 200 205
 Trp Asp Thr Asp Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val Glu
 210 215 220
 Val Leu Glu Asn Val Pro Leu Thr Thr His Asn Phe Val Arg Lys Thr
 225 230 235 240
 Phe Phe Thr Leu Ala Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe Gln
 245 250 255
 Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Gln Arg Cys Ser
 260 265 270

Thr Glu Val Pro Leu Met Cys Val Asn Tyr Asp Gln Leu Asp Leu Leu
 275 280 285

Phe Val Ser Lys Phe Phe Glu His His Pro Ile Pro Gln Glu Glu Ala
 290 295 300

Ser Leu Ala Glu Thr Thr Leu Pro Cys Gly Ser Ser Pro Ser Ala Pro
 305 310 315 320

Pro Ser Asp Ser Ile Gly Pro Pro Ile Leu Thr Ser Pro Ser Pro Ser
 325 330 335

Lys Ser Ile Pro Ile Pro Gln Pro Phe Arg Pro Ala Asp Glu Asp His
 340 345 350

Arg Asn Gln Phe Gly Gln Arg Asp Arg Ser Ser Ser Ala Pro Asn Val
 355 360 365

His Ile Asn Thr Ile Glu Pro Val Asn Ile Asp Asp Leu Ile Arg Asp
 370 375 380

Gln Gly Phe Arg Ser Asp Gly Gly Ser Thr Thr Gly Leu Ser Ala Thr
 385 390 395 400

Pro Pro Ala Ser Leu Pro Gly Ser Leu Ser Asn Val Lys Ala Leu Gln
 405 410 415

Lys Ser Pro Gly Pro Gln Arg Glu Arg Lys Ser Ser Ser Ser Ser Glu
 420 425 430

Asp Arg Asn Arg Met Lys Thr Leu Gly Arg Arg Asp Ser Ser Asp Asp
 435 440 445

Trp Glu Ile Pro Asp Gly Gln Ile Thr Val Gly Gln Arg Ile Gly Ser
 450 455 460

Gly Ser Phe Gly Thr Val Tyr Lys Gly Lys Trp His Gly Asp Val Ala
 465 470 475 480

Val Lys Met Leu Asn Val Thr Ala Pro Thr Pro Gln Gln Leu Gln Ala
 485 490 495

Phe Lys Asn Glu Val Gly Val Leu Arg Lys Thr Arg His Val Asn Ile
 500 505 510

Leu Leu Phe Met Gly Tyr Ser Thr Lys Pro Gln Leu Ala Ile Val Thr
 515 520 525

Gln Trp Cys Glu Gly Ser Ser Leu Tyr His His Leu His Ile Ile Glu
 530 535 540

0398850pct.txt

Thr Lys Phe Glu Met Ile Lys Leu Ile Asp Ile Ala Arg Gln Thr Ala
545 550 555 560

Gln Gly Met Asp Tyr Leu His Ala Lys Ser Ile Ile His Arg Asp Leu
565 570 575

Lys Ser Asn Asn Ile Phe Leu His Glu Asp Leu Thr Val Lys Ile Gly
580 585 590

Asp Phe Gly Leu Ala Thr Val Lys Ser Arg Trp Ser Gly Ser His Gln
595 600 605

Phe Glu Gln Leu Ser Gly Ser Ile Leu Trp Met Ala Pro Glu Val Ile
610 615 620

Arg Met Gln Asp Lys Asn Pro Tyr Ser Phe Gln Ser Asp Val Tyr Ala
625 630 635 640

Phe Gly Ile Val Leu Tyr Glu Leu Met Thr Gly Gln Leu Pro Tyr Ser
645 650 655

Asn Ile Asn Asn Arg Asp Gln Ile Ile Phe Met Val Gly Arg Gly Tyr
660 665 670

Leu Ser Pro Asp Leu Ser Lys Val Arg Ser Asn Cys Pro Lys Ala Met
675 680 685

Lys Arg Leu Met Ala Glu Cys Leu Lys Lys Lys Arg Asp Glu Arg Pro
690 695 700

Leu Phe Pro Gln Ile Leu Ala Ser Ile Glu Leu Leu Ala Arg Ser Leu
705 710 715 720

Pro Lys Ile His Arg Ser Ala Ser Glu Pro Ser Leu Asn Arg Ala Gly
725 730 735

Phe Gln Thr Glu Asp Phe Ser Leu Tyr Ala Cys Ala Ser Pro Lys Thr
740 745 750

Pro Ile Gln Ala Gly Gly Tyr Gly Glu Phe Ala Ala Phe Lys
755 760 765

<210> 25
<211> 4670
<212> DNA
<213> Bos taurus

<400> 25
gggtgtgcat agtgcagcag attgaatgca gaagatatga aaattcagat gtcttctgtt 60
aaggtgtgga atatcaaaca aatgattaag ttgacacagg agcatataga ggcctattg 120
gacaaatttg gtggggagca taatccacca tcaatatatc tggaggccta tgaagaatac 180

0398850pct.txt

accagcaagc	tagatgccct	ccaacaaaga	gaacaacagt	tattggaatc	cctggggaat	240
ggaactgatt	tttctgtttc	tagctctgca	tcaacggaca	ccgttacatc	ttcttcctct	300
tctagccttt	cagtgtctgc	ttcatctctt	tcagtttttc	aaaatcccac	agatgtgtca	360
cggagcaacc	ccaagtcacc	acaaaaacct	atcgtttagag	tcttcctgcc	caataaacag	420
aggacagtgg	tacctgcacg	gtgtggagtc	acagtccggg	acagcctgaa	gaaggcactg	480
atgatgagag	gtctaattcc	agagtgtctgt	gctgtttaca	gaattcagga	tggggagaag	540
aaaccaattg	gctgggacac	tgatattttc	tggcttactg	gagaggagtt	gcatgtagaa	600
gtgttgagga	atgttccact	tacaacacac	aactttgtac	ggaaaacttt	tttcacctta	660
gcattttgtg	acttctgtag	aaagctgctt	ttccagggat	tccgctgtca	aacatgtggt	720
tataaatttc	accagcgttg	tagtacagag	gttccactga	tgtgtgttaa	ttatgaccaa	780
ctagatttgc	tgtttgtctc	caagttcttt	gaacaccacc	caataccaca	ggaggaggcc	840
tccttagcag	agactaccct	tccatgtggc	tcatcccctt	ctgcaccccc	ctccgattct	900
attgggcccc	caattctcac	cagtccatct	ccttcaaaat	ccattccaat	tccacagcct	960
ttccgaccag	cagatgaaga	tcatcgaaat	cagtttggac	aacgagaccg	gtcctcatca	1020
gctccaaatg	tgcatataaa	cacaatagaa	cccgtcaata	ttgatgactt	gattagagac	1080
caagggtttc	gtagtgatgg	aggatcaacc	acaggtttat	ccgccacacc	ccctgcctca	1140
ttacctggct	cactctctaa	tgtgaaagca	ttgcagaaat	ctccaggacc	tcagcgagaa	1200
agaaagtcct	cttcatcctc	agaagacagg	aatcgaatga	aaacgcttgg	tagacgggat	1260
tcaagtgcg	attgggagat	tcctgatgga	cagatcacag	tgggacaaaag	aattggatca	1320
gggtcatttg	ggacagtcta	caagggaaag	tggcatggtg	atgtggcagt	gaaaatgttg	1380
aatgtgacag	caccacacac	tcagcagtta	caggccttca	aaaatgaagt	aggagtactc	1440
aggaaaacgc	gacatgtgaa	tatcctcctc	ttcatgggtt	attcaacaaa	gccacaactg	1500
gctattgtta	cccagtgggtg	tgagggctcc	agtttatatc	atcatctcca	catcattgag	1560
accaaattcg	agatgatcaa	acttatagat	attgcacggc	agactgcaca	gggcatggat	1620
tacttacacg	ccaagtcaat	catccacaga	gacctcaaga	gtaataatat	ttttcttcat	1680
gaagacctca	cagtaaaaaat	aggtgatttt	ggtctagcca	cagtgaaatc	tcgatggagt	1740
gggtcccatc	agtttgaaca	gttgtctgga	tccattttgt	ggatggcacc	agaagtaatc	1800
agaatgcaag	ataaaaaccc	atatagcttt	cagtcagatg	tatatgcatt	tgggattggt	1860
ctgtatgaat	tgatgaccgg	acagttacct	tattcaaata	tcaacaacag	ggaccagata	1920
atttttatgg	tgggacgagg	atatctgtct	ccagatctca	gtaaggtagc	gagtaactgt	1980
ccaaaagcca	tgaagagatt	aatggcagag	tgcttaaaaa	agaaaagaga	tgaaagacca	2040
ctctttcccc	aagtaggaaa	gactctccta	agcaagagac	aaaattcaga	agttatcagg	2100
gaaaaagata	agcagattct	cgcctctatt	gagctgctgg	cccgtctatt	gccaaaaatt	2160
caccgcagtg	catcagaacc	ctccttgaat	cgggctggct	tccaaacaga	ggattttagt	2220

0398850pct.txt

ctatatgctt	gtgcttctcc	aaaaacaccc	attcaggcag	ggggatatga	agcagatttg	2280
gctcttacat	caaataaaaa	tagagtagaa	gttgggattt	agagatttcc	tgacatgcaa	2340
gaaggaataa	gcaagaaaaa	aaggtttggt	ttccccaat	catatctatt	gtcttttact	2400
tctatTTTTT	cttaaatttt	ttgtgatttc	agagacatgt	agagttttat	tgatacctaa	2460
actatgagtt	cttttttttt	tttttttttc	attatTTTga	tttttttggc	caagaggcat	2520
atgggatctt	agcttgagaa	agcaacaatt	ttcttgatgt	cattttgggt	gagggcacat	2580
attgctgtga	acagtgtggg	gatagccacc	agggaccaa	ctcacaccg	ctgcattgaa	2640
aggtgaagtc	ttaaactactg	gaccagcaga	gaaattccta	ctctatgagt	tctttttgtc	2700
atccccctcc	cgcaccctcc	accccccaacc	taaagtctga	tgatgaaatc	aacaactatt	2760
ccattagaag	cagtagattc	tggtagcatg	atcttttagtt	tgttagtaag	attttgtgct	2820
ttgtgggggt	gtgtcgTTTT	aaggctaata	tttaagtttg	tcaaatagaa	tgctgttcag	2880
attgtaaaaa	tgagtaataa	acatctgaag	ttttttttaa	gttattttta	acatggtata	2940
tacagttgag	cttagagttt	atcattttct	gatatttctt	tacttagtag	atgaattcta	3000
gccatttttt	ataaagattt	ctgttaagca	aatcctgttt	tcacatgggc	ttcctttaag	3060
ggattttaga	ttctgctgga	tatgggtgact	gctcataaga	ctgttgaaaa	ttacttttaa	3120
gatgtattag	aatacttctg	aaaaaaaaata	gcaaccttaa	aaccataagc	aaaagtagta	3180
aggggtgttta	tacatttcta	gagtcctgt	ttaggtaata	gcctcctatg	attgtacttt	3240
aaatgTTTTg	ctctccaagg	ttttagtaac	ttggctTTTT	ttctaatacag	tgccaaactc	3300
ccccagtttt	tttaacttta	aatatgaggt	aataaatctt	ttacccttcc	ttgatctttt	3360
gacttataat	accttgggtca	gttgtttctt	aaaaggaatc	cttaaatgga	aagagacaat	3420
atcactgtct	gcagttctga	ttagtagttt	tattcagaat	ggaaaaacag	attattcatt	3480
tttgaaaatt	gttcaggggt	atgttcattg	ttaggacctt	ggactttgga	gtcagtgcc	3540
agctatgcat	tccaggtctg	ccattttctg	gctgtgaaat	tttggaacaag	ttacttaacc	3600
actttaaacc	ccagctttaa	gaagtaaatt	aacccagta	aattaagaag	taatagcagc	3660
cacttcgtag	agttgttatg	aggctcagat	gcagtgcaaa	tgtgtataaa	gtattcaggg	3720
agtcacctgg	tatactataa	tagacactag	aatagttgcc	aatattatca	gcatacaatc	3780
tgaggattct	gtcagccaat	cattagcaat	ctgttgTTTT	ttgggacatg	ccagtgttct	3840
ccagttgaaa	tcagtagcaa	tctaaaaatg	gatagattat	tcctcattta	aatagtgtgt	3900
tcatataagt	gattgcttgg	atccttatca	gaagttgctg	ttactgaaaa	atgataaggc	3960
tgactaaatt	gtgatagtgt	tcagttacta	accaactccc	agaaatgaat	aagaggaacc	4020
tatctctagt	tcctagtaga	aggtatggac	aaaatagtag	gtgaaaaata	atgtcttgaa	4080
cccccaaatt	aagtaagctt	taaagagtac	aatacctcaa	agggcttttg	cggtttaaaa	4140
tttgtatgct	gagaatgatg	ttcattgaca	tgtgcctata	tgtaattttt	tgatagttta	4200
aaaggtgaaa	tgaactacag	atgggagagg	tctgaatttt	cttgccctca	gtcaaagtgt	4260

0398850pct.txt

taatgtggac atattatttg acctgtgaat tttatctttt aaaaaagatt aattcctgct 4320
 tcttccttcc taatagttgc attataataa tgaaaatgag ttgataattt ggggggaaag 4380
 tattctacaa atcaacctta ttattttacc attggtttct gagaaatttt gttcatttga 4440
 accgtttata gcttgattag aatcatagca tgtaaaaccc aactgaggga ttatctgcag 4500
 acttaatgta gtattatgta agttgtcttc tttcatttcg accttttttg cttttgttgt 4560
 tgctagatct gtagtatgta gctagtcacc tttcagcgag gtttcagcga ggcttttctg 4620
 tgtctctagg ttatttgaga taactttttt aaaattagct cttgtcctcc 4670

<210> 26
 <211> 761
 <212> PRT
 <213> Bos taurus

<400> 26

Met Lys Ile Gln Met Ser Ser Val Lys Val Trp Asn Ile Lys Gln Met
1 5 10 15

Ile Lys Leu Thr Gln Glu His Ile Glu Ala Leu Leu Asp Lys Phe Gly
20 25 30

Gly Glu His Asn Pro Pro Ser Ile Tyr Leu Glu Ala Tyr Glu Glu Tyr
35 40 45

Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg Glu Gln Gln Leu Leu Glu
50 55 60

Ser Leu Gly Asn Gly Thr Asp Phe Ser Val Ser Ser Ser Ala Ser Thr
65 70 75 80

Asp Thr Val Thr Ser Ser Ser Ser Ser Ser Leu Ser Val Leu Pro Ser
85 90 95

Ser Leu Ser Val Phe Gln Asn Pro Thr Asp Val Ser Arg Ser Asn Pro
100 105 110

Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe Leu Pro Asn Lys Gln
115 120 125

Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr Val Arg Asp Ser Leu
130 135 140

Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro Glu Cys Cys Ala Val
145 150 155 160

Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile Gly Trp Asp Thr Asp
165 170 175

Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val Glu Val Leu Glu Asn
180 185 190

Val Pro Leu Thr Thr His Asn Phe Val Arg Lys Thr Phe Phe Thr Leu
 195 200 205
 Ala Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe Gln Gly Phe Arg Cys
 210 215 220
 Gln Thr Cys Gly Tyr Lys Phe His Gln Arg Cys Ser Thr Glu Val Pro
 225 230 235 240
 Leu Met Cys Val Asn Tyr Asp Gln Leu Asp Leu Leu Phe Val Ser Lys
 245 250 255
 Phe Phe Glu His His Pro Ile Pro Gln Glu Glu Ala Ser Leu Ala Glu
 260 265 270
 Thr Thr Leu Pro Cys Gly Ser Ser Pro Ser Ala Pro Pro Ser Asp Ser
 275 280 285
 Ile Gly Pro Pro Ile Leu Thr Ser Pro Ser Pro Ser Lys Ser Ile Pro
 290 295 300
 Ile Pro Gln Pro Phe Arg Pro Ala Asp Glu Asp His Arg Asn Gln Phe
 305 310 315 320
 Gly Gln Arg Asp Arg Ser Ser Ser Ala Pro Asn Val His Ile Asn Thr
 325 330 335
 Ile Glu Pro Val Asn Ile Asp Asp Leu Ile Arg Asp Gln Gly Phe Arg
 340 345 350
 Ser Asp Gly Gly Ser Thr Thr Gly Leu Ser Ala Thr Pro Pro Ala Ser
 355 360 365
 Leu Pro Gly Ser Leu Ser Asn Val Lys Ala Leu Gln Lys Ser Pro Gly
 370 375 380
 Pro Gln Arg Glu Arg Lys Ser Ser Ser Ser Ser Glu Asp Arg Asn Arg
 385 390 395 400
 Met Lys Thr Leu Gly Arg Arg Asp Ser Ser Asp Asp Trp Glu Ile Pro
 405 410 415
 Asp Gly Gln Ile Thr Val Gly Gln Arg Ile Gly Ser Gly Ser Phe Gly
 420 425 430
 Thr Val Tyr Lys Gly Lys Trp His Gly Asp Val Ala Val Lys Met Leu
 435 440 445
 Asn Val Thr Ala Pro Thr Pro Gln Gln Leu Gln Ala Phe Lys Asn Glu
 450 455 460

Val Gly Val Leu Arg Lys Thr Arg His Val Asn Ile Leu Leu Phe Met
 465 470 475 480
 Gly Tyr Ser Thr Lys Pro Gln Leu Ala Ile Val Thr Gln Trp Cys Glu
 485 490 495
 Gly Ser Ser Leu Tyr His His Leu His Ile Ile Glu Thr Lys Phe Glu
 500 505 510
 Met Ile Lys Leu Ile Asp Ile Ala Arg Gln Thr Ala Gln Gly Met Asp
 515 520 525
 Tyr Leu His Ala Lys Ser Ile Ile His Arg Asp Leu Lys Ser Asn Asn
 530 535 540
 Ile Phe Leu His Glu Asp Leu Thr Val Lys Ile Gly Asp Phe Gly Leu
 545 550 555 560
 Ala Thr Val Lys Ser Arg Trp Ser Gly Ser His Gln Phe Glu Gln Leu
 565 570 575
 Ser Gly Ser Ile Leu Trp Met Ala Pro Glu Val Ile Arg Met Gln Asp
 580 585 590
 Lys Asn Pro Tyr Ser Phe Gln Ser Asp Val Tyr Ala Phe Gly Ile Val
 595 600 605
 Leu Tyr Glu Leu Met Thr Gly Gln Leu Pro Tyr Ser Asn Ile Asn Asn
 610 615 620
 Arg Asp Gln Ile Ile Phe Met Val Gly Arg Gly Tyr Leu Ser Pro Asp
 625 630 635 640
 Leu Ser Lys Val Arg Ser Asn Cys Pro Lys Ala Met Lys Arg Leu Met
 645 650 655
 Ala Glu Cys Leu Lys Lys Lys Arg Asp Glu Arg Pro Leu Phe Pro Gln
 660 665 670
 Val Gly Lys Thr Leu Leu Ser Lys Arg Gln Asn Ser Glu Val Ile Arg
 675 680 685
 Glu Lys Asp Lys Gln Ile Leu Ala Ser Ile Glu Leu Leu Ala Arg Ser
 690 695 700
 Leu Pro Lys Ile His Arg Ser Ala Ser Glu Pro Ser Leu Asn Arg Ala
 705 710 715 720
 Gly Phe Gln Thr Glu Asp Phe Ser Leu Tyr Ala Cys Ala Ser Pro Lys
 725 730 735

Thr Pro Ile Gln Ala Gly Gly Tyr Glu Ala Asp Leu Ala Leu Thr Ser
 740 745 750

Asn Lys Asn Arg Val Glu Val Gly Ile
 755 760

<210> 27
 <211> 4816
 <212> DNA
 <213> Bos taurus

<400> 27
 ctcagctgcg ccgggtctca caagacggtt cccgaggtgg cccagggcgcc gtcccaccgc 60
 cgacgccgcc cgggccgccc gggccgtccc tccccgctgc ccccgctcct ccgcctccgc 120
 ctccccccgc cctcagcctc ccttccccct cccgcccag cagcggtcgc tcggggcccg 180
 ctctcgggta taagatggcg gcgctgagtg gcggcggcg cggcggcgcc ggtggcgcg 240
 agcagggcca ggctctgttc aacggggaca tggagcccga ggccggcgcc gcggcctctt 300
 cggctgcgga ccccgccatt cccgaggagg tgtggaatat caaacaatg attaagttga 360
 cacaggagca tatagaggcc ctattggaca aatttggtgg ggagcataat ccaccatcaa 420
 tataatctgga ggcctatgaa gaatacacca gcaagctaga tgccctccaa caaagagaac 480
 aacagttatt ggaatccctg ggggaatggaa ctgatttttc tgtttctagc tctgcatcaa 540
 cggacaccgt tacatcttct tcctcttcta gcctttcagt gctgccttca tctctttcag 600
 tttttcaaaa tcccacagat gtgtcacgga gcaaccccaa gtcaccacaa aaacctatcg 660
 ttagagtctt cctgcccatt aaacagagga cagtgggtacc tgcacggtgt ggagtcacag 720
 tccgggacag cctgaagaag gcactgatga tgagaggtct aatcccagag tgctgtgctg 780
 ttacagaat tcaggatggg gagaagaaac caattggctg ggacactgat atttcctggc 840
 ttactggaga ggagttgcat gtagaagtgt tggagaatgt tccacttaca acacacaact 900
 ttgtacggaa aacttttttc accttagcat tttgtgactt ctgtagaaag ctgcttttcc 960
 agggattccg ctgtcaaaca tgtggttata aatttcacca gcgttgtagt acagaggttc 1020
 cactgatgtg tgtaattat gaccaactag agccccaat tctcaccagt ccatctcctt 1080
 caaaatccat tccaattcca cagcctttcc gaccagcaga tgaagatcat cgaaatcagt 1140
 ttggacaacg agaccggtcc tcatcagctc caaatgtgca tataaacaca atagaacccg 1200
 tcaatattga tgacttgatt agagaccaag ggtttcgtag tgatggagga tcaaccacag 1260
 gtttatccgc cacacccct gcctcattac ctggctcact ctctaattgtg aaagcattgc 1320
 agaaatctcc aggacctcag cgagaaagaa agtcctcttc atcctcagaa gacaggaatc 1380
 gaatgaaaac gcttggtaga cgggattcaa gtgacgattg ggagattcct gatggacaga 1440
 tcacagtggg acaaagaatt ggatcagggc ctttgggac agtctacaag ggaaagtggc 1500
 atggtgatgt ggcagtgaaa atgttgaatg tgacagcacc cacacctcag cagttacagg 1560

0398850pct.txt

ccttcaaaaa	tgaagtagga	gtactcagga	aaacgcgaca	tgtgaatatc	ctcctcttca	1620
tgggttattc	aacaaagcca	caactggcta	ttgttaccca	gtggtgtgag	ggctccagtt	1680
tatatcatca	tctccacatc	attgagacca	aattcgagat	gatcaaactt	atagatatgt	1740
cacggcagac	tgcacagggc	atggattact	tacacgcca	gtcaatcatc	cacagagacc	1800
tcaagagtaa	taatattttt	cttcatgaag	acctcacagt	aaaaataggt	gatttttggtc	1860
tagccacagt	gaaatctcga	tggagtgggt	cccacagttt	tgaacagttg	tctggatcca	1920
ttttgtggat	ggcaccagaa	gtaatcagaa	tgcaagataa	aaaccatata	agctttcagt	1980
cagatgtata	tgcatttggg	attgttctgt	atgaattgat	gaccggacag	ttaccttatt	2040
caaatatcaa	caacagggac	cagataattt	ttatggtggg	acgaggatat	ctgtctccag	2100
atctcagtaa	ggtacggagt	aactgtccaa	aagccatgaa	gagattaatg	gcagagtgcc	2160
taaaaaagaa	aagagatgaa	agaccactct	ttccccaagt	aggaaagact	ctcctaagca	2220
agagacaaaa	ttcagaagtt	atcagggaaa	aagataagca	gattctcgcc	tctattgagc	2280
tgctggcccg	ctcattgcc	aaaattcacc	gcagtgcac	agaaccctcc	ttgaatcggg	2340
ctggcttcca	aacagaggat	tttagtctat	atgcttgtgc	ttctccaaaa	acacccattc	2400
aggcaggggg	atatgaagca	gatttggtct	ttacatcaaa	taaaaataga	gtagaagttg	2460
ggatttagag	atttcctgac	atgcaagaag	gaataagcaa	gaaaaaaagg	tttgttttcc	2520
ccaaatcata	tctattgtct	tttacttcta	ttttttctta	aattttttgt	gatttcagag	2580
acatgtagag	ttttattgat	acctaaacta	tgagttcttt	tttttttttt	tttttcatta	2640
ttttgatttt	tttggccaag	aggcatatgg	gatcttagct	tgagaaagca	acaattttct	2700
tgatgtcatt	ttgggtgagg	gcacatattg	ctgtgaacag	tgtggtgata	gccaccaggg	2760
accaaactca	caccgcgtgc	attgaaaggt	gaagtcttaa	acactggacc	agcagagaaa	2820
ttcctactct	atgagttctt	tttgtcatcc	cctccccgca	ccctccaccc	ccaacctaaa	2880
gtctgatgat	gaaatcaaca	actattccat	tagaagcagt	agattctggt	agcatgatct	2940
ttagtttggt	agtaagattt	tgtgctttgt	ggggttgtgt	cgttttaagg	ctaataattta	3000
agtttgtaa	atagaatgct	gttcagattg	taaaaatgag	taataaacat	ctgaagtttt	3060
ttttaagtta	tttttaacat	ggtatataca	gttgagctta	gagtttatca	ttttctgata	3120
ttctcttact	tagtagatga	attctagcca	ttttttataa	agatttctgt	taagcaaatac	3180
ctgttttcac	atgggcttcc	tttaagggat	tttagattct	gctggatatg	gtgactgctc	3240
ataagactgt	tgaaaattac	ttttaagatg	tattagaata	cttctgaaaa	aaaatagcaa	3300
ccttaaaacc	ataagcaaaa	gtagtaaggg	tgtttataca	tttctagagt	ccctgttttag	3360
gtaatagcct	cctatgattg	tactttaaat	gttttgctct	ccaaggtttt	agtaacttgg	3420
ctttttttct	aatcagtgcc	aaactcccc	agttttttta	acttttaata	tgaggtaata	3480
aatcttttac	ccttccttga	tcttttgact	tataatacct	tggtcagttg	tttcttaaaa	3540
ggaatcctta	aatggaaaga	gacaatatca	ctgtctgcag	ttctgattag	tagttttatt	3600

0398850pct.txt

cagaatggaa aaacagatta ttcatttttg aaaattgttc aggggtatgt tcattgttag 3660
gaccttggac tttggagtca gtgcctagct atgcattcca ggtctgccat tttctggctg 3720
tgaaattttg gacaagttac ttaaccactt taaacccag ctttaagaag taaattaacc 3780
ccagtaaatt aagaagtaat agcagccact tcgtagagtt gttatgaggc tcagatgcag 3840
tgcaaatgtg tataaagtat tcagggagtc acctggtata ctataataga cactagaata 3900
gttgccaata ttatcagcat acaatctgag gattctgtca gccaatcatt agcaatctgt 3960
tgtttgttg gacatgccag tgttctccag ttgaaatcag tagcaatcta aaaatggata 4020
gattattcct catttaaata gtgtgttcat ataagtgatt gcttggatcc ttatcagaag 4080
ttgctgttac tgaaaaatga taaggctgac taaattgtga tagttgtcag ttactaacca 4140
actcccagaa atgaataaga ggaacctatc tctagttcct agtagaaggt atggacaaaa 4200
tagtaggtga aaaataatgt cttgaacccc caaattaagt aagctttaaa gagtacaata 4260
cctcaaaggg tctttgcggg ttaaaatttg tatgctgaga atgatgttca ttgacatgtg 4320
cctatatgta attttttgat agtttaaaag gtgaaatgaa ctacagatgg gagaggctctg 4380
aattttcttg ctttcagtca aatgtgtaat gtggacatat tatttgacct gtgaatttta 4440
tcttttaaaa aagattaatt cctgcttctt ccttcctaag agttgcatta taataatgaa 4500
aatgagttga taatttgggg ggaaagtatt ctacaaatca accttattat tttaccattg 4560
gtttctgaga aattttgttc atttgaaccg tttatagctt gattagaatc atagcatgta 4620
aaaccaact gagggattat ctgcagactt aatgtagtat tatgtaagtt gtcttctttc 4680
atttcgacct tttttgcttt tgttgttgct agatctgtag tatgtagcta gtcacctttc 4740
agcgagggtt cagcgaggct tttctgtgtc tctaggttat ttgagataac ttttttaaaa 4800
ttagctcttg tcctcc 4816

<210> 28
<211> 757
<212> PRT
<213> Bos taurus

<400> 28

Met Ala Ala Leu Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ala Glu
1 5 10 15

Gln Gly Gln Ala Leu Phe Asn Gly Asp Met Glu Pro Glu Ala Gly Ala
20 25 30

Ala Ala Ser Ser Ala Ala Asp Pro Ala Ile Pro Glu Glu Val Trp Asn
35 40 45

Ile Lys Gln Met Ile Lys Leu Thr Gln Glu His Ile Glu Ala Leu Leu
50 55 60

Asp Lys Phe Gly Gly Glu His Asn Pro Pro Ser Ile Tyr Leu Glu Ala
65 70 75 80

Tyr Glu Glu Tyr Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg Glu Gln
 85 90 95
 Gln Leu Leu Glu Ser Leu Gly Asn Gly Thr Asp Phe Ser Val Ser Ser
 100 105 110
 Ser Ala Ser Thr Asp Thr Val Thr Ser Ser Ser Ser Ser Ser Leu Ser
 115 120 125
 Val Leu Pro Ser Ser Leu Ser Val Phe Gln Asn Pro Thr Asp Val Ser
 130 135 140
 Arg Ser Asn Pro Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe Leu
 145 150 155 160
 Pro Asn Lys Gln Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr Val
 165 170
 Arg Asp Ser Leu Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro Glu
 180 185 190
 Cys Cys Ala Val Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile Gly
 195 200 205
 Trp Asp Thr Asp Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val Glu
 210 215 220
 Val Leu Glu Asn Val Pro Leu Thr Thr His Asn Phe Val Arg Lys Thr
 225 230 235 240
 Phe Phe Thr Leu Ala Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe Gln
 245 250 255
 Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Gln Arg Cys Ser
 260 265 270
 Thr Glu Val Pro Leu Met Cys Val Asn Tyr Asp Gln Leu Glu Pro Pro
 275 280 285
 Ile Leu Thr Ser Pro Ser Pro Ser Lys Ser Ile Pro Ile Pro Gln Pro
 290 295 300
 Phe Arg Pro Ala Asp Glu Asp His Arg Asn Gln Phe Gly Gln Arg Asp
 305 310 315 320
 Arg Ser Ser Ser Ala Pro Asn Val His Ile Asn Thr Ile Glu Pro Val
 325 330 335
 Asn Ile Asp Asp Leu Ile Arg Asp Gln Gly Phe Arg Ser Asp Gly Gly
 340 345 350

Ser Thr Thr Gly Leu Ser Ala Thr Pro Pro Ala Ser Leu Pro Gly Ser
 355 360 365
 Leu Ser Asn Val Lys Ala Leu Gln Lys Ser Pro Gly Pro Gln Arg Glu
 370 375 380
 Arg Lys Ser Ser Ser Ser Ser Glu Asp Arg Asn Arg Met Lys Thr Leu
 385 390 395 400
 Gly Arg Arg Asp Ser Ser Asp Asp Trp Glu Ile Pro Asp Gly Gln Ile
 405 410 415
 Thr Val Gly Gln Arg Ile Gly Ser Gly Ser Phe Gly Thr Val Tyr Lys
 420 425 430
 Gly Lys Trp His Gly Asp Val Ala Val Lys Met Leu Asn Val Thr Ala
 435 440 445
 Pro Thr Pro Gln Gln Leu Gln Ala Phe Lys Asn Glu Val Gly Val Leu
 450 455 460
 Arg Lys Thr Arg His Val Asn Ile Leu Leu Phe Met Gly Tyr Ser Thr
 465 470 475 480
 Lys Pro Gln Leu Ala Ile Val Thr Gln Trp Cys Glu Gly Ser Ser Leu
 485 490 495
 Tyr His His Leu His Ile Ile Glu Thr Lys Phe Glu Met Ile Lys Leu
 500 505 510
 Ile Asp Ile Ala Arg Gln Thr Ala Gln Gly Met Asp Tyr Leu His Ala
 515 520 525
 Lys Ser Ile Ile His Arg Asp Leu Lys Ser Asn Asn Ile Phe Leu His
 530 535 540
 Glu Asp Leu Thr Val Lys Ile Gly Asp Phe Gly Leu Ala Thr Val Lys
 545 550 555 560
 Ser Arg Trp Ser Gly Ser His Gln Phe Glu Gln Leu Ser Gly Ser Ile
 565 570 575
 Leu Trp Met Ala Pro Glu Val Ile Arg Met Gln Asp Lys Asn Pro Tyr
 580 585 590
 Ser Phe Gln Ser Asp Val Tyr Ala Phe Gly Ile Val Leu Tyr Glu Leu
 595 600 605
 Met Thr Gly Gln Leu Pro Tyr Ser Asn Ile Asn Asn Arg Asp Gln Ile
 610 615 620

0398850pct.txt

Ile Phe Met Val Gly Arg Gly Tyr Leu Ser Pro Asp Leu Ser Lys Val
625 630 635 640

Arg Ser Asn Cys Pro Lys Ala Met Lys Arg Leu Met Ala Glu Cys Leu
645 650 655

Lys Lys Lys Arg Asp Glu Arg Pro Leu Phe Pro Gln Val Gly Lys Thr
660 665 670

Leu Leu Ser Lys Arg Gln Asn Ser Glu Val Ile Arg Glu Lys Asp Lys
675 680 685

Gln Ile Leu Ala Ser Ile Glu Leu Leu Ala Arg Ser Leu Pro Lys Ile
690 695 700

His Arg Ser Ala Ser Glu Pro Ser Leu Asn Arg Ala Gly Phe Gln Thr
705 710 715 720

Glu Asp Phe Ser Leu Tyr Ala Cys Ala Ser Pro Lys Thr Pro Ile Gln
725 730 735

Ala Gly Gly Tyr Glu Ala Asp Leu Ala Leu Thr Ser Asn Lys Asn Arg
740 745 750

Val Glu Val Gly Ile
755

<210> 29
<211> 2499
<212> DNA
<213> Bos taurus

<400> 29
ctcagctgcg ccgggtctca caagacggtt cccgaggtgg cccagggcgcc gtcccaccgc 60
cgacgccgcc cgggccgccc gggccgtccc tccccgtgc ccccgctcct ccgcctccgc 120
ctccccccgc cctcagcctc ccttccccct ccccgcccag cagcggtcgc tcgggcccgg 180
ctctcggtta taagatggcg gcgctgagtg gcggcggcgg cggcggcgcc ggtggcgcg 240
agcagggcca ggctctgttc aacggggaca tggagcccga ggccggcgcc gcggcctctt 300
cggctgcgga ccccgccatt cccgaggagg tgtggaatat caaacaatg attaagttga 360
cacaggagca tatagaggcc ctattggaca aatttggtgg ggagcataat ccaccatcaa 420
tatatctgga ggcctatgaa gaatacacca gcaagctaga tgccctccaa caaagagaac 480
aacagttatt ggaatccctg gggaatggaa ctgatttttc tgtttctagc tctgcatcaa 540
cggacaccgt tacatcttct tcctcttcta gcctttcagt gctgccttca tctctttcag 600
tttttcaaaa tcccacagat gtgtcacgga gcaaccccaa gtcaccacaa aaacctatcg 660
ttagagtctt cctgccaat aaacagagga cagtgggtacc tgcacggtgt ggagtcacag 720

0398850pct.txt

tccgggacag	cctgaagaag	gcactgatga	tgagaggtct	aatcccagag	tgctgtgctg	780
tttacagaat	tcaggatggg	gagaagaaac	caattggctg	ggacactgat	atttcctggc	840
ttactggaga	ggagttgcat	gtagaagtgt	tgagaaatgt	tccacttaca	acacacaact	900
ttgtacggaa	aacttttttc	accttagcat	tttgtgactt	ctgtagaaag	ctgcttttcc	960
agggattccg	ctgtcaaaca	tgtggttata	aatttcacca	gcgttgtagt	acagaggttc	1020
cactgatgtg	tgtaattat	gaccaactag	atttgctggt	tgtctccaag	ttctttgaac	1080
accaccaat	accacaggag	gaggcctcct	tagcagagac	tacccttcca	tgtggctcat	1140
ccccttctgc	acccccctcc	gattctattg	ggcccccaat	tctcaccagt	ccatctcctt	1200
caaaatccat	tccaattcca	cagcctttcc	gaccagcaga	tgaagatcat	cgaaatcagt	1260
ttggacaacg	agaccggtcc	tcacagctc	caaagtgtga	tataaacaca	atagaacctg	1320
tcaatattga	tgacttgatt	agagaccaag	ggtttcgtag	tgatggagga	tcaaccacag	1380
gtttatccgc	cacacccct	gcctcattac	ctggctcact	ctctaattgt	aaagcattgc	1440
agaaatctcc	aggacctcag	cgagaaagaa	agtcctcttc	atcctcagaa	gacaggaatc	1500
gaatgaaaac	gcttggtaga	cgggattcaa	gtgacgattg	ggagattcct	gatggacaga	1560
tcacagtggg	acaagaatt	ggatcagggt	catttgggac	agtctacaag	ggaaagtggc	1620
atggtgatgt	ggcagtgaag	atgttgaatg	tgacagcacc	cacacctcag	cagttacagg	1680
ccttcaaaaa	tgaagtagga	gtactcagga	aaacgcgaca	tgtgaatatc	ctcctcttca	1740
tggtgtattc	aacaaagcca	caactggcta	ttgttaccca	gtggtgtgag	ggctccagtt	1800
tatatcatca	tctccacatc	attgagacca	aattcgagat	gatcaaactt	atagatatgt	1860
cacggcagac	tgacagggc	atggattact	tacacgcca	gtcaatcatc	cacagagacc	1920
tcaagagtaa	taatattttt	cttcatgaag	acctcacagt	aaaaataggt	gattttggtc	1980
tagccacagt	gaaatctcga	tggagtgggt	cccatcagtt	tgaacagttg	tctggatcca	2040
ttttgtggat	ggcaccagaa	gtaatcagaa	tgcaagataa	aaaccatata	agctttcagt	2100
cagatgtata	tgcatattgg	attgttctgt	atgaattgat	gaccggacag	ttaccttatt	2160
caaatatcaa	caacagggac	cagataattt	ttatgggtgg	acgaggatat	ctgtctccag	2220
atctcagtaa	ggtacggagt	aactgtccaa	aagccatgaa	gagattaatg	gcagagtgcc	2280
taaaaaagaa	aagagatgaa	agaccactct	ttccccaggt	aggaaagact	ctcctaagca	2340
agagacaaaa	ttcagaagtt	atcagggaaa	aagataagca	ggaaaagtat	gtttctttag	2400
tacattccag	gcatttggga	ttacagtaaa	aacaatatct	tcgcctctat	tgagctgctg	2460
gcccgtcat	tgccaaaaat	tcaccgcagt	gcacagaaa			2499

<210> 30
 <211> 744
 <212> PRT
 <213> Bos taurus
 <400> 30

Met Ala Ala Leu Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ala Glu
 1 5 10 15
 Gln Gly Gln Ala Leu Phe Asn Gly Asp Met Glu Pro Glu Ala Gly Ala
 20 25 30
 Ala Ala Ser Ser Ala Ala Asp Pro Ala Ile Pro Glu Glu Val Trp Asn
 35 40 45
 Ile Lys Gln Met Ile Lys Leu Thr Gln Glu His Ile Glu Ala Leu Leu
 50 55 60
 Asp Lys Phe Gly Gly Glu His Asn Pro Pro Ser Ile Tyr Leu Glu Ala
 65 70 75 80
 Tyr Glu Glu Tyr Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg Glu Gln
 85 90 95
 Gln Leu Leu Glu Ser Leu Gly Asn Gly Thr Asp Phe Ser Val Ser Ser
 100 105 110
 Ser Ala Ser Thr Asp Thr Val Thr Ser Ser Ser Ser Ser Ser Leu Ser
 115 120 125
 Val Leu Pro Ser Ser Leu Ser Val Phe Gln Asn Pro Thr Asp Val Ser
 130 135 140
 Arg Ser Asn Pro Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe Leu
 145 150 155 160
 Pro Asn Lys Gln Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr Val
 165 170 175
 Arg Asp Ser Leu Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro Glu
 180 185 190
 Cys Cys Ala Val Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile Gly
 195 200 205
 Trp Asp Thr Asp Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val Glu
 210 215 220
 Val Leu Glu Asn Val Pro Leu Thr Thr His Asn Phe Val Arg Lys Thr
 225 230 235 240
 Phe Phe Thr Leu Ala Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe Gln
 245 250 255
 Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Gln Arg Cys Ser
 260 265 270

Thr Glu Val Pro Leu Met Cys Val Asn Tyr Asp Gln Leu Asp Leu Leu
 275 280 285

Phe Val Ser Lys Phe Phe Glu His His Pro Ile Pro Gln Glu Glu Ala
 290 295 300

Ser Leu Ala Glu Thr Thr Leu Pro Cys Gly Ser Ser Pro Ser Ala Pro
 305 310 315 320

Pro Ser Asp Ser Ile Gly Pro Pro Ile Leu Thr Ser Pro Ser Pro Ser
 325 330 335

Lys Ser Ile Pro Ile Pro Gln Pro Phe Arg Pro Ala Asp Glu Asp His
 340 345 350

Arg Asn Gln Phe Gly Gln Arg Asp Arg Ser Ser Ser Ala Pro Asn Val
 355 360 365

His Ile Asn Thr Ile Glu Pro Val Asn Ile Asp Asp Leu Ile Arg Asp
 370 375 380

Gln Gly Phe Arg Ser Asp Gly Gly Ser Thr Thr Gly Leu Ser Ala Thr
 385 390 395 400

Pro Pro Ala Ser Leu Pro Gly Ser Leu Ser Asn Val Lys Ala Leu Gln
 405 410 415

Lys Ser Pro Gly Pro Gln Arg Glu Arg Lys Ser Ser Ser Ser Ser Glu
 420 425 430

Asp Arg Asn Arg Met Lys Thr Leu Gly Arg Arg Asp Ser Ser Asp Asp
 435 440 445

Trp Glu Ile Pro Asp Gly Gln Ile Thr Val Gly Gln Arg Ile Gly Ser
 450 455 460

Gly Ser Phe Gly Thr Val Tyr Lys Gly Lys Trp His Gly Asp Val Ala
 465 470 475 480

Val Lys Met Leu Asn Val Thr Ala Pro Thr Pro Gln Gln Leu Gln Ala
 485 490 495

Phe Lys Asn Glu Val Gly Val Leu Arg Lys Thr Arg His Val Asn Ile
 500 505 510

Leu Leu Phe Met Gly Tyr Ser Thr Lys Pro Gln Leu Ala Ile Val Thr
 515 520 525

Gln Trp Cys Glu Gly Ser Ser Leu Tyr His His Leu His Ile Ile Glu
 530 535 540

0398850pct.txt

Thr Lys Phe Glu Met Ile Lys Leu Ile Asp Ile Ala Arg Gln Thr Ala
545 550 555 560

Gln Gly Met Asp Tyr Leu His Ala Lys Ser Ile Ile His Arg Asp Leu
565 570 575

Lys Ser Asn Asn Ile Phe Leu His Glu Asp Leu Thr Val Lys Ile Gly
580 585 590

Asp Phe Gly Leu Ala Thr Val Lys Ser Arg Trp Ser Gly Ser His Gln
595 600 605

Phe Glu Gln Leu Ser Gly Ser Ile Leu Trp Met Ala Pro Glu Val Ile
610 615 620

Arg Met Gln Asp Lys Asn Pro Tyr Ser Phe Gln Ser Asp Val Tyr Ala
625 630 635 640

Phe Gly Ile Val Leu Tyr Glu Leu Met Thr Gly Gln Leu Pro Tyr Ser
645 650 655

Asn Ile Asn Asn Arg Asp Gln Ile Ile Phe Met Val Gly Arg Gly Tyr
660 665 670

Leu Ser Pro Asp Leu Ser Lys Val Arg Ser Asn Cys Pro Lys Ala Met
675 680 685

Lys Arg Leu Met Ala Glu Cys Leu Lys Lys Lys Arg Asp Glu Arg Pro
690 695 700

Leu Phe Pro Gln Val Gly Lys Thr Leu Leu Ser Lys Arg Gln Asn Ser
705 710 715 720

Glu Val Ile Arg Glu Lys Asp Lys Gln Glu Lys Tyr Val Ser Leu Val
725 730 735

His Ser Arg His Leu Gly Leu Gln
740

<210> 31
<211> 2404
<212> DNA
<213> Bos taurus

<400> 31
ctcagctgcg ccgggtctca caagacggtt cccgaggtgg cccaggcgcc gtcccaccgc 60
cgacgccgcc cgggccgcc gggccgtccc tccccgtgc ccccgctcct ccgcctccgc 120
ctccccccgc cctcagcctc ccttccccct cccgcccag cagcggtcgc tcgggcccgg 180
ctctcggtta taagatggcg gcgctgagtg gcggcggcgg cggcggcgcc ggtggcgcg 240
agcagggcca ggctctgttc aacggggaca tggagcccga ggccggcgcc gcggcctctt 300

0398850pct.txt

cggtgcgga	ccccgccatt	cccgaggagg	tgtggaatat	caaacaaatg	attaagttga	360
cacaggagca	tatagaggcc	ctattggaca	aatttggtgg	ggagcataat	ccaccatcaa	420
tatatctgga	ggcctatgaa	gaatacacca	gcaagctaga	tgccctccaa	caaagagaac	480
aacagttatt	ggaatccctg	gggaatggaa	ctgatttttc	tgtttctagc	tctgcatcaa	540
cggacaccgt	tacatcttct	tcctcttcta	gcctttcagt	gctgccttca	tctctttcag	600
tttttcaaaa	tcccacagat	gtgtcacgga	gcaaccccaa	gtcaccacaa	aaacctatcg	660
ttagagtctt	cctgcccatt	aaacagagga	cagtgggtacc	tgacagggtg	ggagtcacag	720
tccgggacag	cctgaagaag	gcactgatga	tgagaggtct	aatcccagag	tgctgtgctg	780
tttacagaat	tcaggatggg	gagaagaaac	caattggctg	ggacactgat	atttcctggc	840
ttactggaga	ggagttgcat	gtagaagtgt	tggagaatgt	tccacttaca	acacacaact	900
ttgtacggaa	aacttttttc	accttagcat	tttgtgactt	ctgtagaaag	ctgcttttcc	960
agggattccg	ctgtcaaaca	tgtggttata	aatttcacca	gcgttgtagt	acagagggttc	1020
cactgatgtg	tgtaattat	gaccaactag	atttgctgtt	tgtctccaag	ttctttgaac	1080
accacccaat	accacaggag	gaggcctcct	tagcagagac	tacccttcca	tgtggctcat	1140
ccccttctgc	acccccctcc	gattctattg	ggcccccaat	tctcaccagt	ccatctcctt	1200
caaaatccat	tccaattcca	cagcctttcc	gaccagcaga	tgaagatcat	cgaaatcagt	1260
ttggacaacg	agaccggtcc	tcacagctc	caaagtgtga	tataaacaca	atagaacccg	1320
tcaatattga	tgacttgatt	agagaccaag	ggtttcgtag	tgatggagga	tcaaccacag	1380
gtttatccgc	cacacccctt	gcctcattac	ctggctcact	ctctaattgt	aaagcattgc	1440
agaaatctcc	aggacctcag	cgagaaagaa	agtcctcttc	atcctcagaa	gacaggaatc	1500
gaatgaaaac	gcttggtaga	cgggattcaa	gtgacgattg	ggagattcct	gatggacaga	1560
tcacagtggg	acaaagaatt	ggatcagggt	catttgggac	agtctacaag	ggaaagtggc	1620
atggtgatgt	ggcagtgaat	atgttgaaat	tgacagcacc	cacacctcag	cagttacagg	1680
ccttcaaaaa	tgaagtagga	gtactcagga	aaacgcgaca	tgtgaatatc	ctcctcttca	1740
tgggttattc	aacaaagcca	caactggcta	ttgttaccca	gtgggtgtgag	ggctccagtt	1800
tatatcatca	tctccacatc	attgagacca	aattcgagat	gatcaaactt	atagatattg	1860
cacggcagac	tgacagggc	atggattact	tacacgcca	gtcaatcatc	cacagagacc	1920
tcaagagtaa	taatattttt	cttcatgaag	acctcacagt	aaaaataggt	gattttggtc	1980
tagccacagt	gaaatctcga	tggagtgggt	cccatcagtt	tgaacagttg	tctggatcca	2040
ttttgtggat	ggcaccagaa	gtaatcagaa	tgcaagataa	aaaccatata	agctttcagt	2100
cagatgtata	tgcatttggg	attgttctgt	atgaattgat	gaccggacag	ttaccttatt	2160
caaatatcaa	caacagggac	cagataattt	ttatgggtggg	acgaggatat	ctgtctccag	2220
atctcagtaa	ggtacggagt	aactgtccaa	aagccatgaa	gagattaatg	gcagagtgcc	2280
taaaaaagaa	aagagatgaa	agaccactct	ttccccaaga	tctctcttcc	caccatagac	2340

acaaaaattt cagatggcta caggtttaca tgtaaaaaac agaattataa caaatgattt 2400
 ttat 2404

<210> 32
 <211> 726
 <212> PRT
 <213> Bos taurus

<400> 32

Met Ala Ala Leu Ser Gly Gly Gly Gly Gly Gly Gly Gly Ala Glu
 1 5 10 15

Gln Gly Gln Ala Leu Phe Asn Gly Asp Met Glu Pro Glu Ala Gly Ala
 20 25 30

Ala Ala Ser Ser Ala Ala Asp Pro Ala Ile Pro Glu Glu Val Trp Asn
 35 40 45

Ile Lys Gln Met Ile Lys Leu Thr Gln Glu His Ile Glu Ala Leu Leu
 50 55 60

Asp Lys Phe Gly Gly Glu His Asn Pro Pro Ser Ile Tyr Leu Glu Ala
 65 70 75 80

Tyr Glu Glu Tyr Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg Glu Gln
 85 90 95

Gln Leu Leu Glu Ser Leu Gly Asn Gly Thr Asp Phe Ser Val Ser Ser
 100 105 110

Ser Ala Ser Thr Asp Thr Val Thr Ser Ser Ser Ser Ser Ser Leu Ser
 115 120 125

Val Leu Pro Ser Ser Leu Ser Val Phe Gln Asn Pro Thr Asp Val Ser
 130 135 140

Arg Ser Asn Pro Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe Leu
 145 150 155 160

Pro Asn Lys Gln Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr Val
 165 170 175

Arg Asp Ser Leu Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro Glu
 180 185 190

Cys Cys Ala Val Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile Gly
 195 200 205

Trp Asp Thr Asp Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val Glu
 210 215 220

Val Leu Glu Asn Val Pro Leu Thr Thr His Asn Phe Val Arg Lys Thr
 225 230 235 240
 Phe Phe Thr Leu Ala Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe Gln
 245 250 255
 Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Gln Arg Cys Ser
 260 265 270
 Thr Glu Val Pro Leu Met Cys Val Asn Tyr Asp Gln Leu Asp Leu Leu
 275 280 285
 Phe Val Ser Lys Phe Phe Glu His His Pro Ile Pro Gln Glu Glu Ala
 290 295 300
 Ser Leu Ala Glu Thr Thr Leu Pro Cys Gly Ser Ser Pro Ser Ala Pro
 305 310 315 320
 Pro Ser Asp Ser Ile Gly Pro Pro Ile Leu Thr Ser Pro Ser Pro Ser
 325 330 335
 Lys Ser Ile Pro Ile Pro Gln Pro Phe Arg Pro Ala Asp Glu Asp His
 340 345 350
 Arg Asn Gln Phe Gly Gln Arg Asp Arg Ser Ser Ser Ala Pro Asn Val
 355 360 365
 His Ile Asn Thr Ile Glu Pro Val Asn Ile Asp Asp Leu Ile Arg Asp
 370 375 380
 Gln Gly Phe Arg Ser Asp Gly Gly Ser Thr Thr Gly Leu Ser Ala Thr
 385 390 395 400
 Pro Pro Ala Ser Leu Pro Gly Ser Leu Ser Asn Val Lys Ala Leu Gln
 405 410 415
 Lys Ser Pro Gly Pro Gln Arg Glu Arg Lys Ser Ser Ser Ser Ser Glu
 420 425 430
 Asp Arg Asn Arg Met Lys Thr Leu Gly Arg Arg Asp Ser Ser Asp Asp
 435 440 445
 Trp Glu Ile Pro Asp Gly Gln Ile Thr Val Gly Gln Arg Ile Gly Ser
 450 455 460
 Gly Ser Phe Gly Thr Val Tyr Lys Gly Lys Trp His Gly Asp Val Ala
 465 470 475 480
 Val Lys Met Leu Asn Val Thr Ala Pro Thr Pro Gln Gln Leu Gln Ala
 485 490 495

Phe Lys Asn Glu Val Gly Val Leu Arg Lys Thr Arg His Val Asn Ile
500 505 510

Leu Leu Phe Met Gly Tyr Ser Thr Lys Pro Gln Leu Ala Ile Val Thr
515 520 525

Gln Trp Cys Glu Gly Ser Ser Leu Tyr His His Leu His Ile Ile Glu
530 535 540

Thr Lys Phe Glu Met Ile Lys Leu Ile Asp Ile Ala Arg Gln Thr Ala
545 550 555 560

Gln Gly Met Asp Tyr Leu His Ala Lys Ser Ile Ile His Arg Asp Leu
565 570 575

Lys Ser Asn Asn Ile Phe Leu His Glu Asp Leu Thr Val Lys Ile Gly
580 585 590

Asp Phe Gly Leu Ala Thr Val Lys Ser Arg Trp Ser Gly Ser His Gln
595 600 605

Phe Glu Gln Leu Ser Gly Ser Ile Leu Trp Met Ala Pro Glu Val Ile
610 615 620

Arg Met Gln Asp Lys Asn Pro Tyr Ser Phe Gln Ser Asp Val Tyr Ala
625 630 635 640

Phe Gly Ile Val Leu Tyr Glu Leu Met Thr Gly Gln Leu Pro Tyr Ser
645 650 655

Asn Ile Asn Asn Arg Asp Gln Ile Ile Phe Met Val Gly Arg Gly Tyr
660 665 670

Leu Ser Pro Asp Leu Ser Lys Val Arg Ser Asn Cys Pro Lys Ala Met
675 680 685

Lys Arg Leu Met Ala Glu Cys Leu Lys Lys Lys Arg Asp Glu Arg Pro
690 695 700

Leu Phe Pro Gln Asp Leu Ser Ser His His Arg His Lys Asn Phe Arg
705 710 715 720

Trp Leu Gln Val Tyr Met
725

<210> 33

<211> 2331

<212> DNA

<213> Bos taurus

<400> 33

ctcagctgcg ccgggtctca caagacggtt cccgaggtgg cccaggcgcc gtcccaccgc

60

0398850pct.txt

cgacgccgcc	cgggccgccc	gggccgtccc	cccccgctgc	cccccgtcct	ccgcctccgc	120
ctccccccgc	cctcagcctc	ccttccccct	ccccgcccag	cagcggtcgc	tcgggcccgg	180
ctctcggtta	taagatggcg	gcgctgagtg	gcggcggcgg	cggcggcgcc	ggtggcgcg	240
agcagggcca	ggctctgttc	aacggggaca	tggagcccga	ggccggcgcc	gcggcctctt	300
cggctgcgga	ccccgccatt	cccgaggagg	tgtggaatat	caaacaaatg	attaagttga	360
cacaggagca	tatagaggcc	ctattggaca	aatttggtgg	ggagcataat	ccaccatcaa	420
tatatctgga	ggcctatgaa	gaatacacca	gcaagctaga	tgccctccaa	caaagagaac	480
aacagttatt	ggaatccctg	gggaatggaa	ctgatttttc	tgtttctagc	tctgcatcaa	540
cggacaccgt	tacatcttct	tcctcttcta	gcctttcagt	gctgccttca	tctctttcag	600
tttttcaaaa	tcccacagat	gtgtcacgga	gcaaccccaa	gtcaccacaa	aaacctatcg	660
ttagagtctt	cctgccaat	aaacagagga	cagtgggtacc	tgcacgggtgt	ggagtcacag	720
tccgggacag	cctgaagaag	gcactgatga	tgagaggtct	aatcccagag	tgctgtgctg	780
tttacagaat	tcaggatggg	gagaagaaac	caattggctg	ggacactgat	atttcctggc	840
ttactggaga	ggagttgcat	gtagaagtgt	tggagaatgt	tccacttaca	acacacaact	900
ttgtacggaa	aacttttttc	accttagcat	tttgtgactt	ctgtagaaag	ctgcttttcc	960
agggattccg	ctgtcaaaca	tgtggttata	aatttcacca	gcgttgtagt	acagaggttc	1020
actgatgtg	tgtaattat	gaccaactag	atttgctggt	tgtctccaag	ttctttgaac	1080
accaccaat	accacaggag	gaggcctcct	tagcagagac	tacccttcca	tgtggctcat	1140
ccccttctgc	acccccctcc	gattctattg	ggcccccaat	tctcaccagt	ccatctcctt	1200
caaatccat	tccaattcca	cagcctttcc	gaccagcaga	tgaagatcat	cgaaatcagt	1260
ttggacaacg	agaccggtcc	tcacagctc	caaatgtgca	tataaacaca	atagaacccg	1320
tcaatattga	tgacttgatt	agagaccaag	ggtttcgtag	tgatggagga	tcaaccacag	1380
gtttatccgc	cacacccctc	gcctcattac	ctggctcact	ctctaattgt	aaagcattgc	1440
agaaatctcc	aggacctcag	cgagaaagaa	agtcctcttc	atcctcagaa	gacaggaatc	1500
gaatgaaaac	gcttggtaga	cgggattcaa	gtgacgattg	ggagattcct	gatggacaga	1560
tcacagtggg	acaagaatt	ggatcagggt	catttgggac	agtctacaag	ggaaagtggc	1620
atggtgatgt	ggcagtgaat	atgttgaatg	tgacagcacc	cacacctcag	cagttacagg	1680
ccttcaaaaa	tgaagtagga	gtactcagga	aaacgcgaca	tgtgaatatc	ctcctcttca	1740
tggtgtattc	aacaaagcca	caactggcta	ttgttaccca	gtggtgtgag	ggctccagtt	1800
tatatcatca	tctccacatc	attgagacca	aattcgagat	gatcaaactt	atagatatgt	1860
cacggcagac	tgacagggc	atggattact	tacacgcaa	gtcaatcatc	cacagagacc	1920
tcaagagtaa	taatattttt	cttcatgaag	acctcacagt	aaaaataggt	gattttggtc	1980
tagccacagt	gaaatctcga	tggagtgggt	cccatcagtt	tgaacagttg	tctggatcca	2040
ttttgtggat	ggcaccagaa	gtaatcagaa	tgcaagataa	aaaccatata	agctttcagt	2100

0398850pct.txt

cagatgtata tgcatttggg attgttctgt atgaattgat gaccggacag ttaccttatt 2160
 caaatatcaa caacaggac caggtgcttt gtcctccatg ggagtgtaat aaatgctgtg 2220
 caagggctta cttcccatga gagaagttag tgaccaacag aaggataatt tttatggtgg 2280
 gacgaggata tctgtctcca gatctcagta aggtacggag taactgtcca a 2331

<210> 34
 <211> 681
 <212> PRT
 <213> Bos taurus

<400> 34

Met Ala Ala Leu Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ala Glu
 1 5 10 15

Gln Gly Gln Ala Leu Phe Asn Gly Asp Met Glu Pro Glu Ala Gly Ala
 20 25 30

Ala Ala Ser Ser Ala Ala Asp Pro Ala Ile Pro Glu Glu Val Trp Asn
 35 40 45

Ile Lys Gln Met Ile Lys Leu Thr Gln Glu His Ile Glu Ala Leu Leu
 50 55 60

Asp Lys Phe Gly Gly Glu His Asn Pro Pro Ser Ile Tyr Leu Glu Ala
 65 70 75 80

Tyr Glu Glu Tyr Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg Glu Gln
 85 90 95

Gln Leu Leu Glu Ser Leu Gly Asn Gly Thr Asp Phe Ser Val Ser Ser
 100 105 110

Ser Ala Ser Thr Asp Thr Val Thr Ser Ser Ser Ser Ser Ser Leu Ser
 115 120 125

Val Leu Pro Ser Ser Leu Ser Val Phe Gln Asn Pro Thr Asp Val Ser
 130 135 140

Arg Ser Asn Pro Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe Leu
 145 150 155 160

Pro Asn Lys Gln Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr Val
 165 170 175

Arg Asp Ser Leu Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro Glu
 180 185 190

Cys Cys Ala Val Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile Gly
 195 200 205

Trp Asp Thr Asp Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val Glu
 210 215 220
 Val Leu Glu Asn Val Pro Leu Thr Thr His Asn Phe Val Arg Lys Thr
 225 230 235 240
 Phe Phe Thr Leu Ala Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe Gln
 245 250 255
 Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Gln Arg Cys Ser
 260 265 270
 Thr Glu Val Pro Leu Met Cys Val Asn Tyr Asp Gln Leu Asp Leu Leu
 275 280 285
 Phe Val Ser Lys Phe Phe Glu His His Pro Ile Pro Gln Glu Glu Ala
 290 295 300
 Ser Leu Ala Glu Thr Thr Leu Pro Cys Gly Ser Ser Pro Ser Ala Pro
 305 310 315 320
 Pro Ser Asp Ser Ile Gly Pro Pro Ile Leu Thr Ser Pro Ser Pro Ser
 325 330 335
 Lys Ser Ile Pro Ile Pro Gln Pro Phe Arg Pro Ala Asp Glu Asp His
 340 345 350
 Arg Asn Gln Phe Gly Gln Arg Asp Arg Ser Ser Ser Ala Pro Asn Val
 355 360 365
 His Ile Asn Thr Ile Glu Pro Val Asn Ile Asp Asp Leu Ile Arg Asp
 370 375 380
 Gln Gly Phe Arg Ser Asp Gly Gly Ser Thr Thr Gly Leu Ser Ala Thr
 385 390 395 400
 Pro Pro Ala Ser Leu Pro Gly Ser Leu Ser Asn Val Lys Ala Leu Gln
 405 410 415
 Lys Ser Pro Gly Pro Gln Arg Glu Arg Lys Ser Ser Ser Ser Ser Glu
 420 425 430
 Asp Arg Asn Arg Met Lys Thr Leu Gly Arg Arg Asp Ser Ser Asp Asp
 435 440 445
 Trp Glu Ile Pro Asp Gly Gln Ile Thr Val Gly Gln Arg Ile Gly Ser
 450 455 460
 Gly Ser Phe Gly Thr Val Tyr Lys Gly Lys Trp His Gly Asp Val Ala
 465 470 475 480

Val Lys Met Leu Asn Val Thr Ala Pro Thr Pro Gln Gln Leu Gln Ala
 485 490 495

Phe Lys Asn Glu Val Gly Val Leu Arg Lys Thr Arg His Val Asn Ile
 500 505 510

Leu Leu Phe Met Gly Tyr Ser Thr Lys Pro Gln Leu Ala Ile Val Thr
 515 520 525

Gln Trp Cys Glu Gly Ser Ser Leu Tyr His His Leu His Ile Ile Glu
 530 535 540

Thr Lys Phe Glu Met Ile Lys Leu Ile Asp Ile Ala Arg Gln Thr Ala
 545 550 555 560

Gln Gly Met Asp Tyr Leu His Ala Lys Ser Ile Ile His Arg Asp Leu
 565 570 575

Lys Ser Asn Asn Ile Phe Leu His Glu Asp Leu Thr Val Lys Ile Gly
 580 585 590

Asp Phe Gly Leu Ala Thr Val Lys Ser Arg Trp Ser Gly Ser His Gln
 595 600 605

Phe Glu Gln Leu Ser Gly Ser Ile Leu Trp Met Ala Pro Glu Val Ile
 610 615 620

Arg Met Gln Asp Lys Asn Pro Tyr Ser Phe Gln Ser Asp Val Tyr Ala
 625 630 635 640

Phe Gly Ile Val Leu Tyr Glu Leu Met Thr Gly Gln Leu Pro Tyr Ser
 645 650 655

Asn Ile Asn Asn Arg Asp Gln Val Leu Cys Pro Pro Trp Glu Cys Asn
 660 665 670

Lys Cys Cys Ala Arg Ala Tyr Phe Pro
 675 680

<210> 35

<211> 2319

<212> DNA

<213> Bos taurus

<400> 35

ctcagctgcg ccgggtctca caagacggtt cccgaggtgg cccaggcgcc gtcccaccgc 60

cgacgccgcc cgggccgcc gggccgtccc tccccgtgc ccccgctcct ccgcctccgc 120

ctccccccgc cctcagcctc ccttccccct cccgcccag cagcggtcgc tcggggcccg 180

ctctcggtta taagatggcg gcgctgagtg gcggcggcgg cggcggcggc ggtggcgcgg 240

agcagggcca ggctctgttc aacggggaca tggagcccga ggccggcgcc gcggcctctt 300

0398850pct.txt

cggctgcgga	ccccgccatt	cccgaggagg	tgtggaatat	caaacaaatg	attaagttga	360
cacaggagca	tatagaggcc	ctattggaca	aatttggtgg	ggagcataat	ccaccatcaa	420
tatatctgga	ggcctatgaa	gaatacacca	gcaagctaga	tgccctccaa	caaagagaac	480
aacagttatt	ggaatccctg	gggaatggaa	ctgatttttc	tgtttctagc	tctgcatcaa	540
cggacaccgt	tacatcttct	tcctcttcta	gcctttcagt	gctgccttca	tctctttcag	600
tttttcaaaa	tcccacagat	gtgtcacgga	gcaaccccaa	gtcaccacaa	aaacctatcg	660
ttagagtctt	cctgcccatt	aaacagagga	cagtgggtacc	tgcacggtgt	ggagtcacag	720
tccgggacag	cctgaagaag	gcactgatga	tgagaggtct	aatcccagag	tgctgtgctg	780
tttacagaat	tcaggatggg	gagaagaaac	caattggctg	ggacactgat	atttcctggc	840
ttactggaga	ggagttgcat	gtagaagtgt	tggagaatgt	tccacttaca	acacacaact	900
ttgtacggaa	aacttttttc	accttagcat	tttgtgactt	ctgtagaaag	ctgcttttcc	960
agggattccg	ctgtcaaaca	tgtggttata	aatttcacca	gcgttgtagt	acagagggttc	1020
cactgatgtg	tgtaattat	gaccaactag	atttgctgtt	tgtctccaag	ttctttgaac	1080
accacccaat	accacaggag	gaggcctcct	tagcagagac	tacccttcca	tgtggctcat	1140
ccccttctgc	acccccctcc	gattctattg	ggcccccaat	tctcaccagt	ccatctcctt	1200
caaaatccat	tccaattcca	cagcctttcc	gaccagcaga	tgaagatcat	cgaaatcagt	1260
ttggacaacg	agaccggtcc	tcatcagctc	caaatgtgca	tataaacaca	atagaacccg	1320
tcaatattga	tgacttgatt	agagaccaag	ggtttcgtag	tgatggagga	tcaaccacag	1380
gtttatccgc	cacaccccct	gcctcattac	ctggctcact	ctctaattgt	aaagcattgc	1440
agaaatctcc	aggacctcag	cgagaaagaa	agtcctcttc	atcctcagaa	gacaggaatc	1500
gaatgaaaac	gcttggtaga	cgggattcaa	gtgacgattg	ggagattcct	gatggacaga	1560
tcacagtggg	aaaagaatt	ggatcagggt	catttgggac	agtctacaag	ggaaagtggc	1620
atggtgatgt	ggcagtgaaa	atgttgaatg	tgacagcacc	cacacctcag	cagttacagg	1680
ccttcaaaaa	tgaagtagga	gtactcagga	aaacgcgaca	tgtgaatatc	ctcctcttca	1740
tgggttattc	aacaaagcca	caactggcta	ttgttaccba	gtgggtgtgag	ggctccagtt	1800
tatatcatca	tctccacatc	attgagacca	aattcgagat	gatcaaactt	atagatattg	1860
cacggcagac	tgcacagggc	atggattact	tacacgccaa	gtcaatcatc	cacagagacc	1920
tcaagagtaa	taatattttt	cttcatgaag	acctcacagt	aaaaataggt	gatttttggtc	1980
tagccacagt	gaaatctcga	tggagtgggt	cccatcagtt	tgaacagttg	tctggatcca	2040
ttttgtggat	ggcaccagaa	gtaatcagaa	tgcaagataa	aaaccatata	agctttcagt	2100
cagatgtata	tgcatttggg	attgttctgt	atgaattgat	gaccggacag	ttaccttatt	2160
caaatatcaa	caacagggac	caggtgcttt	gtcctccatg	ggagtgtaat	aaatgctgtg	2220
caagggctta	cttcccatga	gagaagtgag	tgaccaacag	aaggctctgtg	caaggaaaag	2280
agacaaagcc	acggatcaga	agcacatggc	cataactga			2319

<210> 36
 <211> 681
 <212> PRT
 <213> Bos taurus

<400> 36

Met Ala Ala Leu Ser Gly Gly Gly Gly Gly Gly Gly Gly Ala Glu
 1 5 10 15

Gln Gly Gln Ala Leu Phe Asn Gly Asp Met Glu Pro Glu Ala Gly Ala
 20 25 30

Ala Ala Ser Ser Ala Ala Asp Pro Ala Ile Pro Glu Glu Val Trp Asn
 35 40 45

Ile Lys Gln Met Ile Lys Leu Thr Gln Glu His Ile Glu Ala Leu Leu
 50 55 60

Asp Lys Phe Gly Gly Glu His Asn Pro Pro Ser Ile Tyr Leu Glu Ala
 65 70 75 80

Tyr Glu Glu Tyr Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg Glu Gln
 85 90 95

Gln Leu Leu Glu Ser Leu Gly Asn Gly Thr Asp Phe Ser Val Ser Ser
 100 105 110

Ser Ala Ser Thr Asp Thr Val Thr Ser Ser Ser Ser Ser Ser Leu Ser
 115 120 125

Val Leu Pro Ser Ser Leu Ser Val Phe Gln Asn Pro Thr Asp Val Ser
 130 135 140

Arg Ser Asn Pro Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe Leu
 145 150 155 160

Pro Asn Lys Gln Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr Val
 165 170 175

Arg Asp Ser Leu Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro Glu
 180 185 190

Cys Cys Ala Val Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile Gly
 195 200 205

Trp Asp Thr Asp Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val Glu
 210 215 220

Val Leu Glu Asn Val Pro Leu Thr Thr His Asn Phe Val Arg Lys Thr
 225 230 235 240

Phe Phe Thr Leu Ala Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe Gln
 245 250 255
 Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Gln Arg Cys Ser
 260 265 270
 Thr Glu Val Pro Leu Met Cys Val Asn Tyr Asp Gln Leu Asp Leu Leu
 275 280 285
 Phe Val Ser Lys Phe Phe Glu His His Pro Ile Pro Gln Glu Glu Ala
 290 295 300
 Ser Leu Ala Glu Thr Thr Leu Pro Cys Gly Ser Ser Pro Ser Ala Pro
 305 310 315
 Pro Ser Asp Ser Ile Gly Pro Pro Ile Leu Thr Ser Pro Ser Pro Ser
 325 330 335
 Lys Ser Ile Pro Ile Pro Gln Pro Phe Arg Pro Ala Asp Glu Asp His
 340 345 350
 Arg Asn Gln Phe Gly Gln Arg Asp Arg Ser Ser Ser Ala Pro Asn Val
 355 360 365
 His Ile Asn Thr Ile Glu Pro Val Asn Ile Asp Asp Leu Ile Arg Asp
 370 375 380
 Gln Gly Phe Arg Ser Asp Gly Gly Ser Thr Thr Gly Leu Ser Ala Thr
 385 390 395
 Pro Pro Ala Ser Leu Pro Gly Ser Leu Ser Asn Val Lys Ala Leu Gln
 405 410 415
 Lys Ser Pro Gly Pro Gln Arg Glu Arg Lys Ser Ser Ser Ser Ser Glu
 420 425 430
 Asp Arg Asn Arg Met Lys Thr Leu Gly Arg Arg Asp Ser Ser Asp Asp
 435 440 445
 Trp Glu Ile Pro Asp Gly Gln Ile Thr Val Gly Gln Arg Ile Gly Ser
 450 455 460
 Gly Ser Phe Gly Thr Val Tyr Lys Gly Lys Trp His Gly Asp Val Ala
 465 470 475 480
 Val Lys Met Leu Asn Val Thr Ala Pro Thr Pro Gln Gln Leu Gln Ala
 485 490 495
 Phe Lys Asn Glu Val Gly Val Leu Arg Lys Thr Arg His Val Asn Ile
 500 505 510

Leu Leu Phe Met Gly Tyr Ser Thr Lys Pro Gln Leu Ala Ile Val Thr
 515 520 525

Gln Trp Cys Glu Gly Ser Ser Leu Tyr His His Leu His Ile Ile Glu
 530 535 540

Thr Lys Phe Glu Met Ile Lys Leu Ile Asp Ile Ala Arg Gln Thr Ala
 545 550 555 560

Gln Gly Met Asp Tyr Leu His Ala Lys Ser Ile Ile His Arg Asp Leu
 565 570 575

Lys Ser Asn Asn Ile Phe Leu His Glu Asp Leu Thr Val Lys Ile Gly
 580 585 590

Asp Phe Gly Leu Ala Thr Val Lys Ser Arg Trp Ser Gly Ser His Gln
 595 600 605

Phe Glu Gln Leu Ser Gly Ser Ile Leu Trp Met Ala Pro Glu Val Ile
 610 615 620

Arg Met Gln Asp Lys Asn Pro Tyr Ser Phe Gln Ser Asp Val Tyr Ala
 625 630 635 640

Phe Gly Ile Val Leu Tyr Glu Leu Met Thr Gly Gln Leu Pro Tyr Ser
 645 650 655

Asn Ile Asn Asn Arg Asp Gln Val Leu Cys Pro Pro Trp Glu Cys Asn
 660 665 670

Lys Cys Cys Ala Arg Ala Tyr Phe Pro
 675 680

<210> 37
 <211> 2661
 <212> DNA
 <213> Bos taurus

<400> 37
 tcagctgctc cgggtctcac aagacggttc ccgaggtggc ccaggcgccg tcccaccgcc 60
 gacgccgccc gggccgcccg ggccgtccct ccccgctgcc ccccgctcctc cgcctccgcc 120
 tcccccgcc ctcagcctcc cttccccctc cccgcccagc agcggtcgct cgggcccggc 180
 tctcggttat aagatggcgg cgctgagtgg cggcggcggc ggcggcgccg gtggcgcgga 240
 gcagggccag gctctgttca acggggacat ggagcccag gccggcgccg cggcctcttc 300
 ggctgcggac cccgccattc ccgaggaggt gtggaatc aaacaaatga ttaagttgac 360
 acaggagcat atagaggccc tattggacaa atttggtggg gagcataatc caccatcaat 420
 atatctggag gcctatgaag aatacaccag caagctagat gccctccaac aaagagaaca 480
 acagttattg gaatccctgg ggaatggaac tgatttttct gtttctagct ctgcatcaac 540

0398850pct.txt

ggacaccgtt	acatcttctt	cctcttctag	ccttttcagtg	ctgccttcat	ctctttcagt	600
ttttcaaaat	cccacagatg	tgtcacggag	caaccccaag	tcaccacaaa	aacctatcgt	660
tagagtcttc	ctgccaata	aacagaggac	agtggtagct	gcacggtgtg	gagtcacagt	720
ccgggacagc	ctgaagaagg	cactgatgat	gagaggtcta	atcccagagt	gctgtgctgt	780
ttacagaatt	caggatgggg	agaagaaacc	aattggctgg	gacactgata	tttcctggct	840
tactggagag	gagttgcatg	tagaagtgtt	ggagaatgtt	ccacttaca	cacacaactt	900
tgtacggaaa	acttttttca	ccttagcatt	ttgtgacttc	tgtagaaagc	tgcttttcca	960
gggattccgc	tgtcaaacat	gtggttataa	atttcaccag	cgttgtagta	cagaggttcc	1020
actgatgtgt	gttaattatg	accaactaga	tttgcgtgtt	gtctccaagt	tctttgaaca	1080
ccaccaata	ccacaggagg	aggcctcctt	agcagagact	acccttccat	gtggctcatc	1140
cccttctgca	ccccctccg	attctattgg	gcccccaatt	ctcaccagtc	catctccttc	1200
aaaatccatt	ccaattccac	agcctttccg	accagcagat	gaagatcatc	gaaatcagtt	1260
tggacaacga	gaccggtcct	catcagctcc	aaatgtgcat	ataaacacaa	tagaaccctg	1320
caatattgat	gacttgatta	gagaccaagg	gtttcgtagt	gatggaggat	caaccacagg	1380
tttatccgcc	acaccccctg	cctcattacc	tggctcactc	tctaattgtga	aagcattgca	1440
gaaatctcca	ggacctcagc	gagaaagaaa	gtcctcttca	tcctcagaag	acaggaatcg	1500
aatgaaaacg	cttggtagac	gggattcaag	tgacgattgg	gagattcctg	atggacagat	1560
cacagtggga	caaagaattg	gatcagggtc	atttgggaca	gtctacaagg	gaaagtggca	1620
tggatgatgtg	gcagtgaaaa	tgttgaaatg	gacagcacc	acacctcagc	agttacaggc	1680
cttcaaaaat	gaagtaggag	tactcaggaa	aacgcgacat	gtgaatatcc	tcctcttcat	1740
gggttattca	acaaagccac	aactggctat	tgttaccag	tgggtgtgagg	gctccagttt	1800
atatcatcat	ctccacatca	ttgagaccaa	attcgagatg	atcaaactta	tagatattgc	1860
acggcagact	gcacagggca	tggattactt	acacgccaa	tcaatcatcc	acagagacct	1920
caagagtaat	aatatttttc	ttcatgaaga	cctcacagta	aaaataggtg	attttggctt	1980
agccacagtg	aaatctcgat	ggagtgggtc	ccatcagttt	gaacagttgt	ctggatccat	2040
tttgtggatg	gcaccagaag	taatcagaat	gcaagataaa	aacccatata	gctttcagtc	2100
agatgtatat	gcatttgga	ttgttctgta	tgaattgatg	accggacagt	taccttattc	2160
aaatatcaac	aacagggacc	agtctgtgca	aggaaaagag	acaaagccac	ggatcagaag	2220
cacatggcca	taactgaaga	ttttgtgaac	tctcacagg	aaaaaatttg	ctctttgaac	2280
aataagaagg	aactcactaa	aatgtaactg	agaactgttc	aacaggttga	aagctgaaag	2340
atgccattgg	aactgacaaa	atgtttctta	aacataaatg	atgaaacagt	gaaactacat	2400
aatatctcct	ctggctgaaa	cattcaagaa	gtttaaaatg	cttaagttaa	aaataaaatc	2460
ctagtaaaca	atggacttac	tgtgcaacat	agagaatatc	ttacgataac	ctgtaatgga	2520
aaagaatctg	aaaaagaatg	tatataactg	aatcactttg	ctgtaaacta	gaatctgaca	2580

caacactgta aatcactaca cttttctgtt gcatgccaaa gattatttaa taacgtcatt 2640

aaaaaattat ttttaataatt a 2661

<210> 38

<211> 679

<212> PRT

<213> Bos taurus

<400> 38

Met Ala Ala Leu Ser Gly Gly Gly Gly Gly Gly Gly Gly Ala Glu
1 5 10 15

Gln Gly Gln Ala Leu Phe Asn Gly Asp Met Glu Pro Glu Ala Gly Ala
20 25 30

Ala Ala Ser Ser Ala Ala Asp Pro Ala Ile Pro Glu Glu Val Trp Asn
35 40 45

Ile Lys Gln Met Ile Lys Leu Thr Gln Glu His Ile Glu Ala Leu Leu
50 55 60

Asp Lys Phe Gly Gly Glu His Asn Pro Pro Ser Ile Tyr Leu Glu Ala
65 70 75 80

Tyr Glu Glu Tyr Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg Glu Gln
85 90 95

Gln Leu Leu Glu Ser Leu Gly Asn Gly Thr Asp Phe Ser Val Ser Ser
100 105 110

Ser Ala Ser Thr Asp Thr Val Thr Ser Ser Ser Ser Ser Ser Leu Ser
115 120 125

Val Leu Pro Ser Ser Leu Ser Val Phe Gln Asn Pro Thr Asp Val Ser
130 135 140

Arg Ser Asn Pro Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe Leu
145 150 155 160

Pro Asn Lys Gln Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr Val
165 170 175

Arg Asp Ser Leu Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro Glu
180 185 190

Cys Cys Ala Val Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile Gly
195 200 205

Trp Asp Thr Asp Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val Glu
210 215 220

Val Leu Glu Asn Val Pro Leu Thr Thr His Asn Phe Val Arg Lys Thr
 225 230 235 240
 Phe Phe Thr Leu Ala Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe Gln
 245 250 255
 Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Gln Arg Cys Ser
 260 265 270
 Thr Glu Val Pro Leu Met Cys Val Asn Tyr Asp Gln Leu Asp Leu Leu
 275 280 285
 Phe Val Ser Lys Phe Phe Glu His His Pro Ile Pro Gln Glu Glu Ala
 290 295 300
 Ser Leu Ala Glu Thr Thr Leu Pro Cys Gly Ser Ser Pro Ser Ala Pro
 305 310 315 320
 Pro Ser Asp Ser Ile Gly Pro Pro Ile Leu Thr Ser Pro Ser Pro Ser
 325 330 335
 Lys Ser Ile Pro Ile Pro Gln Pro Phe Arg Pro Ala Asp Glu Asp His
 340 345 350
 Arg Asn Gln Phe Gly Gln Arg Asp Arg Ser Ser Ser Ala Pro Asn Val
 355 360 365
 His Ile Asn Thr Ile Glu Pro Val Asn Ile Asp Asp Leu Ile Arg Asp
 370 375 380
 Gln Gly Phe Arg Ser Asp Gly Gly Ser Thr Thr Gly Leu Ser Ala Thr
 385 390 395 400
 Pro Pro Ala Ser Leu Pro Gly Ser Leu Ser Asn Val Lys Ala Leu Gln
 405 410 415
 Lys Ser Pro Gly Pro Gln Arg Glu Arg Lys Ser Ser Ser Ser Ser Glu
 420 425 430
 Asp Arg Asn Arg Met Lys Thr Leu Gly Arg Arg Asp Ser Ser Asp Asp
 435 440 445
 Trp Glu Ile Pro Asp Gly Gln Ile Thr Val Gly Gln Arg Ile Gly Ser
 450 455 460
 Gly Ser Phe Gly Thr Val Tyr Lys Gly Lys Trp His Gly Asp Val Ala
 465 470 475 480
 Val Lys Met Leu Asn Val Thr Ala Pro Thr Pro Gln Gln Leu Gln Ala
 485 490 495

Phe Lys Asn Glu Val Gly Val Leu Arg Lys Thr Arg His Val Asn Ile
500 505 510

Leu Leu Phe Met Gly Tyr Ser Thr Lys Pro Gln Leu Ala Ile Val Thr
515 520 525

Gln Trp Cys Glu Gly Ser Ser Leu Tyr His His Leu His Ile Ile Glu
530 535 540

Thr Lys Phe Glu Met Ile Lys Leu Ile Asp Ile Ala Arg Gln Thr Ala
545 550 555 560

Gln Gly Met Asp Tyr Leu His Ala Lys Ser Ile Ile His Arg Asp Leu
565 570 575

Lys Ser Asn Asn Ile Phe Leu His Glu Asp Leu Thr Val Lys Ile Gly
580 585 590

Asp Phe Gly Leu Ala Thr Val Lys Ser Arg Trp Ser Gly Ser His Gln
595 600 605

Phe Glu Gln Leu Ser Gly Ser Ile Leu Trp Met Ala Pro Glu Val Ile
610 615 620

Arg Met Gln Asp Lys Asn Pro Tyr Ser Phe Gln Ser Asp Val Tyr Ala
625 630 635 640

Phe Gly Ile Val Leu Tyr Glu Leu Met Thr Gly Gln Leu Pro Tyr Ser
645 650 655

Asn Ile Asn Asn Arg Asp Gln Ser Val Gln Gly Lys Glu Thr Lys Pro
660 665 670

Arg Ile Arg Ser Thr Trp Pro
675

<210> 39

<211> 7434

<212> DNA

<213> Bos taurus

<400> 39

acaccgttac atcttcttcc tcttctagcc tttcagtgct gccttcatct ctttcagttt 60

ttcaaaatcc cacagatgtg tcacggagca accccaagtc accacaaaaa cctatcgtta 120

gagtcttcct gcccaataaa cagaggacag tggtagctgc acggtgtgga gtcacagtcc 180

gggacagcct gaagaaggca ctgatgatga gaggtctaata cccagagtgc tgtgctgttt 240

acagaattca ggatggggag aagaaaccaa ttggctggga cactgatatt tcctggctta 300

ctggagagga gttgcatgta gaagtgttg agaatgttcc acttacaaca cacaactttg 360

tacggaaaac ttttttcacc ttagcatttt gtgacttctg tagaaagctg cttttccagg 420

0398850pct.txt

gattccgctg	tcaaacatgt	ggttataaat	ttcaccagcg	ttgtagtaca	gaggttccac	480
tgatgtgtgt	taattatgac	caactagatt	tgctgtttgt	ctccaagttc	tttgaacacc	540
acccaatacc	acaggaggag	gcctccttag	cagagactac	ccttccatgt	ggctcatccc	600
cttctgcacc	cccctccgat	tctattgggc	ccccaattct	caccagtcca	tctccttcaa	660
aatccattcc	aattccacag	cctttccgac	cagcagatga	agatcatcga	aatcagtttg	720
gacaacgaga	ccggtcctca	tcagctccaa	atgtgcatat	aaacacaata	gaacccgtca	780
atattgatga	cttgattaga	gaccaagggg	ttcgtagtga	tggaggatca	accacagggt	840
tatccgccac	accccctgcc	tcattacctg	gctcactctc	taatgtgaaa	gcattgcaga	900
aatctccagg	acctcagcga	gaaagaaagt	cctcttcatc	ctcagaagac	aggaatcgaa	960
tgaaaacgct	tggtagacgg	gattcaagtg	acgattggga	gattcctgat	ggacagatca	1020
cagtgggaca	aagaattgga	tcagggtcat	ttgggacagt	ctacaaggga	aagtggcatg	1080
gtgatgtggc	agtgaaaatg	ttgaatgtga	cagcaccac	acctcagcag	ttacaggcct	1140
tcaaaaatga	agtaggagta	ctcaggaaaa	cgcgacatgt	gaatatcctc	ctcttcatgg	1200
gttattcaac	aaagccacaa	ctggctattg	ttaccagtg	gtgtgagggc	tccagtttat	1260
atcatcatct	ccacatcatt	gagaccaa	tcgagatgat	caaacttata	gatattgcac	1320
ggcagactgc	acagggcatg	gattacttac	acgccaagtc	aatcatccac	agagacctca	1380
agagtaataa	tatTTTTctt	catgaagacc	tcacagtaaa	aataggtgat	tttgggtctag	1440
ccacagtga	atctcgatgg	agtgggtccc	atcagtttga	acagttgtct	ggatccat	1500
tgtggatggc	accagaagta	atcagaatgc	aagataaaaa	cccatatagc	tttcagtcag	1560
atgtatatgc	atttgggatt	gttctgtatg	aattgatgac	cggacagtta	ccttattcaa	1620
atatcaacaa	cagggaccag	ataattttta	tggtgggacg	aggatatctg	tctccagatc	1680
tcagtaaggt	acggagtaac	tgtccaaaag	ccatgaagag	attaatggca	gagtgcctaa	1740
aaaagaaaag	agatgaaaga	ccactctttc	cccaagtagg	aaagactctc	ctaagcaaga	1800
gacaaaattc	agaagttatc	agggaaaaag	ataagcagat	tctcgctctc	attgagctgc	1860
tggcccgtc	attgccaaaa	attcaccgca	gtgcatcaga	accctccttg	aatcgggctg	1920
gcttccaaac	agaggatttt	agtctatatg	cttgtgtctc	tccaaaaaca	cccattcagg	1980
cagggggata	tggagaat	gcagccttca	agtagccaca	ccatcatgac	agcatctact	2040
cttatttctt	aagtcttgtg	ttcgtacaat	ttgttaacat	caaaacacag	ttctgttcct	2100
caactctttt	taaagttaaa	atttttcagt	gcataagctg	gtgtggaaca	gaaggaaatt	2160
tcccatccaa	caaaagaggg	aagaatgttt	taggaaccag	aattctctgc	tgccagtgtt	2220
tcttcttcaa	cacaaatc	acaagtctgc	ccactcccag	gaagaaagag	gagagaccct	2280
gagttctgac	cttttgatgg	tcaggcatga	tggaaagaaa	ctgctgtctac	agcttgggag	2340
atttgctctg	ggaagtctgc	cagtcaactt	tgcccttcta	accaccagat	caatatgtgg	2400
ctgatcatct	gatggggcag	ttgcaatcac	caagccttgt	tctctttcct	gttctgggat	2460

tgtgttgtgg	aacccttttc	cctagccacc	accagttcat	ttctgagggg	tggaacaaaa	2520
atgcagcatg	cccttcctgt	gtggtgcatg	ttcagtcctt	gacaaatfff	tacaaaaatg	2580
aagctacttt	atttaaaagg	aggggtgagag	gtgaggaggt	cactttgggt	gtggcggaaa	2640
gggaatgctg	catctttttc	ctgggctgct	ggggctctgg	ccttggcttg	ccagccggaa	2700
gcgctggcac	gcatcgcctt	cttttcccat	tgggtccagc	aatgaagacg	agtgtttggg	2760
gttttttttt	tctccaccat	gtagcaagtt	ctcaggaaaa	tacaattgat	atcttcctcc	2820
taagctcttc	caatcagtca	ccaagtactt	atgtggttac	tttgtccagg	gcacaaaatg	2880
cctgtatcta	attaaaagcc	tacaaaactg	cttgataaca	gttttgaatg	tgagacattt	2940
atgtaattta	aatgtaaggt	acaagtttta	atttctgagt	ttcttctatt	atatttttat	3000
taaaaaaaga	aaataatfff	cagattgaat	tggagtaaaa	taatattact	tcccactaga	3060
attatatatc	ctggaaaatt	gtatttttgt	tacataagca	gcttttaaaag	aaagatcatt	3120
acccttttct	ctacataaat	atatggggag	tcttagccta	atgacaaata	tttataatff	3180
ttaaattaat	ggtacttgct	ggatccatac	taacatcttt	actaatacct	cattgtttct	3240
tccaacttac	tcctacacta	catcctacat	cttcttccta	gtcttttatc	tagaatatgc	3300
aacctcaa	aaaaatgggt	gtgtcctcat	tcattctcct	ccttcctfff	ttcccaagcc	3360
tgatcttcaa	aaggttgggt	aatttggcag	ctgagttcct	cccaggcag	agaatagacc	3420
aattttaggt	gtattgggac	tgagggagga	tgtgtaaaga	ttaacatcag	taaagaaccg	3480
ctgtggagta	attaagaact	ttgttcttta	taactggaga	atataaccta	accctaacat	3540
ccctcagcct	ttactaaagt	gtggcgtaaa	tcacagtagt	agcaaagaaa	gtgactctgg	3600
atgtgttcct	ggccagtacc	tcccttatca	tgaatgtaga	ctctctcatc	aagatttagg	3660
aatataaatc	aaatcaa	tgcccagcca	agctatgtag	taagggactt	gaacaatatt	3720
aggcagaacc	tataaaataa	atcagggaat	tagaaattat	ttaaagtttt	caaattgtaa	3780
attgccccgg	tgtctttcag	cctactgcca	ttatttttgc	tacaatacct	acatttcaga	3840
ggagggccta	ctgaaaattc	catgcaagt	gaaaataatc	ctcaagttat	taatgagttt	3900
gaaaagcaat	gagttcttaa	gtctttgtga	gtagagcaag	atcctacaaa	attcagaaat	3960
agtaaaaatg	gattcatgct	gatttgaaga	gcatctgtgt	gcataatata	atgctgcatc	4020
tcttttaaaa	gcagtctatt	tttcttttta	aatttgtccc	catagatgct	tttgaacatg	4080
aacatgctta	tgttaccttt	tccgagggtg	ggaagagcca	ggagctctca	ggcagggccc	4140
cctccctcag	ctgggcagga	gctgctcagg	aggagctagt	tatagaggaa	gcttagcggt	4200
ggcattttca	aaattcaagg	tgataacgct	ttcttcttcc	tttctgtttt	agaatagatt	4260
gctgtctgat	ttgaaaaagg	gaaatagatt	tgatctcaaa	tgaatctgtg	cccagaagcc	4320
aggctcaggg	tattcagaga	tttgtatagt	gccctcaaaa	aataacaaaa	ttttagcttt	4380
ccttttttct	tcttttctcc	atcaaattct	tttttctcta	gtttacaaat	gacatggaaa	4440
aggaatttcc	cctgagtttt	gtatgccttt	tttttttgg	cttagactat	agataggcgt	4500

0398850pct.txt

gttgagctcc	taagaaaata	caaggaggaa	ctctttgttg	tgacagagcac	tttatgagta	4560
gtttgtgtgg	ataatatgtg	actgcttccc	tgacgagctt	gtgaggctgt	acttatgtct	4620
ttcctgtaag	gcagcttcag	tgcccttctgt	agtgtatata	aggaaagatt	acgccttctg	4680
aaaaatctca	gagcaacat	aagattat	taaaatatgt	agtatgactg	atggactttt	4740
tcatcattaa	attagtctag	catctaaact	tttaccactg	aaataatatt	gaccaaaaag	4800
caatttataa	aaggtatttg	tgaatagaaa	atacaatgtg	atcatttgta	cttatgtgca	4860
ccttaaaaga	ggaattctgt	ctagctgtca	aattctgggt	ccttaacatc	cagtccttga	4920
ttgtgattga	gatctggtag	gacgtgctgg	ggcacgctag	cagataaaat	cccgtatact	4980
ttaggataga	tgttacattt	atgtcagtg	tggcaaagag	cattgtgtag	taataaagaa	5040
ttcaagactt	cagcaatgtc	aacctgaaac	tttgtaaata	tttcctagat	tgttatttga	5100
tgacgtcaca	gctctttatc	acacaatgtt	gtctttccct	catcaggcaa	ttttagaact	5160
gctgcacacc	cctcctcaga	tctcacctgc	ccctcctgta	cattcacctc	tccagccttg	5220
tgacacctc	atttagcttt	agtttgaaac	acattgcagg	gttcagggtga	cctcttcaaa	5280
aactacctcc	tcagaatgag	gtaatgaata	gttattttatt	ttaaaatatg	aaaagtcagg	5340
agctctagaa	tatgaagatg	atctaagatt	ttaactttta	tgtatacttg	ttgagcactc	5400
tccttttgtc	ctaaagggca	ttatacattt	aagcagtaat	actgaaaaat	gtagctcaga	5460
gtaactgaat	gttggtgaaa	gtggtgccag	aatctgtttt	aggggtacgt	atcagaatct	5520
taatcttaaa	tcggttacat	gaaattaaat	agttaatggt	aacacttgac	taacagatat	5580
aattttaatt	ttcggtaggc	ttttagcaag	acagtaagta	catcttcata	atgagttagc	5640
cacagcttca	tcacatgcac	agattttcct	gttgagagac	tgcccagtta	agagggtaga	5700
atgatgaacc	atttttcagg	attctcttct	ttgtccaaac	tggcattgtg	agtgctagaa	5760
tatcagcact	ttcaaactag	tgattccaac	tattaggcta	ttaaaaagca	aaacaaacca	5820
aacaaacat	agccagacat	gggaagttaa	ctatgagtat	aaacagcaaa	tagcttacag	5880
gtcatacatt	gaaatggtgt	aggtaaggcg	ttagaaaaat	accttgacaa	tttgccaaat	5940
gatcttactg	tgcttcatg	atgcaataaa	aaaaaaaaaa	atttagcata	aatcagtgat	6000
ttgtgaagag	agcagccacc	ctggtctaac	tcagctgtgt	taatattttt	tagcgtgcaa	6060
tttagactgc	aaagataaat	gcactaaaga	gtttatagcc	aaaatcacat	ttaaaaaatg	6120
agagaaaaca	caggtaaatt	ttcagtgaac	aaaattat	ttttaagta	cataatccct	6180
agtatagtca	gatataat	tcacatagag	caaataaggt	gaaatcacia	ttcagtgaca	6240
tttctagaga	aactttttct	actcccatag	gttcttcaaa	gcatggaact	tttatataac	6300
agaaatgtgt	gacggtcatt	ttaaattgct	gtagtttggg	gctgaagtac	tgtgtgctgg	6360
gcagcaatca	catgtattaa	ctagtgagaa	aggagaaatt	aagatatagg	acagaatttg	6420
attttcttgt	tcccagatta	ctgctgccaa	cctagacact	gagtttccag	aggctgaaac	6480
gtaaacttgc	agctcagcaa	ctgttttgca	aagttagtgg	gactgtcctg	cttatgtctgt	6540

tcaaaaatgc tctgagggcc aggtggggcc tccaggggct cctctctgag gggacatcag 6600
 actagctaac gacctggcgg gcggatgtga accggacaca ctccatgggtg tgcttcttgt 6660
 atcgggtccct cgccaccctc aagaaaggct tcagcgggtt ctctagacgt ctccactaag 6720
 gtgtgttact aacagccatg ggttgttgag cacccgagga gtgcaatagc atctctgcat 6780
 gattgtatat tggcccgaag agaatgaagt ggccagtgtg ctcatgttcc atgttgctag 6840
 ctctggtaaa ctgaaaatac tggttaagatt tttgttttat cagtacacta gagagtaagc 6900
 tttgttttgt tgttttttaga taatgttttc acttccatit ggaaagacat ttaaattgag 6960
 tttcagtcct aaattttgcc agtcatggta attagcagtt tctatcaggt atttttaagg 7020
 tagaagagga tagaaacata agttctaaaa gcttaaggta accgtgggtt attttaaaat 7080
 gtttaggggt ggtagtctc tacctcaaaa aaagtgaagt aatcttttat ttcagcattc 7140
 acaagttcgg ctgttgtttt tgtaatacat ttttttttta accttttgac ccccttttac 7200
 ctaagtgtca atgtagtttt attaattact aagtcagttt cattaaaatg tttatttagc 7260
 agttttgact aattgcaatg attaatatag ccagttgtgc atgaggacac agccagtgag 7320
 tatactctggg ttttttttgt gatgcttttt ttcttaagac ttctgtagat ttatgaagta 7380
 ctcatgaaa acaactaaaa tacgtttatt cgtgttaata tggaaaaaaa aaaa 7434

<210> 40
 <211> 603
 <212> PRT
 <213> Bos taurus

<400> 40

Met Met Arg Gly Leu Ile Pro Glu Cys Cys Ala Val Tyr Arg Ile Gln
1 5 10 15

Asp Gly Glu Lys Lys Pro Ile Gly Trp Asp Thr Asp Ile Ser Trp Leu
20 25 30

Thr Gly Glu Glu Leu His Val Glu Val Leu Glu Asn Val Pro Leu Thr
35 40 45

Thr His Asn Phe Val Arg Lys Thr Phe Phe Thr Leu Ala Phe Cys Asp
50 55 60

Phe Cys Arg Lys Leu Leu Phe Gln Gly Phe Arg Cys Gln Thr Cys Gly
65 70 75 80

Tyr Lys Phe His Gln Arg Cys Ser Thr Glu Val Pro Leu Met Cys Val
85 90 95

Asn Tyr Asp Gln Leu Asp Leu Leu Phe Val Ser Lys Phe Phe Glu His
100 105 110

His Pro Ile Pro Gln Glu Glu Ala Ser Leu Ala Glu Thr Thr Leu Pro
115 120 125

Cys Gly Ser Ser Pro Ser Ala Pro Pro Ser Asp Ser Ile Gly Pro Pro
 130 135 140
 Ile Leu Thr Ser Pro Ser Pro Ser Lys Ser Ile Pro Ile Pro Gln Pro
 145 150 155 160
 Phe Arg Pro Ala Asp Glu Asp His Arg Asn Gln Phe Gly Gln Arg Asp
 165 170 175
 Arg Ser Ser Ser Ala Pro Asn Val His Ile Asn Thr Ile Glu Pro Val
 180 185 190
 Asn Ile Asp Asp Leu Ile Arg Asp Gln Gly Phe Arg Ser Asp Gly Gly
 195 200 205
 Ser Thr Thr Gly Leu Ser Ala Thr Pro Pro Ala Ser Leu Pro Gly Ser
 210 215 220
 Leu Ser Asn Val Lys Ala Leu Gln Lys Ser Pro Gly Pro Gln Arg Glu
 225 230 235 240
 Arg Lys Ser Ser Ser Ser Ser Glu Asp Arg Asn Arg Met Lys Thr Leu
 245 250 255
 Gly Arg Arg Asp Ser Ser Asp Asp Trp Glu Ile Pro Asp Gly Gln Ile
 260 265 270
 Thr Val Gly Gln Arg Ile Gly Ser Gly Ser Phe Gly Thr Val Tyr Lys
 275 280 285
 Gly Lys Trp His Gly Asp Val Ala Val Lys Met Leu Asn Val Thr Ala
 290 295 300
 Pro Thr Pro Gln Gln Leu Gln Ala Phe Lys Asn Glu Val Gly Val Leu
 305 310 315 320
 Arg Lys Thr Arg His Val Asn Ile Leu Leu Phe Met Gly Tyr Ser Thr
 325 330 335
 Lys Pro Gln Leu Ala Ile Val Thr Gln Trp Cys Glu Gly Ser Ser Leu
 340 345 350
 Tyr His His Leu His Ile Ile Glu Thr Lys Phe Glu Met Ile Lys Leu
 355 360 365
 Ile Asp Ile Ala Arg Gln Thr Ala Gln Gly Met Asp Tyr Leu His Ala
 370 375 380
 Lys Ser Ile Ile His Arg Asp Leu Lys Ser Asn Asn Ile Phe Leu His
 385 390 395 400

Glu Asp Leu Thr Val Lys Ile Gly Asp Phe Gly Leu Ala Thr Val Lys
 405 410 415

Ser Arg Trp Ser Gly Ser His Gln Phe Glu Gln Leu Ser Gly Ser Ile
 420 425 430

Leu Trp Met Ala Pro Glu Val Ile Arg Met Gln Asp Lys Asn Pro Tyr
 435 440 445

Ser Phe Gln Ser Asp Val Tyr Ala Phe Gly Ile Val Leu Tyr Glu Leu
 450 455 460

Met Thr Gly Gln Leu Pro Tyr Ser Asn Ile Asn Asn Arg Asp Gln Ile
 465 470 475 480

Ile Phe Met Val Gly Arg Gly Tyr Leu Ser Pro Asp Leu Ser Lys Val
 485 490 495

Arg Ser Asn Cys Pro Lys Ala Met Lys Arg Leu Met Ala Glu Cys Leu
 500 505 510

Lys Lys Lys Arg Asp Glu Arg Pro Leu Phe Pro Gln Val Gly Lys Thr
 515 520 525

Leu Leu Ser Lys Arg Gln Asn Ser Glu Val Ile Arg Glu Lys Asp Lys
 530 535 540

Gln Ile Leu Ala Ser Ile Glu Leu Leu Ala Arg Ser Leu Pro Lys Ile
 545 550 555 560

His Arg Ser Ala Ser Glu Pro Ser Leu Asn Arg Ala Gly Phe Gln Thr
 565 570 575

Glu Asp Phe Ser Leu Tyr Ala Cys Ala Ser Pro Lys Thr Pro Ile Gln
 580 585 590

Ala Gly Gly Tyr Gly Glu Phe Ala Ala Phe Lys
 595 600

<210> 41
 <211> 2295
 <212> DNA
 <213> Equus caballus

<220>
 <221> misc_feature
 <222> (79)..(79)
 <223> n is a, c, g, or t

<400> 41
 atgaagacgc tgagcggcgg cggcggcggc gcggagcagg gccaggctct gttcaacggg

60

gacatggaac	ccggaggcnc	cgcgccggcg	cccgcggcct	cgtcggccgc	ggaccctgcc	120
attcccagg	aggtatgaa	tatcaaaca	atgattaaat	tgacacagga	acatatagag	180
gccctattg	acaaatttg	tggggagcat	aatccacat	caatatatct	ggaggcctat	240
gaagaataca	ccagcaagct	agatgccctc	caacaaagag	aacaacagtt	attggaatcc	300
ctggggaatg	gaactgattt	ttctgtttct	agttctgcat	caacggacac	cgttacatct	360
tcttcctctt	ctagcctttc	agtgtctac	tcattctctt	cagtttttca	aaatcccaca	420
gatgtgtcac	ggagcaaccc	taagtcacca	caaaaaccta	tcgttagagt	cttcctgccc	480
aacaaacaga	ggacagtgg	acctgcaagg	tgtggcggtta	cagtccggga	cagtctaaag	540
aaagcactga	tgatgagagg	tctaattcca	gagtgtctgt	ctgtttacag	aattcaggat	600
ggagagaaga	aaccaattgg	ctgggacact	gatatttcct	ggctcactgg	agaggaattg	660
catgtagaag	tgttggagaa	tgttccactt	acaacacaca	actttgtacg	gaaaactttt	720
ttcaccttag	cattttgtga	ctttgtcga	aagctgcttt	tccagggttt	ccgctgtcaa	780
acatgtgggt	ataaatttca	ccagcgttgt	agtacagagg	ttccactgat	gtgtgttaat	840
tatgaccaac	ttgatttgct	gtttgtctcc	aagttctttg	aacaccaccc	agtatcacag	900
gaggaggcct	ccttagcaga	gactgccctt	acatctggat	catccccttc	tgcaccccc	960
tccgattcca	ttgggcccc	aattctcacc	agtccatctc	cttcaaaatc	cattccaatt	1020
ccacagcctt	tccgaccagc	agatgaagat	catcgaaatc	agtttgga	acgagaccgg	1080
tcctcatcag	ctccaaatgt	acatataaac	acaatagaac	ctgtcaatat	tgatgacttg	1140
attagagacc	aagggtttcg	tagtgatgga	ggatcaacca	caggtttatc	tgccaccccc	1200
cctgcctcat	tacctggctc	actcactaat	gtgaaggcat	tacagaaatc	tccaggacct	1260
caacgggaaa	ggaaatcatc	ttcatcctca	gaagacagga	atcgaatgaa	aactcttggt	1320
agacgggatt	caagtgcga	ttgggagatt	cctgatgggc	agatcacagt	gggacaaaga	1380
attggatctg	ggtcatttgg	gacagtctac	aagggaaggt	ggcatggtga	tgtggcagtg	1440
aaaatgttga	atgtgacagc	accacacact	cagcagttac	aggccttcaa	aatgaagta	1500
ggagtactca	ggaaaactcg	acatgtgaat	atcctactct	tcattgggcta	ttcaacaaag	1560
ccacaactgg	ctattgttac	ccagtgggtg	gagggctcca	gcttatatca	ccatctccac	1620
atcattgaga	ccaaatttga	gatgatcaaa	cttatagata	ttgctcggca	aactgcacag	1680
ggcatggatt	acttacacgc	caagtcaatc	atccacagag	acctcaagag	taataatatt	1740
tttcttcatg	aagacctcac	agtaaaaata	ggtgattttg	gtctagccac	agtgaatct	1800
cgatggagtg	ggtcccatca	gtttgaacag	ttgtctggat	ccattttgtg	gatggcacca	1860
gaagtaatca	gaatgcaaga	taaaaacccg	tatagctttc	aatcagatgt	atatgccttt	1920
gggattgttc	tgtatgaatt	gatgactgga	cagttacctt	attcaaacat	caacaacagg	1980
gaccagataa	tttttatggg	gggaagagga	tatctatctc	cagatctcag	taaggtagcg	2040
agtaactgtc	caaaagccat	gaagagatta	atggcagagt	gcctaaaaaa	gaaaagagac	2100

gagagaccac tcttccccca aattctcgcc tctattgagc tgctggcccg ctcattgccca 2160
 aaaattcacc gcagtgcac agagccctcc ttgaatcggg ctggcttcca gacagaggat 2220
 tttagtctat atgcttgatg tttctccgaaa acacccatcc aggcagggggg atatggtgcg 2280
 tttcctgtcc actga 2295

<210> 42
 <211> 764
 <212> PRT
 <213> Equus caballus

<220>
 <221> misc_feature
 <222> (27)..(27)
 <223> Xaa can be any naturally occurring amino acid

<400> 42

Met Lys Thr Leu Ser Gly Gly Gly Gly Gly Ala Glu Gln Gly Gln Ala
 1 5 10 15

Leu Phe Asn Gly Asp Met Glu Pro Gly Gly Xaa Ala Pro Ala Pro Ala
 20 25 30

Ala Ser Ser Ala Ala Asp Pro Ala Ile Pro Glu Glu Val Trp Asn Ile
 35 40 45

Lys Gln Met Ile Lys Leu Thr Gln Glu His Ile Glu Ala Leu Leu Asp
 50 55 60

Lys Phe Gly Gly Glu His Asn Pro Pro Ser Ile Tyr Leu Glu Ala Tyr
 65 70 75 80

Glu Glu Tyr Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg Glu Gln Gln
 85 90 95

Leu Leu Glu Ser Leu Gly Asn Gly Thr Asp Phe Ser Val Ser Ser Ser
 100 105 110

Ala Ser Thr Asp Thr Val Thr Ser Ser Ser Ser Ser Ser Leu Ser Val
 115 120 125

Leu Pro Ser Ser Leu Ser Val Phe Gln Asn Pro Thr Asp Val Ser Arg
 130 135 140

Ser Asn Pro Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe Leu Pro
 145 150 155 160

Asn Lys Gln Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr Val Arg
 165 170 175

Asp Ser Leu Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro Glu Cys
 180 185 190

Cys Ala Val Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile Gly Trp
 195 200 205
 Asp Thr Asp Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val Glu Val
 210 215 220
 Leu Glu Asn Val Pro Leu Thr Thr His Asn Phe Val Arg Lys Thr Phe
 225 230 235 240
 Phe Thr Leu Ala Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe Gln Gly
 245 250 255
 Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Gln Arg Cys Ser Thr
 260 265 270
 Glu Val Pro Leu Met Cys Val Asn Tyr Asp Gln Leu Asp Leu Leu Phe
 275 280 285
 Val Ser Lys Phe Phe Glu His His Pro Val Ser Gln Glu Glu Ala Ser
 290 295 300
 Leu Ala Glu Thr Ala Leu Thr Ser Gly Ser Ser Pro Ser Ala Pro Pro
 305 310 315 320
 Ser Asp Ser Ile Gly Pro Gln Ile Leu Thr Ser Pro Ser Pro Ser Lys
 325 330 335
 Ser Ile Pro Ile Pro Gln Pro Phe Arg Pro Ala Asp Glu Asp His Arg
 340 345 350
 Asn Gln Phe Gly Gln Arg Asp Arg Ser Ser Ser Ala Pro Asn Val His
 355 360 365
 Ile Asn Thr Ile Glu Pro Val Asn Ile Asp Asp Leu Ile Arg Asp Gln
 370 375 380
 Gly Phe Arg Ser Asp Gly Gly Ser Thr Thr Gly Leu Ser Ala Thr Pro
 385 390 395 400
 Pro Ala Ser Leu Pro Gly Ser Leu Thr Asn Val Lys Ala Leu Gln Lys
 405 410 415
 Ser Pro Gly Pro Gln Arg Glu Arg Lys Ser Ser Ser Ser Ser Glu Asp
 420 425 430
 Arg Asn Arg Met Lys Thr Leu Gly Arg Arg Asp Ser Ser Asp Asp Trp
 435 440 445
 Glu Ile Pro Asp Gly Gln Ile Thr Val Gly Gln Arg Ile Gly Ser Gly
 450 455 460

Ser Phe Gly Thr Val Tyr Lys Gly Lys Trp His Gly Asp Val Ala Val
 465 470 475 480
 Lys Met Leu Asn Val Thr Ala Pro Thr Pro Gln Gln Leu Gln Ala Phe
 485 490 495
 Lys Asn Glu Val Gly Val Leu Arg Lys Thr Arg His Val Asn Ile Leu
 500 505 510
 Leu Phe Met Gly Tyr Ser Thr Lys Pro Gln Leu Ala Ile Val Thr Gln
 515 520 525
 Trp Cys Glu Gly Ser Ser Leu Tyr His His Leu His Ile Ile Glu Thr
 530 535 540
 Lys Phe Glu Met Ile Lys Leu Ile Asp Ile Ala Arg Gln Thr Ala Gln
 545 550 555 560
 Gly Met Asp Tyr Leu His Ala Lys Ser Ile Ile His Arg Asp Leu Lys
 565 570 575
 Ser Asn Asn Ile Phe Leu His Glu Asp Leu Thr Val Lys Ile Gly Asp
 580 585 590
 Phe Gly Leu Ala Thr Val Lys Ser Arg Trp Ser Gly Ser His Gln Phe
 595 600 605
 Glu Gln Leu Ser Gly Ser Ile Leu Trp Met Ala Pro Glu Val Ile Arg
 610 615 620
 Met Gln Asp Lys Asn Pro Tyr Ser Phe Gln Ser Asp Val Tyr Ala Phe
 625 630 635 640
 Gly Ile Val Leu Tyr Glu Leu Met Thr Gly Gln Leu Pro Tyr Ser Asn
 645 650 655
 Ile Asn Asn Arg Asp Gln Ile Ile Phe Met Val Gly Arg Gly Tyr Leu
 660 665 670
 Ser Pro Asp Leu Ser Lys Val Arg Ser Asn Cys Pro Lys Ala Met Lys
 675 680 685
 Arg Leu Met Ala Glu Cys Leu Lys Lys Lys Arg Asp Glu Arg Pro Leu
 690 695 700
 Phe Pro Gln Ile Leu Ala Ser Ile Glu Leu Leu Ala Arg Ser Leu Pro
 705 710 715 720
 Lys Ile His Arg Ser Ala Ser Glu Pro Ser Leu Asn Arg Ala Gly Phe
 725 730 735

Gln Thr Glu Asp Phe Ser Leu Tyr Ala Cys Ala Ser Pro Lys Thr Pro
740 745 750

Ile Gln Ala Gly Gly Tyr Gly Ala Phe Pro Val His
755 760

<210>	43
<211>	2678
<212>	DNA
<213>	Gallus gallus

<400>	43					
tccccctccc	tcgccccagc	gcttcgatcc	aagatggcgg	cgctgagcag	cggcagcagc	60
gccgaggggg	cctcgctctt	caacggggac	atggagcccg	agccgccgcc	gcccgtgctg	120
ggcgcctgct	acgccgggag	cggcggcggc	gacccggcca	tcccggagga	ggtgtggaat	180
atcaaacaga	tgattaaatt	aacacaagaa	catatagaag	cgctgttaga	caagtttggg	240
ggagagcata	accaccatc	aatatattta	gaggcctatg	aggagtacac	cagcaaaacta	300
gatgctctac	agcagagaga	acagcagtta	ttggaatcca	tgggaaatgg	aactgatttc	360
tctgtttcca	gttcagcttc	aacggacaca	gttgcatcat	cttcctcctc	tagcctctct	420
gtagcacctt	catccctttc	agtttatcaa	aatcctactg	atatgtcgcg	gaataaccct	480
aagtctccac	agaagcctat	tgttagagtc	ttcctgcca	acaagcaaag	gactgtgggt	540
ccggcaagat	gtggggtgac	agtccgagac	agcctgaaga	aagctctgat	gatgagaggt	600
cttattccag	aatgctgtgc	tgtttacaga	atacaggatg	gagagaagaa	gccaattggc	660
tgggacactg	acatttcctg	gctaaccgga	gaggagttag	acgtggaggt	cttggagaat	720
gtgccactca	caacacacaa	ttttgtacga	aaaacattct	tcacgttagc	gttctgcgac	780
ttctgtcgaa	agctgctttt	ccagggattc	cgatgccaga	catgtggcta	caaatttcac	840
cagcgctgta	gcacagaagt	gccactgatg	tgtgttaact	acgaccaact	cgatttgctg	900
tttgtctcca	agttctttga	acatcacccc	atatcgcagg	aggagaccac	cttaggagag	960
accaccccgg	catcgggatc	gtaccctca	gtgcccccat	cagattctgt	tggaccacca	1020
attctcccta	gtccttctcc	ttcaaaatcc	attccaatcc	cacagccctt	ccgaccagca	1080
gatgaagacc	atcggaatca	gtttgggcaa	cgcgaccgat	cctcttcagc	tcccaatgtt	1140
cacatcaata	caattgagcc	agtcaatatt	gatgacttga	ttagagacca	gggtgtacga	1200
ggagagggag	cccctttgaa	ccagctgatg	cgctgtcttc	ggaaatacca	atcccggact	1260
cccagtcccc	tccttcattc	tgtccccagt	gaaatagtgt	ttgattttga	gcctggccca	1320
gtgttcagag	gttcaactgc	aggtttgtct	gcaacacctc	ctgcatcttt	gcctgggtca	1380
cttaccaatg	tgaaagcatt	acagaaatca	ccaggccccc	aacgggaaag	gaaatcatcc	1440
tcatcctcag	aagacagaaa	taggatgaaa	acccttggtc	gacgagattc	aagtgatgat	1500
tgggaaatac	cagatgggca	gatcacagtt	ggacaaagga	taggatctgg	atcatttggg	1560

0398850pct.txt

acagtctaca aaggaaagtg gcatgggtgac gtggcagtga aaatgttgaa tgttacagca 1620
 cccacacctc aacagttaca ggctttcaaa aatgaagtag gagtgtcag gaaaacacgg 1680
 catgtgaata tcctactttt tatgggttat tcaacaaaac ctcagttggc tattgttaca 1740
 cagtgggtgtg aggggtccag cttatatcac catctgcaca taattgagac caagtttgaa 1800
 atgatcaaac taattgatat tgcacgacag actgcacaag gcatggatta tttgcatgcc 1860
 aagtcaatca tccacagaga cctcaagagt aataatattt ttcttcatga agacctcaca 1920
 gtaaaaatag gtgacttcgg tctgggtaca gtgaaatcac gatggagtgg atctcatcaa 1980
 tttgaacagt tatctggatc aattctatgg atggcaccgg aagtgatcag gatgcaagac 2040
 aaaaacccat atagctttca gtcagatgtg tatgcattcg ggattgtgct ttatgaactg 2100
 atgactggac agttaccata ctcaaacatc aacaacaggg accagataat ttttatggtg 2160
 ggacgaggat atctatctcc agacctcagt aaagtaagaa gtaactgtcc aaaagctatg 2220
 aagagactaa tggcagaatg cttgaaaaag aaaagagatg agagacctct tttccacag 2280
 attcttgctt ccattgagct tctggcccgg tcgttgccaa aaattcaccg cagtgcattc 2340
 gagccgtcac taaaccgggc tggcttccag accgaggatt tcagtctgta tgcttgtgct 2400
 tctccaaaaa cgcccatcca agcaggggga tacggtgggt ttccagtaca ctgaaaagaa 2460
 atgtgaaagc gtgtgcctgt ttgctcatgt gctggtgtgt tcctgtgtgt gcaacgcata 2520
 cgtacgttct cagttcctac cagcgacttt ttaaggttta ctgaggggaat gaagactcat 2580
 ttctaacaat ggggcattga acgtcctgag cacaagtcag tgctggtaag gaatgtcttg 2640
 ggaacagctg gcaagaagaa ttagaaggta cttaaagg 2678

<210> 44
 <211> 806
 <212> PRT
 <213> Gallus gallus

<400> 44

Met Ala Ala Leu Ser Ser Gly Ser Ser Ala Glu Gly Ala Ser Leu Phe
 1 5 10 15

Asn Gly Asp Met Glu Pro Glu Pro Pro Pro Pro Val Leu Gly Ala Cys
 20 25 30

Tyr Ala Gly Ser Gly Gly Gly Asp Pro Ala Ile Pro Glu Glu Val Trp
 35 40 45

Asn Ile Lys Gln Met Ile Lys Leu Thr Gln Glu His Ile Glu Ala Leu
 50 55 60

Leu Asp Lys Phe Gly Gly Glu His Asn Pro Pro Ser Ile Tyr Leu Glu
 65 70 75 80

Ala Tyr Glu Glu Tyr Thr Ser Lys Leu Asp Ala Leu Gln Gln Arg Glu
 85 90 95

Gln Gln Leu Leu Glu Ser Met Gly Asn Gly Thr Asp Phe Ser Val Ser
 100 105 110
 Ser Ser Ala Ser Thr Asp Thr Val Ala Ser Ser Ser Ser Ser Ser Leu
 115 120 125
 Ser Val Ala Pro Ser Ser Leu Ser Val Tyr Gln Asn Pro Thr Asp Met
 130 135 140
 Ser Arg Asn Asn Pro Lys Ser Pro Gln Lys Pro Ile Val Arg Val Phe
 145 150 155 160
 Leu Pro Asn Lys Gln Arg Thr Val Val Pro Ala Arg Cys Gly Val Thr
 165 170 175
 Val Arg Asp Ser Leu Lys Lys Ala Leu Met Met Arg Gly Leu Ile Pro
 180 185 190
 Glu Cys Cys Ala Val Tyr Arg Ile Gln Asp Gly Glu Lys Lys Pro Ile
 195 200 205
 Gly Trp Asp Thr Asp Ile Ser Trp Leu Thr Gly Glu Glu Leu His Val
 210 215 220
 Glu Val Leu Glu Asn Val Pro Leu Thr Thr His Asn Phe Val Arg Lys
 225 230 235 240
 Thr Phe Phe Thr Leu Ala Phe Cys Asp Phe Cys Arg Lys Leu Leu Phe
 245 250 255
 Gln Gly Phe Arg Cys Gln Thr Cys Gly Tyr Lys Phe His Gln Arg Cys
 260 265 270
 Ser Thr Glu Val Pro Leu Met Cys Val Asn Tyr Asp Gln Leu Asp Leu
 275 280 285
 Leu Phe Val Ser Lys Phe Phe Glu His His Pro Ile Ser Gln Glu Glu
 290 295 300
 Thr Thr Leu Gly Glu Thr Thr Pro Ala Ser Gly Ser Tyr Pro Ser Val
 305 310 315 320
 Pro Pro Ser Asp Ser Val Gly Pro Pro Ile Leu Pro Ser Pro Ser Pro
 325 330 335
 Ser Lys Ser Ile Pro Ile Pro Gln Pro Phe Arg Pro Ala Asp Glu Asp
 340 345 350
 His Arg Asn Gln Phe Gly Gln Arg Asp Arg Ser Ser Ser Ala Pro Asn
 355 360 365

Val His Ile Asn Thr Ile Glu Pro Val Asn Ile Asp Asp Leu Ile Arg
 370 375 380
 Asp Gln Gly Val Arg Gly Glu Gly Ala Pro Leu Asn Gln Leu Met Arg
 385 390 395 400
 Cys Leu Arg Lys Tyr Gln Ser Arg Thr Pro Ser Pro Leu Leu His Ser
 405 410 415
 Val Pro Ser Glu Ile Val Phe Asp Phe Glu Pro Gly Pro Val Phe Arg
 420 425 430
 Gly Ser Thr Ala Gly Leu Ser Ala Thr Pro Pro Ala Ser Leu Pro Gly
 435 440 445
 Ser Leu Thr Asn Val Lys Ala Leu Gln Lys Ser Pro Gly Pro Gln Arg
 450 455 460
 Glu Arg Lys Ser Ser Ser Ser Ser Glu Asp Arg Asn Arg Met Lys Thr
 465 470 475 480
 Leu Gly Arg Arg Asp Ser Ser Asp Asp Trp Glu Ile Pro Asp Gly Gln
 485 490 495
 Ile Thr Val Gly Gln Arg Ile Gly Ser Gly Ser Phe Gly Thr Val Tyr
 500 505 510
 Lys Gly Lys Trp His Gly Asp Val Ala Val Lys Met Leu Asn Val Thr
 515 520 525
 Ala Pro Thr Pro Gln Gln Leu Gln Ala Phe Lys Asn Glu Val Gly Val
 530 535 540
 Leu Arg Lys Thr Arg His Val Asn Ile Leu Leu Phe Met Gly Tyr Ser
 545 550 555 560
 Thr Lys Pro Gln Leu Ala Ile Val Thr Gln Trp Cys Glu Gly Ser Ser
 565 570 575
 Leu Tyr His His Leu His Ile Ile Glu Thr Lys Phe Glu Met Ile Lys
 580 585 590
 Leu Ile Asp Ile Ala Arg Gln Thr Ala Gln Gly Met Asp Tyr Leu His
 595 600 605
 Ala Lys Ser Ile Ile His Arg Asp Leu Lys Ser Asn Asn Ile Phe Leu
 610 615 620
 His Glu Asp Leu Thr Val Lys Ile Gly Asp Phe Gly Leu Ala Thr Val
 625 630 635 640

Lys Ser Arg Trp Ser Gly Ser His Gln Phe Glu Gln Leu Ser Gly Ser
645 650 655

Ile Leu Trp Met Ala Pro Glu Val Ile Arg Met Gln Asp Lys Asn Pro
660 665 670

Tyr Ser Phe Gln Ser Asp Val Tyr Ala Phe Gly Ile Val Leu Tyr Glu
675 680 685

Leu Met Thr Gly Gln Leu Pro Tyr Ser Asn Ile Asn Asn Arg Asp Gln
690 695 700

Ile Ile Phe Met Val Gly Arg Gly Tyr Leu Ser Pro Asp Leu Ser Lys
705 710 715 720

Val Arg Ser Asn Cys Pro Lys Ala Met Lys Arg Leu Met Ala Glu Cys
725 730 735

Leu Lys Lys Lys Arg Asp Glu Arg Pro Leu Phe Pro Gln Ile Leu Ala
740 745 750

Ser Ile Glu Leu Leu Ala Arg Ser Leu Pro Lys Ile His Arg Ser Ala
755 760 765

Ser Glu Pro Ser Leu Asn Arg Ala Gly Phe Gln Thr Glu Asp Phe Ser
770 775 780

Leu Tyr Ala Cys Ala Ser Pro Lys Thr Pro Ile Gln Ala Gly Gly Tyr
785 790 795 800

Gly Gly Phe Pro Val His
805

<210> 45
<211> 4454
<212> DNA
<213> Homo sapiens

<400> 45
gaaacgtccc gtgtgggagg ggcgggtctg ggtgcggcct gccgcatgac tcgtggttcg 60
gaggccacg tggccggggc ggggactcag gcgcctgggg cgccgactga ttacgtagcg 120
ggcggggccg gaagtgccgc tccttggttg gggctgttca tggcggttcc ggggtctcca 180
acatttttcc cggctgtggt cctaaatctg tccaaagcag aggcagtgga gcttgaggtt 240
cttgctggtg tgaaatgact gagtacaaac tggtggtggt tggagcaggt ggtgttgga 300
aaagcgact gacaatccag ctaatccaga accactttgt agatgaatat gatccacca 360
tagaggattc ttacagaaaa caagtgggta tagatggtga aacctgtttg ttggacatac 420
tggatacagc tggacaagaa gagtacagt ccatgagaga ccaatacatg aggacaggcg 480

aaggcttcct	ctgtgtat	ttt gccatcaata	atagcaagtc	atttgcgat	attaacctct	540
acagggagca	gattaagcga	gtaaaagact	cggatgatgt	acctatggtg	ctagtgggaa	600
acaagtgtga	tttgccaaca	aggacagttg	atacaaaaca	agcccacgaa	ctggccaaga	660
gttacgggat	tccattcatt	gaaacctcag	ccaagaccag	acaggggtgtt	gaagatgctt	720
tttacacact	ggtaagagaa	atacgccagt	accgaatgaa	aaaactcaac	agcagtgatg	780
atgggactca	gggttgtatg	ggattgccat	gtgtggtgat	gtaacaagat	acttttaaag	840
ttttgtcaga	aaagagccac	tttcaagctg	cactgacacc	ctggtcctga	cttccctgga	900
ggagaagtat	tcctgttgct	gtcttcagtc	tcacagagaa	gctcctgcta	cttccccagc	960
tctcagtagt	ttagtacaat	aatctctatt	tgagaagttc	tcagaataac	tacctcctca	1020
cttggctgtc	tgaccagaga	atgcacctct	tgttactccc	tgttatTTTT	ctgccctggg	1080
ttcttccaca	gcacaaacac	acctctgcca	ccccaggttt	ttcatctgaa	aagcagttca	1140
tgtctgaaac	agagaaccaa	accgcaaacg	tgaaattcta	ttgaaaacag	tgtcttgagc	1200
tctaaagtag	caactgctgg	tgattTTTTT	tttctTTTTa	ctgttgaact	tagaactatg	1260
ctaattTTTT	gagaaatgtc	ataaattact	gttttgccaa	gaatatagtt	attattgctg	1320
tttggtttgt	ttataatggt	atcggtctta	ttctctaaac	tggcatctgc	tctagattca	1380
taaatacaaaa	aatgaatact	gaattttgag	tctatcctag	tcttcacaac	tttgacgtaa	1440
ttaaatccaa	ctttcacagt	gaagtgcctt	tttcttagaa	gtggtttgta	gacttccttt	1500
ataatatttc	agtggaatag	atgtctcaaa	aatccttatg	catgaaatga	atgtctgaga	1560
tacgtctgtg	acttatctac	cattgaagga	aagctatatc	tatttgagag	cagatgccat	1620
tttgtacatg	tatgaaattg	gttttccaga	ggcctgtttt	ggggctttcc	caggagaaaag	1680
atgaaactga	aagcacatga	ataatttcac	ttaataatTT	ttacctaatc	tccactTTTT	1740
tcataggtta	ctacctatac	aatgtatgta	atttgtttcc	cctagcttac	tgataaacct	1800
aatattcaat	gaacttccat	ttgtattcaa	atttggtgta	taccagaaaag	ctctacattt	1860
gcagatgttc	aaatattgta	aaactttggt	gcattgttat	ttaatagctg	tgatcagtga	1920
ttttcaaacc	tcaaatatag	tatattaaca	aattacattt	tactgtata	tcatggtatc	1980
ttaatgatgt	atataattgc	cttcaatccc	cttctcacc	cacctctac	agcttcccc	2040
acagcaatag	gggcttgatt	atttcagttg	agtaaagcat	ggtgctaata	gaccaggggtc	2100
acagtttcaa	aacttgaaca	atccagttag	catcacagag	aaagaaattc	ttctgcattt	2160
gctcattgca	ccagtaactc	cagctagtaa	ttttgctagg	tagctgcagt	tagccctgca	2220
aggaaagaag	aggtcagtta	gcacaaaccc	tttaccatga	ctggaaaact	cagtatcacg	2280
tatttaaaca	tttttttttc	ttttagccat	gtagaaactc	taaattaagc	caatattctc	2340
atttgagaat	gaggatgtct	cagctgagaa	acgtttttaa	ttctctttat	tcataatggt	2400
ctttgaaggg	tttaaaacaa	gatgttgata	aatctaagct	gatgagtttg	ctcaaaacag	2460
gaagttgaaa	ttgttgagac	aggaatggaa	aatataatta	attgatacct	atgaggattt	2520

0398850pct.txt

ggaggcttgg	cattttaatt	tgcagataat	accctggtaa	ttctcatgaa	aaatagactt	2580
ggataacttt	tgataaaaga	ctaattccaa	aatggccact	ttgttcctgt	ctttaatatc	2640
taaatactta	ctgaggtcct	ccatcttcta	tattatgaat	tttcatttat	taagcaaagt	2700
tcatattacc	ttgaaattca	gaagagaaga	aacatatact	gtgtccagag	tataatgaac	2760
ctgcagagtt	gtgcttctta	ctgctaattc	tgggagcttt	cacagtactg	tcatcatttg	2820
taaatggaaa	ttctgctttt	ctgtttctgc	tccttctgga	gcagtgtctac	tctgtaattt	2880
tcctgaggct	tatcacctca	gtcatttctt	ttttaaatgt	ctgtgactgg	cagtgtattct	2940
ttttcttaaa	aatctattaa	atttgatgtc	aaattagggg	gaaagatagt	tactcatctt	3000
gggctcttgt	gccaatagcc	cttgatgtga	tgtacttaga	gttttccaag	tatgtttctaa	3060
gcacagaagt	ttctaaatgg	ggccaaaatt	cagacttgag	tatgttcttt	gaatacctta	3120
agaagttaca	attagccggg	catgggtggc	cgtgcctgta	gtcccagcta	cttgagaggc	3180
tgaggcagga	gaatcacttc	aaccaggag	gtggagggtta	cagttagcag	agatcgtgcc	3240
actgcactcc	agcctgggtg	acaagagaga	cttgtctcca	aaaaaaaaagt	tacacctagg	3300
tgtgaatttt	ggcaciaaagg	agtgacaaac	ttatagttaa	aagctgaata	acttcagtgt	3360
ggataaaaac	gtggttttta	ggctatgttt	gtgattgctg	aaaagaattc	tagttttacct	3420
caaaatcctt	ctctttcccc	aaattaagtg	cctggccagc	tgtcataaat	tacatattcc	3480
ttttggtttt	tttaaagggtt	acatgttcaa	gagtgaaaat	aagatgttct	gtctgaaggc	3540
taccatgccg	gatctgtaaa	tgaacctgtt	aaatgctgta	tttgctccaa	cggcttacta	3600
tagaatgtta	cttaatacaa	tatcatactt	attacaattt	ttactatagg	agtgtaatag	3660
gtaaaattaa	tctctatttt	agtggggcca	tgtttagtct	ttcaccatcc	tttaaactgc	3720
tgtgaatttt	tttgtcatga	cttgaaagca	aggatagaga	aacacttttag	agatatgtgg	3780
ggttttttta	ccattccaga	gcttgtgagc	ataatcatat	ttgctttata	tttatagtca	3840
tgaactccta	agttggcagc	tacaaccaag	aacaaaaaaa	tgggtgcgttc	tgcttcttgt	3900
aattcatctc	tgctaataaa	ttataagaag	caaggaaaat	tagggaaaat	attttatttg	3960
gatggtttct	ataaacaagg	gactataatt	cttgtacatt	atttttcatc	tttgctgttt	4020
ctttgagcag	tctaattgtc	cacacaatta	tctaagggtat	ttgttttcta	taagaattgt	4080
tttaaaagta	ttcttgttac	cagagtagtt	gtattatatt	tcaaaacgta	agatgatttt	4140
taaaagcctg	agtactgacc	taagatggaa	ttgtatgaac	tctgctctgg	agggagggga	4200
ggatgtccgt	ggaagttgta	agacttttat	ttttttgtgc	catcaaatat	aggtaaaaat	4260
aattgtgcaa	ttctgctgtt	taaacaggaa	ctattggcct	ccttggccct	aaatggaagg	4320
gccgatattt	taagttgatt	attttattgt	aaattaatcc	aacctagttc	tttttaattt	4380
ggttgaatgt	tttttcttgt	taaatgatgt	ttaaaaaata	aaaactggaa	gttcttggct	4440
tagtcataat	tctt					4454

<211> 189
 <212> PRT
 <213> Homo sapiens

<400> 46

Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Gly Val Gly Lys
 1 5 10 15

Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr
 20 25 30

Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly
 35 40 45

Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu Glu Tyr
 50 55 60

Ser Ala Met Arg Asp Gln Tyr Met Arg Thr Gly Glu Gly Phe Leu Cys
 65 70 75 80

Val Phe Ala Ile Asn Asn Ser Lys Ser Phe Ala Asp Ile Asn Leu Tyr
 85 90 95

Arg Glu Gln Ile Lys Arg Val Lys Asp Ser Asp Asp Val Pro Met Val
 100 105 110

Leu Val Gly Asn Lys Cys Asp Leu Pro Thr Arg Thr Val Asp Thr Lys
 115 120 125

Gln Ala His Glu Leu Ala Lys Ser Tyr Gly Ile Pro Phe Ile Glu Thr
 130 135 140

Ser Ala Lys Thr Arg Gln Gly Val Glu Asp Ala Phe Tyr Thr Leu Val
 145 150 155 160

Arg Glu Ile Arg Gln Tyr Arg Met Lys Lys Leu Asn Ser Ser Asp Asp
 165 170 175

Gly Thr Gln Gly Cys Met Gly Leu Pro Cys Val Val Met
 180 185

<210> 47
 <211> 1326
 <212> DNA
 <213> Rattus norvegicus

<400> 47

gccgttcattg gcggtttcgg ggtctccaac agcttctcag gttgaaatcc aaaagcctcc 60
 cgaggcgggg tctgcggagt ttgagatttt tgcagggtgtg aaatgactga gtacaaactg 120
 gtggtggttg gagcagggtgg cgttgggaaa agtgctttga caatccagct aatccagaac 180
 cactttgtgg atgaatatga tcccaccata gaggattctt accgaaaaca agtggtgatt 240

0398850pct.txt

gacggtgaga cctgtctact ggacatactg gacacagctg gacaagagga gtacagtgcc 300
atgagagacc aatacatgag gacaggcgaa gggttcctct gtgtgtttgc catcaataat 360
agcaaacccct ttgcagatat taacctctac agggagcaaa ttaagcgcggt gaaagactct 420
gatgatgtac ccatggtgct ggtagggaac aagtgtgact tgccaacaag gacagttgac 480
acaaagcaag cccacgagct ggccaagagt tatggaattc cattcattga aacctcagcc 540
aagacccgac aggggtgtgga ggatgccttt tacacgcttg taaggagat acgccagtac 600
cggatgaaga agctcaacag cagtgaggat ggcaactcaag gctgtatggg gctgccctgt 660
gtggtgatgt agtaagaccc tttaaaagtt ctgtcatcag aaacgagcca ctttcaagcc 720
tactgatgc cctgggttctg acatccctgg aggagacgtg tttctgctgc tctctgcac 780
tcagagaagc tcctgcttcc tgcttcccca acttagttac tgagcacagc catctaacct 840
gagacctctt cagaataact acctcctcac tcggctgtcc gaccagagaa atgaacctgt 900
ttctcccag tagttctctg ccctgggttt ccctagaaa caaacacacc tgccagctgg 960
ctttgtcctc cgaaaagcag ttacattga tgcagagaac caaactatag acaagcaatt 1020
ctgttgtcaa cagtttctta agctctaagg taacaattgc tgggtgatttc cccctttgcc 1080
cccaactgtt gaacttggcc ttgttagttt tgggggaaat gtcaaaaatt aatctcttcc 1140
cgagaataga attagtgttg ctgattgcct gatttgcaat gtgacagct atattctata 1200
agctggcgctc tgctctgtat tcataaatgc aaacatgagt actgacgtaa gtgcatccct 1260
agtcttctca gctgcatgca attaaatcca acgttcacaa caaaaaaaaaa aaaaaaaaaa 1320
aaaaaa 1326

<210> 48
<211> 189
<212> PRT
<213> Rattus norvegicus

<400> 48

Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Gly Val Gly Lys
1 5 10 15

Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr
20 25 30

Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly
35 40 45

Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu Glu Tyr
50 55 60

Ser Ala Met Arg Asp Gln Tyr Met Arg Thr Gly Glu Gly Phe Leu Cys
65 70 75 80

Val Phe Ala Ile Asn Asn Ser Lys Ser Phe Ala Asp Ile Asn Leu Tyr
85 90 95

Arg Glu Gln Ile Lys Arg Val Lys Asp Ser Asp Asp Val Pro Met Val
 100 105 110

Leu Val Gly Asn Lys Cys Asp Leu Pro Thr Arg Thr Val Asp Thr Lys
 115 120 125

Gln Ala His Glu Leu Ala Lys Ser Tyr Gly Ile Pro Phe Ile Glu Thr
 130 135 140

Ser Ala Lys Thr Arg Gln Gly Val Glu Asp Ala Phe Tyr Thr Leu Val
 145 150 155 160

Arg Glu Ile Arg Gln Tyr Arg Met Lys Lys Leu Asn Ser Ser Glu Asp
 165 170 175

Gly Thr Gln Gly Cys Met Gly Leu Pro Cys Val Val Met
 180 185

<210> 49
 <211> 4470
 <212> DNA
 <213> Mus musculus

<400> 49
 gggactgggg cgccttgggc gcctagtgat tacgtagcgg gtggggccgg aagtgccgct 60
 ccctggcggg ggctgttcat ggcggtttcg gggctctcaa cagcttctca ggttgaagtc 120
 caaaagcctc ccgaggcggg gtctgcggag tttgaggttt ttgctggtgt gaaatgactg 180
 agtacaaact ggtggtggtt ggagcaggtg gtgttgggaa aagcgccttg acgatccagc 240
 taatccagaa ccactttgtg gatgaatatg atcccacat agaggattct taccgaaagc 300
 aagtggatgat tgatggtgag acctgcctgc tggacatact ggacacagct ggacaagagg 360
 agtacagtgc catgagagac cagtacatga ggacaggcga agggttcctc tgtgtatttg 420
 ccatcaataa tagcaaatca tttgcagata ttaacctcta caggagcaa attaagcgtg 480
 tgaaagattc tgatgatgtc cccatggtgc tggtaggcaa caagtgtgac ttgccaacaa 540
 ggacagttga cacaaagcaa gcccacgaac tggccaagag ttacggaatt ccattcattg 600
 agacctcagc caagaccga cagggtgtgg aggatgcctt ttacacactg gtaagggaga 660
 tacgccagta ccgaatgaaa aagctcaaca gcagtgcga tggcactcaa ggttgtatgg 720
 ggctgccctg tgtgtgatg tagtaagaca ctttgaaagt tctgtcatca gaaaagagcc 780
 actttgaagc tgcactgatg ccctggttct gacatccctg gaggagacct gttcctgctg 840
 ctctctgcat ctcagagaag ctctgcttc ctgcttcccc gactcagtta ctgagcacag 900
 ccatctaacc tgagacctct tcagaataac tacctcctca ctcggctgtc tgaccagaga 960
 aatagacctg tctctcccg tcttctctg ccctgggttc ccctagaaac agacacagcc 1020
 tccagctggc tttgtcctct gaaaagcagt ttacattgat gcagagaacc aaactagaca 1080

tgccattctg	ttgacaacag	tttcttatac	tctaaggtaa	caactgctgg	tgattttccc	1140
ctgcccccaa	ctgttgaact	tggccttggt	ggtttggggg	gaaaatgtca	taaattactt	1200
tcttcccaaa	atataattag	tgttgctgat	tgatttgtaa	tgtgatcagc	tatattccat	1260
aaactggcat	ctgctctgta	ttcataaatg	caaacacgaa	tactctcaac	tgcatgcaat	1320
taaatccaac	attcacaaca	aagtgccttt	ttcctaaaag	tgctctgtag	gctccattac	1380
agtttgtaat	tggaatagat	gtgtcaagaa	ccattgtata	ggaaagtgac	tctgagccat	1440
ctacctttga	gggaaagggt	tatgtacctg	atggcagatg	ctttgtgtat	gcacatgaag	1500
atagtttccc	tgtctgggat	tctcccagga	gaaagatgga	actgaaacaa	ttacaagtaa	1560
tttcatttaa	ttctagctaa	tctttttttt	tttttttttt	tttttttggt	gactatcacc	1620
tataaatatt	tggaatatct	tctagcttac	tgataatcta	ataattaatg	agcttccatt	1680
ataatgaatt	ggttcatacc	aggaagccct	ccatttatag	tatagatact	gtaaaaattg	1740
gcatgttggt	actttatagc	tgtgattaat	gattcctcag	accttgctga	gatatagtta	1800
ttagcagaca	ggttatatct	ttgctgcata	gtttcttcat	ggaatatata	tctatctgta	1860
tgtggagaga	acgtggccct	cagttccctt	ctcagcatcc	ctcatctctc	agcctagaga	1920
agttcgagca	tcctagaggg	gcttgaacag	ttatctcggt	taaaccatgg	tgctaattga	1980
ccgggtcatg	gtttcaaaac	ttgaacaagc	cagttagcat	cacagagaaa	cagtccatcc	2040
atatttgctc	cctgcctatt	attcctgctt	acagactttt	gcctgatgcc	tgctgttagt	2100
gctacaagga	taaagcttgt	gtggttctca	ccaggactgg	aagtacctgg	tgagctctgg	2160
ggtaagccta	gatatcttta	cattttcaga	cccttattct	tagccacgtg	gaaactgaag	2220
ccagagtcca	tacctccatc	tccttcccc	cccaaaaaaa	ttagattaat	gttctttata	2280
tagctttttt	aaagtattta	aaacatgtct	ataagttagg	ctgccaaact	acaaaagctg	2340
atgtgtttgt	tcaaataaag	aggtatcctt	cgctactcga	gagaagaatg	taaaatgcca	2400
ttgattgttg	tcacttgagg	gcttgatggt	tgccctgata	attcattagt	gggttttggt	2460
tgtcacatga	tacctaagat	gtaactcagc	tcagtaattc	taatgaaaac	ataaattgga	2520
taccttaatt	gaaaaaagca	aacctaatc	caaaatggcc	atcttctctt	ctgatcttgt	2580
aatacctaaa	attctgaggt	ccttgggatt	cttttgttta	taacaggatc	ttgctgtgta	2640
gtcctagctg	gcctcaaact	cacaatactc	ttcctggatc	aatctcccaa	gtgctgggat	2700
tacaggcaca	ttccaccaca	cacacctgac	tgagctcggt	cctaatgagt	tttcattaag	2760
caaattcccc	atcaccttga	aactaatcag	aagggggaag	aaacatttgc	tatgctcctg	2820
agtgctaaca	ctgggatcat	tcacatgggg	tttgcatctc	taggcaaact	aaactgctgc	2880
cttttacaac	aaggctcagt	catcttcctg	aagctgctga	gaccagcact	tggtcttggt	2940
ttgttttaat	atgtctatat	gactgggtgg	ggatccctaa	atagtttatt	aattaaactc	3000
cagttaagga	gaaagttact	caccttgacc	cgtttgacca	tatcccgtgt	gtgtgtgtgt	3060
gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgcacgcgt	atgtacgtac	gtatgtatgt	3120

```

aggatatgtag gtggtttcca gtataaacac agaaacaaat ggagccaatt caggtttcag 3180
atgcccttac taacatatat tcccacgggg tgtggggtttt ggcacaacag tgacaaactt 3240
aaaagccaag taagagccgg gcgtgggtggc gcacgccttt aatcccagca cttgggaggc 3300
agaggcaggc ggatttctga gttctaggcc atcctggtct acagtgagtt ccaggacagc 3360
cagtgtaca cagagaaacc ctgtctcgaa aagccaaaaa aaaaaaaaaa aaaaaaaaaa 3420
aaaagccaag taggtccagt tggatatagta tcaaagtgtt tttagagtaa ttagtgaagg 3480
tctgctttac ctcaaagttg cagagcctct cttcctgagt ttaagtgcct ggccggcagt 3540
cacaaattaa catgttgctg taaggcagtt agttgaagct ttgttcacac attggagagt 3600
atgaaaataa agtgttctaa gagcgctgat actggatctg tgtaaacctg gtaaatgccg 3660
tttgtccagg acttagcgtg tgtgagttgg tagctcagta cgagtttact agttccgcag 3720
tgtgtacaat ggaggcgggt ttgttttagc tggccacctg tagaatcagc ctttaaactg 3780
ctgtgaactt tgtcatgact tgaatatgaa gatagacaaa aactctgtaa agacaaatgt 3840
ttgttttccc cttacagaa cgtgtgagct tggttttatc ttcctttgta tttagtcata 3900
accttcaag ctggcagctc cgaccaagga tcagaagctg tgtgcgttcc acctggtgga 3960
attagctcag ctctatatga gaagtggagt taatggaaaa cgtgttgact ggggtggttc 4020
tatttaaaag agtgatgata attcttgaac agtagttttt attttgctat ttctttaagc 4080
tgactgatgt gccacaaat tattttaagg tatttgtgtt ttaagagtgt tctcatgaga 4140
ttagttgtag atatttttta aaatacaact ggtttttaaa atctgagtat tgctctaagc 4200
aagtgttag actcttacgg gaaggtgggt ggaagtgtgt tggcttccgt atttccatgc 4260
gtgccgtcag acataggtca gaacccaac tgtgcatcct gctgtttaaa gacctcttgg 4320
cctctgtgac cctcatgaag gggctgatat tttaagttga ctgtttgatt gtaaattaat 4380
cctttctaata ttttaaagac ttgcttgact gttttccttg ttaaataatt ttaaaaaaat 4440
aaaaaactgg aagttctttg cttactgta 4470

```

<210> 50
 <211> 189
 <212> PRT
 <213> Mus musculus

<400> 50

Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Gly Val Gly Lys
 1 5 10 15

Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr
 20 25 30

Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly
 35 40 45

Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu Glu Tyr
 50 55 60

0398850pct.txt

Ser Ala Met Arg Asp Gln Tyr Met Arg Thr Gly Glu Gly Phe Leu Cys
65 70 75 80

Val Phe Ala Ile Asn Asn Ser Lys Ser Phe Ala Asp Ile Asn Leu Tyr
85 90 95

Arg Glu Gln Ile Lys Arg Val Lys Asp Ser Asp Asp Val Pro Met Val
100 105 110

Leu Val Gly Asn Lys Cys Asp Leu Pro Thr Arg Thr Val Asp Thr Lys
115 120 125

Gln Ala His Glu Leu Ala Lys Ser Tyr Gly Ile Pro Phe Ile Glu Thr
130 135 140

Ser Ala Lys Thr Arg Gln Gly Val Glu Asp Ala Phe Tyr Thr Leu Val
145 150 155 160

Arg Glu Ile Arg Gln Tyr Arg Met Lys Lys Leu Asn Ser Ser Asp Asp
165 170 175

Gly Thr Gln Gly Cys Met Gly Leu Pro Cys Val Leu Met
180 185

<210> 51
<211> 570
<212> DNA
<213> Cavia porcellus

<400> 51
atgactgagt ataaactggt ggtggttga gcaggtggtg tcgggaaaag tgcactgacc 60
atccagctaa ttcagaacca ctttgtcgat gaatatgata ccaccataga ggattcttac 120
cgaaaacagg tgggttataga tgggtgaaact tgtctgttgg atattctgga tacagctgga 180
caagaggagt acagtgccat gagagaccaa tacatgagga caggcgaagg cttcctctgt 240
gtgtttgcca tcaataatag caaatcattt gcagatatta acctctacag ggagcagatt 300
aaacgagtaa aagactcaga tgatgtacct atggtgctgg tagggaacaa gtgtgatttg 360
ccaacaagga ctgttgacac aaaacaagcc catgaactgg ccaagagtta cgggattcca 420
ttcattgaaa cctcagccaa gaccagacag ggtgttgaag atgcatttta cacactcgta 480
agagaaatac gccagtacag aatgaaaaaa ctcaacagca atgatgatgg gactcaaggt 540
tgtatggggg tgccatgtgt ggtgatgtaa 570

<210> 52
<211> 189
<212> PRT
<213> Cavia porcellus

<400> 52

Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Gly Val Gly Lys
1 5 10 15

Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr
20 25 30

Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly
35 40 45

Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu Glu Tyr
50 55 60

Ser Ala Met Arg Asp Gln Tyr Met Arg Thr Gly Glu Gly Phe Leu Cys
65 70 75 80

Val Phe Ala Ile Asn Asn Ser Lys Ser Phe Ala Asp Ile Asn Leu Tyr
85 90 95

Arg Glu Gln Ile Lys Arg Val Lys Asp Ser Asp Asp Val Pro Met Val
100 105 110

Leu Val Gly Asn Lys Cys Asp Leu Pro Thr Arg Thr Val Asp Thr Lys
115 120 125

Gln Ala His Glu Leu Ala Lys Ser Tyr Gly Ile Pro Phe Ile Glu Thr
130 135 140

Ser Ala Lys Thr Arg Gln Gly Val Glu Asp Ala Phe Tyr Thr Leu Val
145 150 155 160

Arg Glu Ile Arg Gln Tyr Arg Met Lys Lys Leu Asn Ser Asn Asp Asp
165 170 175

Gly Thr Gln Gly Cys Met Gly Leu Pro Cys Val Val Met
180 185

<210> 53

<211> 1220

<212> DNA

<213> *Cavia porcellus*

<400> 53

gttccggggt cctcaacgtt tctcagggtt gagattctat atccttttga agctggggcg 60

gcagagcttg aggttcttgc tgggtgtgaaa tgactgagta taaactggtg gtggttggag 120

caggtggtgt cgggaaaagt gcactgacca tccagctaata tcagaaccac tttgtcgatg 180

aatatgatcc caccatagag gattcttacc gaaaacaggt gggttatagat ggtgaaactt 240

gtctgttgga tattctggat acagctggac aagaggagta cagtgccatg agagaccaat 300

acatgaggac aggcgaaggc ttcctctgtg tgtttgccat caataatagc aaatcatttg 360

cagatattaa cctctacagg gagcagatta aacgagtaaa agactcagat gatgtaccta 420

```

tggtgctggt aggggaacaag tgtgatttgc caacaaggac tgttgacaca aaacaagccc 480
atgaactggc caagagttac gggattccat tcattgaaac ctcagccaag accagacagg 540
gtgttgaaga tgcattttac aactcgtaa gagaaatacg ccagtaacaga atgaaaaaac 600
tcaacagcaa tgatgatggg actcaagggt gtatgggggt gccatgtgtg gtgatgtaac 660
aagatattta acaaagttct atcagaaaag agccactttc aagctgcact gataccctgg 720
tcctgacttc cctggaggag aagtatccct gttgctctct tcatctcaga gaagctcctg 780
ctgtttgtcc acctctcagt gtatgagcac agtctctgct tgagaacttc tcagaataac 840
tacctcctca cttggttgtc tgaccagaga aatgcacctc ttgttaattc cccaataatt 900
ttctgccctg ggctctcccc aacaaaaaac aaacacttct gccatccaaa aagcaacttg 960
gtctgaaaca gaaccaaact gtagattgaa attctcttaa aaagtcttga gctctaaagt 1020
tagcaaccgc tggtgatttt tttttcctt tttatttttg aacttggaac tgacctatgt 1080
tagattttgg agaaatgtca taaagtactg ttgtgccaag aagataatta tgttgctgaa 1140
tggttgattt atagtgttat cagctatatt ttacaaactg gcattctgctc tgtattcata 1200
aatacaaaaa tgaagccagg 1220

```

```

<210> 54
<211> 189
<212> PRT
<213> Cavia porcellus

```

```
<400> 54
```

```
Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Gly Val Gly Lys
1          5          10          15
```

```
Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr
          20          25          30
```

```
Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly
          35          40          45
```

```
Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu Glu Tyr
          50          55          60
```

```
Ser Ala Met Arg Asp Gln Tyr Met Arg Thr Gly Glu Gly Phe Leu Cys
          65          70          75          80
```

```
Val Phe Ala Ile Asn Asn Ser Lys Ser Phe Ala Asp Ile Asn Leu Tyr
          85          90          95
```

```
Arg Glu Gln Ile Lys Arg Val Lys Asp Ser Asp Asp Val Pro Met Val
          100          105          110
```

```
Leu Val Gly Asn Lys Cys Asp Leu Pro Thr Arg Thr Val Asp Thr Lys
          115          120          125
```

0398850pct.txt

Gln Ala His Glu Leu Ala Lys Ser Tyr Gly Ile Pro Phe Ile Glu Thr
 130 135 140

Ser Ala Lys Thr Arg Gln Gly Val Glu Asp Ala Phe Tyr Thr Leu Val
 145 150 155 160

Arg Glu Ile Arg Gln Tyr Arg Met Lys Lys Leu Asn Ser Asn Asp Asp
 165 170 175

Gly Thr Gln Gly Cys Met Gly Leu Pro Cys Val Val Met
 180 185

<210> 55

<211> 1307

<212> DNA

<213> Canis familiaris

<400> 55

tgattacgta gcgggcgggg ccggaagtgc cgctccctag tgggggctgt tcatggcggg	60
tccgggggtct ccaacctttc tcctagttgt ggtcctaaat acgtcgggaag cggaggcggc	120
gaagcttgag gttcttgctg gtgtgaaatg actgagtaca aactgggtggg gggtggagca	180
gggtgggtgtg ggaaaagcgc actgacaatc cagctaatacc agaaccactt tgtagatgaa	240
tatgatccca ccatagagga ttcttaccga aaacaggtgg ttatagacgg tgaaacctgt	300
ctgtttggata tactggatac agctgggtcaa gaagagtaca gtgccatgag agaccaatac	360
atgaggacag gcgaaggctt cctctgtgta tttgccatca ataatagcaa atcatttgca	420
gacattaacc tctacaggga acagattaag cgagtaaaag attcagatga tgtacctatg	480
gtgctagtag gaaacaagtg tgatttgcca acaaggacag ttgacacaaa acaagcccat	540
gaactggcca agagttatgg gattccattc attgaaacct cagccaagac cagacagggg	600
gtcgaggatg ccttttacac actggtaaga gaaatacgtc agtaccgaat gaagaaactc	660
aacagcagtg atgatgggac tcaaggttgt atggggttac catgtgtggg gatgtaacaa	720
gacactttta aagttctagc atcagaaaag agccactgtc aagctgcact gacaccctgg	780
tcctgacttc cctggaggag aagtattcct gttgctatct tcagtctcac aaagaagctc	840
ctgctacttc cccaactctc agtagatcag tacaatgttc tctatttgag aagttctccg	900
aacaactacc tcctcacttg gttgtctgac cagagaaatg aacctcttgt tccttcccgc	960
tgtttttcca ccctgaattc tcccccaaca cacataaaca aacctctgcc atcccaggtt	1020
tttcatctga aaaataattc atgctctgaa acagagaaca aaactgtaga catgaaattc	1080
tgtaggaaac aaggtcttga gctcaaaagt agcaactgct ggtgaccttt ttttcccccc	1140
tttttactgt tgaacttga actatgttgg tttttggaga aatgtcataa gttactgttt	1200
tgctgagaat atagttaagt tgacatttgg tttgtttgta atatcattag ctattttcta	1260
taaattggca tctgctctgc attcataaat acacgagtga attctga	1307

<210> 56

<211> 189
 <212> PRT
 <213> Canis familiaris

<400> 56

Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Gly Val Gly Lys
 1 5 10 15

Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr
 20 25 30

Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly
 35 40 45

Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu Glu Tyr
 50 55 60

Ser Ala Met Arg Asp Gln Tyr Met Arg Thr Gly Glu Gly Phe Leu Cys
 65 70 75 80

Val Phe Ala Ile Asn Asn Ser Lys Ser Phe Ala Asp Ile Asn Leu Tyr
 85 90 95

Arg Glu Gln Ile Lys Arg Val Lys Asp Ser Asp Asp Val Pro Met Val
 100 105 110

Leu Val Gly Asn Lys Cys Asp Leu Pro Thr Arg Thr Val Asp Thr Lys
 115 120 125

Gln Ala His Glu Leu Ala Lys Ser Tyr Gly Ile Pro Phe Ile Glu Thr
 130 135 140

Ser Ala Lys Thr Arg Gln Gly Val Glu Asp Ala Phe Tyr Thr Leu Val
 145 150 155 160

Arg Glu Ile Arg Gln Tyr Arg Met Lys Lys Leu Asn Ser Ser Asp Asp
 165 170 175

Gly Thr Gln Gly Cys Met Gly Leu Pro Cys Val Val Met
 180 185

<210> 57
 <211> 3104
 <212> DNA
 <213> Felis catus

<400> 57

aaaaataaaa taaatttaag aaaccatttt aaaattatgc acagttgcag cctggaaaac 60
 ttaaggtggc gccttatagt atcaatctta ggagctttat ttggtgcatt taacgcaact 120
 ggtaattgca aaatccactt cgctgtgta agtgaaaaat atagactggt atcttggttg 180
 ccctatgaaa ttctgcactt ggtatttagc atatactcta ccttcattac tatctggcaa 240

0398850pct.txt

gatgttctgc	cttagcactc	agttgcattc	ttttcctttt	ctttcctggt	cattatgctt	300
taattctgag	gaccatatga	gggtagaata	tattaaaaat	tacaaaaatt	ataaaaaattt	360
gtataggcaa	accatttcct	taagttgatg	gccaaatggt	aaaatgttat	ttttcatatc	420
atttataatc	ttgtcacagt	ccacttaacg	aagtttggtt	agatttcagt	gaaaattatc	480
ttccagagta	gttttttttt	ttttttcctg	ggattagggg	ggggggtaac	tttactgcaa	540
ttagtatgta	tggtgcagaa	tttcatgcaa	atgaggtgtg	ccagcagtggt	ggtaatttaa	600
tcgtatttaa	acaaaaacaa	acaaaaaaaa	aacgaatgca	caaacttgct	gctgcttaga	660
tcactgcagc	ttctaggacc	cagtttcttt	tactgatttc	aaaacaaaac	aaaacaaaaa	720
aataaaaaaa	gttgtgcctg	aaatgaatct	tgtttttttt	ataagtagcc	gcctggttcc	780
tgtgtcctgt	gaaatacagg	cacttgaccc	ttggtgtagc	ttctgttcga	ctttatatca	840
cgggaaatgga	ttggtctgat	ttcttgcccc	tcactctgaa	ttggccacat	ccagggtccc	900
tggccagtg	actgaaggct	ttgtctaaga	ggacaagggc	agctcagggg	atgtggggga	960
gggcgctttt	atcttccccg	ttgtcgtttg	aggttttgat	cttctctggg	taaagaggcc	1020
gtttatcttt	gtaaacacaa	aacatttttg	ctttctccag	ttttctgtta	atggcgaaag	1080
aatggaagcg	aataaagttt	tactgatttt	tgagactcta	gcacctagcg	ctttcatttt	1140
tgaaacgtcc	tgtgtgggag	gggcgggtct	gggtgcggcc	cgccgcgtga	ctcctgagtc	1200
gggggcccac	gtggctgggg	cggggactcg	gacgccccgg	gcgccgactg	attacgtagc	1260
gggcggggcc	ggaagtgccg	ctccctagtg	ggggctgttc	atggcggttc	cggggtctcc	1320
atcctttttc	ccagttgttc	taaatcagtc	ggaagcggag	gcagcgaagt	ttgaggttct	1380
cgctggtgtg	aaatgactga	gtacaaactg	gtggtgggtg	gagcaggtgg	tgttgggaaa	1440
agcgcactga	caatccagct	aatccagaac	cactttgtag	atgaatatga	tcccaccata	1500
gaggattctt	accgaaaaca	ggtggttata	gacggtgaaa	cctgtctgtt	ggacatactg	1560
gatacagctg	gtcaagaaga	gtacagtgcc	atgagagacc	aatacatgag	gacaggcgaa	1620
ggcttcctct	gtgtatttgc	catcaacaat	agcaaactcat	ttgcagatat	taacctttac	1680
agggaaacaga	ttaagcgagt	aaaagactcc	gatgatgtac	ctatggtgct	agtaggaaac	1740
aagtgtgatt	tgccaacaag	gaccgtcgac	acaaaacaag	cccacgaact	ggccaagagt	1800
tatgggattc	cattcattga	aacctcagcc	aagaccagac	aggggtgttg	agatgccttt	1860
tacacactgg	taagagaaat	acgtcagtac	cgaatgaaga	aactcaacag	cagtgatgac	1920
gggactcaag	gttgtatggg	gttaccgtgt	gtggtgatgt	aacaagatac	ttttaagttt	1980
ctagcatcag	aaaagagcca	ctgtcaagct	gcactgacac	cctggtcctg	acttccctgg	2040
aggagaagcg	ttcctgttgc	tattttcagt	ttcacaaaga	agctcctgct	atttccccaa	2100
ctctccgtag	atcagtacat	tattctctgt	ttgagaagtt	ctccgaataa	ctacctctc	2160
acttggttgt	ctgaccagag	aatgaacct	cttgttactc	cccactgttt	ttccaccctg	2220
gttctcccc	agcacatata	aacaaacctc	ccagggtttt	catctgaaaa	gtaattcatg	2280

```

ctctgaaaca gagaaccaa ctgtagacat gaaattctgt aggaacaat gtcttgagct 2340
ctaaagtagc aactgctggg gacttttttt tttttttttt cctttttact gttgaacttg 2400
gaactatggt gggttttgga gaaatgtcgt aagttactgt tttgctgagt atatagttaa 2460
gtttaccatt cgggtttgttt gtaatgtcat tggctatact ctgtacctgg catctgctct 2520
gcattcataa atacaaaagt gaattctgac ttttgagtct atcctagtgt tctcaacttc 2580
cacataatta aatctaactt ttgcagcaaa gtgccttttt cctagaagtg gtttgtagat 2640
ttgctttata atactttggg ggaatagatg tctcaaaaac cattatacat gaaaatgaat 2700
gtctgagata cgtctatgat ctgtctacct ttgagggaaa aatataccga cataatagca 2760
gatgccatgt cttacgtgta tgaagttgga tttccagaga cctgatttgg gtctcttcca 2820
agagaaagat gaaactggaa acaattatga ataacttcac ttaattttta cctaattctt 2880
acttcggggg gggagggcag ggagtaggtt accacttaca aaatatatgc aatttgtttc 2940
ttctagctta ctgataatga acttccattc ttatttaaat ttaggtcata tcctaaagct 3000
ttacatttgc aggtgttcga aattgtaagt ttaatgcagt tttatttaat agctatgatc 3060
aatgattttc aagcctcaga tgtattaacg gacacatttt cact 3104

```

<210> 58
 <211> 189
 <212> PRT
 <213> Felis catus

<400> 58

Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Gly Val Gly Lys
 1 5 10 15

Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr
 20 25 30

Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly
 35 40 45

Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu Glu Tyr
 50 55 60

Ser Ala Met Arg Asp Gln Tyr Met Arg Thr Gly Glu Gly Phe Leu Cys
 65 70 75 80

Val Phe Ala Ile Asn Asn Ser Lys Ser Phe Ala Asp Ile Asn Leu Tyr
 85 90 95

Arg Glu Gln Ile Lys Arg Val Lys Asp Ser Asp Asp Val Pro Met Val
 100 105 110

Leu Val Gly Asn Lys Cys Asp Leu Pro Thr Arg Thr Val Asp Thr Lys
 115 120 125

Gln Ala His Glu Leu Ala Lys Ser Tyr Gly Ile Pro Phe Ile Glu Thr
 130 135 140

Ser Ala Lys Thr Arg Gln Gly Val Glu Asp Ala Phe Tyr Thr Leu Val
 145 150 155 160

Arg Glu Ile Arg Gln Tyr Arg Met Lys Lys Leu Asn Ser Ser Asp Asp
 165 170 175

Gly Thr Gln Gly Cys Met Gly Leu Pro Cys Val Val Met
 180 185

<210> 59
 <211> 4283
 <212> DNA
 <213> Bos taurus

<400> 59
 ggccgctccc tagtgggggc tgttcatggc ggttccgggg tctcccaaca attttcccgg 60
 ttgtggtcgt aatctatccg aagtggaggc agtggagcta gaggttcttg ctggtgtgaa 120
 atgactgagt acaaaactggt ggtggttggg gcagggtggtg ttgggaaaag tgcactgaca 180
 atccagctaa tccagaacca cttttagat gaatatgac ccaccataga ggattcctac 240
 cgaaaacagg tggttataga tggtgaaacc tgtctgttgg acatactgga tacagctgga 300
 caagaggagt acagtgccat gagagaccaa tacatgagga caggcgaagg cttcctttgt 360
 gtgtttgcca tcaataatag caaatcattt gcagatatta acctctacag ggaacagata 420
 aagcgtgtaa aggactcgga tgatgtacct atggtgctag taggaaacaa gtgtgatttg 480
 ccaacaagga cagttgacac aaaacaagcc catgaactgg ccaaaagtta tgggattcca 540
 ttcatgaaa cctcagccaa gaccagacag ggtgttgaag atgcctttta cacttggtta 600
 agagaaatac gtcagtaccg aatgaaaaag ctcaacagca gtgatgatgg cactcaaggc 660
 tgtatggggg tgccgtgtgt ggtgatgtaa caagatactt ttaaagttct cacatcagaa 720
 aagagccact gtcaagctgc actgacaccc tggtcctgac ttccctggag gagaagtatt 780
 cctgttgcta tcttcagttt caaaaagaag ctctgctat tcccccaact cttagtagat 840
 caatataata ttctctatctt gagaagttct caagaataac tacctcctca cttgggtgtc 900
 tgaccagaga attgaacctc ttgttactcc cagtattttt ccaccctggg ttctcccca 960
 gcacacacaa acgcacctct gccaccagg tttttcatct gaaaagcaat taatactctg 1020
 aaacagagaa ccaaactgta gaaacatgaa attctgtaga aaacaatgtc ttgagctcta 1080
 aagtagcaac tgctggtgat tttttttttt ttttttctt ttttattgtt gaacttgga 1140
 ctatgttggg ttgtggagaa atgtcataaa ttactgtttt gctgagaata tagttaatgt 1200
 tgctctctgg tttgtttgta atgttatcag ctatattcta taaactggca tctactctgt 1260
 atttagaaat acaaaaatga atactgacct tttgagtcta ccctcatctt ctgactttc 1320
 ttgtaattaa atgtaacttt cacgatgaag tgccttttgc ctgggagtga ctcgtagact 1380

0398850pct.txt

tcctttaaaa	tacttcagtg	gaatagatgt	ctcagaaact	gttatacata	agaataaatg	1440
tctgagatat	gtctatgacc	catctagctt	tgaggggaaag	atataccaat	atgatagcag	1500
atgccatttc	ttacatctat	aacgttgatt	ttctggagac	ctattttggg	gctctccgag	1560
agaaagatga	gactataaat	gattaggaat	aatttcactt	aatttttaca	taacctccac	1620
tttttgtttt	gtagtttact	acctgcaaaa	catataattt	gattcctttt	agcttacaga	1680
taatctaata	ttaaataaac	ttccattcat	attttaattt	ggatcatatc	aggaagtcta	1740
catttgcagg	tgttcaaaaa	ttgtaaaagt	gtgatgcagt	tttatttaat	agctgtgata	1800
aatgattttc	aagcctcaaa	tatgttaata	gacacatttt	cactgtatat	catgggtatta	1860
ataattattg	atgtatataa	ttgtccttgg	tccccttctc	tgttcatcac	ctcatggcaa	1920
tggcttgatt	aattatttca	gctgagtaaa	gcatggtgct	aatagaccag	ggtcacagtg	1980
tcaaaacttc	agtgaaccag	taagcatcac	agagaaagaa	attctttcac	atttgctcac	2040
cattaactcc	agctaatagt	tttgccagat	gtgtgtggtt	agtcctgcaa	ggaaaggaga	2100
agtcagttaa	tacaaattct	taaccaggac	tggaaaaact	tgttttcctg	agaaggggtca	2160
gcttagaagt	ctttatctgg	actctatttt	tagccacatg	gaaatcaaat	taagctgata	2220
ttttttctca	agtttttgag	agtgaggatg	cctcagatca	acatttttaa	aatattcttt	2280
attcttacgt	tcttttaagg	gtttaaaaca	acgttgagta	attagtctgg	gcataccagg	2340
taacaagctg	ataagtttgt	gctgaacaag	aagtagcctt	tggattgaaa	ttgctgtttt	2400
gagaagggat	agaaaatata	attaataatt	atgagacttg	acttttctat	ttgcagataa	2460
tatcctgata	attctgatga	aaatagactt	ggataatttt	tgataaaaga	atcgttccaa	2520
aatggccact	tgtgtttctt	gtcttctaata	gtgtaaatac	ttactgaggt	cctcttctaa	2580
tatgagttgt	catttattaa	gcaaattcca	cattgccttg	aaatgaattc	ggaagagaag	2640
aaaaagtcac	agtataccca	gagaatgaaa	aatccagaga	attgtgctcc	ttagtgttaa	2700
ttctgaagcc	ttcgtagtcc	acacccatag	acagaaactc	tctgccactt	tgtttctgct	2760
cctcttggag	cattgcgctg	tcatttcctt	gaggatagat	tgaggcttgt	caactcagtt	2820
gtattgtctt	cctcctcttc	ctcttgtctg	tgtgactgac	agtgtgactc	ttactaatgt	2880
cagatgcggg	gatgcgggga	gggtggggggg	agtagctcat	tttaggctct	tgcacccttt	2940
accgttgtat	gtgtgtgtct	tttagttttc	tcaagaatgt	tctaagcaca	gaagtatcta	3000
aatggggcca	aaattcagac	ttgaaaatgt	tcttttaata	gcttcttaaa	aagttacact	3060
ttggtgtgaa	ttttggcagg	atagagtgac	aaactcttaa	acgctgaata	acttcagtta	3120
gtgtgttata	gttttttagaa	tatgtttgtg	attgctgaaa	acaattatag	tttacctcaa	3180
aatctgaaag	tctctttccc	caagttaagt	gcctggccag	ctgtcaaaga	ttacatatta	3240
ctttatgttt	gtttgttttt	taaaggttgc	acattcaaga	ttgtgaaaat	aagggtgttct	3300
gtctgaaagc	taccatgcct	gtctgtaaat	gaatccactg	agtgtgttac	ttgttccaac	3360
agcttactac	agaatgctac	ttggtaatat	catactcggt	acagttttca	cttcaggagt	3420

```

gtactaggta gaatgatcct gtgtgtattg tagtgggctc catgtttagt cttttcagca 3480
tcctttaaac tgctgtgaat ttttgtcttg acttgaaagc aaggatagag aaacacttta 3540
aagagatact ttgggttttt ttccattcca gaattggtga gcatagttag attttgcttt 3600
acatttacag tcatgaactc ttaagctggc agctacaacc aagaaccaa agagggtgca 3660
ttctgcttct tgtaattcat ctttgctaataaattatgag aagcaaagat aattaattag 3720
agaaactatt ttatttgggt ggtttctata aacaaggac tataattctt aaacattatt 3780
tttcattttt gctgtttctt taagaaacct aatgtgccac aacattattt taaggtgttt 3840
cttaaaagaa ttgtttttaa aagtgttctc attttcagag taattgtaga tatatttcaa 3900
aatataactg ataattttta aaggcctgag tactgaccta agaagcagtt gtatgaattc 3960
tctgggggga agggaggagc tcagtgaag ttgtatgact tttatatttc tgtgccatca 4020
aataaaggta aaaatgtctt ttgtgcagtt ttgctgttca aacagaaact attggcctcc 4080
ttggccctaa atgaaagggc tggatattta agttgactat tttattgtaa attaatccat 4140
cttaattttt ttaaatttgg ttgaatgttc tcttgttaaa tgtttaaaaa ataaaaactg 4200
gaagttcttt gcttagtcat aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 4260
aaaaaaaaataa aaaaaaaaaa aaa 4283

```

<210> 60
 <211> 189
 <212> PRT
 <213> Bos taurus

<400> 60

Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Gly Val Gly Lys
 1 5 10 15

Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr
 20 25 30

Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly
 35 40 45

Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu Glu Tyr
 50 55 60

Ser Ala Met Arg Asp Gln Tyr Met Arg Thr Gly Glu Gly Phe Leu Cys
 65 70 75 80

Val Phe Ala Ile Asn Asn Ser Lys Ser Phe Ala Asp Ile Asn Leu Tyr
 85 90 95

Arg Glu Gln Ile Lys Arg Val Lys Asp Ser Asp Asp Val Pro Met Val
 100 105 110

Leu Val Gly Asn Lys Cys Asp Leu Pro Thr Arg Thr Val Asp Thr Lys
 115 120 125

0398850pct.txt

Gln Ala His Glu Leu Ala Lys Ser Tyr Gly Ile Pro Phe Ile Glu Thr
130 135 140

Ser Ala Lys Thr Arg Gln Gly Val Glu Asp Ala Phe Tyr Thr Leu Val
145 150 155 160

Arg Glu Ile Arg Gln Tyr Arg Met Lys Lys Leu Asn Ser Ser Asp Asp
165 170 175

Gly Thr Gln Gly Cys Met Gly Leu Pro Cys Val Val Met
180 185

<210> 61
<211> 4825
<212> DNA
<213> Gallus gallus

<400> 61
gcgccgggac cggaagccgg aagctttgca gaaggggtgtt ccgcgttcgc ggtgcgggag 60
cggtcagccg ggggtggcggg gctggggccg gccggggcag gcggctccgc gctccgcact 120
gggccgctgg gagggcgatg actgaataca agctgggtgtt ggtgggagct ggcggcgctcg 180
ggaagagcgc gttgaccatc cagctcatcc agaaccactt cgtggacgag tacgacccca 240
ccatcgagga ttctgtacaga aagcagggtt tcatcgatgg agagacgtgc ttgttggaca 300
ttctggacac tgcaggacag gaagaataca gtgctatgcg tgatcagtac atgagaactg 360
gggaaggatt cctttgtgtg tttgccatta acaacagtaa atcattcgct gatattaacc 420
tttacagaga gcaaatcaag agagtgaag attcagacga tgtgccaatg gtgctggtgg 480
ggaataagtg cgatttgcca acaaggacag tagacaccaa acaggctcaa gagttagcaa 540
aaagctacgg cattcccttc atagagacat cagccaaaac gagacagggt gtggaagatg 600
cgttttacac actggtgagg gagattcggc agtaccggat gaaaaagctc aacagcaacg 660
aagatgggaa tcagggctgt atgggggtgt cctgcattgt gatgtgataa gatgccaggt 720
tcagatgtag ctgctggaca agtctcgatg ctactgtatt gtgtctcatg ctgatgccct 780
gcagtatttt ggtgccagcg accagactct tggtaccagt taattagctc aggatccttt 840
cctgtgctcc atctgaagaa aacatctctg gtatctacct ccttgctcag ctcacagagc 900
agtcataatc cttggtgtac tgggattctt ttctagctgt gttgtctggg tttgttcaag 960
aagaaaacca gtcacaagaa aagtgaatta cagagactaa atgctgtgaa aaagatcaca 1020
ctttacctcc agagtaaaag ctagaagtgg cgtttgacct ctttgcatg gattcagatt 1080
tgcggtgttg tcagaggagt ggcagaagta attttgccat taaaagggtt tctgtcacca 1140
gtcggattgg tatctgctgt ctgtgcaccc acacagtgt tctgcaacat ctgcattgtg 1200
ccagaagtat cacttaactg atgaactgat cctttatctt tctgtaataa aaaggagata 1260
tctttgctaa ctttaagtgc tgtttgctca gaagggttga ggttgatgc tgttccttg 1320

0398850pct.txt

ggctgaggag	aacccaagg	atgaatttct	tggtgtctca	ttgtcttgag	caggcaagtt	1380
ttgtgtgggt	gatctctttt	catggcagga	tattaaaatg	ggaatttgta	gtctggaaga	1440
tggagcagct	gtttgtgaga	ctcttgagtt	agggagagaa	atgtatacca	cgtctgttct	1500
cgatccatca	gaatggatcc	atccacctct	ttgtgtgtgg	aactgtgtat	agtctgtatt	1560
ggttttctac	agcacttgga	tctcttttga	ccaaattagc	gagctgttca	ttttaacata	1620
actgccagta	tttatagaca	atttcttacg	gacagataat	gaatttagaa	actggaggtt	1680
actttgggca	gctgttcctc	agctctgtct	gtaacttgca	aattattctg	agttattttc	1740
tgcagaacct	ccttccttat	cacgggagga	gcctgggagt	tgaggttgac	tgtaattggg	1800
tcaatggttg	tcacagactt	aagggtgtcca	ggctgattgg	aggaggcact	gagccctaac	1860
agagcactga	gctgacttct	aattgcagca	tccttgcaaa	atgaggaagg	gagttcagtg	1920
atgtctgcac	tgaagatgta	tgatacactg	atagcagttc	tgggtatggt	gtaacagctt	1980
caaagtagaa	ccgcagtact	gcgtgagctg	tgtgacttct	tcctagaaca	cagcactgtc	2040
accccatatg	gttgggacgt	gcaggtgaga	ccaacaccta	ccaggttccc	tggcgtaccg	2100
tggccttctc	agttcttggt	ccagtgatac	tgggttctgt	tctgtggtgt	cagacagcgt	2160
cctgtagcaa	agctgaattc	ccacttagtc	tggtgagaga	ataaagagcc	atcagccaac	2220
agagggagcg	ttcattctgc	tggagcagtg	cgagctgtaa	gcattacgag	aggcgtagtt	2280
tcagtttggt	gcagtcaggt	tcctatatatt	tcaaagctga	aatcagaaat	aagtaaatac	2340
ggagaaaata	agctgttgct	tttaatgctc	tttcctccac	taattgtact	cttaattttc	2400
ttcttgggag	gccgaggatc	catctgcata	acttttagctg	tgatgctcca	gataagtgtt	2460
tagaattcat	tttatctttg	actgatggga	ctgataagaa	gttaacgcac	aatattttta	2520
catacaacat	cgttttccag	tgacctcctg	agcggtgggg	agcattatgg	gatagcaccg	2580
gctgtgactc	gagttcattt	gaaggcgatc	tcttgccctgc	aggttaaatg	ggacggagtc	2640
agaatcactg	tgagccgtct	gtaatcagca	aacagtctgt	gggccttttct	tactgtgttc	2700
tctctgtttg	ccttagtttg	gtgcaggaag	agttccttgt	gacagcgtcc	tttgaggtgt	2760
gttgaggag	ctgaccattt	gctccttgag	ctgtgtgatg	aactgttgtc	cacttaatgg	2820
agttacagaa	gcagcttctg	ggagtcgcat	ctggtcgcat	acattcagtg	ttttgggaag	2880
ctgtcagtg	ggtgttttga	ctgtgtttga	atggtgttca	tgggtgggtct	gttatgctcc	2940
tggatgattt	ggggagatgt	ggggctgctt	ccgtggcaga	caggatcagc	tcagggcgct	3000
gctgcctatg	gctgtgggaa	acctcacagt	tggtgtttga	atagtggcca	agtatgtcaa	3060
ttaaaaatac	atthttgaagg	gaggtttgtc	atagctctgt	actttggcat	gctctgttta	3120
ctgaaaacat	actagctgta	gctcaaaaaa	agttgtgaat	cctcagaata	atacaggagc	3180
tggcaattgt	ggctgctttc	tctttgtgtt	ccttttctct	tgggttggtg	gaagctttta	3240
aaaggaagga	gccctggtga	gggttggtca	gtgtgcattt	cattcttgga	accagagagg	3300
aagttgcatc	aactttcagg	acgctgcaga	gctcacttgc	acaggtggtg	ctccagtcta	3360

0398850pct.txt

tgtgattttt ggggtcaaat cttgagatga tcttacaaaa tcagattttg taccatcat 3420
 gagcatgagg tgagtgggtg tgctcgggtt ctagctgcat gtatgtatac agacacgtgt 3480
 atgcagacat gtctatgtgt gagtagttcg agtcagtcaa gggtactggc agcacctaaa 3540
 gcgtatgcac cacataatgc atgcaggcaa aagtcctatc ttaggagcca tctcttcatg 3600
 gggttggtt tatataggca gtatttttaa acagaatatc cgaagcactt tctggagtgc 3660
 tgtggtaatg cagtgcacac tatttggtatg aaggaagatg tgtctgagga gcacgtaagc 3720
 agatttgctg ccctaacaga gaggttttgg taaccgtgga aaagggtttc tcttggtatc 3780
 gtgtgtgctc ttggtgagct gcaatccatg acagggcaca accagatgag aaggaaaccc 3840
 ggcatccca tgcttgagca cagctctgac tcagtagttc caccagatgt gccctttcag 3900
 tcaaagtgtt ctgatctctt agagctttct gtagttcaag ttaccactca ctctccagct 3960
 tgctcgggtt atgtctgttg gcggcgttga gttggacttg ggaaagggtg gtgtggtagg 4020
 aacaagcaga gtgtgatgtg cttctgttat caggacttaa gctagagtgg ttggcagata 4080
 ggaaatgcag ctattccttg aaagcaagca gatcatggat ggtcagccaa actgccctgg 4140
 ctttggtggg agctgcactg cagaaggacc aaaccccaac aagatttggc acatttgttt 4200
 agaagataag cacagatggt tttgcacaag gcagctcctc ataatggtgg cttttagat 4260
 ttagtccaaa tgttcttatt tagatctagc agcacatcac tgtgtccgtg cccatctaac 4320
 ctcgctatcc taagtagagc agaccccaaa caacctgtt caaaaactac cagtgcacaa 4380
 aactgaacta aatatttgtt actgctgact gagaacagct gttcgagtgt agcattgtgg 4440
 cttgttaatg tgagtcccc aactctatgg tcttattaaa gaaacccaaa cattgctcag 4500
 attttgttct tattgtcatc ataagacttg aatagtgatg gtaatgctta cgtagacgtg 4560
 tcttgtgagt gcacttcagt gatttagaaa gaactggatt tcaagcaact ttggacctgt 4620
 ggggggaggg agattaatga aggtttgaat cacattctaa ttctatgtac agtccttcat 4680
 tactccacaa gcctaaatcc tatacagcct ccaggatagc tggaaactgt tgagatctgg 4740
 actttttttt tttaatccaa gggctaactt gttgtaactt ggtataatta tctgctttcg 4800
 gaaatgcatc tctgttggtt tgaac 4825

<210> 62
 <211> 189
 <212> PRT
 <213> Gallus gallus

<400> 62

Met Thr Glu Tyr Lys Leu Val Val Val Gly Ala Gly Gly Val Gly Lys
1 5 10 15

Ser Ala Leu Thr Ile Gln Leu Ile Gln Asn His Phe Val Asp Glu Tyr
20 25 30

Asp Pro Thr Ile Glu Asp Ser Tyr Arg Lys Gln Val Val Ile Asp Gly
35 40 45

0398850pct.txt

Glu Thr Cys Leu Leu Asp Ile Leu Asp Thr Ala Gly Gln Glu Glu Tyr
50 55 60

Ser Ala Met Arg Asp Gln Tyr Met Arg Thr Gly Glu Gly Phe Leu Cys
65 70 75 80

Val Phe Ala Ile Asn Asn Ser Lys Ser Phe Ala Asp Ile Asn Leu Tyr
85 90 95

Arg Glu Gln Ile Lys Arg Val Lys Asp Ser Asp Asp Val Pro Met Val
100 105 110

Leu Val Gly Asn Lys Cys Asp Leu Pro Thr Arg Thr Val Asp Thr Lys
115 120 125

Gln Ala Gln Glu Leu Ala Lys Ser Tyr Gly Ile Pro Phe Ile Glu Thr
130 135 140

Ser Ala Lys Thr Arg Gln Gly Val Glu Asp Ala Phe Tyr Thr Leu Val
145 150 155 160

Arg Glu Ile Arg Gln Tyr Arg Met Lys Lys Leu Asn Ser Asn Glu Asp
165 170 175

Gly Asn Gln Gly Cys Met Gly Leu Ser Cys Ile Val Met
180 185

<210> 63
<211> 2603
<212> DNA
<213> Homo sapiens

<400> 63
aggcgaggct tccccctccc cgccccctccc ccggcctcca gtccctccca gggccgcttc 60
gcagagcggc taggagcacg gcggcgggcg cactttcccc ggcaggagct ggagctgggc 120
tctggtgcg gcgcggctgt gccgcccag ccggagggac tggttggttg agagagagag 180
aggaagggaa tcccgggctg ccgaaccgca cgttcagccc gctccgctcc tgcagggcag 240
cctttcggct ctctgcgcgc gaagccgagt cccgggcggg tggggcgggg gtccactgag 300
accgctaccg gccctcggc gctgacggga ccgcgcgggg cgcacccgct gaaggcagcc 360
ccggggcccg cggcccggac ttggtcctgc gcagcgggcg cggggcagcg cagcgggagg 420
aagcgagagg tgctgccctc ccccggagt tggaagcgcg ttaccgggt ccaaaatgcc 480
caagaagaag ccgacgcca tccagctgaa cccggccccc gacggctctg cagttaacgg 540
gaccagctct gcggagacca acttgaggc cttgcagaag aagctggagg agctagagct 600
tgatgagcag cagcgaaagc gccttgaggc ctttcttacc cagaagcaga aggtgggaga 660
actgaaggat gacgactttg agaagatcag tgagctgggg gctggcaatg gcggtgtggt 720

0398850pct.txt

gttcaaggtc	tcccacaagc	cttctggcct	ggatcatggcc	agaaagctaa	ttcatctgga	780
gatcaaacc	gcaatccgga	accagatcat	aaggagctg	caggttctgc	atgagtgcaa	840
ctctccgtac	atcgtgggct	tctatggtgc	gttctacagc	gatggcgaga	tcagtatctg	900
catggagcac	atggatggag	gttctctgga	tcaagtcctg	aagaaagctg	gaagaattcc	960
tgaacaaatt	ttaggaaaag	ttagcattgc	tgtataaaaa	ggcctgacat	atctgaggga	1020
gaagcacaag	atcatgcaca	gagatgtcaa	gccctccaac	atcctagtca	actcccgtgg	1080
ggagatcaag	ctctgtgact	ttgggggtcag	cgggcagctc	atcgactcca	tggccaactc	1140
cttcgtgggc	acaaggctct	acatgtcgcc	agaaagactc	caggggactc	attactctgt	1200
gcagtcagac	atctggagca	tgggactgtc	tctggtagag	atggcggttg	ggaggtatcc	1260
catccctcct	ccagatgcc	aggagctgga	gctgatgttt	gggtgccagg	tggaaggaga	1320
tgcggctgag	acccaccca	ggccaaggac	ccccgggagg	ccccttagct	catacggaat	1380
ggacagccga	cctcccatgg	caatttttga	gttggttgat	tacatagtca	acgagcctcc	1440
tccaaaactg	cccagtggag	tgttcagtct	ggaatttcaa	gattttgtga	ataaatgctt	1500
aataaaaaac	cccgcagaga	gagcagattt	gaagcaactc	atggttcatg	cttttatcaa	1560
gagatctgat	gctgaggaag	tggattttgc	aggttggctc	tgctccacca	tcggccttaa	1620
ccagcccagc	acaccaacc	atgctgctgg	cgtctaagtg	tttggaagc	aacaaagagc	1680
gagtcccctg	cccggtgggt	tgccatgtcg	cttttgggcc	tccttcccat	gcctgtctct	1740
gttcagatgt	gcatttcacc	tgtgacaaag	gatgaagaac	acagcatgtg	ccaagattct	1800
actcttgta	tttttaatat	tactgtcttt	attcttatta	ctattattgt	tcccctaagt	1860
ggattggctt	tgtgcttggg	gctattttgt	tgtatgctga	tgatcaaaac	ctgtgccagg	1920
ctgaattaca	gtgaaatfff	ggtgaatgtg	ggtagtcatt	cttacaattg	cactgctgtt	1980
cctgtcccat	gactggctgt	ctgcctgtat	tttcgggatt	ctttgacatt	tggtgggtact	2040
ttattcttgc	tgggcatact	ttctctctag	gagggagcct	tgtgagatcc	ttcacaggca	2100
gtgcatgtga	agcatgcttt	gctgctatga	aaatgagcat	cagagagtgt	acatcatgtt	2160
attttattat	tattatttgc	ttttcatgta	gaactcagca	gttgacatcc	aaatctagcc	2220
agagcccttc	actgccatga	tagctggggc	ttcaccagtc	tgtctactgt	ggtgatctgt	2280
agacttctgg	ttgtatttct	atatttattt	tcagtatact	gtgtgggata	cttagtggtg	2340
tgtctcttta	agttttgatt	aatgtttctt	aaatggaatt	atgttgatg	tcacaaattg	2400
atcaagatat	taaaatgtcg	gatttatctt	tccccatata	caagtaccaa	tgctgttgta	2460
aacaacgtgt	atagtcctta	aaattgtatg	aaaatccttt	taaccatttt	aacctagatg	2520
tttaacaaat	ctaattctct	attctaataa	atatactatg	aaataaaaaa	aaaaggatga	2580
aagctaaaaa	aaaaaaaaaa	aaa				2603

<210> 64
 <211> 393
 <212> PRT

<213> Homo sapiens

<400> 64

Met Pro Lys Lys Lys Pro Thr Pro Ile Gln Leu Asn Pro Ala Pro Asp
 1 5 10 15

Gly Ser Ala Val Asn Gly Thr Ser Ser Ala Glu Thr Asn Leu Glu Ala
 20 25 30

Leu Gln Lys Lys Leu Glu Glu Leu Glu Leu Asp Glu Gln Gln Arg Lys
 35 40 45

Arg Leu Glu Ala Phe Leu Thr Gln Lys Gln Lys Val Gly Glu Leu Lys
 50 55 60

Asp Asp Asp Phe Glu Lys Ile Ser Glu Leu Gly Ala Gly Asn Gly Gly
 65 70 75 80

Val Val Phe Lys Val Ser His Lys Pro Ser Gly Leu Val Met Ala Arg
 85 90 95

Lys Leu Ile His Leu Glu Ile Lys Pro Ala Ile Arg Asn Gln Ile Ile
 100 105 110

Arg Glu Leu Gln Val Leu His Glu Cys Asn Ser Pro Tyr Ile Val Gly
 115 120 125

Phe Tyr Gly Ala Phe Tyr Ser Asp Gly Glu Ile Ser Ile Cys Met Glu
 130 135 140

His Met Asp Gly Gly Ser Leu Asp Gln Val Leu Lys Lys Ala Gly Arg
 145 150 155 160

Ile Pro Glu Gln Ile Leu Gly Lys Val Ser Ile Ala Val Ile Lys Gly
 165 170 175

Leu Thr Tyr Leu Arg Glu Lys His Lys Ile Met His Arg Asp Val Lys
 180 185 190

Pro Ser Asn Ile Leu Val Asn Ser Arg Gly Glu Ile Lys Leu Cys Asp
 195 200 205

Phe Gly Val Ser Gly Gln Leu Ile Asp Ser Met Ala Asn Ser Phe Val
 210 215 220

Gly Thr Arg Ser Tyr Met Ser Pro Glu Arg Leu Gln Gly Thr His Tyr
 225 230 235 240

Ser Val Gln Ser Asp Ile Trp Ser Met Gly Leu Ser Leu Val Glu Met
 245 250 255

0398850pct.txt

Ala Val Gly Arg Tyr Pro Ile Pro Pro Pro Asp Ala Lys Glu Leu Glu
260 265 270

Leu Met Phe Gly Cys Gln Val Glu Gly Asp Ala Ala Glu Thr Pro Pro
275 280 285

Arg Pro Arg Thr Pro Gly Arg Pro Leu Ser Ser Tyr Gly Met Asp Ser
290 295 300

Arg Pro Pro Met Ala Ile Phe Glu Leu Leu Asp Tyr Ile Val Asn Glu
305 310 315 320

Pro Pro Pro Lys Leu Pro Ser Gly Val Phe Ser Leu Glu Phe Gln Asp
325 330 335

Phe Val Asn Lys Cys Leu Ile Lys Asn Pro Ala Glu Arg Ala Asp Leu
340 345 350

Lys Gln Leu Met Val His Ala Phe Ile Lys Arg Ser Asp Ala Glu Glu
355 360 365

Val Asp Phe Ala Gly Trp Leu Cys Ser Thr Ile Gly Leu Asn Gln Pro
370 375 380

Ser Thr Pro Thr His Ala Ala Gly Val
385 390

<210> 65
<211> 2151
<212> DNA
<213> Rattus norvegicus

<400> 65
cggccgcgcg ctccctgctg agttgcaggc tgtttcccg ctcgaagatg cccaagaaga 60
agccgacgcc catccagctg aaccgcggccc ccgatggctc cgcggttaac gggaccagct 120
cggccgagac caacctggag gccttgacaga agaagctgga ggagctggag ctggacgagc 180
agcagcgga ggccttgag gcctttctga cgcagaagca gaaggtggga gagttgaagg 240
atgatgactt tgagaagatc agtgaactgg gggctggcaa tgggtggagtg gtgttcaagg 300
tctcccacaa gccatctggc ctggttatgg ctaggaagct aattcacctg gagatcaaac 360
ccgcaatccg gaaccagatc atccgggagc tgcaggtgct gcatgagtgc aactccccgt 420
acatagtggg cttctacggg gccttctaca gtgacggcga gatcagcatc tgcattggagc 480
acatggatgg tgggtccttg gatcaagtgc tgaagaaagc tggaagaatt cctgagcaaa 540
ttttaggaaa agtcagcatc gctgtgataa aaggcctgac atatctacga gagaagcaca 600
agattatgca cagagatgac aagccttcca acattctagt gaactcacgt ggggagatca 660
aactctgcga ttttggggtc agcgggcagc taattgactc catggccaac tccttcgtgg 720
gaacaaggtc ctacatgtcg cctgagagac tccaggggac tcactactct gtgcagtcgg 780

0398850pct.txt

```

acatctggag catggggctc tctctggtgg agatggcagt tggaagatac cccattcctc 840
ctcctgatgc caaggagctg gagctgctgt ttggatgcca ggtggaagga gacgcggccg 900
aaacgccacc caggccaagg acccctggga ggcccctcag ctcatatgga atggatagcc 960
gacctcccat ggcaattttt gagttgttgg attacatcgt caatgagcct cctccaaaac 1020
tgcccagtgg agtattcagt ctggaatttc aggattttgt gaataagtgc ttaataaaga 1080
accctgcaga gagagcagat ctgaagcagc tcatggtaca tgctttcatc aagagatctg 1140
atgccgagga ggtagacttc gcaggctggc tctgctccac cattgggctt aaccagccca 1200
gcacaccaac ccacgctgcc agcatctgag cctttgggaa gcagcagaga ggaatcctct 1260
gccagtgggc atgccatgtt gctttcaggc ctctcccatg cttgtctatg ttcagatgtg 1320
catctcatct gtgacaaagg atgaagaaca cagcatgtgc caaatcgtac ttgtgtcatt 1380
tttaatatgg tctttatcgc tatggttact cccctaagtg gattggcttt gtgcttgggg 1440
ctatttgtct gtcatcaaa tacatgccag gttgaactac agtgaaaccc tggtgacctg 1500
ggtggtcttc ttactgatgt ttgcgtgct gttcatcgtg actcactagc tggctgcctg 1560
tattgtcagg attctcggac ccttggtact tcaactctgc tggtgacctc tcagtctgag 1620
gagagggggc cttctgagac ccttcacagg cagtgcacgc atgaaaagca tgctttgctg 1680
ctactgaaat gagcaccaga acgtgtacat catggtatct ttttttgct tttggtatag 1740
aactcagcag ttcccattta aaaaaaaaaa ctaaccagag cccatcactg ccatgatagc 1800
tggggcttca gtctgtctac tgtggtgatt tttagacttc tggttgtatt tctatattta 1860
tttttaaata tactgtgtgg gatacttagt ggtatatgtc tctgagtttg gattagtgtt 1920
tctaaattgg tagttatctt gaatgtcaca aatggattaa ggaatcaacg tatcaagagt 1980
tctatctttc ttccagtcta agtaccaatg ctattgtaaa cgtgtatagt gcctacaaat 2040
tgtatgaaaa cccttttaac cactttactc aagatgttta tcaaactctaa tctcttattc 2100
taataaaaaat actatcaagt taaagtaaaa aaaaaaaaaa aaaaaaaaaa a 2151

```

<210> 66
 <211> 393
 <212> PRT
 <213> Rattus norvegicus

<400> 66

Met Pro Lys Lys Lys Pro Thr Pro Ile Gln Leu Asn Pro Ala Pro Asp
 1 5 10 15

Gly Ser Ala Val Asn Gly Thr Ser Ser Ala Glu Thr Asn Leu Glu Ala
 20 25 30

Leu Gln Lys Lys Leu Glu Glu Leu Glu Leu Asp Glu Gln Gln Arg Lys
 35 40 45

Arg Leu Glu Ala Phe Leu Thr Gln Lys Gln Lys Val Gly Glu Leu Lys
 50 55 60

Asp Asp Asp Phe Glu Lys Ile Ser Glu Leu Gly Ala Gly Asn Gly Gly
 65 70 75 80
 Val Val Phe Lys Val Ser His Lys Pro Ser Gly Leu Val Met Ala Arg
 85 90 95
 Lys Leu Ile His Leu Glu Ile Lys Pro Ala Ile Arg Asn Gln Ile Ile
 100 105 110
 Arg Glu Leu Gln Val Leu His Glu Cys Asn Ser Pro Tyr Ile Val Gly
 115 120 125
 Phe Tyr Gly Ala Phe Tyr Ser Asp Gly Glu Ile Ser Ile Cys Met Glu
 130 135 140
 His Met Asp Gly Gly Ser Leu Asp Gln Val Leu Lys Lys Ala Gly Arg
 145 150 155 160
 Ile Pro Glu Gln Ile Leu Gly Lys Val Ser Ile Ala Val Ile Lys Gly
 165 170 175
 Leu Thr Tyr Leu Arg Glu Lys His Lys Ile Met His Arg Asp Val Lys
 180 185 190
 Pro Ser Asn Ile Leu Val Asn Ser Arg Gly Glu Ile Lys Leu Cys Asp
 195 200 205
 Phe Gly Val Ser Gly Gln Leu Ile Asp Ser Met Ala Asn Ser Phe Val
 210 215 220
 Gly Thr Arg Ser Tyr Met Ser Pro Glu Arg Leu Gln Gly Thr His Tyr
 225 230 235 240
 Ser Val Gln Ser Asp Ile Trp Ser Met Gly Leu Ser Leu Val Glu Met
 245 250 255
 Ala Val Gly Arg Tyr Pro Ile Pro Pro Pro Asp Ala Lys Glu Leu Glu
 260 265 270
 Leu Leu Phe Gly Cys Gln Val Glu Gly Asp Ala Ala Glu Thr Pro Pro
 275 280 285
 Arg Pro Arg Thr Pro Gly Arg Pro Leu Ser Ser Tyr Gly Met Asp Ser
 290 295 300
 Arg Pro Pro Met Ala Ile Phe Glu Leu Leu Asp Tyr Ile Val Asn Glu
 305 310 315 320
 Pro Pro Pro Lys Leu Pro Ser Gly Val Phe Ser Leu Glu Phe Gln Asp
 325 330 335

0398850pct.txt

Phe Val Asn Lys Cys Leu Ile Lys Asn Pro Ala Glu Arg Ala Asp Leu
340 345 350

Lys Gln Leu Met Val His Ala Phe Ile Lys Arg Ser Asp Ala Glu Glu
355 360 365

Val Asp Phe Ala Gly Trp Leu Cys Ser Thr Ile Gly Leu Asn Gln Pro
370 375 380

Ser Thr Pro Thr His Ala Ala Ser Ile
385 390

<210> 67
<211> 2387
<212> DNA
<213> Mus musculus

<400> 67
agtcctcac tgggacgtct gtgcgcggcg tctcggagcg ccggagcagc ggtggccgca 60
ctttctccaa gctggggctg tagctgagct gtgggtagtg cgcagggagc cgtccgagcc 120
cgaggaaccg gtgtgctgag gcgagagttc ccggccggcg agcgcgcgca gctggttctc 180
cgcgtgggtt gggcggaggg tcccaggagc gcggcggtga tcgagccgcc ccgactctgg 240
gcagagccga gggaggaagc gagaagcggc gcgcgcgtcc ctgctgagtt gcaggctctt 300
tcccggctgc aagatgccca agaagaagcc gacgcccatc cagctgaacc cggccccga 360
tggctcggcg gttaacggga ccagctcggc cgagaccaac ctggaggcct tgcagaagaa 420
gctggaggag ctggagcttg acgagcagca gcggaagcgg ctcgaggcct ttctgacgca 480
gaagcagaag gtgggggaac tgaaggatga tgactttgag aagatcagcg aactgggagc 540
tggcaacggt ggagtgtct tcaaggtctc ccacaagcca tctggcctgg ttatggctag 600
aaagctgac cacctggaga tcaaaccgc aatccggaac cagatcatcc gggagctgca 660
ggtactgcac gagtgcaact ccccgtagat cgtgggcttc tacggggcct tctacagcga 720
cggcgagatc agcatctgca tggagcacat ggatggtggg tccttgatc aagttctgaa 780
gaaagctgga agaattcctg agcaaatttt agggaaagtt agcattgctg tgataaaagg 840
cctgacctat cttcgggaga agcacaagat tatgcacaga gatgtcaagc catccaacat 900
tctagtgaac tcacgtgggg agatcaaact ctgtgatttt ggggtcagcg ggcagctaata 960
tgactctatg gccaaactct tcgtgggcac gagatcctac atgtcgctg agagactcca 1020
ggggactcac tactctgtgc agtcggacat ctggagcatg gggctctctc tgggtggagat 1080
ggcagttggg agatacccca ttctcctcc tgatgccaag gagctggagc tactgtttgg 1140
atgccatgtg gaaggagacg cagccgaaac accaccagg ccaaggaccc ctgggaggcc 1200
tctcagctca tatggaatgg acagccgacc tcccatggca atttttgagt tgttggatta 1260
cattgtcaat gagcctcctc caaaactgcc cagtggagta ttcagtctgg agtttcagga 1320

0398850pct.txt

```

ttttgtgaat aaatgcttaa taaagaaccc tgcagagaga gcagatctga agcagctcat 1380
ggtacatgct ttcataaaaa gatctgacgc cgaggaggta gacttcgcag gctggctctg 1440
ctccaccatt gggcttaacc agcccagcac accaaccac gctgccagca tctgagcctt 1500
taggaagcag caaagaggaa ttctctgccc agtggcatgc catgttgctt tcaggcctct 1560
cccatgcttg tctatgttca gacgtgcatc tcatctgtga caaaggatga agaacacagc 1620
atgtgcaaaa ttgtacttgt gtcattttta atatcattgt ctttatcact atggttactc 1680
ccctaagtgg attggctttg tgcttggggc tatttgtctg ttcataaac acatgccagg 1740
ctgaactaca gtgaaaccct agtgacctgg gtggtcgttc ttactgatgt ttgcaactgt 1800
gttcatcgtg actcactagc tggctgcctg tattgtcagg attctcggac cttggtactt 1860
cactcttgct ggtgacctct cagtctgaga gggagccttg tgagaccctt cacaggcagt 1920
gcatgcatgg aaagcatgct ttgctgctac tgaaatgagc atcagaacgt gtacgtcatg 1980
gtatttttat ttttgcctt tggtatagaa ctacagcaatt cccatcaaaa aaacctgaagc 2040
agagcccatc actgccatga tagctgggct tcagtctgtc tactgtggtg atttttagac 2100
ttctgggtgt atttctatat ttatttttaa atatacagtg tgggatactt agtgggtgtgt 2160
gtctctaagt ttggattagt gtttctaaat tgggtggtat tttgaatgtc acaaattggat 2220
taaagcatca atgtatcaag agttctatct ttcttccagt ctaagtacca atgctattgt 2280
aaacaacgtg tatagtgcct acaaattgta tgaaaccctt ttaaccact ttaatcaaga 2340
tgtttatcaa atctaattctc ttattctaataaaaaatacta tcaagtt 2387

```

<210> 68
 <211> 393
 <212> PRT
 <213> Mus musculus

<400> 68

Met Pro Lys Lys Lys Pro Thr Pro Ile Gln Leu Asn Pro Ala Pro Asp
 1 5 10 15

Gly Ser Ala Val Asn Gly Thr Ser Ser Ala Glu Thr Asn Leu Glu Ala
 20 25 30

Leu Gln Lys Lys Leu Glu Glu Leu Glu Leu Asp Glu Gln Gln Arg Lys
 35 40 45

Arg Leu Glu Ala Phe Leu Thr Gln Lys Gln Lys Val Gly Glu Leu Lys
 50 55 60

Asp Asp Asp Phe Glu Lys Ile Ser Glu Leu Gly Ala Gly Asn Gly Gly
 65 70 75 80

Val Val Phe Lys Val Ser His Lys Pro Ser Gly Leu Val Met Ala Arg
 85 90 95

Lys Leu Ile His₁₀₀ Leu Glu Ile Lys Pro Ala Ile Arg Asn Gln Ile Ile
 105 110
 Arg Glu Leu₁₁₅ Gln Val Leu His Glu₁₂₀ Cys Asn Ser Pro Tyr₁₂₅ Ile Val Gly
 Phe Tyr₁₃₀ Gly Ala Phe Tyr Ser₁₃₅ Asp Gly Glu Ile Ser₁₄₀ Ile Cys Met Glu
 His₁₄₅ Met Asp Gly Gly Ser₁₅₀ Leu Asp Gln Val Leu₁₅₅ Lys Lys Ala Gly Arg₁₆₀
 Ile Pro Glu Gln Ile₁₆₅ Leu Gly Lys Val Ser₁₇₀ Ile Ala Val Ile Lys₁₇₅ Gly
 Leu Thr Tyr Leu₁₈₀ Arg Glu Lys His Lys₁₈₅ Ile Met His Arg Asp₁₉₀ Val Lys
 Pro Ser Asn₁₉₅ Ile Leu Val Asn Ser₂₀₀ Arg Gly Glu Ile Lys₂₀₅ Leu Cys Asp
 Phe Gly₂₁₀ Val Ser Gly Gln Leu₂₁₅ Ile Asp Ser Met Ala₂₂₀ Asn Ser Phe Val
 Gly₂₂₅ Thr Arg Ser Tyr Met₂₃₀ Ser Pro Glu Arg Leu₂₃₅ Gln Gly Thr His Tyr₂₄₀
 Ser Val Gln Ser Asp₂₄₅ Ile Trp Ser Met Gly₂₅₀ Leu Ser Leu Val Glu₂₅₅ Met
 Ala Val Gly Arg₂₆₀ Tyr Pro Ile Pro Pro₂₆₅ Pro Asp Ala Lys Glu₂₇₀ Leu Glu
 Leu Leu Phe₂₇₅ Gly Cys His Val Glu₂₈₀ Gly Asp Ala Ala Glu₂₈₅ Thr Pro Pro
 Arg Pro Arg Thr Pro Gly Arg₂₉₅ Pro Leu Ser Ser Tyr₃₀₀ Gly Met Asp Ser
 Arg₃₀₅ Pro Pro Met Ala Ile₃₁₀ Phe Glu Leu Leu Asp₃₁₅ Tyr Ile Val Asn Glu₃₂₀
 Pro Pro Pro Lys Leu₃₂₅ Pro Ser Gly Val Phe₃₃₀ Ser Leu Glu Phe Gln Asp₃₃₅
 Phe Val Asn Lys₃₄₀ Cys Leu Ile Lys Asn₃₄₅ Pro Ala Glu Arg Ala₃₅₀ Asp Leu
 Lys Gln Leu₃₅₅ Met Val His Ala Phe₃₆₀ Ile Lys Arg Ser Asp₃₆₅ Ala Glu Glu

Val Asp Phe Ala Gly Trp Leu Cys Ser Thr Ile Gly Leu Asn Gln Pro
 370 375 380

Ser Thr Pro Thr His Ala Ala Ser Ile
 385 390

<210> 69
 <211> 1182
 <212> DNA
 <213> *Oryctolagus cuniculus*

<400> 69
 atgccaaaga agaagcccac ccccatccag ctgaatcctg cccctgacgg ctcggcggtg 60
 aatggtacca gtcggcgga gaccaacctg gaggccttgc agaagaagct ggaggagctg 120
 gagcttgacg agcagcagcg gaagcgctg gaggccttcc tcaccagaa gcagaaagtg 180
 ggagagctga aggacgatga cttcagaaag atcagtgagc tgggagccgg caacggcggc 240
 gtggtgttca aggtctccca caagcccagt ggcctggtga tggccagaaa gcttattcac 300
 ctggagatca aacctgctat ccggaaccag atcataaggg agctgcaggt tctgcacgag 360
 tgcaactccc cgtacatcgt gggcttctac ggggcattct acagcgatgg cgagatcagc 420
 atctgcatgg agcacatgga cgggggttcc ttggatcaag tcctgaagaa agctggacgg 480
 attcccagac aaattttggg gaaagttagc attgctgtga tcaagggcct gacgtatctg 540
 agggagaagc acaagatcat gcacagagat gtgaagccct ccaacatcct ggtcaactcc 600
 cgcggggaga tcaagctctg tgacttcggg gtcagtgggc agctcatcga ctccatggcc 660
 aactccttcg tgggcaccag gtcttatatg tcgcccagaga gactccaggg gacacactac 720
 tctgtgcagt cggacatctg gagcatgggg ctgtccctgg tggagatggc ggtggggcgg 780
 taccatcccg cgcccccgga cgccaaggag ctggagctga tgtttgggtg ccagggtggag 840
 ggcgatgcgg ccgagactcc gccaggccc aggaccctg ggcggcccct cagctcgtat 900
 ggaatggata gccggcctcc catggcgatt tttgagctgc tggattacat cgtcaatgag 960
 cctcctccga aactccccag cgcagtcttc agcctggagt ttcaagattt tgtgaataaa 1020
 tgcttaataa aaaaccccg cagagagagca gacttgaagc agctcatggt tcatgctttt 1080
 atcaagaggt ctgatgccga ggaggtggat tttgctggtt ggctgtgctc caccatcggc 1140
 cttaccagc ccagcacgcc gacgcacgcg gccggtgtgt ga 1182

<210> 70
 <211> 393
 <212> PRT
 <213> *Oryctolagus cuniculus*

<400> 70

Met Pro Lys Lys Lys Pro Thr Pro Ile Gln Leu Asn Pro Ala Pro Asp
 1 5 10 15

Gly Ser Ala Val Asn Gly Thr Ser Ser Ala Glu Thr Asn Leu Glu Ala
 20 25 30

Leu Gln Lys Lys Leu Glu Glu Leu Glu Leu Asp Glu Gln Gln Arg Lys
 35 40 45
 Arg Leu Glu Ala Phe Leu Thr Gln Lys Gln Lys Val Gly Glu Leu Lys
 50 55 60
 Asp Asp Asp Phe Glu Lys Ile Ser Glu Leu Gly Ala Gly Asn Gly Gly
 65 70 75 80
 Val Val Phe Lys Val Ser His Lys Pro Ser Gly Leu Val Met Ala Arg
 85 90 95
 Lys Leu Ile His Leu Glu Ile Lys Pro Ala Ile Arg Asn Gln Ile Ile
 100 105 110
 Arg Glu Leu Gln Val Leu His Glu Cys Asn Ser Pro Tyr Ile Val Gly
 115 120 125
 Phe Tyr Gly Ala Phe Tyr Ser Asp Gly Glu Ile Ser Ile Cys Met Glu
 130 135 140
 His Met Asp Gly Gly Ser Leu Asp Gln Val Leu Lys Lys Ala Gly Arg
 145 150 155 160
 Ile Pro Glu Gln Ile Leu Gly Lys Val Ser Ile Ala Val Ile Lys Gly
 165 170 175
 Leu Thr Tyr Leu Arg Glu Lys His Lys Ile Met His Arg Asp Val Lys
 180 185 190
 Pro Ser Asn Ile Leu Val Asn Ser Arg Gly Glu Ile Lys Leu Cys Asp
 195 200 205
 Phe Gly Val Ser Gly Gln Leu Ile Asp Ser Met Ala Asn Ser Phe Val
 210 215 220
 Gly Thr Arg Ser Tyr Met Ser Pro Glu Arg Leu Gln Gly Thr His Tyr
 225 230 235 240
 Ser Val Gln Ser Asp Ile Trp Ser Met Gly Leu Ser Leu Val Glu Met
 245 250 255
 Ala Val Gly Arg Tyr Pro Ile Pro Pro Pro Asp Ala Lys Glu Leu Glu
 260 265 270
 Leu Met Phe Gly Cys Gln Val Glu Gly Asp Ala Ala Glu Thr Pro Pro
 275 280 285
 Arg Pro Arg Thr Pro Gly Arg Pro Leu Ser Ser Tyr Gly Met Asp Ser
 290 295 300

0398850pct.txt

Arg Pro Pro Met Ala Ile Phe Glu Leu Leu Asp Tyr Ile Val Asn Glu
305 310 315 320

Pro Pro Pro Lys Leu Pro Ser Ala Val Phe Ser Leu Glu Phe Gln Asp
325 330 335

Phe Val Asn Lys Cys Leu Ile Lys Asn Pro Ala Glu Arg Ala Asp Leu
340 345 350

Lys Gln Leu Met Val His Ala Phe Ile Lys Arg Ser Asp Ala Glu Glu
355 360 365

Val Asp Phe Ala Gly Trp Leu Cys Ser Thr Ile Gly Leu Asn Gln Pro
370 375 380

Ser Thr Pro Thr His Ala Ala Gly Val
385 390

<210> 71
<211> 1872
<212> DNA
<213> Cavia porcellus

<400> 71
cgtgtcttcg tcgggaccgc cctcctcctt gagtcctccc cccaccggga cggccgagtg 60
gagaggccgg acgaaggcgg cggccccggc ggcggctttt cctcggcttc gctgtgcagc 120
gtgcgcggcg aggttgaccg cccgcgagcg cccgtgactg agggaacagg gagagagctc 180
gggcgggcca gcgcgcagcc ctccgtgggc attgccgcct ggacctcccg gaaggcaccc 240
cgggccgcgg ccgccacccg tcccgccttc gttcggagct gagacgccgt cgccgcgcaa 300
gatgcccaag aagaagccga cgcccatcca gctgaaccgc gccccgacg gctcggcggt 360
gaacgggacc agctcggccg agaccaacct agaggctttg cagaagaagc tggaggagct 420
ggagctggat gagcagcagc ggaagcgcct cgaagctttc ctgacacaga agcagaaggt 480
gggcgagctg aaggacgatg actttgagaa gatcagtgag ctgggtgccg gcaatggcgg 540
tgtggtgttc aaggtctccc acaagccatc tggcctggtc atggcccgaa agcttatcca 600
cctggagatc aagccagcca tccgcaatca gatcatccgt gagctgcagg ttctgcacga 660
gtgcaactcg ccctacattg tgggcttcta tggggccttc tacagtgatg gcgagatcag 720
catctgcatg gagcacatgg atggaggttc cttggatcaa gtcctgaaga aagctggaag 780
aattcctgag caaatTTtag gaaaagttag cattgctgtg atcaaaggcc tgacatacct 840
gagggagaag cacaagatta tgcacagaga tgtcaagccc tccaacatcc tggtaactc 900
ccgcggggag atcaagctct gtgactttgg ggtcagcggg cagctcatcg attccatggc 960
caactccttc gtgggcaccc ggtcctacat gtcgccagag agactgcagg gcacacacta 1020
ctcagtgcag tcggacatct ggagcatggg actgtcactg gtggagatgg cggttgggag 1080

```

gtaccccatc cccctccag atgccaagga gctggagctg gtgttcgggt gccaggtgga 1140
aggagatgca gctgagatgc cgcccaggcc caggaccccc ggaagacccc tgagctcata 1200
tggaatggac agccggcctc ccatggcgat tttcgagctg ttggattaca tagtcaacga 1260
gccacctccc aaactgccc gtggagtctt cagtctggaa ttccaggact ttgtaaataa 1320
atgcttaata aagaaccctg cggagagagc agacttgaag cagctcatgg ttcatgcctt 1380
catcaagcgc tctgatgctg aggaggtgga cttcgaggtg ttgctctgtg ccaccatcgg 1440
ccttaaccag cccagtaccc cgaccacagt ggccagcatc tgagctgcgg cccggcccag 1500
acgtgctctg ccagcagccg ctatgctctg gcctctccct cgcttctctt cagacgtgcg 1560
tttcacctcc gaccagggtg cagacacagc atgtgccaag ctgtatttgt gttccttttc 1620
agtctttatt gccaccgtgt cacccgagtg gatttgcttt gtgcttaggg ctgtttgtgc 1680
tgatgatcac acacacgctg agctgaacag tgacacttgg tgatgtgggt gtcactgttc 1740
tcactccatg tggctggcct gttgcctcca gtgtctccag acttggggat gtctggtggc 1800
acttcccctg ccagggcac tcctcagcag agaggaggc ctctggggcc ttgtccttgg 1860
cagtgaagt ga 1872

```

<210> 72
 <211> 393
 <212> PRT
 <213> *Cavia porcellus*

<400> 72

Met Pro Lys Lys Lys Pro Thr Pro Ile Gln Leu Asn Pro Ala Pro Asp
1 5 10 15

Gly Ser Ala Val Asn Gly Thr Ser Ser Ala Glu Thr Asn Leu Glu Ala
20 25 30

Leu Gln Lys Lys Leu Glu Glu Leu Glu Leu Asp Glu Gln Gln Arg Lys
35 40 45

Arg Leu Glu Ala Phe Leu Thr Gln Lys Gln Lys Val Gly Glu Leu Lys
50 55 60

Asp Asp Asp Phe Glu Lys Ile Ser Glu Leu Gly Ala Gly Asn Gly Gly
65 70 75 80

Val Val Phe Lys Val Ser His Lys Pro Ser Gly Leu Val Met Ala Arg
85 90 95

Lys Leu Ile His Leu Glu Ile Lys Pro Ala Ile Arg Asn Gln Ile Ile
100 105 110

Arg Glu Leu Gln Val Leu His Glu Cys Asn Ser Pro Tyr Ile Val Gly
115 120 125

Phe Tyr Gly Ala Phe Tyr Ser Asp Gly Glu Ile Ser Ile Cys Met Glu
 130 135 140
 His Met Asp Gly Gly Ser Leu Asp Gln Val Leu Lys Lys Ala Gly Arg
 145 150 155 160
 Ile Pro Glu Gln Ile Leu Gly Lys Val Ser Ile Ala Val Ile Lys Gly
 165 170 175
 Leu Thr Tyr Leu Arg Glu Lys His Lys Ile Met His Arg Asp Val Lys
 180 185 190
 Pro Ser Asn Ile Leu Val Asn Ser Arg Gly Glu Ile Lys Leu Cys Asp
 195 200 205
 Phe Gly Val Ser Gly Gln Leu Ile Asp Ser Met Ala Asn Ser Phe Val
 210 215 220
 Gly Thr Arg Ser Tyr Met Ser Pro Glu Arg Leu Gln Gly Thr His Tyr
 225 230 235 240
 Ser Val Gln Ser Asp Ile Trp Ser Met Gly Leu Ser Leu Val Glu Met
 245 250 255
 Ala Val Gly Arg Tyr Pro Ile Pro Pro Pro Asp Ala Lys Glu Leu Glu
 260 265 270
 Leu Val Phe Gly Cys Gln Val Glu Gly Asp Ala Ala Glu Met Pro Pro
 275 280 285
 Arg Pro Arg Thr Pro Gly Arg Pro Leu Ser Ser Tyr Gly Met Asp Ser
 290 295 300
 Arg Pro Pro Met Ala Ile Phe Glu Leu Leu Asp Tyr Ile Val Asn Glu
 305 310 315 320
 Pro Pro Pro Lys Leu Pro Ser Gly Val Phe Ser Leu Glu Phe Gln Asp
 325 330 335
 Phe Val Asn Lys Cys Leu Ile Lys Asn Pro Ala Glu Arg Ala Asp Leu
 340 345 350
 Lys Gln Leu Met Val His Ala Phe Ile Lys Arg Ser Asp Ala Glu Glu
 355 360 365
 Val Asp Phe Ala Gly Trp Leu Cys Ala Thr Ile Gly Leu Asn Gln Pro
 370 375 380
 Ser Thr Pro Thr His Val Ala Ser Ile
 385 390

<210> 73
 <211> 1257
 <212> DNA
 <213> Canis familiaris

<400> 73
 ggagagcgag acacgggccg ctctccgctc ggagccggac ggccttccc gcgtccaaaa 60
 tgcccaagaa gaagccgacg cccatccagc tgaacccggc ccccgacggc tcggcggtga 120
 acgggaccag ctcggcggag accaacctgg aggccttgca gaagaagctg gaggagctgg 180
 agcttgatga gcagcagcgg aagcgccttg aggcctttct caccagaag cagaaggctg 240
 gggaactgaa ggatgacgac ttcgagaaga tcagtgaact ggggtgctggc aacggtggcg 300
 tgggtgttaa ggtctccac aagccgtccg gcctagtcac ggccagaaaag ctaattcacc 360
 tggagatcaa acctgcaatc cggaaccaga tcataagga gctacagggt ctacatgagt 420
 gcaactcccc gtacatcgtg ggcttctatg gtgcattcta cagcgatggc gagatcagta 480
 tctgcatgga gcacatggat gggggttcct tggatcaagt cctgaagaaa gctggaagaa 540
 ttcctgaaca aattctagga aaagttagca tcgctgtaat aaaaggctctg acataacctga 600
 gagagaagca caagattatg cacagagatg tcaagccttc caacatcctc gtgaactccc 660
 gtggggagat caagctctgt gactttgggg tcagcgggca gctcattgac tccatggcca 720
 actccttcgt gggcacaagg tcctacatgt cgccagaaag actccagggg actcattact 780
 ccgtgcagtc ggacatctgg agcatggggc tctctctggt ggagatggca gttgggaggt 840
 atcccatccc tcctccggat gccaaggagc tggagctgat gtttgggtgc caagtggagg 900
 gagacgtggc tgagaccca cccagaccaa ggaccccgga aagaccctt agctcttatg 960
 gaatggacag ccgaccgccc atggcaattt ttgagctggt ggattacata gtcaacgagc 1020
 cccctccaaa actgcccagt ggagtattca gtctggaatt tcaagatttt gtgaataaat 1080
 gcttaataaa aaaccagca gagagagcag atctgaagca actcatggtt catgccttca 1140
 tcaagagatc tgacggtgaa gaagtggatt ttgcagggtg gctctgctcc cccattggc 1200
 cttaccagc ccagcacgcc gaccacgca gctggcgtct aactcgagtc tagagat 1257

<210> 74
 <211> 381
 <212> PRT
 <213> Canis familiaris

<400> 74
 Met Pro Lys Lys Lys Pro Thr Pro Ile Gln Leu Asn Pro Ala Pro Asp
 1 5 10 15
 Gly Ser Ala Val Asn Gly Thr Ser Ser Ala Glu Thr Asn Leu Glu Ala
 20 25 30
 Leu Gln Lys Lys Leu Glu Glu Leu Glu Leu Asp Glu Gln Gln Arg Lys
 35 40 45

Arg Leu Glu Ala Phe Leu Thr Gln Lys Gln Lys Val Gly Glu Leu Lys
 50 55 60
 Asp Asp Asp Phe Glu Lys Ile Ser Glu Leu Gly Ala Gly Asn Gly Gly
 65 70 75 80
 Val Val Phe Lys Val Ser His Lys Pro Ser Gly Leu Val Met Ala Arg
 85 90 95
 Lys Leu Ile His Leu Glu Ile Lys Pro Ala Ile Arg Asn Gln Ile Ile
 100 105 110
 Arg Glu Leu Gln Val Leu His Glu Cys Asn Ser Pro Tyr Ile Val Gly
 115 120 125
 Phe Tyr Gly Ala Phe Tyr Ser Asp Gly Glu Ile Ser Ile Cys Met Glu
 130 135 140
 His Met Asp Gly Gly Ser Leu Asp Gln Val Leu Lys Lys Ala Gly Arg
 145 150 155 160
 Ile Pro Glu Gln Ile Leu Gly Lys Val Ser Ile Ala Val Ile Lys Gly
 165 170 175
 Leu Thr Tyr Leu Arg Glu Lys His Lys Ile Met His Arg Asp Val Lys
 180 185 190
 Pro Ser Asn Ile Leu Val Asn Ser Arg Gly Glu Ile Lys Leu Cys Asp
 195 200 205
 Phe Gly Val Ser Gly Gln Leu Ile Asp Ser Met Ala Asn Ser Phe Val
 210 215 220
 Gly Thr Arg Ser Tyr Met Ser Pro Glu Arg Leu Gln Gly Thr His Tyr
 225 230 235 240
 Ser Val Gln Ser Asp Ile Trp Ser Met Gly Leu Ser Leu Val Glu Met
 245 250 255
 Ala Val Gly Arg Tyr Pro Ile Pro Pro Pro Asp Ala Lys Glu Leu Glu
 260 265 270
 Leu Met Phe Gly Cys Gln Val Glu Gly Asp Val Ala Glu Thr Pro Pro
 275 280 285
 Arg Pro Arg Thr Pro Gly Arg Pro Leu Ser Ser Tyr Gly Met Asp Ser
 290 295 300
 Arg Pro Pro Met Ala Ile Phe Glu Leu Leu Asp Tyr Ile Val Asn Glu
 305 310 315 320

Pro Pro Pro Lys Leu Pro Ser Gly Val Phe Ser Leu Glu Phe Gln Asp
 325 330 335

Phe Val Asn Lys Cys Leu Ile Lys Asn Pro Ala Glu Arg Ala Asp Leu
 340 345 350

Lys Gln Leu Met Val His Ala Phe Ile Lys Arg Ser Asp Gly Glu Glu
 355 360 365

Val Asp Phe Ala Gly Trp Leu Cys Ser Pro His Trp Pro
 370 375 380

<210> 75
 <211> 2095
 <212> DNA
 <213> Felis catus

<400> 75
 agccggcaag gagttgagcg tgcggggtgc ataggcgcgg gtcgtgggag atgaagctgg 60
 agaggaccaa cctggaggcc ttgcagaaga agctggagga gctggagctc gatgagcagc 120
 aacggaagcg cctggaggcc tttcttacct agaagcagaa ggtcggggaa ttgaaggatg 180
 acgacttcga gaagatcagc gagctgggcg ctggcaacgg tgggtgtggtg ttcaaggtct 240
 ccataagcc gtctggcctg gtcattggcca gaaagctaatt tcacctggag atcaaacctg 300
 caatccggaa ccagatcata agggagctgc aggttctaca tgagtgaac tccccataca 360
 tcgtgggctt ctatggcgcg ttctacagcg acggcgagat cagtatctgt atggagcaca 420
 tggatggggg ttccttggat caagtcctga agaaagctgg aagaattcct gaacaaattt 480
 taggaaaagt tagcattgct gtaataaaaag gtctgacata cctgagggag aagcacaaga 540
 ttatgcacag agatgtcaag ccttccaaca tcctagtga ctctcgtggg gagatcaagc 600
 tctgtgactt tggggtcagc gggcagctca tcgactccat ggccaactcc ttcgtgggca 660
 caaggtccta catgtcgcca gaaagactcc aggggactca ttactccgtg cagtcggaca 720
 tctggagcat ggggctatct ctgggtgaga tggcagtcgg gaggtatccc atccctcctc 780
 ccgatgcaa ggagctggag ctgatgtttg ggtgccaagt ggaggagat gcggctgaga 840
 cgccaccag gccgaggacc ccggaaggc ccctcagctc gtatggaatg gacagccgac 900
 ctcccatggc aatttttgag ttgttgatt acatagtcaa cgagcctcct ccaaagctgc 960
 ccagtggagt attcagtctg gaatttcaag attttgtgaa taaatgcctc ataaaaaacc 1020
 cagcagagag agcagatctg aaacaactca tggttcatgc ctttatcaag agatctgatg 1080
 gtgaggaagt ggattttgca ggttggctct gctccaccat cggccttaac cagcccagca 1140
 caccgacca cgcgccggc gtctaagtat ctgggaagca gcaaagagcg agtcccctgc 1200
 ccagtgggtg gccattgtcg ctttcaggcc tctttgccat gcctgtctcc gttcagacgt 1260
 gcatttcgcc tacgacaaag gatgaagaac acagcatgtg caaaattct atttgtgtct 1320
 tttttaatat tactgtcatt tattctgtta tttccctaag tggattggct ttgtgcttgg 1380

0398850pct.txt

```

ggctatTTTT gtgtatgttg atccaaacat gcgcaacgtt cagttacagt gaaaccttgg 1440
tgactgtggg tagtcattct tactgaaaat tgcactgctc ttccccacc gtgactggct 1500
agctgcctgt agttttggga ttcttttgac acttggtgtg actgcattct tgccggg'gcgc 1560
accttccttc tgttggggta ggagccttgt aagatccttc acaggcactg catgtgaagc 1620
atgctttgct gctatgaaaa agaacatcag aaagtataga tcttgttatt ttattatatt 1680
tttgcttttg gtgtagaatg aagcaatttc tgtcaaaatc tagccagagc ctttactgc 1740
cacgatagct ggggcttcac cagtctgtct actgtgatga tttgtagact tctggttgta 1800
tttctatatt tattttaaaa tatattatgt gggatattta gtggtatgtg tctctttaag 1860
tttgaattag tgtttctaaa atgatgggta ctttgaatgt taaaaatgga tcaaggcatt 1920
aaaatgtatg agatttatct ttccccaaat ccaagtaccg atgctattgt aaacaacagt 1980
gtgtatagtg cctaagaatt gtatgaaaat cttttaacc atttcaacc agatgtttaa 2040
caaatctaatt ctctattct aataaatata ctatcaagtt aaaaggatga aaaaa 2095

```

<210> 76
 <211> 371
 <212> PRT
 <213> Felis catus

<400> 76

```

Met Lys Leu Glu Arg Thr Asn Leu Glu Ala Leu Gln Lys Lys Leu Glu
1          5          10          15

Glu Leu Glu Leu Asp Glu Gln Gln Arg Lys Arg Leu Glu Ala Phe Leu
20          25          30

Thr Gln Lys Gln Lys Val Gly Glu Leu Lys Asp Asp Asp Phe Glu Lys
35          40          45

Ile Ser Glu Leu Gly Ala Gly Asn Gly Gly Val Val Phe Lys Val Ser
50          55          60

His Lys Pro Ser Gly Leu Val Met Ala Arg Lys Leu Ile His Leu Glu
65          70          75          80

Ile Lys Pro Ala Ile Arg Asn Gln Ile Ile Arg Glu Leu Gln Val Leu
85          90          95

His Glu Cys Asn Ser Pro Tyr Ile Val Gly Phe Tyr Gly Ala Phe Tyr
100         105         110

Ser Asp Gly Glu Ile Ser Ile Cys Met Glu His Met Asp Gly Gly Ser
115         120         125

Leu Asp Gln Val Leu Lys Lys Ala Gly Arg Ile Pro Glu Gln Ile Leu
130         135         140

```

Gly Lys Val Ser Ile Ala Val Ile Lys Gly Leu Thr Tyr Leu Arg Glu
145 150 155 160

Lys His Lys Ile Met His Arg Asp Val Lys Pro Ser Asn Ile Leu Val
165 170 175

Asn Ser Arg Gly Glu Ile Lys Leu Cys Asp Phe Gly Val Ser Gly Gln
180 185 190

Leu Ile Asp Ser Met Ala Asn Ser Phe Val Gly Thr Arg Ser Tyr Met
195 200 205

Ser Pro Glu Arg Leu Gln Gly Thr His Tyr Ser Val Gln Ser Asp Ile
210 215 220

Trp Ser Met Gly Leu Ser Leu Val Glu Met Ala Val Gly Arg Tyr Pro
225 230 235 240

Ile Pro Pro Pro Asp Ala Lys Glu Leu Glu Leu Met Phe Gly Cys Gln
245 250 255

Val Glu Gly Asp Ala Ala Glu Thr Pro Pro Arg Pro Arg Thr Pro Gly
260 265 270

Arg Pro Leu Ser Ser Tyr Gly Met Asp Ser Arg Pro Pro Met Ala Ile
275 280 285

Phe Glu Leu Leu Asp Tyr Ile Val Asn Glu Pro Pro Pro Lys Leu Pro
290 295 300

Ser Gly Val Phe Ser Leu Glu Phe Gln Asp Phe Val Asn Lys Cys Leu
305 310 315 320

Ile Lys Asn Pro Ala Glu Arg Ala Asp Leu Lys Gln Leu Met Val His
325 330 335

Ala Phe Ile Lys Arg Ser Asp Gly Glu Glu Val Asp Phe Ala Gly Trp
340 345 350

Leu Cys Ser Thr Ile Gly Leu Asn Gln Pro Ser Thr Pro Thr His Ala
355 360 365

Ala Gly Val
370

<210> 77
<211> 2405
<212> DNA
<213> Bos taurus

<400> 77
ccggttgact gagggagagt gggaggggaat cccgggctgc cgagctgcgc cggcggggaa

0398850pct.txt

gcccttcggt	tccctgtgca	ctgagcaagt	gggccggggg	gttccccag	accgccactg	120
gccctttggc	cctgacggga	ccgcgcaggg	cgcgccccc	gaaggcagcc	ttcgggcttg	180
cggcccagac	ttggccccgc	gaggccggcg	cggggcagct	cagagggagg	aagctagagg	240
ggccgccctc	agagttggga	gcgcctttcc	tgggtccaaa	atgcccaaga	agaagccgac	300
gcccattccag	ctgaaccg	ccccggacgg	ctccgcggtt	aacgggacca	gctcggcgga	360
gaccaacctg	gaggccttgc	agaagaagct	ggaggagctg	gagctcgatg	aacagcagcg	420
gaagcgcctc	gaggcctttc	tgaccagaa	gcagaagggtg	ggggaactga	aggatgatga	480
ctttgagaag	atcagtgagc	tgggtgccgg	caatggaggt	gtggtgttca	aggtctccca	540
caagccgtcc	ggacttgta	tggccagaaa	gctaattcac	ctggagatca	aacctgccat	600
ccggaaccag	atcataagg	agctgcaggt	tctccatgag	tgcaactcgc	cttatatcgt	660
gggcttctac	ggggcgttct	acagcgacgg	cgagatcagc	atctgcatgg	agcacatgga	720
tgggggttcc	ttgatcaag	ttctgaagaa	agctggaaga	attcctgaac	aaattttagg	780
aaaagttagc	attgctgtaa	taaaaggcct	gacataacctg	agggagaagc	acaagattat	840
gcacagagat	gtcaagccgt	ccaacatcct	agtgaacagc	cgtggagaga	tcaagctctg	900
tgactttggg	gtcagcgggc	agctcatcga	ctccatggcc	aactccttcg	tgggcaccag	960
gtcctacatg	tcgccagagc	gactccaggg	gaccattac	tccgtgcagt	cggacatctg	1020
gagcatgggg	ctctctctgg	ttgagatggc	tgtcgggagg	tatcccatcc	ctcctccaga	1080
tgccaaggag	ctggagctga	tgtttgggtg	ccagggtggag	ggagatgcgg	ctgagacccc	1140
gcccaggcca	aggacccccg	ggaggcccct	cagctcttat	ggaatggaca	gccgacctcc	1200
aatggcaatt	tttgagttgt	tggattacat	agtcaatgag	cctcctccaa	aactgcccag	1260
tggagtattc	agtctggaat	ttcaagattt	tgtgaataaa	tgcttaataa	aaaacccgc	1320
agagagagca	gatttgaagc	aactcatggg	tcatgctttt	atcaagagat	ctgatgctga	1380
ggaagtggat	tttgaggtt	ggctctgctc	caccatcggc	cttaaccaac	ccagcacacc	1440
cacccatgcg	gctggcgtct	aagtggttgg	gaagcagcag	tccctgccca	agggcattga	1500
ctgttgcttc	cgggcagcct	tcccatgcct	gtctctgttc	agacgtgcat	ttcacctatg	1560
acaaaggatg	aagaacacag	catgtgccaa	aattctat	gtgtcatttt	caatattatc	1620
atctttactc	ttattactat	tgttattccc	ctaagtggat	tggctttgtg	cttggggcta	1680
tttttggtga	tattgatgat	gaagacatgt	gcaatgtaga	attacagtga	aactctggtg	1740
actgtgggta	gtcattctta	ctgaaaactg	cactgctttc	ccacaccatg	aactggctgg	1800
tcgcctctat	tttcgggatt	ctttgacact	tgggtggtact	tcattcttgc	caggcatacc	1860
ttctaactga	gtaggaagga	gccttgtaag	atccttcaca	ggcagtgcac	gtgaagcatg	1920
ctttgctgct	ataaaaaatga	gcatcagaaa	gtgtgtatca	tgttat	ttatgttctt	1980
gcttttggtg	tagaattcag	caaattttca	tcaaaatcta	gccagagccc	ttcactgcca	2040
tgatagctgg	ggcttcacca	gtctgtctac	tgtgatgatt	tgtagacttc	tggttgtatt	2100

0398850pct.txt

tctgtattta tttttaaatc taccggtgtg atatttagtg ctatgtctct ttaagtttgg 2160
 attagtgttt ctaaaatggt ggagttgctc tgaatgttac aaatggatca aggcattaaa 2220
 atgaatgaga tctacctttc accaagtact gatgctattg taaacaacag tgtgtatagt 2280
 gcctaacaac tgtatgaaaa tccttttacc attttaatcc agatgtttta caagcctaata 2340
 ctcttactct aataaatata ctatcaaatt caaaggaaaa aaaaaaaaaa aaaaaaaaaa 2400
 aaaaaa 2405

<210> 78
 <211> 393
 <212> PRT
 <213> Bos taurus

<400> 78

Met Pro Lys Lys Lys Pro Thr Pro Ile Gln Leu Asn Pro Ala Pro Asp
 1 5 10 15

Gly Ser Ala Val Asn Gly Thr Ser Ser Ala Glu Thr Asn Leu Glu Ala
 20 25 30

Leu Gln Lys Lys Leu Glu Glu Leu Glu Leu Asp Glu Gln Gln Arg Lys
 35 40 45

Arg Leu Glu Ala Phe Leu Thr Gln Lys Gln Lys Val Gly Glu Leu Lys
 50 55 60

Asp Asp Asp Phe Glu Lys Ile Ser Glu Leu Gly Ala Gly Asn Gly Gly
 65 70 75 80

Val Val Phe Lys Val Ser His Lys Pro Ser Gly Leu Val Met Ala Arg
 85 90 95

Lys Leu Ile His Leu Glu Ile Lys Pro Ala Ile Arg Asn Gln Ile Ile
 100 105 110

Arg Glu Leu Gln Val Leu His Glu Cys Asn Ser Pro Tyr Ile Val Gly
 115 120 125

Phe Tyr Gly Ala Phe Tyr Ser Asp Gly Glu Ile Ser Ile Cys Met Glu
 130 135 140

His Met Asp Gly Gly Ser Leu Asp Gln Val Leu Lys Lys Ala Gly Arg
 145 150 155 160

Ile Pro Glu Gln Ile Leu Gly Lys Val Ser Ile Ala Val Ile Lys Gly
 165 170 175

Leu Thr Tyr Leu Arg Glu Lys His Lys Ile Met His Arg Asp Val Lys
 180 185 190

Pro Ser Asn Ile Leu Val Asn Ser Arg Gly Glu Ile Lys Leu Cys Asp
 195 200 205

Phe Gly Val Ser Gly Gln Leu Ile Asp Ser Met Ala Asn Ser Phe Val
 210 215 220

Gly Thr Arg Ser Tyr Met Ser Pro Glu Arg Leu Gln Gly Thr His Tyr
 225 230 235 240

Ser Val Gln Ser Asp Ile Trp Ser Met Gly Leu Ser Leu Val Glu Met
 245 250 255

Ala Val Gly Arg Tyr Pro Ile Pro Pro Pro Asp Ala Lys Glu Leu Glu
 260 265 270

Leu Met Phe Gly Cys Gln Val Glu Gly Asp Ala Ala Glu Thr Pro Pro
 275 280 285

Arg Pro Arg Thr Pro Gly Arg Pro Leu Ser Ser Tyr Gly Met Asp Ser
 290 295 300

Arg Pro Pro Met Ala Ile Phe Glu Leu Leu Asp Tyr Ile Val Asn Glu
 305 310 315 320

Pro Pro Pro Lys Leu Pro Ser Gly Val Phe Ser Leu Glu Phe Gln Asp
 325 330 335

Phe Val Asn Lys Cys Leu Ile Lys Asn Pro Ala Glu Arg Ala Asp Leu
 340 345 350

Lys Gln Leu Met Val His Ala Phe Ile Lys Arg Ser Asp Ala Glu Glu
 355 360 365

Val Asp Phe Ala Gly Trp Leu Cys Ser Thr Ile Gly Leu Asn Gln Pro
 370 375 380

Ser Thr Pro Thr His Ala Ala Gly Val
 385 390

<210> 79

<211> 2146

<212> DNA

<213> Equus caballus

<400> 79

caagtgggaa agcttgggat gcgtggagga gccagctact agtttagtgt gctgggtgcg 60

tcggtgcagg tcgcaggaga tgaagccgga gaggaccaac ctggaggcct tgcagaagaa 120

gctggaggag ctggagctcg atgaacagca gcgaaagcgc cttgaggcct ttcttactca 180

gaagcagaag gttggggaac tgaaggatga tgactttgag aagatcagtg agctgggtgc 240

tggcaatggt ggtgtggtat tcaaggttgc ccacaaaccg tctggtttgg tcatggccag 300

0398850pct.txt

aaagctaatt	cacctggaga	tcaagcctgc	aatccggaac	cagatcataa	gggagctgca	360
ggttctacat	gagtgaact	ccccatatat	tgtgggcttc	tatggcgcat	tctacagcga	420
tggtgagatc	agcatctgca	tggagcacat	ggatgggggt	tccttgatc	aagtcctaaa	480
gaaagctgga	agaattcctg	agcaaatttt	aggaaaagtt	agcattgctg	taataaaagg	540
cctgacgtat	ctgagggaga	agcacaagat	tatgcacaga	gatgtcaagc	cctccaacat	600
cctagtgaac	tcccgtgggg	agatcaagct	gtgtgatttt	ggggtcagcg	ggcagctcat	660
cgactccatg	gccaaactcct	tcgtgggcac	aaggctttac	atgtcgccgg	aaagactcca	720
ggggactcat	tattcagtgc	agtcggacat	ctggagcatg	gggctctctc	tggttgagat	780
ggcggtcggg	aggtatccca	tccctcctcc	agatgccaa	gagctggagc	tgatgtttgg	840
gtgccaagt	gagggagatg	cggctgagac	tccgcctagg	ccaaggaccc	ctggaagacc	900
cctcagctct	tatggaatgg	acagccgacc	tcctatggca	atTTTTgagt	tactggatta	960
catagtcaac	gagcctcctc	ccaagctgcc	cagtggagta	ttcagtctgg	aatttcagga	1020
ttttgtgaat	aaatgcttaa	tcaaaaaccc	tgcagagaga	gcagatttga	agcaactcat	1080
ggttcacgct	tttatcaaga	gatctgatgc	cgaggaagt	gattttgcag	gttggctctg	1140
ctccaccatt	ggccttaacc	agcccagcac	accaaccac	gcggctggcg	tctaagcggt	1200
tggaagcag	caaaaagcga	gccccctgcc	gcgtggtgtg	ccatgttgct	ttcgggcctc	1260
cttcccatgc	ctgtctgttc	acacgtgcat	ttcacctgtg	acaaaggatg	aagaacacag	1320
catgtgcaa	aattctat	gtgtcatttt	taatagtact	gtctttattc	ttattactat	1380
tgttattccc	ctaagtggat	tggtttgtg	cttgggacta	ttttgtgtat	gttgatgatc	1440
aaaacatgcg	caatgttgaa	ttaccgtgaa	actggtgact	gtgggtagtc	cttcttattg	1500
aaaattgcac	tgctcttccc	tccctgtcac	tggttggtg	cctgtatttc	tggggttctt	1560
tgacacttgg	tggtacttca	ttcttgcagg	gcatacctcc	tattcgagta	ggaaggagcc	1620
tttaagatcc	ttcacaggca	gtgcatgtga	agcatgcttt	gctgctatga	aaatgagcat	1680
cagaaagtgt	atatcatgtt	atTTtattat	tattatgttt	ttgcttttgg	tgtagaattc	1740
agcaatttcc	atcaagatct	agccagagcc	cttactgcc	atgatagctg	gggcttcacc	1800
agtctgccta	ctgtgatgat	ttgtagactt	ctggttgat	ttctatat	atTTTTaaat	1860
atactgtgtg	ggatatttag	tggtatatgt	ctctctaagt	ttggagtgg	gtttctaaaa	1920
tggaattact	ttgaatgtta	tagatggatc	aaggcataaa	atgtatgaga	tttatttttc	1980
cccaaatacca	aatactgatg	ctattgtaaa	caacaaacag	tgtgtatagt	gcctaaaaat	2040
tgtatgaaag	tccttttaac	cattttaatc	cagatgttta	acaaatctaa	tctcttattc	2100
taataaatat	actatcaagt	taaacggaca	aaagatttct	actttc		2146

<210> 80
 <211> 371
 <212> PRT
 <213> Equus caballus

<400> 80

```

Met Lys Pro Glu Arg Thr Asn Leu Glu Ala Leu Gln Lys Lys Leu Glu
1      5      10      15

Glu Leu Glu Leu Asp Glu Gln Gln Arg Lys Arg Leu Glu Ala Phe Leu
20      25      30

Thr Gln Lys Gln Lys Val Gly Glu Leu Lys Asp Asp Asp Phe Glu Lys
35      40      45

Ile Ser Glu Leu Gly Ala Gly Asn Gly Gly Val Val Phe Lys Val Ala
50      55      60

His Lys Pro Ser Gly Leu Val Met Ala Arg Lys Leu Ile His Leu Glu
65      70      75      80

Ile Lys Pro Ala Ile Arg Asn Gln Ile Ile Arg Glu Leu Gln Val Leu
85      90      95

His Glu Cys Asn Ser Pro Tyr Ile Val Gly Phe Tyr Gly Ala Phe Tyr
100     105     110

Ser Asp Gly Glu Ile Ser Ile Cys Met Glu His Met Asp Gly Gly Ser
115     120     125

Leu Asp Gln Val Leu Lys Lys Ala Gly Arg Ile Pro Glu Gln Ile Leu
130     135     140

Gly Lys Val Ser Ile Ala Val Ile Lys Gly Leu Thr Tyr Leu Arg Glu
145     150     155     160

Lys His Lys Ile Met His Arg Asp Val Lys Pro Ser Asn Ile Leu Val
165     170     175

Asn Ser Arg Gly Glu Ile Lys Leu Cys Asp Phe Gly Val Ser Gly Gln
180     185     190

Leu Ile Asp Ser Met Ala Asn Ser Phe Val Gly Thr Arg Ser Tyr Met
195     200     205

Ser Pro Glu Arg Leu Gln Gly Thr His Tyr Ser Val Gln Ser Asp Ile
210     215     220

Trp Ser Met Gly Leu Ser Leu Val Glu Met Ala Val Gly Arg Tyr Pro
225     230     235     240

Ile Pro Pro Pro Asp Ala Lys Glu Leu Glu Leu Met Phe Gly Cys Gln
245     250     255

Val Glu Gly Asp Ala Ala Glu Thr Pro Pro Arg Pro Arg Thr Pro Gly
260     265     270

```


Arg Pro Leu Ser Ser Tyr Gly Met Asp Ser Arg Pro Pro Met Ala Ile
 275 280 285

Phe Glu Leu Leu Asp Tyr Ile Val Asn Glu Pro Pro Pro Lys Leu Pro
 290 295 300

Ser Gly Val Phe Ser Leu Glu Phe Gln Asp Phe Val Asn Lys Cys Leu
 305 310 315 320

Ile Lys Asn Pro Ala Glu Arg Ala Asp Leu Lys Gln Leu Met Val His
 325 330 335

Ala Phe Ile Lys Arg Ser Asp Ala Glu Glu Val Asp Phe Ala Gly Trp
 340 345 350

Leu Cys Ser Thr Ile Gly Leu Asn Gln Pro Ser Thr Pro Thr His Ala
 355 360 365

Ala Gly Val
 370

<210> 81
 <211> 2274
 <212> DNA
 <213> Gallus gallus

<400> 81
 ctaaccaggc gggagctgtc ggtgcggagc tcggtgtcgc tccgccgggc aggccgggtc 60
 gacggccgcg ctgtgccgga gcggcagcgt cgcgggctcg gctccttctc ggggagggcg 120
 ccgcgcgctg ctccggcgct gaggggcggc cccgaagttt gcttcgcgtc gggaagtccg 180
 tcggacctgg ccgaagtggg gccgcggccg ctccgtccgt cacgctctgc gctggccggg 240
 gggcaacatg cccaagaaga agccagggcc gatccagctc aaccccgctc cggatggctc 300
 cgccgtcaac gggaccagct ctgccgagac aaacttgaa gctcttcaga agaagctgga 360
 agagctagag ctggatgaac agcaaaggaa gcgccttgaa gctttcctta ccagaaaaca 420
 aaaagttggg gagctgaagg atgatgactt cgagaagatc agtgagctgg gagcagggaa 480
 tggcgggggtg gtgttcaaag tatctcacia gccttctggc ctcatcatgg caagaaaatt 540
 gattcatcta gaaatcaagc cagctattcg aaaccagatc atccgtgagc tgcaggttct 600
 acatgagtgc aattcacat acatagtggg cttttatgga gctttttaca gtgatgggga 660
 aatcagcatt tgcattggaac acatggatgg tggctcattg gatcaagtgc tgaaaaaggc 720
 tggaagaatt ccagagcaga tactgggcaa agtcagcatt gcagtaataa aaggactcac 780
 atatctgaga gaaaagcata aaataatgca cagagatgtt aaaccatcta acatcttggg 840
 aaactctaga ggtgagatca agctttgtga ttttggtgtc agtggacaac tgatagattc 900
 tatggcaaac tcatttggtg gcacgcgctc ctacatgtct ccggaaagac tgcagggaaac 960

0398850pct.txt

```

tcattattca gtgcagtcag atatatggag tatggggctg tctctggtag aaatggccat 1020
tggcagatac ccgattcctc ctcctgactc taaggagctc gagttgatgt ttggctgccc 1080
ggtagaggga gattctccag tcacagagac ctcaccagc caaagaacac ctggctcgacc 1140
aatgagctcc tatggaccag acagcagacc cccgatggca atctttgaac ttctggatta 1200
catcgtcaat gagccacctc caaaactgcc caatggtgtc tttggttctg aatttcaaga 1260
ttttgttaac aaatgtttta ttaaaaatcc tgctgagaga gctgatttga agcagctgat 1320
gattcacgct ttcattaaga gatctgaagc agaggaggtg gattttgcag gatggctttg 1380
ctcaaccata ggccttaacc aaccgagtac acccagcat gctgctggag tctgaatgtg 1440
gaagagcaaa tcctgtcccg tacatctgtt aacagcgcta ctttggtcct atttcctaag 1500
cttgtagctg ttcaaactg tatttcacct ctttaaggaag aatgtcttta tagcatgtgc 1560
caaattgttt tcaattttgt catcaactaa ttggtattgt actgggttac atttgtttgc 1620
tgacaaaaat gtaaaatgtt taagttacag tgcttgctga ttttaagtga ttatggaatt 1680
atggatattc tttcttaatg aaaatatcac tgggggggaa tttaccctg gattgtttga 1740
actttatcaa gactctttgt aaactgttgg tacttcagtc atgcttacct aatctcccat 1800
gcaaaaaaag gggtagggat gctccaaaac tgtatctgtt gagcatgctt ttgctgctgc 1860
caaactgtat cttggaagtt aggcctaatt gttccaattt ggtgttgtgt agagatcact 1920
ctttccaggt aaagaaggta agagctctgc attccttggg atggacaggg cagtataccta 1980
cttgtagact tgttcatatt tctatattta tttttaaaat gtatcatcat acttggaattt 2040
agtgatatat gtctttccaa ttgattttta aaggtttagct ctcagaagcg tcctacagaa 2100
tcatgacaaa gatctgggct ttcttttaac ctttaagattc atgacagctg tgtttggtgt 2160
ctaaaatgta tgaagatcct ctattgtttt attctctcag atgttttagca atggtttctc 2220
ttaataaata tattatcaag taaaaaaaaa aaaaaataa aaaaaaaaaa aaaa 2274

```

<210> 82
 <211> 395
 <212> PRT
 <213> Gallus gallus

<400> 82

Met Pro Lys Lys Lys Pro Gly Pro Ile Gln Leu Asn Pro Ala Pro Asp
 1 5 10 15

Gly Ser Ala Val Asn Gly Thr Ser Ser Ala Glu Thr Asn Leu Glu Ala
 20 25 30

Leu Gln Lys Lys Leu Glu Glu Leu Glu Leu Asp Glu Gln Gln Arg Lys
 35 40 45

Arg Leu Glu Ala Phe Leu Thr Gln Lys Gln Lys Val Gly Glu Leu Lys
 50 55 60

Asp 65 Asp 65 Asp 65 Phe 65 Glu 65 Lys 70 Ile 70 Ser 70 Glu 70 Leu 75 Gly 75 Ala 75 Gly 75 Asn 75 Gly 75
 Val 85 Val 85 Phe 85 Lys 85 Val 85 Ser 85 His 85 Lys 85 Pro 90 Ser 90 Gly 90 Leu 90 Ile 90 Met 95 Ala 95 Arg 95
 Lys 100 Leu 100 Ile 100 His 100 Leu 100 Glu 100 Ile 100 Lys 105 Pro 105 Ala 105 Ile 105 Arg 105 Asn 110 Gln 110 Ile 110
 Arg 115 Glu 115 Leu 115 Gln 115 Val 115 Leu 115 His 120 Glu 120 Cys 120 Asn 120 Ser 120 Pro 125 Tyr 125 Ile 125 Val 125 Gly 125
 Phe 130 Tyr 130 Gly 130 Ala 130 Phe 130 Tyr 135 Ser 135 Asp 135 Gly 135 Glu 135 Ile 135 Ser 140 Ile 140 Cys 140 Met 140 Glu 140
 His 145 Met 145 Asp 145 Gly 145 Gly 145 Ser 150 Leu 150 Asp 150 Gln 150 Val 150 Leu 155 Lys 155 Lys 155 Ala 155 Gly 155 Arg 160
 Ile 165 Pro 165 Glu 165 Gln 165 Ile 165 Leu 165 Gly 165 Lys 165 Val 170 Ser 170 Ile 170 Ala 170 Val 170 Ile 175 Lys 175 Gly 175
 Leu 180 Thr 180 Tyr 180 Leu 180 Arg 180 Glu 180 Lys 180 His 185 Lys 185 Ile 185 Met 185 His 185 Arg 185 Asp 190 Val 190 Lys 190
 Pro 195 Ser 195 Asn 195 Ile 195 Leu 195 Val 195 Asn 195 Ser 200 Arg 200 Gly 200 Glu 200 Ile 200 Lys 205 Leu 205 Cys 205 Asp 205
 Phe 210 Gly 210 Val 210 Ser 210 Gly 210 Gln 215 Leu 215 Ile 215 Asp 215 Ser 215 Met 215 Ala 220 Asn 220 Ser 220 Phe 220 Val 220
 Gly 225 Thr 225 Arg 225 Ser 225 Tyr 225 Met 230 Ser 230 Pro 230 Glu 230 Arg 230 Leu 235 Gln 235 Gly 235 Thr 235 His 235 Tyr 240
 Ser 245 Val 245 Gln 245 Ser 245 Asp 245 Ile 245 Trp 245 Ser 245 Met 245 Gly 250 Leu 250 Ser 250 Leu 250 Val 250 Glu 255 Met 255
 Ala 260 Ile 260 Gly 260 Arg 260 Tyr 260 Pro 260 Ile 260 Pro 265 Pro 265 Asp 265 Ser 265 Lys 265 Glu 270 Leu 270 Glu 270
 Leu 275 Met 275 Phe 275 Gly 275 Cys 275 Pro 275 Val 275 Glu 280 Gly 280 Asp 280 Ser 280 Pro 285 Val 285 Thr 285 Glu 285 Thr 285
 Ser 290 Pro 290 Arg 290 Gln 290 Arg 290 Thr 290 Pro 295 Gly 295 Arg 295 Pro 295 Met 295 Ser 300 Ser 300 Tyr 300 Gly 300 Pro 300
 Asp 305 Ser 305 Arg 305 Pro 305 Pro 305 Met 310 Ala 310 Ile 310 Phe 310 Glu 310 Leu 315 Leu 315 Asp 315 Tyr 315 Ile 315 Val 320
 Asn 325 Glu 325 Pro 325 Pro 325 Lys 325 Leu 325 Pro 325 Asn 325 Gly 330 Val 330 Phe 330 Gly 330 Ser 330 Glu 335 Phe 335

Gln Asp Phe Val Asn Lys Cys Leu Ile Lys Asn Pro Ala Glu Arg Ala
340 345 350

Asp Leu Lys Gln Leu Met Ile His Ala Phe Ile Lys Arg Ser Glu Ala
355 360 365

Glu Glu Val Asp Phe Ala Gly Trp Leu Cys Ser Thr Ile Gly Leu Asn
370 375 380

Gln Pro Ser Thr Pro Thr His Ala Ala Gly Val
385 390 395